0000859737-20-000018.txt : 20200429 0000859737-20-000018.hdr.sgml : 20200429 20200429161128 ACCESSION NUMBER: 0000859737-20-000018 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 104 CONFORMED PERIOD OF REPORT: 20200328 FILED AS OF DATE: 20200429 DATE AS OF CHANGE: 20200429 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HOLOGIC INC CENTRAL INDEX KEY: 0000859737 STANDARD INDUSTRIAL CLASSIFICATION: X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844] IRS NUMBER: 042902449 STATE OF INCORPORATION: DE FISCAL YEAR END: 0928 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36214 FILM NUMBER: 20830405 BUSINESS ADDRESS: STREET 1: 250 CAMPUS DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: 5082632900 MAIL ADDRESS: STREET 1: 250 CAMPUS DRIVE CITY: MARLBOROUGH STATE: MA ZIP: 01752 10-Q 1 holxq2-2020.htm 10-Q Document
false--09-28Q220200000859737P2YP3MP9YP9YP8Y3M18D17800000160000000.010.01750000000750000000292323000294142000000003000008000008100000640000000.010.011623000162300000P6MP1YP1YP1YP1Y00002463800035941000 0000859737 2019-09-29 2020-03-28 0000859737 2019-12-29 2020-03-28 0000859737 2020-04-23 0000859737 2018-09-30 2019-03-30 0000859737 2018-12-30 2019-03-30 0000859737 2020-03-28 0000859737 2019-09-28 0000859737 us-gaap:CommonStockMember 2019-03-31 2019-06-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-12-29 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-12-30 2019-03-30 0000859737 us-gaap:TreasuryStockMember 2018-09-30 2018-12-29 0000859737 2019-06-30 2019-09-28 0000859737 us-gaap:CommonStockMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 2019-09-28 0000859737 holx:ShareRepurchaseProgramMember us-gaap:TreasuryStockMember 2019-09-29 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-03-30 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-12-29 0000859737 us-gaap:TreasuryStockMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-09-29 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-06-29 0000859737 2018-12-29 0000859737 us-gaap:CommonStockMember 2019-06-30 2019-09-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-30 2019-03-30 0000859737 us-gaap:RetainedEarningsMember 2019-03-30 0000859737 us-gaap:CommonStockMember 2019-09-28 0000859737 2019-09-29 2019-12-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 2019-09-28 0000859737 2019-03-30 0000859737 us-gaap:AccountingStandardsUpdate201616Member 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-29 0000859737 us-gaap:TreasuryStockMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2019-03-30 0000859737 us-gaap:CommonStockMember 2018-09-30 2018-12-29 0000859737 2018-09-30 2018-12-29 0000859737 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-12-29 0000859737 2019-06-29 0000859737 holx:ShareRepurchaseProgramMember us-gaap:TreasuryStockMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-29 0000859737 us-gaap:CommonStockMember 2019-09-29 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-09-29 2019-12-28 0000859737 us-gaap:AccountingStandardsUpdate201801Member us-gaap:RetainedEarningsMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2019-06-29 0000859737 us-gaap:TreasuryStockMember 2019-03-31 2019-06-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 2019-06-29 0000859737 us-gaap:TreasuryStockMember 2019-12-29 2020-03-28 0000859737 2019-03-31 2019-06-29 0000859737 us-gaap:RetainedEarningsMember 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-09-28 0000859737 us-gaap:RetainedEarningsMember 2018-09-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-29 2019-12-28 0000859737 us-gaap:RetainedEarningsMember 2019-09-28 0000859737 us-gaap:RetainedEarningsMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-12-28 0000859737 2019-12-28 0000859737 us-gaap:RetainedEarningsMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2018-09-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-29 0000859737 us-gaap:CommonStockMember 2018-12-30 2019-03-30 0000859737 us-gaap:TreasuryStockMember 2018-09-29 0000859737 2018-09-29 0000859737 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-09-28 0000859737 us-gaap:CommonStockMember 2019-12-29 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-06-29 0000859737 us-gaap:TreasuryStockMember 2018-12-29 0000859737 us-gaap:CommonStockMember 2018-12-29 0000859737 us-gaap:AccountingStandardsUpdate201409Member 2018-12-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-09-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 2019-06-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-30 0000859737 us-gaap:RetainedEarningsMember 2019-06-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 2018-12-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-03-30 0000859737 holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 country:US holx:MedicalAestheticsDomain 2018-09-30 2019-03-30 0000859737 country:US 2018-09-30 2019-03-30 0000859737 holx:InternationalMember holx:GynSurgicalMember 2019-09-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2018-09-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 country:US holx:GynSurgicalMember 2019-09-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2018-09-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 country:US holx:SkeletalHealthMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 country:US holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 country:US holx:GynSurgicalMember 2018-09-30 2019-03-30 0000859737 holx:GynSurgicalMember 2018-09-30 2019-03-30 0000859737 country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2018-09-30 2019-03-30 0000859737 holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 country:US holx:SkeletalHealthMember 2018-09-30 2019-03-30 0000859737 holx:InternationalMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:InternationalMember 2019-09-29 2020-03-28 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 country:US 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:SkeletalHealthMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:InternationalMember 2018-09-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:GynSurgicalMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 country:US holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2019-09-29 2020-03-28 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:SkeletalHealthMember 2018-09-30 2019-03-30 0000859737 holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:GynSurgicalMember 2018-09-30 2019-03-30 0000859737 country:US holx:MedicalAestheticsDomain 2019-09-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 2024-03-29 2020-03-28 0000859737 2023-03-29 2020-03-28 0000859737 2022-03-29 2020-03-28 0000859737 2021-03-29 2020-03-28 0000859737 2020-03-29 2020-03-28 0000859737 holx:ConsumablesMember 2018-09-30 2019-03-30 0000859737 holx:ConsumablesMember 2019-12-29 2020-03-28 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2019-12-29 2020-03-28 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2018-12-30 2019-03-30 0000859737 holx:ConsumablesMember 2019-09-29 2020-03-28 0000859737 holx:OtherTypeofRevenueMember 2018-12-30 2019-03-30 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2019-09-29 2020-03-28 0000859737 holx:OtherTypeofRevenueMember 2019-09-29 2020-03-28 0000859737 holx:OtherTypeofRevenueMember 2019-12-29 2020-03-28 0000859737 us-gaap:ServiceMember 2019-09-29 2020-03-28 0000859737 us-gaap:ServiceMember 2018-09-30 2019-03-30 0000859737 holx:OtherTypeofRevenueMember 2018-09-30 2019-03-30 0000859737 us-gaap:ServiceMember 2018-12-30 2019-03-30 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2018-09-30 2019-03-30 0000859737 us-gaap:ServiceMember 2019-12-29 2020-03-28 0000859737 holx:ConsumablesMember 2018-12-30 2019-03-30 0000859737 srt:AsiaPacificMember 2018-09-30 2019-03-30 0000859737 srt:EuropeMember 2019-12-29 2020-03-28 0000859737 srt:AsiaPacificMember 2019-12-29 2020-03-28 0000859737 holx:RestofWorldMember 2018-12-30 2019-03-30 0000859737 srt:AsiaPacificMember 2019-09-29 2020-03-28 0000859737 country:US 2018-12-30 2019-03-30 0000859737 srt:EuropeMember 2018-09-30 2019-03-30 0000859737 country:US 2019-12-29 2020-03-28 0000859737 holx:RestofWorldMember 2019-12-29 2020-03-28 0000859737 srt:EuropeMember 2018-12-30 2019-03-30 0000859737 srt:EuropeMember 2019-09-29 2020-03-28 0000859737 holx:RestofWorldMember 2019-09-29 2020-03-28 0000859737 holx:RestofWorldMember 2018-09-30 2019-03-30 0000859737 srt:AsiaPacificMember 2018-12-30 2019-03-30 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2019-12-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:GynSurgicalMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:SkeletalHealthMember 2018-12-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 country:US holx:GynSurgicalMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 country:US holx:SkeletalHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember 2019-12-29 2020-03-28 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 country:US holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:GynSurgicalMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember 2018-12-30 2019-03-30 0000859737 country:US holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:SkeletalHealthMember 2019-12-29 2020-03-28 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 country:US holx:MedicalAestheticsDomain 2019-12-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2019-12-29 2020-03-28 0000859737 holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:GynSurgicalMember 2019-12-29 2020-03-28 0000859737 country:US holx:GynSurgicalMember 2019-12-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:GynSurgicalMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 country:US holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 country:US holx:SkeletalHealthMember 2019-12-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 srt:MinimumMember 2019-09-29 2020-03-28 0000859737 srt:MaximumMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccruedLiabilitiesMember 2020-03-28 0000859737 holx:FinanceLeaseObligationsLongTermMember 2020-03-28 0000859737 us-gaap:OtherAssetsMember 2020-03-28 0000859737 us-gaap:OtherNoncurrentLiabilitiesMember 2020-03-28 0000859737 holx:FinanceLeaseObligationsShortTermMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member 2020-03-28 0000859737 us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateSwapMember 2020-03-28 0000859737 holx:FocalTherapeuticsInc.Member 2019-09-29 2020-03-28 0000859737 holx:FaxitronMember 2019-09-29 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 holx:AcquiredintangibleassetsMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:CreditAgreementMember 2020-03-28 0000859737 us-gaap:EquipmentMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:A2028SeniorNotesMember 2020-03-28 0000859737 holx:A2025SeniorNotesMember 2020-03-28 0000859737 holx:HealthBeaconsMember 2020-03-28 0000859737 holx:FocalTherapeuticsInc.Member 2018-10-01 2018-10-01 0000859737 holx:HealthBeaconsMember 2019-12-29 2020-03-28 0000859737 holx:FocalTherapeuticsInc.Member 2019-10-01 2019-10-01 0000859737 holx:FocalTherapeuticsInc.Member 2019-03-30 0000859737 2019-11-21 2019-11-21 0000859737 holx:SuperSonicImagineMember 2019-11-21 2019-11-21 0000859737 us-gaap:OtherIncomeMember 2019-07-28 2019-09-28 0000859737 holx:SuperSonicImagineMember 2019-09-01 2019-09-30 0000859737 holx:AlphaImagingMember 2020-03-28 0000859737 holx:SuperSonicImagineMember 2019-08-01 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:TradeNamesMember 2018-10-01 2018-10-01 0000859737 holx:AlphaImagingMember 2019-12-30 2019-12-30 0000859737 holx:FocalTherapeuticsInc.Member 2018-10-01 0000859737 2019-11-01 2019-11-30 0000859737 holx:AlphaImagingMember 2019-03-30 0000859737 holx:SuperSonicImagineMember 2019-11-20 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:DevelopedTechnologyRightsMember 2018-10-01 2018-10-01 0000859737 holx:SuperSonicImagineMember 2019-08-01 2019-08-01 0000859737 srt:MaximumMember holx:FocalTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2018-10-01 2018-10-01 0000859737 srt:MinimumMember holx:FocalTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2018-10-01 2018-10-01 0000859737 holx:SuperSonicImagineMember 2020-03-28 0000859737 holx:SuperSonicImagineMember 2019-11-21 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2018-10-01 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:TradeNamesMember 2018-10-01 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:DevelopedTechnologyRightsMember 2018-10-01 0000859737 holx:FaxitronMember us-gaap:CustomerRelationshipsMember 2018-07-31 2018-07-31 0000859737 holx:FaxitronMember us-gaap:DevelopedTechnologyRightsMember 2018-07-31 2018-07-31 0000859737 holx:EmsorMember 2017-12-11 2017-12-11 0000859737 holx:FaxitronMember us-gaap:TradeNamesMember 2018-07-31 2018-07-31 0000859737 us-gaap:CostOfSalesMember 2019-09-29 2019-12-28 0000859737 us-gaap:OperatingExpenseMember 2019-09-29 2019-12-28 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:MedicalAestheticsDomain 2019-11-20 2019-11-20 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:MedicalAestheticsDomain 2019-11-20 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:MedicalAestheticsDomain 2019-12-28 0000859737 holx:TermLoanMember 2019-09-28 0000859737 holx:AccountsReceivableSecuritizationMember 2020-03-28 0000859737 holx:RevolverMember 2019-09-28 0000859737 holx:TermLoanMember 2020-03-28 0000859737 holx:A2025SeniorNotesMember 2019-09-28 0000859737 holx:A2025SeniorNotesMember 2020-03-28 0000859737 holx:A2028SeniorNotesMember 2020-03-28 0000859737 holx:AccountsReceivableSecuritizationMember 2019-09-28 0000859737 holx:RevolverMember 2020-03-28 0000859737 holx:SSIMember 2019-09-28 0000859737 holx:SSIMember 2020-03-28 0000859737 holx:A2028SeniorNotesMember 2019-09-28 0000859737 holx:CreditAgreementMember 2019-03-30 0000859737 holx:CreditAgreementMember 2019-12-29 2020-03-28 0000859737 holx:CreditAgreementMember 2018-09-30 2019-03-30 0000859737 holx:CreditAgreementMember 2019-09-29 2020-03-28 0000859737 holx:CreditAgreementMember 2018-12-30 2019-03-30 0000859737 2018-01-19 0000859737 2017-10-10 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-01-19 0000859737 holx:A2028SeniorNotesMember 2018-01-19 0000859737 holx:AmendedRevolverMember holx:PercentageAddedtoEurodollarRateMember 2019-09-29 2020-03-28 0000859737 holx:AmendedCreditAgreementMember 2019-09-29 2019-12-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2017-10-10 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2018-01-19 0000859737 holx:A2025SeniorNotesMember 2018-01-19 0000859737 holx:AmendedTermLoanMember holx:PercentageAddedtoEurodollarRateMember 2019-09-29 2020-03-28 0000859737 holx:AccountsReceivableSecuritizationMember 2019-12-29 2020-03-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-30 2019-03-30 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-30 2019-03-30 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2018-09-30 2019-03-30 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-29 2020-03-28 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2020-03-28 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-29 2020-03-28 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-09-30 2019-03-30 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2019-09-29 2020-03-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2020-03-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2019-09-29 2020-03-28 0000859737 holx:AmendedCreditAgreementMember holx:AmendedTermLoanMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-28 0000859737 us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:ForeignExchangeOptionMember 2019-09-29 2020-03-28 0000859737 us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 2018-09-30 2019-09-28 0000859737 us-gaap:ForeignExchangeForwardMember 2019-09-29 2020-03-28 0000859737 us-gaap:ForeignExchangeForwardMember 2019-12-29 2020-03-28 0000859737 us-gaap:ForeignExchangeForwardMember 2018-12-30 2019-03-30 0000859737 us-gaap:ForeignExchangeOptionMember 2019-12-29 2020-03-28 0000859737 us-gaap:ForeignExchangeForwardMember 2018-09-30 2019-03-30 0000859737 us-gaap:ForeignExchangeOptionMember 2018-12-30 2019-03-30 0000859737 us-gaap:ForeignExchangeOptionMember 2018-09-30 2019-03-30 0000859737 us-gaap:InterestRateSwapMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2019-12-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateCapMember 2019-12-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2018-09-30 2019-03-30 0000859737 us-gaap:InterestRateSwapMember 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateCapMember 2018-09-30 2019-03-30 0000859737 holx:CynosureMember 2019-09-29 2020-03-28 0000859737 holx:MinervaMember 2016-03-04 2016-03-04 0000859737 holx:MinervaMember 2018-07-27 0000859737 us-gaap:StockCompensationPlanMember 2019-12-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2018-12-30 2019-03-30 0000859737 us-gaap:StockCompensationPlanMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 2019-03-30 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2019-09-29 2020-03-28 0000859737 us-gaap:StockCompensationPlanMember 2018-12-30 2019-03-30 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2019-12-29 2020-03-28 0000859737 us-gaap:StockCompensationPlanMember 2018-09-30 2019-03-30 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2019-12-29 2020-03-28 0000859737 us-gaap:SellingAndMarketingExpenseMember 2018-12-30 2019-03-30 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2019-09-29 2020-03-28 0000859737 us-gaap:CostOfSalesMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestructuringChargesMember 2018-12-30 2019-03-30 0000859737 us-gaap:SellingAndMarketingExpenseMember 2018-09-30 2019-03-30 0000859737 us-gaap:CostOfSalesMember 2018-09-30 2019-03-30 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2019-09-29 2020-03-28 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2018-09-30 2019-03-30 0000859737 us-gaap:RestructuringChargesMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestructuringChargesMember 2019-12-29 2020-03-28 0000859737 us-gaap:RestructuringChargesMember 2018-09-30 2019-03-30 0000859737 us-gaap:CostOfSalesMember 2019-12-29 2020-03-28 0000859737 us-gaap:SellingAndMarketingExpenseMember 2019-12-29 2020-03-28 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-30 2019-03-30 0000859737 us-gaap:CostOfSalesMember 2018-12-30 2019-03-30 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2019-12-29 2020-03-28 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2018-09-30 2019-03-30 0000859737 us-gaap:SellingAndMarketingExpenseMember 2019-09-29 2020-03-28 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2018-12-30 2019-03-30 0000859737 us-gaap:PerformanceSharesMember 2019-09-29 2020-03-28 0000859737 us-gaap:PerformanceSharesMember 2018-09-30 2019-03-30 0000859737 holx:RSUPSUMSUMember 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 2019-03-30 0000859737 us-gaap:EmployeeStockOptionMember 2020-03-28 0000859737 holx:MarketBasedAwardsMember 2019-09-29 2020-03-28 0000859737 us-gaap:EmployeeStockOptionMember 2018-09-30 2019-03-30 0000859737 holx:MarketBasedAwardsMember 2018-09-30 2019-03-30 0000859737 holx:PSUFreeCashFlowMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2019-09-29 2020-03-28 0000859737 us-gaap:EmployeeStockOptionMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2020-03-28 0000859737 holx:AllOtherCountriesMember 2019-09-29 2020-03-28 0000859737 holx:AllOtherCountriesMember 2018-12-30 2019-03-30 0000859737 holx:AllOtherCountriesMember 2018-09-30 2019-03-30 0000859737 holx:AllOtherCountriesMember 2019-12-29 2020-03-28 0000859737 us-gaap:IntersegmentEliminationMember 2019-12-29 2020-03-28 0000859737 holx:DiagnosticsMember 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2020-03-28 0000859737 holx:BreastHealthMember 2019-09-28 0000859737 holx:GynSurgicalMember 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2019-09-28 0000859737 holx:SkeletalHealthMember 2019-09-28 0000859737 us-gaap:CorporateMember 2020-03-28 0000859737 holx:SkeletalHealthMember 2020-03-28 0000859737 holx:BreastHealthMember 2020-03-28 0000859737 us-gaap:CorporateMember 2019-09-28 0000859737 holx:GynSurgicalMember 2019-09-28 0000859737 holx:DiagnosticsMember 2019-09-28 0000859737 us-gaap:CorporateMember 2019-09-29 2020-03-28 0000859737 us-gaap:CorporateMember 2018-09-30 2019-03-30 0000859737 us-gaap:CorporateMember 2018-12-30 2019-03-30 0000859737 us-gaap:CorporateMember 2019-12-29 2020-03-28 0000859737 us-gaap:IntersegmentEliminationMember 2018-09-30 2019-03-30 0000859737 us-gaap:IntersegmentEliminationMember 2019-09-29 2020-03-28 0000859737 us-gaap:IntersegmentEliminationMember 2018-12-30 2019-03-30 0000859737 holx:AcquiredintangibleassetsMember 2019-09-28 0000859737 holx:InternalusesoftwareMember 2020-03-28 0000859737 holx:DevelopedTechnologyMember 2019-09-28 0000859737 holx:InternalusesoftwareMember 2019-09-28 0000859737 holx:DevelopedTechnologyMember 2020-03-28 0000859737 holx:DistributionagreementMember 2020-03-28 0000859737 us-gaap:TradeNamesMember 2020-03-28 0000859737 holx:AcquiredintangibleassetsMember 2020-03-28 0000859737 holx:CapitalizedsoftwareMember 2019-09-28 0000859737 holx:BusinessLicensesMember 2019-09-28 0000859737 holx:DistributionagreementMember 2019-09-28 0000859737 holx:CustomerRelationshipsContractsMember 2020-03-28 0000859737 us-gaap:TradeNamesMember 2019-09-28 0000859737 us-gaap:NoncompeteAgreementsMember 2020-03-28 0000859737 us-gaap:NoncompeteAgreementsMember 2019-09-28 0000859737 holx:CapitalizedsoftwareMember 2020-03-28 0000859737 holx:CustomerRelationshipsContractsMember 2019-09-28 0000859737 holx:BusinessLicensesMember 2020-03-28 0000859737 us-gaap:CustomerRelationshipsMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 holx:DistributionagreementMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 us-gaap:TradeNamesMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 us-gaap:TradeNamesMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 us-gaap:CustomerRelationshipsMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:DevelopedTechnologyMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:DevelopedTechnologyMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 holx:DistributionagreementMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-29 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-29 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-29 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-30 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-29 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-30 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-29 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-29 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-29 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-29 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-29 0000859737 holx:COVID19Member 2019-12-29 2020-03-28 0000859737 holx:SunnyvaleMember 2019-12-29 2020-03-28 0000859737 holx:CynosureMember 2019-12-29 2020-03-28 0000859737 holx:TepnelMember 2019-12-29 2020-03-28 0000859737 2019-11-20 2019-11-20 0000859737 holx:November192019PlanMember 2019-12-29 2020-03-28 0000859737 holx:June132019PlanMember 2019-12-29 2020-03-28 xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:USD holx:Segment holx:petition

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
__________________________________________________________ 
FORM 10-Q
 
 __________________________________________________________ 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 28, 2020
or 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from                      to                     
Commission File Number: 1-36214
__________________________________________________________ 
HOLOGIC, INC.
(Exact name of registrant as specified in its charter)
 __________________________________________________________
Delaware
 
04-2902449
(State or other jurisdiction of incorporation or organization)
 
(I.R.S. Employer Identification No.)
250 Campus Drive,
 

Marlborough,
 
 
Massachusetts
 
01752
(Address of principal executive offices)
 
(Zip Code)
(508) 263-2900
(Registrant’s telephone number, including area code)
 __________________________________________________________
*Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value
HOLX
NASDAQ
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.:
Large accelerated filer
 
  
Accelerated filer
 
Non-accelerated filer
 
  
Smaller reporting company
 
 
 
 
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of April 23, 2020, 258,205,678 shares of the registrant’s Common Stock, $0.01 par value, were outstanding.
 



HOLOGIC, INC.
INDEX
 
 
Page
 
 
 
 
 
Item 1.
 
 
 
 

 
 
 

 
 
 

 
 
 

 
 
 
 

 
 
 
 
 
Item 2.
 
 
Item 3.
 
 
Item 4.
 
 
 
 
 
 
Item 1.
 
 
 
Item 1A.
 
 
 
Item 2.
 
 
 
Item 6.
 
 
 
 
EXHIBITS
 


2



PART I – FINANCIAL INFORMATION
 

Item 1.
Financial Statements (unaudited)
HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)

(In millions, except number of shares, which are reflected in thousands, and per share data)
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Revenues:
 
 
 
 
 
 
 
Product
$
623.6

 
$
667.8

 
$
1,322.9

 
$
1,350.9

Service and other
132.5

 
150.6

 
283.7

 
298.2

 
756.1

 
818.4

 
1,606.6

 
1,649.1

Costs of revenues:
 
 
 
 
 
 
 
Product
223.3

 
232.9

 
460.8

 
465.0

Amortization of acquired intangible assets
62.9

 
80.4

 
126.5

 
161.4

Impairment of intangible assets and equipment

 
374.6

 
25.8

 
374.6

Service and other
74.1

 
88.1

 
163.9

 
171.6

Gross profit
395.8

 
42.4

 
829.6

 
476.5

Operating expenses:
 
 
 
 
 
 
 
Research and development
49.3

 
57.3

 
110.4

 
110.5

Selling and marketing
110.6

 
133.5

 
255.4

 
279.5

General and administrative
66.5

 
89.9

 
155.1

 
168.5

Amortization of acquired intangible assets
10.1

 
14.1

 
19.2

 
28.2

Impairment of intangible assets and equipment

 
69.2

 
4.4

 
69.2

Restructuring and divestiture charges
2.9

 
1.6

 
3.9

 
3.3

 
239.4

 
365.6

 
548.4

 
659.2

Income (loss) from operations
156.4

 
(323.2
)
 
281.2

 
(182.7
)
Interest income
1.3

 
0.8

 
3.5

 
2.1

Interest expense
(31.3
)
 
(34.8
)
 
(64.1
)
 
(70.9
)
Debt extinguishment loss

 

 

 
(0.8
)
Other (expense) income, net
(7.5
)
 
3.5

 
(4.2
)
 
2.9

Income (loss) before income taxes
118.9

 
(353.7
)
 
216.4

 
(249.4
)
Provision (benefit) for income taxes
24.1

 
(81.1
)
 
(264.3
)
 
(75.4
)
Net income (loss)
$
94.8

 
$
(272.6
)
 
$
480.7

 
$
(174.0
)
Net loss attributable to noncontrolling interest
(1.5
)
 

 
(1.8
)
 

Net income (loss) attributable to Hologic
$
96.3

 
$
(272.6
)
 
$
482.5

 
$
(174.0
)
Net income (loss) per common share attributable to Hologic:
 
 
 
 
 
 
 
Basic
$
0.37

 
$
(1.01
)
 
$
1.82

 
$
(0.64
)
Diluted
$
0.36

 
$
(1.01
)
 
$
1.81

 
$
(0.64
)
Weighted average number of shares outstanding:
 
 
 
 
 
 
 
Basic
263,238

 
269,235

 
265,566

 
269,913

Diluted
264,506

 
269,235

 
267,114

 
269,913



See accompanying notes.

3


HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
(Unaudited)
(In millions)
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Net income (loss)
$
94.8

 
$
(272.6
)
 
$
480.7

 
$
(174.0
)
Changes in foreign currency translation adjustment
(5.4
)
 
2.4

 
2.9

 
(0.8
)
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019.
 
 
 
 
 
 
 
Loss recognized in other comprehensive income, net
(25.2
)
 
(1.5
)
 
(21.2
)
 
(5.4
)
Loss reclassified from accumulated other comprehensive loss to the statements of operations
0.4

 
0.5

 
1.7

 
1.2

Other comprehensive income (loss)
(30.2
)
 
1.4

 
(16.6
)
 
(5.0
)
Comprehensive income (loss)
$
64.6

 
$
(271.2
)
 
$
464.1

 
$
(179.0
)
Components of comprehensive income (loss) attributable to noncontrolling interest:
 
 
 
 
 
 
 
Net loss attributable to noncontrolling interest
1.5

 

 
1.8

 

Comprehensive loss attributable to noncontrolling interest
1.5

 

 
1.8

 

Comprehensive income (loss) attributable to Hologic
$
66.1

 
$
(271.2
)
 
$
465.9

 
$
(179.0
)
See accompanying notes.



4


HOLOGIC, INC.

CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In millions, except number of shares, which are reflected in thousands, and par value)
 
 
March 28,
2020
 
September 28,
2019
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
799.8

 
$
601.8

Accounts receivable, less reserves of $16.0 and $17.8, respectively
597.2

 
648.7

Inventories
401.3

 
444.9

Prepaid income taxes
62.6

 
34.9

Prepaid expenses and other current assets
75.7

 
62.8

Total current assets
1,936.6

 
1,793.1

Property, plant and equipment, net
445.3

 
470.9

Intangible assets, net
1,328.8

 
1,459.8

Goodwill
2,592.0

 
2,563.7

Other assets
519.1

 
154.6

Total assets
$
6,821.8

 
$
6,442.1

LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities:
 
 
 
Current portion of long-term debt
$
806.1

 
$
271.4

Accounts payable
134.4

 
186.5

Accrued expenses
366.0

 
430.9

Deferred revenue
172.6

 
179.5

Finance lease obligation (capital lease obligation in 2019)
1.8

 
1.8

Total current liabilities
1,480.9

 
1,070.1

Long-term debt, net of current portion
2,749.3

 
2,783.6

Finance lease obligation - long term (capital lease obligation in 2019)
18.4

 
19.2

Deferred income tax liabilities
235.9

 
275.3

Deferred revenue
15.0

 
15.8

Other long-term liabilities
231.1

 
162.4

Stockholders’ equity:
 
 
 
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued

 

Common stock, $0.01 par value – 750,000 shares authorized; 294,142 and 292,323 shares issued, respectively
2.9

 
2.9

Additional paid-in-capital
5,827.6

 
5,769.8

Accumulated deficit
(2,206.0
)
 
(2,688.7
)
Treasury stock, at cost – 35,941 and 24,638 shares, respectively
(1,479.5
)
 
(926.0
)
Accumulated other comprehensive loss
(58.9
)
 
(42.3
)
Total Hologic's stockholders’ equity
2,086.1

 
2,115.7

Noncontrolling interest
5.1

 

Total stockholders’ equity
2,091.2

 
2,115.7

Total liabilities and stockholders’ equity
$
6,821.8

 
$
6,442.1

See accompanying notes.

5


Hologic, Inc.
Consolidated Statements of Stockholders' Equity
(In millions, except number of shares, which are reflected in thousands)

 
 
Common Stock
 
Additional
Paid-in-
Capital
 
Accumulated
Deficit
 
Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
 
 
 
Total
Stockholders’
Equity
 
 
Number of
Shares
 
Par Value
 
Number of
Shares
 
Amount
 
Noncontrolling Interest
 
Balance at September 29, 2018
 
289,900

 
$
2.9

 
$
5,671.3

 
$
(2,494.0
)
 
$
(25.5
)
 
19,812

 
$
(725.9
)
 
$

 
$
2,428.8

Accounting standard transition adjustment - ASC 606
 

 

 

 
6.4

 

 

 

 

 
6.4

Accounting standard transition adjustment - ASU 2016-16
 

 

 

 
2.5

 

 

 

 

 
2.5

Exercise of stock options
 
373

 

 
9.1

 

 

 

 

 

 
9.1

Vesting of restricted stock units, net of shares withheld for employee taxes
 
575

 

 
(11.6
)
 

 

 

 

 

 
(11.6
)
Stock-based compensation
 

 

 
17.1

 

 

 

 

 

 
17.1

Net income
 

 

 

 
98.6

 

 

 

 

 
98.6

Other comprehensive income activity
 

 

 

 

 
(6.4
)
 

 

 

 
(6.4
)
Repurchase of common stock
 

 

 

 

 

 
3,712

 
(150.1
)
 

 
(150.1
)
Balance at December 29, 2018
 
290,848

 
$
2.9

 
$
5,685.9

 
$
(2,386.5
)
 
$
(31.9
)
 
23,524

 
$
(876.0
)
 
$

 
$
2,394.4

Exercise of stock options
 
454

 

 
11.6

 

 

 

 

 

 
11.6

Vesting of restricted stock units, net of shares withheld for employee taxes
 
33

 

 
(0.4
)
 

 

 

 

 

 
(0.4
)
Common stock issued under the employee stock purchase plan
 
226

 

 
7.9

 

 

 

 

 

 
7.9

Stock-based compensation
 

 

 
17.5

 

 

 

 

 

 
17.5

Net loss
 

 

 

 
(272.6
)
 

 

 

 

 
(272.6
)
Other comprehensive income activity
 

 

 

 

 
1.4

 

 

 

 
1.4

Balance at March 30, 2019
 
291,561

 
$
2.9

 
$
5,722.5

 
$
(2,659.1
)
 
$
(30.5
)
 
23,524

 
$
(876.0
)
 
$

 
$
2,159.8

Exercise of stock options
 
108

 

 
3.1

 

 

 

 

 

 
3.1

Vesting of restricted stock units, net of shares withheld for employee taxes
 
21

 

 
(0.5
)
 

 

 

 

 

 
(0.5
)
Stock-based compensation
 

 

 
13.9

 

 

 

 

 

 
13.9

Net income
 

 

 

 
93.9

 

 

 

 

 
93.9


6


Other comprehensive income activity
 

 

 

 

 
(3.7
)
 

 

 

 
(3.7
)
Repurchase of common stock
 

 

 

 

 

 
1,114

 
(50.0
)
 

 
(50.0
)
Balance at June 29, 2019
 
291,690

 
$
2.9

 
$
5,739.0

 
$
(2,565.2
)
 
$
(34.2
)
 
24,638

 
$
(926.0
)
 
$

 
$
2,216.5

Exercise of stock options
 
369

 

 
9.0

 

 

 

 

 

 
9.0

Vesting of restricted stock units, net of shares withheld for employee taxes
 
16

 

 
(0.3
)
 

 

 

 

 

 
(0.3
)
Common stock issued under the employee stock purchase plan
 
248

 

 
8.6

 

 

 

 

 

 
8.6

Stock-based compensation
 

 

 
13.5

 

 

 

 

 

 
13.5

Net loss
 

 

 

 
(123.5
)
 

 

 

 

 
(123.5
)
Other comprehensive income activity
 

 

 

 

 
(8.1
)
 

 

 

 
(8.1
)
Balance at September 28, 2019
 
292,323

 
$
2.9

 
$
5,769.8

 
$
(2,688.7
)
 
$
(42.3
)
 
24,638

 
$
(926.0
)
 
$

 
$
2,115.7

Noncontrolling interest created in acquisition
 

 

 

 

 

 

 

 
8.6

 
8.6

Accounting standard transition adjustment - ASC 842
 

 

 

 
0.3

 

 

 

 

 
0.3

Exercise of stock options
 
540

 

 
13.8

 

 

 

 

 

 
13.8

Vesting of restricted stock units, net of shares withheld for employee taxes
 
476

 

 
(10.9
)
 

 

 

 

 

 
(10.9
)
Stock-based compensation
 

 

 
18.1

 

 

 

 

 

 
18.1

Net income (loss)
 

 

 

 
386.1

 

 

 

 
(0.3
)
 
385.8

Other comprehensive income activity
 

 

 

 

 
13.6

 

 

 

 
13.6

Repurchase of common stock
 

 

 

 

 

 
1,545

 
(80.9
)
 

 
(80.9
)
Accelerated share repurchase agreement
 

 

 
(41.0
)
 

 

 
3,279

 
(164.0
)
 

 
(205.0
)
Purchase of non-controlling interest
 

 

 

 

 

 

 

 
(1.4
)
 
(1.4
)
Balance at December 28, 2019
 
293,339

 
$
2.9

 
$
5,749.8

 
$
(2,302.3
)
 
$
(28.7
)
 
29,462

 
$
(1,170.9
)
 
$
6.9

 
$
2,257.7

Exercise of stock options
 
503

 

 
13.9

 

 

 

 

 

 
13.9

Vesting of restricted stock units, net of shares withheld for employee taxes
 
86

 

 
(1.6
)
 

 

 

 

 

 
(1.6
)
Common stock issued under the employee stock purchase plan
 
214

 

 
8.8

 

 

 

 

 

 
8.8

Stock-based compensation
 

 

 
15.7

 

 

 

 

 

 
15.7

Net income (loss)
 

 

 

 
96.3

 

 

 

 
(1.5
)
 
94.8


7


Other comprehensive income activity
 

 

 

 

 
(30.2
)
 

 

 

 
(30.2
)
Repurchase of common stock
 

 

 

 

 

 
5,851

 
(267.6
)
 

 
(267.6
)
Completion of Accelerated share repurchase agreement
 

 

 
41.0

 

 

 
628

 
(41.0
)
 

 

Purchase of non-controlling interest
 

 

 

 

 

 

 

 
(0.3
)
 
(0.3
)
Balance at March 28, 2020
 
294,142

 
$
2.9

 
$
5,827.6

 
$
(2,206.0
)
 
$
(58.9
)
 
35,941

 
$
(1,479.5
)
 
$
5.1

 
$
2,091.2




8


HOLOGIC, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In millions)
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
OPERATING ACTIVITIES
 
 
 
Net income (loss)
$
480.7

 
$
(174.0
)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
 
 
 
Depreciation
42.3

 
46.8

Amortization of acquired intangibles
145.8

 
189.6

Stock-based compensation expense
33.8

 
34.6

Deferred income taxes
(44.2
)
 
(173.3
)
Intangible asset and equipment impairment charges
30.2

 
443.8

Other adjustments and non-cash items
14.8

 
14.4

Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:
 
 
 
Accounts receivable
(0.3
)
 
18.6

Inventories
(33.3
)
 
(54.0
)
Prepaid income taxes
(27.7
)
 
(8.3
)
Prepaid expenses and other assets
(317.6
)
 
(10.4
)
Accounts payable
(47.9
)
 
(27.2
)
Accrued expenses and other liabilities
(50.8
)
 
(71.2
)
Deferred revenue
5.8

 
8.7

Net cash provided by operating activities
231.6

 
238.1

INVESTING ACTIVITIES
 
 
 
Acquisition of businesses, net of cash acquired
(43.2
)
 
(108.6
)
Net proceeds from sale of business
142.7

 

Capital expenditures
(29.6
)
 
(23.0
)
Increase in equipment under customer usage agreements
(33.5
)
 
(28.9
)
Purchase of cost-method investment

 
(3.0
)
Purchase of insurance contracts
(2.4
)
 

Other activity
(1.4
)
 
(3.6
)
Net cash provided by (used in) investing activities
32.6

 
(167.1
)
FINANCING ACTIVITIES
 
 
 
Proceeds from long-term debt

 
1,500.0

Repayment of long-term debt
(18.8
)
 
(1,462.5
)
Proceeds from revolving credit line
750.0

 
480.0

Repayments under revolving credit line

 
(695.0
)
Proceeds from accounts receivable securitization agreement
16.0

 

Repayments under accounts receivable securitization agreement
(250.0
)
 
(18.0
)
Purchase of non-controlling interest
(1.7
)
 

Payment of deferred acquisition consideration
(24.3
)
 

Payment of acquired long-term debt
(8.3
)
 
(2.5
)
Payment of debt issuance costs

 
(2.7
)
Payments to repurchase common stock pursuant to ASR agreement
(205.0
)
 

Repurchase of common stock
(348.5
)
 
(150.1
)
Purchase of interest rate caps

 
(1.5
)
Proceeds from issuance of common stock pursuant to employee stock plans
36.6

 
28.8

Payment of minimum tax withholdings on net share settlements of equity awards
(12.5
)
 
(11.9
)
Payments under finance lease obligations
(0.8
)
 
(0.8
)
Net cash used in financing activities
(67.3
)
 
(336.2
)
Effect of exchange rate changes on cash and cash equivalents
1.1

 
(0.5
)
Net increase (decrease) in cash and cash equivalents
198.0

 
(265.7
)
Cash and cash equivalents, beginning of period
601.8

 
666.7

Cash and cash equivalents, end of period
$
799.8

 
$
401.0

See accompanying notes.

9


HOLOGIC, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
(all tabular amounts in millions, except number of shares, which are reflected in thousands, and per share data)
(1) Basis of Presentation
The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 28, 2019 included in the Company’s Form 10-K filed with the SEC on November 27, 2019. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and six months ended March 28, 2020 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 26, 2020.
COVID-19 Considerations
The pandemic caused by the spread of the novel strain of coronavirus disease 2019 ("COVID-19") has created significant volatility, uncertainty and economic disruption in the markets the Company sells its products into, primarily the U.S., Europe and Asia-Pacific. In the second quarter of fiscal 2020, the spread of COVID-19 has negatively impacted business activity globally. As healthcare systems respond to the increasing demands of managing COVID-19 and the resulting economic uncertainties, governments around the world have imposed measures designed to reduce the transmission of COVID-19, and individuals are responding to the fears of contracting COVID-19. In particular, elective procedures and exams are being delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals are postponing or cancelling capital purchases as well as limiting or eliminating services. These responses have had, and the Company believes will continue to have, a negative impact on the Company's operating results and cash flows. While the effects of COVID-19 and the associated economic disruptions were felt primarily in the second half of March in many of the Company's end-markets and earlier in Asia, primarily China, the Company expects the effect on its financial results in the third fiscal quarter to be significant. While the Company believes the impact on its business will begin to lessen in the fourth quarter and continue to do so in subsequent periods the impacts on these periods could be significant.
The Company's belief is that COVID-19’s adverse impact on its operating results, cash flows and financial condition will be primarily driven by: the severity and duration of the COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. and international healthcare system, the U.S. economy and worldwide economy; and the timing, scope and effectiveness of U.S. and international governmental responses to the COVID-19 pandemic and associated economic disruptions.
In addition to adversely affecting demand for the Company's products, COVID-19 and associated economic disruptions could have an adverse impact on the Company's supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that it, other businesses and governments are taking. A reduction or interruption in any of the Company's manufacturing processes could have a material adverse effect on its business.
The Company expects that the uncertainty surrounding world financial markets and deteriorating worldwide macroeconomic conditions resulting from the pandemic have caused and may continue to cause the purchasers of medical equipment to decrease their medical equipment purchasing and procurement activities. Additionally, the pandemic has caused and may further cause constrictions in world credit markets that have and could cause its customers to experience increased difficulty in paying their existing obligations to the Company or in securing the financing necessary to purchase the Company's products. Economic uncertainty has and may continue to result in cost-conscious consumers focusing on acute care rather than wellness, which would also continue to adversely affect demand for the Company's products.

10


The terms of the Company's credit facilities require it to satisfy certain financial covenants. Should the Company's future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions over an extended period of time or otherwise, the Company cannot assure that it will remain in compliance with its current financial covenants. In such event, the factors that adversely affect the Company's business may also similarly adversely affect the capital markets, and the Company cannot assure that it would be able to negotiate alternative covenants or alternative financing on favorable terms if at all. The Company's failure to comply with the covenants contained in its credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect its results of operations and financial condition.
As the Company assessed the potential longer term economic and capital market uncertainties resulting from the COVID-19 pandemic, at the end of March 2020 the Company suspended its accounts receivable securitization program and borrowed $750.0 million under its revolver. The Company used $250.0 million of these proceeds to pay off all amounts then owed under its accounts receivable securitization agreement, and retained the balance as cash reserve. As of March 28, 2020 the Company had another $750.0 million available under its revolver.
In response to the negative impact of COVID-19 on the Company's business, in April 2020 it initiated cost-cutting measures, which included not only reducing discretionary and variable spend, such as travel, marketing programs and the use of contractors, consultants and temporary help, but the Company also implemented employee furloughs, salary cuts primarily in the U.S., reduced hours and in certain instances employee terminations. Further, the Company has shut down certain manufacturing facilities temporarily and implemented reduced work-week schedules in response to lower near-term demand for many of its products. These actions, as they relate to the Company's manufacturing operations, are expected to reduce the efficiency of its manufacturing operations and could further adversely affect its results of operations. Future cost savings initiatives and other measures related to stopping the spread of COVID-19 could also adversely affect the Company's research and development activities, including its clinical trials.
The Company has also taken measures to ensure the safety of its employees and to comply with governmental orders. These measures could require that the Company's employees refrain from traveling to their normal workplace for extended periods of time, which in turn could result in a decrease in its commercial and marketing activities.
During the second quarter of fiscal 2020, the FDA granted Emergency Use Authorization (EUA) for the Company's Panther Fusion SARS-CoV-2 assay for testing for the COVID-19 virus. The Company is in the process of completing development of a second SARS-CoV-2 assay which will run on its more widely distributed Panther instrument. The Company has installed more than 1,800 Panther instruments, which are used by clinical laboratories around the world. Subject to obtaining the required authorizations, the Company expects to introduce the assay in May. However, the Company can give no assurance that this assay will be developed and authorized on a timely basis, if at all, or if introduced, will be commercially successful.
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), referred to as ASC 842. The purpose of ASU 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840.
Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component.
Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not

11


expect to have a significant amount of sales-type leases. Under ASC 840, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract.
Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $96.6 million and $21.0 million, respectively. This includes recording the Company’s existing capital lease as a finance lease at transition. In addition, the Company derecognized $32.6 million of property, plant and equipment and $35.2 million of finance lease obligations recorded in accrued expenses and other long-term liabilities associated with two previously existing build-to-suit lease arrangements. Right-of-use assets and corresponding liabilities for these build-to-suit lease arrangements are included within the total amount recognized upon adoption of the new lease standard. The Company’s adoption of ASC 842 is more fully described in Note 3.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The guidance requires certain changes to the presentation of hedge accounting in the financial statements and also simplifies the application of hedge accounting and expands the strategies that qualify for hedge accounting. The Company adopted the standard in the first quarter of fiscal 2020. The adoption of ASU 2017-12 did not have a material effect on the Company's consolidated financial statements.
Subsequent Events Consideration
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events affecting the unaudited consolidated financial statements as of and for the three and six months ended March 28, 2020.

12


(2) Revenue

The Company accounts for revenue pursuant to ASC Update No. 2014-09, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays, surgical and interventional breast disposable products and until December 28, 2019 medical aesthetic treatment systems, and related services, which were primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:

 
 
Three Months Ended March 28, 2020
 
Three Months Ended March 30, 2019
Business (in millions)
United States
International
Total
 
United States
International
Total
Diagnostics:
 
 
 
 
 
 
 
 
Cytology & Perinatal
$
73.2

$
40.2

$
113.4

 
$
76.6

$
38.9

$
115.5

 
Molecular Diagnostics
149.8

40.8

190.6

 
136.8

31.0

167.8

 
Blood Screening
15.2


15.2

 
13.4


13.4

Total
$
238.2

$
81.0

$
319.2

 
$
226.8

$
69.9

$
296.7

 
 
 
 
 
 
 
 
 
Breast Health:
 
 
 
 
 
 
 
 
Breast Imaging
$
186.0

$
64.2

$
250.2

 
$
206.2

$
59.7

$
265.9

 
Interventional Breast Solutions
48.4

9.2

57.6

 
46.8

8.8

55.6

Total
$
234.4

$
73.4

$
307.8

 
$
253.0

$
68.5

$
321.5

 
 
 
 
 
 
 
 
 
GYN Surgical
$
86.7

$
18.7

$
105.4

 
$
84.1

$
18.1

$
102.2

 
 
 
 
 
 
 
 
 
Medical Aesthetics
$

$

$

 
$
37.6

$
36.2

$
73.8

 
 
 
 
 
 
 
 
Skeletal Health
$
15.6

$
8.1

$
23.7

 
$
14.0

$
10.2

$
24.2

 
 
$
574.9

$
181.2

$
756.1

 
$
615.5

$
202.9

$
818.4



13


 
 
Six Months Ended March 28, 2020
 
Six Months Ended March 30, 2019
Business (in millions)
United States
International
Total
 
United States
International
Total
Diagnostics:
 
 
 
 
 
 
 
 
Cytology & Perinatal
$
150.7

$
83.7

$
234.4

 
$
155.8

$
77.8

$
233.6

 
Molecular Diagnostics
291.9

77.2

369.1

 
270.9

61.2

332.1

 
Blood Screening
27.2


27.2

 
27.6


27.6

Total
$
469.8

$
160.9

$
630.7

 
$
454.3

$
139.0

$
593.3

 
 
 
 
 
 
 
 
 
Breast Health:
 
 
 
 
 
 
 
 
Breast Imaging
$
395.4

$
129.6

$
525.0

 
$
412.7

$
122.9

$
535.6

 
Interventional Breast Solutions
95.5

18.4

113.9

 
92.9

17.7

110.6

Total
$
490.9

$
148.0

$
638.9

 
$
505.6

$
140.6

$
646.2

 
 
 
 
 
 
 
 
 
GYN Surgical
$
185.5

$
39.0

$
224.5

 
$
175.2

$
35.4

$
210.6

 
 
 
 
 
 
 
 
 
Medical Aesthetics
$
30.9

$
34.4

$
65.3

 
$
74.9

$
78.7

$
153.6

 
 
 
 
 
 
 
 
Skeletal Health
$
30.5

$
16.7

$
47.2

 
$
27.2

$
18.2

$
45.4

 
 
$
1,207.6

$
399.0

$
1,606.6

 
$
1,237.2

$
411.9

$
1,649.1


 
 
Three Months Ended
 
Six Months Ended
Geographic Regions (in millions)
 
March 28, 2020
March 30, 2019
 
March 28, 2020
March 30, 2019
United States
 
$
574.9

$
615.5

 
$
1,207.6

$
1,237.2

Europe
 
111.8

102.1

 
221.2

203.2

Asia-Pacific
 
41.7

64.3

 
111.8

134.0

Rest of World
 
27.7

36.5

 
66.0

74.7

 
 
$
756.1

$
818.4

 
$
1,606.6

$
1,649.1


The following table provides revenue recognized by source:

 
 
Three Months Ended
 
Six Months Ended
Revenue by type (in millions)
 
March 28, 2020
March 30, 2019
 
March 28, 2020
March 30, 2019
Capital equipment, components and software
 
$
166.6

$
239.4

 
$
399.5

$
487.8

Consumables
 
457.0

428.4

 
923.4

863.1

Service
 
127.2

141.1

 
272.2

283.0

Other
 
5.3

9.5

 
11.5

15.2

 
 
$
756.1

$
818.4

 
$
1,606.6

$
1,649.1



The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the

14


point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services.

The Company recognizes a receivable when it has an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized.

The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement.

Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of stand-alone selling price using average selling prices over 3 to 12 month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts.

Variable Consideration

The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts.
    
The Company's contracts typically do not provide the right to return product. In general, estimates of variable consideration and constraints are not material to the Company's financial statements.

Remaining Performance Obligations

As of March 28, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $583.5 million. This remaining performance obligation primarily relates to extended warranty and support and maintenance obligations in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 23% of this amount as revenue in 2020, 32% in 2021, 24% in 2022, 14% in 2023, and 7% thereafter. The Company has applied the practical expedient to not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Contract Assets and Liabilities

The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and Skeletal Health reportable segments and until recently the divested Medical Aesthetics segment. Contract liabilities are classified as other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The Company recognized revenue of $26.2 million

15


and $77.5 million in the three and six months ended March 28, 2020 that was included in the contract liability balance at September 28, 2019.

(3) Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of March 28, 2020 was 2.59%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
March 28, 2020
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
82.6

$

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.1

$

Finance lease liabilities (current)
 
Finance lease obligations - short term
$

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
68.7

$

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$

$
18.4



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:


16


 
 
Three Months Ended March 28, 2020
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
5.93

8.14

Weighted average discount rate
 
1.95
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended March 28, 2020
Six Months Ended March 28, 2020
Operating lease cost (a)
$
6.8

$
13.8

Finance lease cost - amortization of right-of-use assets
$

$
0.3

Finance lease cost - interest cost
$
0.3

$
0.5

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from finance leases
$
0.3

$
0.5

 
Operating cash flows from operating leases
$
5.7

$
11.7

 
Financing cash flows from finance leases
$
0.4

$
0.9

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.4

$
13.1

 
 
 
 
ROU assets arising from entering into new operating lease obligations
$
3.3

$
4.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for both the three and six months ended March 28, 2020.


17


In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.

(4) Fair Value Measurements
Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
The Company has investments in derivative instruments consisting of interest rate caps, interest rate swaps and foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 8 for further discussion and information on derivative instruments.
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 28, 2020: 
 
 
 
Fair Value at Reporting Date Using
 
Balance as of March 28, 2020
 
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Foreign currency option contracts
0.9

 

 
0.9

 

Forward foreign currency contracts
1.9

 

 
1.9

 

Total
$
2.8

 
$

 
$
2.8

 
$

Liabilities:
 
 
 
 
 
 
 
Contingent consideration
$
0.9

 
$

 
$

 
$
0.9

Interest rate swaps - derivative
$
22.9

 
$

 
$
22.9

 
$

Total
$
23.8

 
$

 
$
22.9

 
$
0.9


Assets Measured and Recorded at Fair Value on a Recurring Basis
The Company had contingent consideration liabilities related to its Emsor S.A. and Faxitron Bioptics, LLC acquisitions. The remeasurement of these liabilities in the second quarter of fiscal 2020 was insignificant, and the Company settled these obligations for $9.8 million.
Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. There were no such remeasurements for equity investments in the three and six months ended March 28, 2020 and March 30, 2019. During the first quarter of fiscal 2020, the Company's Medical Aesthetics division met the criteria to be classified as assets-held-for sale and the Company recorded a $30.2 million loss to record the asset group at its fair value less costs to sell. This is a level 1 measurement. See Note 6 for additional information. During the second quarter of fiscal 2019, the Company identified indicators of impairment related to its long-lived assets of its Medical Aesthetics reportable segment and recorded impairment charges of $443.8 million, of which $437.0 million was allocated to intangible assets and $6.8 million was allocated to equipment. This was a level 3 measurement. See Note 15.
Disclosure of Fair Value of Financial Instruments
The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, interest rate caps, interest rate swaps, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts are recorded at

18


fair value. The carrying amount of the insurance contracts is recorded at the cash surrender value, as required by GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value.
Amounts outstanding under the Company’s 2018 Credit Agreement (as defined below) of $2.2 billion aggregate principal as of March 28, 2020 are subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2025 Senior Notes and 2028 Senior Notes had fair values of $947.6 million and $402.1 million, respectively, as of March 28, 2020 based on their trading prices, representing Level 1 measurements. Refer to Note 7 for the carrying amounts of the various components of the Company’s debt.

(5) Business Combinations

Focal Therapeutics

On October 1, 2018, the Company completed the acquisition of Focal Therapeutics, Inc. ("Focal") for a purchase price of $120.1 million, which included hold-backs of $14.0 million payable up to one year from the date of acquisition. In the second quarter of fiscal 2019, $1.5 million of the hold-back was paid, and the remaining $12.5 million was paid on October 1, 2019. Focal, headquartered in California, manufactures and markets its BioZorb marker, which is an implantable three-dimensional marker that helps clinicians overcome certain challenges in breast conserving surgery.

The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below:

Cash
$
2.2

Accounts receivable
2.0

Inventory
7.9

Other assets
0.5

Accounts payable and accrued expenses
(5.6
)
Long-term debt
(2.5
)
Identifiable intangible assets:
 
       Developed technology
83.1

       In-process research and development
11.4

       Trade names
2.7

Deferred income taxes, net
(12.7
)
Goodwill
31.1

Purchase Price
$
120.1



In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Focal's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, in-process research and development ("IPR&D"), and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15.5% to 16.5%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names was 11 years and 13 years, respectively. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the amount of goodwill were based on synergistic benefits that are expected to be realized from this acquisition. Benefits include the expectation of broadening the Company's Breast Health portfolio of products and technology. None of the goodwill is expected to be deductible for income tax purposes.

SuperSonic Imagine

On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine ("SSI") for $18.2 million. SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares

19


for a price of 1.50 per share in cash. The Company determined that SSI was a Variable Interest Entity (“VIE”) but it was not the primary beneficiary as it was not a party to the initial design of the entity nor did it have control over SSI's operations until November 21, 2019 when the Company's ownership of SSI's voting stock exceeded 50%. Accordingly, the Company initially accounted for this investment under the equity method of accounting and included its proportionate share of SSI's net loss of $3.3 million for the two months ended September 28, 2019 within Other (expense) income, net.

On November 21, 2019, the Company acquired an additional 7.6 million shares of SSI for $12.6 million. As a result, the Company owned approximately 78% of the outstanding shares of SSI at November 21, 2019 and controlled SSI's voting interest and operations. The Company performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within the Company's consolidated financial statements. The Company remeasured the initial investment of 46% of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of $3.2 million recorded in the first quarter of fiscal 2020. The total accounting purchase price was $69.3 million, which consisted of $17.9 million for the equity method investment in SSI, $12.6 million for shares acquired on November 21, 2019, $30.2 million for loans the Company provided to SSI prior to the acquisition that are considered forgiven, and $8.6 million representing the fair value of the noncontrolling interest as of November 21, 2019. As of March 28, 2020, the Company owned approximately 81% of the outstanding shares of SSI.

The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows:

Cash
$
2.6

Accounts receivable
7.1

Inventory
10.0

Property, plant and equipment
6.5

Other assets
4.4

Accounts payable and accrued expenses
(13.0
)
Deferred revenue
(1.8
)
Short and long-term debt
(8.8
)
Other liabilities
(3.8
)
Identifiable intangible assets:

       Developed technology
38.3

       Customer relationships
4.0

       Trade names
3.0

Deferred income taxes, net
(1.5
)
Goodwill
22.4

Purchase Price
$
69.4



In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of SSI's business. The Company has not yet obtained all of the information related to the fair value of the acquired assets and liabilities, primarily taxes, to finalize the purchase price allocation. 

As part of the preliminary purchase price allocation, the Company has determined the identifiable intangible assets are developed technology, customer relationships, and trade names. The preliminary fair value of the intangible assets has been estimated using the income approach, and the cash flow projections were discounted using a 12.0% rate. The cash flows are based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life for the developed technology is 9 years, customer relationships is 9 years and for trade names it is 8.6 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the preliminary amount of goodwill are based on synergistic benefits of SSI's products being complementary to Breast Health's 3D mammography systems and using the Company's existing U.S. sales force as SSI's presence in the U.S. is limited. None of the goodwill is expected to be deductible for income tax purposes.


20


Alpha Imaging

On December 30, 2019, the Company completed the acquisition of assets from Alpha Imaging, LLC ("Alpha Imaging"), for a purchase price of $18.0 million, which included a hold-back of $1.0 million and contingent consideration which the Company has estimated at $0.9 million. The contingent consideration is payable upon shipment of backlog orders entered into by Alpha Imaging prior to the acquisition. Alpha Imaging was a long-standing distributor of the Company's Breast and Skeletal products in the U.S. Based on the Company's preliminary valuation, it has allocated $18.1 million of the purchase price to a customer relationships intangible asset, which has a useful life of 5 years. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities.

Health Beacons

On February 3, 2020, the Company completed the acquisition of Health Beacons, Inc. ("Health Beacons"), for a purchase price of $19.3 million, which included hold-backs of $2.3 million that are payable up to eighteen months from the date of acquisition. Health Beacons manufactures the LOCalizer product that is sold by Faxitron Bioptics, LLC ("Faxitron"), which the Company acquired in July 2018. Based on the Company's preliminary valuation, it has allocated $10.7 million of the purchase price to the preliminary value of intangible assets and $5.7 million to goodwill. The remaining $2.9 million of the purchase price has been allocated to acquired tangible assets and liabilities. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities.

21



(6) Disposition
Sale of Medical Aesthetics

On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of $153.4 million. The sale price remains subject to adjustment pursuant to the terms of the definitive agreement. The Company agreed to provide certain transition services for three to fifteen months, depending on the nature of the service. The Company also agreed to indemnify CD&R for certain legal and tax matters that existed as of the date of disposition. In connection with its accounting for the sale, the Company recorded indemnification liabilities of $10.9 million within accrued expenses associated with its obligations under the sale agreement.

As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, asset groups under this designation are required to be recorded at fair value less costs to sell. The Company determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or will have a major effect on the Company's operations and financial results. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services and the amount that must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&R, the Company recorded an impairment charge of $30.2 million in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which $25.8 million was allocated to cost of product revenues and $4.4 million to operating expenses. The Company is currently in the process of evaluating adjustments to the final sales price.

The assets and liabilities of the disposed business at the date of disposition were as follows:

Assets:
 
 
Cash
 
$
10.7

Accounts Receivable
 
59.6

Inventory
 
90.6

Prepaid expenses and other current assets
 
7.7

Property, plant, and equipment
 
4.0

Intangible assets
 
28.2

Other assets
 
9.8

Total assets disposed of
 
$
210.6

 
 
 
Liabilities:
 
 
Accounts payable
 
$
12.3

Accrued expenses
 
49.0

Deferred revenue
 
16.6

Total liabilities disposed of
 
$
77.9



Loss from operations of the disposed business presented below represents the operating loss of the business as it was operated prior to the date of disposition. The operating expenses include only those that were incurred directly by and were retained by the disposed business. As noted above, the Company is performing a number of transition services and the financial impact from these services are not included in the amounts presented below. In addition, the Company will continue to incur expenses related to this business under the indemnification provisions primarily related to legal and tax matters that existed as of the date of disposition, which it will continued to report in the Medical Aesthetic reportable segment. In the second quarter of fiscal 2020, the Company recorded accelerated stock compensation in connection with the disposition, legal expenses for retained cases and other adjustments totaling $2.4 million, which is not included below. Loss from operations of the disposed business for the three and six month periods ended March 28, 2020 and March 30, 2019 was as follows:


22


 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
March 30, 2019
 
 
 
 
 
 
 
Loss from operations
$

 
(468.3
)
 
$
(46.5
)
$
(488.7
)


(7) Borrowings and Credit Arrangements
The Company’s borrowings consisted of the following: 
 
March 28,
2020
 
September 28,
2019
Current debt obligations, net of debt discount and deferred issuance costs:
 
 
 
Term Loan
$
56.1

 
$
37.4

Revolver
750.0

 

Securitization Program

 
234.0

Total current debt obligations
$
806.1

 
$
271.4

Long-term debt obligations, net of debt discount and deferred issuance costs:
 
 
 
Term Loan
1,416.2

 
1,452.4

Debt assumed from SSI acquisition
0.6

 

2025 Senior Notes
938.3

 
937.3

2028 Senior Notes
394.2

 
393.9

Total long-term debt obligations
$
2,749.3

 
$
2,783.6

Total debt obligations
$
3,555.4

 
$
3,055.0


2018 Amended and Restated Credit Agreement
On December 17, 2018, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement dated as of October 3, 2017 (the "2017 Credit Agreement"). The borrowings of the 2018 Amended Term Loan bear interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate, which was equal to 1.375% as of March 28, 2020. The borrowings of the 2018 Amended Revolver bear interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate equal to 1.375%.

Pursuant to ASC 470, Debt (ASC 470), the accounting related to entering into the 2018 Credit Agreement and using the proceeds to pay off the 2017 Credit Agreement was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2017 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $0.8 million in the first quarter of fiscal 2019. For the remainder of the creditors, this transaction was accounted for as a modification because on a creditor-by-creditor basis the present value of the cash flows between the two debt instruments before and after the transaction was less than 10%. Pursuant to ASC 470, subtopic 50-40, third-party costs of $0.8 million related to this transaction were recorded as interest expense and $1.9 million was recorded as a reduction to debt representing deferred issuance costs and debt discount for fees paid directly to the lenders.

In response to the current market uncertainties created by the COVID-19 pandemic, in March 2020, the Company borrowed $750 million under its revolver, which it intends to repay within one year, $250 million of which was used to pay off amounts outstanding under the asset securitization agreement, in order to have sufficient cash on hand. The Company has another $750 million available under its revolver as of March 28, 2020.

Interest expense, weighted average interest rate, and interest rate at the end of period under the Credit Agreements were as follows: 


23


 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
Interest expense
$
13.0

 
$
16.8

 
$
26.6

 
$
35.5

Weighted average interest rate
2.75
%
 
3.86
%
 
2.93
%
 
3.84
%
Interest rate at end of period
2.33
%
 
3.87
%
 
2.33
%
 
3.87
%

The 2018 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2018 Credit Agreement. As of March 28, 2020, the Company was in compliance with these covenants.

Senior Notes

On October 10, 2017, the Company completed a private placement of $350 million aggregate principal amount of its 4.375% Senior Notes due 2025 (the "2025 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2025 Senior Notes.

On January 19, 2018, the Company completed a private placement of $1.0 billion aggregate principal amount of senior notes, allocated between (i) an additional $600 million aggregate principal amounts of its 2025 Senior Notes pursuant to a supplement to the indenture governing the Company's existing 2025 Senior Notes at an offering price of 100% of the aggregate principal amount of the 2025 Senior Notes and (ii) $400 million aggregate principal amounts of its 4.625% Senior Notes due 2028 (the "2028 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2028 Senior Notes.

2025 Senior Notes

The total aggregate principal balance of 2025 Senior Notes is $950 million. The 2025 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on October 15, 2025.

2028 Senior Notes
    
The aggregate principal balance of the 2028 Senior Notes is $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on February 1, 2028.
Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows:
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
 
Interest Rate
 
Interest Expense
 
Interest Expense
 
Interest Expense
 
Interest Expense
2028 Senior Notes
4.625
%
 
$
4.8

 
$
4.8

 
$
9.6

 
$
9.6

2025 Senior Notes
4.375
%
 
10.9

 
10.9

 
21.8

 
21.8

Total
 
 
$
15.7

 
$
15.7

 
$
31.4

 
$
31.4


Accounts Receivable Securitization Program

On March 26, 2020, the Company paid-off the total amount outstanding of $250.0 million previously borrowed under the Accounts Receivable Securitization Program (the "Securitization Program"). As of March 28, 2020, the Company did not have any borrowings under this program. On April 13, 2020, the Company amended the Credit and Security agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year.


24


(8) Derivatives
Interest Rate Cap - Cash Flow Hedge
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Operations.
During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable interest rate on amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was $3.7 million, which was the initial fair value of the instruments recorded in the Company's financial statements.
During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was $1.5 million, which was the initial fair value of the instruments recorded in the Company’s financial statements.    
The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under its Credit Agreement, that has been amended multiple times, and therefore are highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal, which ended on December 27, 2019 for the contracts entered into in fiscal 2018, and which will end on December 23, 2020 for the interest rate cap agreements entered into in fiscal 2019.
As of March 28, 2020, all changes in the fair value of the interest rate caps were recorded in the Consolidated Statements of Comprehensive Income (Loss).
During the three and six months ended March 28, 2020 and March 30, 2019, the Company reclassified $0.4 million and $1.7 million, respectively and $0.5 million and $1.2 million, respectively from AOCI to the Consolidated Statements of Operations related to the interest rate cap agreements. The Company expects to similarly reclassify a loss of approximately $1.1 million from AOCI to the Consolidated Statements of Operations in the next nine months.
The aggregate fair value of these interest rate caps was $0.0 million and $0.1 million at March 28, 2020 and September 28, 2019, respectively, and is included in prepaid expenses and other current assets on the Company’s Consolidated Balance Sheet. Refer to Note 4 “Fair Value Measurements” above for related fair value disclosures.
Interest Rate Swap - Cash Flow Hedge
In fiscal 2019, in order to hedge a portion of its variable rate debt beyond the contracted period under interest cap agreements, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The notional amount of this swap is $1.0 billion. The interest rate swap effectively fixes the LIBOR component of the variable interest rate on $1.0 billion of the notional amount under the 2018 Credit Agreement at 1.23%. The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the LIBOR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of this derivative was in a liability position of $22.9 million as of March 28, 2020.
Forward Foreign Currency Contracts and Foreign Currency Option Contracts
The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these forward foreign currency contracts and foreign currency option contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the three and six months ended March 28, 2020, for the forward foreign currency exchange contracts the

25


Company recorded net realized gains of $0.1 million in both periods from settling forward foreign currency exchange contracts and net unrealized gains of $2.6 million and $1.1 million, respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the three and six months ended March 30, 2019, the Company recorded net realized gains of $1.8 million and $3.5 million, respectively, from settling forward foreign currency contracts and net unrealized loss of $1.4 million and net realized gain of $2.0 million, respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the three and six months ended March 28, 2020, for the foreign currency option contracts the Company recorded net unrealized gains of $1.1 million and net unrealized losses of $0.4 million, respectively, on outstanding option contracts. During the three and six months ended March 28, 2020, for the foreign currency option contracts, the Company recorded net realized losses of $0.5 million and $0.7 million, respectively, on outstanding option contracts.
As of March 28, 2020, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Australian dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $51.0 million. As of March 28, 2020, the Company had outstanding foreign currency option contracts that were not designated for hedge accounting and are used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro and UK Pound with a notional amount of $80.6 million.
Financial Instrument Presentation
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 28, 2020:
 
Balance Sheet Location
 
March 28, 2020
 
September 28, 2019
Assets:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate cap agreements
Prepaid expenses and other current assets
 
$

 
$
0.1

Interest rate swap contract
Other assets
 

 
4.7

 
 
 
$

 
$
4.8

 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Prepaid expenses and other current assets
 
$
1.9

 
$
0.9

Foreign currency option contracts
Prepaid expenses and other current assets
 
0.9

 
2.0

 
 
 
$
2.8

 
$
2.9

 
 
 
 
 
 
Liabilities:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate swap contract
Accrued expenses
 
$
2.4

 
$

Interest rate swap contract
Other long-term liabilities
 
20.5

 

Total
 
 
$
22.9

 
$

Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Accrued expenses
 
$

 
$
0.1


The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods:

26


 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
Amount of loss recognized in other comprehensive income, net of taxes:
 
 
 
 
 
 
 
Interest rate swap
$
(25.2
)
 
$

 
$
(20.8
)
 
$

Interest rate cap agreements
(0.1
)
 
(1.5
)
 
(0.4
)
 
(5.4
)
Total
$
(25.3
)
 
$
(1.5
)
 
$
(21.2
)
 
$
(5.4
)

The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:
Derivatives not classified as hedging instruments
Amount of (Loss) Gain Recognized in Income
 
Three Months Ended March 28, 2020
 
Three Months Ended March 30, 2019
 
Six Months Ended March 28, 2020
 
Six Months Ended March 30, 2019
Forward foreign currency contracts
$
2.7

 
$
0.4

 
$
1.3

 
$
5.5

Foreign currency option contracts
0.6

 

 
(1.1
)
 

Total
$
3.3

 
$
0.4

 
$
0.2

 
$
5.5



(9) Commitments and Contingencies
Litigation and Related Matters
    
On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses or any reliance on collateral findings regarding invalidity from inter partes review proceedings. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition. On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company $4.8 million in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages continued to accrue as Minerva continues its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions. On March 4, 2016, Minerva filed two petitions at the USPTO for inter partes review of the '348 patent. On September 12, 2016, the PTAB declined both petitions to review patentability of the '348 patent. On April 11, 2016, Minerva filed a petition for inter partes review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018 the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 22, 2020, the Court of Appeals affirmed the district court’s summary judgment ruling in favor of the Company of no invalidity and infringement, and summary judgment that assignor estoppel bars Minerva from challenging the validity of the ‘348 patent. The Court of Appeals also denied the Company’s motion for a permanent injunction and ongoing royalties for infringement of the ‘183 patent. The Court of Appeals denied Minerva’s motion for no damages or, alternatively, a new trial.
    

27


On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208. Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. The original trial date of July 20, 2020 was vacated and the parties are now waiting for a new trial date to be set by the court. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
    
On February 3, 2017, bioMérieux, S.A. and bioMérieux, Inc. (collectively “bioMérieux”) filed suit against the Company in the United States District Court for the Middle District of North Carolina ("MDNC"), alleging that the Company’s HIV products, including blood screening products previously manufactured by the Company for its former blood screening partner Grifols Diagnostic Solutions Inc. ("Grifols USA"), infringe U.S. Patent Nos. 8,697,352 and 9,074,262. On January 3, 2018, the MDNC Court granted the parties’ consent motion to transfer the case to Delaware. On June 11, 2019, the Court issued a claim construction ruling regarding the disputed terms in the patents. Motions for summary judgment were filed by the parties on September 30, 2019, and a hearing on these motions was held on December 18, 2019. A six-day trial concluded on February 25, 2020, with the jury finding that all claims of U.S. Patent No. 8,697,352 are invalid (U.S. Patent No. 9,074,262 was dropped from the case by bioMérieux prior to trial). On March 18, 2020, the parties agreed to a settlement under which bioMérieux agreed to dismiss all claims with prejudice and to waive the filing of post-trial motions and pursuing an appeal in exchange for a de minimis payment from the Company and Grifols USA.

As described in Note 6, the Company has agreed to indemnify CD&R for certain legal matters related to the Medical Aesthetics business that existed at the date of disposition. The Company currently has $8.5 million accrued for such matters as of March 28, 2020, but this amount could become greater if some or all of the cases which it is indemnifying have an adverse result.
    
The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.

(10) Net Income Per Share
A reconciliation of basic and diluted share amounts is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Basic weighted average common shares outstanding
263,238

 
269,235

 
265,566

 
269,913

Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units
1,268

 

 
1,548

 

Diluted weighted average common shares outstanding
264,506

 
269,235

 
267,114

 
269,913

Weighted-average anti-dilutive shares related to:
 
 
 
 
 
 
 
Outstanding stock options
1,677

 
4,031

 
1,483

 
4,578

Stock Units
10

 

 
6

 


In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock options’ combined exercise price and average unrecognized stock compensation expense upon exercise is greater than the average stock price. In those reporting periods in which the Company has a net loss, anti-dilutive shares are comprised of the impact of those number of shares that would have been dilutive had the Company had net income plus the number of common stock equivalents that would be anti-dilutive had the company had net income.


28


(11) Stock-Based Compensation
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Cost of revenues
$
1.7

 
$
2.0

 
$
3.8

 
$
4.0

Research and development
2.3

 
2.7

 
4.6

 
5.4

Selling and marketing
2.8

 
2.7

 
5.6

 
5.4

General and administrative
6.5

 
10.1

 
17.4

 
19.8

Restructuring
2.4

 

 
2.4

 

 
$
15.7

 
$
17.5

 
$
33.8

 
$
34.6


The Company granted options to purchase 0.9 million and 0.9 million shares of the Company's common stock during the six months ended March 28, 2020 and March 30, 2019, respectively, with weighted-average exercise prices of $45.82 and $41.25, respectively. There were 5.3 million options outstanding at March 28, 2020 with a weighted-average exercise price of $38.74.
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Risk-free interest rate
1.7
%
 
3.0
%
 
1.7
%
 
3.0
%
Expected volatility
33.6
%
 
34.3
%
 
33.6
%
 
34.3
%
Expected life (in years)
4.8

 
4.8

 
4.8

 
4.8

Dividend yield

 

 

 

Weighted average fair value of options granted
$
14.45

 
$
15.33

 
$
13.87

 
$
13.50


The Company granted 0.8 million and 0.9 million restricted stock units (RSUs) during the six months ended March 28, 2020 and March 30, 2019, respectively, with weighted-average grant date fair values of $45.76 and $41.11 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (PSUs) during the six months ended March 28, 2020 and March 30, 2019, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $45.76 and $40.97 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million of PSUs based on a one-year free cash flow measure (FCF) to its senior management team, which had a grant date fair value of $45.76. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the one-year measurement period, but the FCF PSUs vest at the end of the three year service period. The Company is recognizing compensation expense for PSUs and FCF PSUs ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company cumulatively adjusts compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (MSUs) to its senior management team during the six months ended March 28, 2020 and March 30, 2019, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $43.90 and $55.13 per share using the Monte Carlo simulation model. The Company is recognizing compensation expense for the MSUs ratably over the service period. At March 28, 2020, there was 2.5 million in aggregate RSUs, PSUs, FCF PSUs and MSUs outstanding.
At March 28, 2020, there was $26.7 million and $70.6 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.6 and 2.0 years, respectively.

29



(12) Other Balance Sheet Information

 
March 28,
2020
 
September 28,
2019
Inventories
 
 
 
Raw materials
$
155.1

 
$
166.1

Work-in-process
56.4

 
54.5

Finished goods
189.8

 
224.3

 
$
401.3

 
$
444.9


Property, plant and equipment
 
 
 
Equipment
$
407.6

 
$
379.2

Equipment under customer usage agreements
452.8

 
435.5

Building and improvements
162.9

 
196.7

Leasehold improvements
42.8

 
61.7

Land
40.6

 
46.3

Furniture and fixtures
15.6

 
17.5

 
1,122.3

 
1,136.9

Less – accumulated depreciation and amortization
(677.0
)
 
(666.0
)
 
$
445.3

 
$
470.9



(13) Business Segments and Geographic Information
During the first fiscal quarter of 2020 and during fiscal 2019, the Company had five reportable segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. The Company completed the sale of its Medical Aesthetics business on December 30, 2019, but will continue to have operating expenses related to indemnifying CD&R for legal and tax matters that existed as of the date of disposition. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.

30


Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 28, 2020 and March 30, 2019. Segment information is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Total revenues:
 
 
 
 
 
 
 
Diagnostics
$
319.2

 
$
296.7

 
$
630.7

 
$
593.3

Breast Health
307.8

 
321.5

 
638.9

 
646.2

GYN Surgical
105.4

 
102.2

 
224.5

 
210.6

Medical Aesthetics

 
73.8

 
65.3

 
153.6

Skeletal Health
23.7

 
24.2

 
47.2

 
45.4

 
$
756.1


$
818.4


$
1,606.6


$
1,649.1

Income (loss) from operations:
 
 
 
 
 
 
 
Diagnostics
$
57.3

 
$
31.1

 
$
106.8

 
$
74.4

Breast Health
75.9

 
99.0

 
169.8

 
196.8

GYN Surgical
23.9

 
20.5

 
55.4

 
47.6

Medical Aesthetics
(2.4
)
 
(473.9
)
 
(53.4
)
 
(499.1
)
Skeletal Health
1.7

 
0.1

 
2.6

 
(2.4
)
 
$
156.4


$
(323.2
)
 
$
281.2

 
$
(182.7
)
Depreciation and amortization:
 
 
 
 
 
 
 
Diagnostics
$
59.3

 
$
61.6

 
$
118.4

 
$
123.4

Breast Health
13.1

 
8.9

 
23.1

 
18.2

GYN Surgical
21.1

 
21.9

 
42.1

 
43.9

Medical Aesthetics

 
25.1

 
4.1

 
50.6

Skeletal Health
0.2

 
0.1

 
0.4

 
0.3

 
$
93.7


$
117.6


$
188.1


$
236.4

Capital expenditures:
 
 
 
 
 
 
 
Diagnostics
$
17.1

 
$
16.0

 
$
35.3

 
$
30.4

Breast Health
8.1

 
4.7

 
14.5

 
6.8

GYN Surgical
5.3

 
3.1

 
10.6

 
6.6

Medical Aesthetics

 
3.4

 
1.4

 
4.5

Skeletal Health
0.1

 
0.3

 
0.2

 
0.6

Corporate
1.1

 
1.8

 
1.1

 
3.0

 
$
31.7


$
29.3


$
63.1


$
51.9

 
 
March 28,
2020
 
September 28,
2019
Identifiable assets:
 
 
 
Diagnostics
$
2,193.8

 
$
2,276.6

Breast Health
1,243.9

 
1,127.8

GYN Surgical
1,284.4

 
1,328.6

Medical Aesthetics

 
159.3

Skeletal Health
30.2

 
27.3

Corporate
2,069.5

 
1,522.5

 
$
6,821.8

 
$
6,442.1


31


The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 28, 2020 and March 30, 2019.
The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
United States
76.0
%
 
75.1
%
 
75.1
%
 
75.0
%
Europe
14.8
%
 
12.5
%
 
13.8
%
 
12.3
%
Asia-Pacific
5.5
%
 
7.9
%
 
7.0
%
 
8.1
%
Rest of World
3.7
%
 
4.5
%
 
4.1
%
 
4.6
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%


(14) Income Taxes

In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.

The Company’s effective tax rate for the three and six months ended March 28, 2020 was a provision of 20.3% and a benefit of 122.1%, respectively, compared to a benefit of 22.9% and 30.2%, respectively, for the corresponding periods in the prior year. The effective tax rate for the three months ended March 28, 2020 differed from the statutory tax rate primarily due to taxation of foreign earnings at a tax rate lower than the statutory tax rate including the impact to global intangible low tax income and foreign derived intangible income, partially offset by unbenefited foreign losses. The effective tax rate for the six months ended March 28, 2020 differed from the statutory tax rate primarily due to a $310.9 million discrete net tax benefit related to the loss on the sale of the Medical Aesthetics business.

For the three months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, and earnings in jurisdictions subject to lower tax rates. For the six months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, earnings in jurisdictions subject to lower tax rates, a discrete benefit related to an internal restructuring, and finalizing the impact of the enactment of the Tax Cuts and Jobs Act in the first quarter of fiscal 2019.

During the six months ended March 28, 2020, the Company's gross unrecognized tax benefits excluding interest increased from $101.6 million to $212.7 million primarily as a result of uncertain tax positions related to the divestiture of the Medical Aesthetics business, and to a lesser extent intercompany transfer pricing related to ordinary business operations.

Other Tax Accounting Pronouncements

On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. Under ASU 2016-16, the selling (transferring) entity is required to recognize a current tax expense or benefit upon transfer of the asset. Similarly, the purchasing (receiving) entity is required to recognize a deferred tax asset or deferred tax liability, as well as the related deferred tax benefit or expense, upon receipt of the asset.

This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis through a cumulative-

32


effect adjustment to decrease the opening balance of accumulated deficit within stockholders' equity as of September 30, 2018, the first day of fiscal 2019. This change in accounting principle resulted in an increase in deferred tax assets of $2.9 million, a decrease in accumulated deficit of $2.5 million, and a decrease in prepaid taxes of $0.4 million as of the beginning of the Company’s fiscal year beginning September 30, 2018.

The Company was required to account for the internal restructuring discussed above under ASU 2016-16 and recorded a $29.5 million increase to income tax expense and income tax liabilities and a decrease of $48.7 million to deferred tax expense and net deferred tax liabilities for the six months ended March 30, 2019. The net result was an increase to net income of $19.2 million, or an earnings per share increase of $0.07.

Non-Income Tax Matters

The Company is subject to tax examinations for value added, sales-based, payroll, and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates pursuant to ASC 450. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.


(15) Intangible Assets
Intangible assets consisted of the following:
 
Description
As of March 28, 2020
 
As of September 28, 2019
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Acquired intangible assets:
 
 
 
 
 
 
 
Developed technology
$
3,925.6

 
$
2,779.6

 
$
3,927.7

 
$
2,654.8

Customer relationships
546.8

 
461.4

 
525.5

 
447.5

Trade names
244.0

 
176.1

 
245.4

 
171.1

Distribution agreement

 

 
2.5

 

Non-competition agreements
1.5

 
1.1

 
1.4

 
0.9

Business licenses
2.3

 
2.2

 
2.3

 
2.2

Total acquired intangible assets
$
4,720.2

 
$
3,420.4

 
$
4,704.8

 
$
3,276.5

 
 
 
 
 
 
 
 
Internal-use software
51.4

 
41.7

 
53.9

 
43.4

Capitalized software embedded in products
28.2

 
8.9

 
27.9

 
6.9

Total intangible assets
$
4,799.8


$
3,471.0


$
4,786.6


$
3,326.8


In the first quarter of fiscal 2020, the Company's Medical Aesthetics business met the criteria to be designated as assets held-for-sale. As a result, the Company recorded a $30.2 million charge to record the asset group at fair value less costs to sell. In addition, developed technology, customer lists, tradenames, and distribution agreement related to Medical Aesthetics of $24.1 million, $0.9 million, $2.0 million, and $1.2 million, respectively, were reclassified accordingly in the Company's Consolidated Balance Sheet to assets held-for-sale as of December 28, 2019 and subsequently disposed of in the second quarter of fiscal 2020.
In the second quarter of fiscal 2020, the Company reviewed its long-lived assets for indicators of impairment as a result of lowering its expectations for revenue and operating income in the short term from the impact of COVID-19 on its business as discussed in Note 1. The Company updated its long-term forecasts and performed an undiscounted cash flow analysis which indicated that the estimated future cash flows are sufficient to recover the carrying values of its asset groups. In addition, the Company had significant cushion from its most recent goodwill impairment test in each of its reporting units and believes, based on its procedures, current facts and expectations, that as of the date of this report it is it not more likely than not that the fair value of each of its reporting units is below their respective carrying values. Given the current uncertainty of the duration and scope of the COVID-19 pandemic, the related economic impact, and the potential longer term impact on the

33


Company's business, financial condition and results of operations, in the future the Company may be required to perform an interim impairment test, in addition to its annual test, and record an impairment charge.
Medical Aesthetics Impairment - Fiscal 2019

During the second quarter of fiscal 2019, in connection with commencing its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Medical Aesthetics reporting unit (comprised solely of the Cynosure business), the Company reduced its short term and long term revenue and operating income forecasts. The updated forecast reflected reduced volume and market penetration projections primarily in the Body Contouring business due to increased competition in the non-invasive fat reduction category, and lower Women's Health product sales primarily from reduced sales volume of the MonaLisa Touch device, which the Company believed was primarily driven by the FDA's public letter in the fourth quarter of fiscal 2018 challenging various medical aesthetics companies marketing of devices for so called "vaginal rejuvenation" procedures relative to their FDA approvals. As a result of the revised forecasts in the second quarter of fiscal 2019, the Company determined indicators of impairment existed and performed an undiscounted cash flow analysis pursuant to ASC 360, Property, Plant, and Equipment - Overall, to determine if the cash flows expected to be generated by this asset group over the estimated remaining useful life of the primary assets were sufficient to recover the carrying value of the asset group, which was determined to be at the reporting unit level. Based on this analysis, which included evaluating various cash flow scenarios, the undiscounted cash flows were not sufficient to recover the carrying value of the asset group. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculates the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company's most recent strategic plan and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used is intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 11.0%. As a result of this analysis, the fair value of the Medical Aesthetics asset group was below its carrying value, and the Company recorded an impairment charge of $443.8 million during the second quarter of fiscal 2019. The impairment charge was allocated to the long-lived assets as follows: $373.3 million to developed technology, $14.4 million to customer relationships, $31.5 million to trade names, $17.8 million to distribution agreements and $6.8 million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. The Company completed the sale of the Medical Aesthetics business in the second quarter of fiscal 2020. Please refer to Note 6 for additional details.
The estimated remaining amortization expense of the Company's acquired intangible assets as of March 28, 2020 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2020
$
145.1

Fiscal 2021
$
269.1

Fiscal 2022
$
258.7

Fiscal 2023
$
161.2

Fiscal 2024
$
150.4



(16) Product Warranties
Product warranty activity was as follows:
 
 
Balance at
Beginning of
Period
 
Provisions
 
Acquired
 
Divested
 
Settlements/
Adjustments
 
Balance at
End of Period
Six Months Ended:
 
 
 
 
 
 
 
 
 
 
 
March 28, 2020
$
13.9

 
$
5.5

 
$
0.5

 
$
(6.1
)
 
$
(6.2
)
 
$
7.6

March 30, 2019
$
15.9

 
$
5.4

 
$

 
$

 
$
(6.9
)
 
$
14.4



34



(17) Accumulated Other Comprehensive Loss

The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:

 
Three Months Ended March 28, 2020
 
Six Months Ended March 28, 2020
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Hedged Interest Rate Swaps
 
Total
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Hedged Interest Rate Swaps
Total
Beginning Balance
$
(33.1
)
 
$
(1.7
)
 
$
(1.4
)
 
$
7.5

 
$
(28.7
)
 
$
(41.4
)
 
$
(1.7
)
 
$
(2.7
)
 
$
3.5

$
(42.3
)
Other comprehensive income (loss) before reclassifications
(5.4
)
 

 
(0.1
)
 
(25.1
)
 
(30.6
)
 
2.9

 

 
(0.1
)
 
(21.1
)
(18.3
)
Amounts reclassified to statement of income

 

 
0.4

 

 
0.4

 

 

 
1.7

 

1.7

Ending Balance
$
(38.5
)
 
$
(1.7
)
 
$
(1.1
)
 
$
(17.6
)
 
$
(58.9
)
 
$
(38.5
)
 
$
(1.7
)
 
$
(1.1
)
 
$
(17.6
)
$
(58.9
)

 
Three Months Ended March 30, 2019
 
Six Months Ended March 30, 2019
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(29.8
)
 
$
(1.1
)
 
$
(1.0
)
 
$
(31.9
)
 
$
(26.6
)
 
$
(1.1
)
 
$
2.2

 
$
(25.5
)
Other comprehensive income (loss) before reclassifications
2.4

 

 
(1.5
)
 
0.9

 
(0.8
)
 

 
(5.4
)
 
(6.2
)
Amounts reclassified to statement of income

 

 
0.5

 
0.5

 

 

 
1.2

 
1.2

Ending Balance
$
(27.4
)
 
$
(1.1
)
 
$
(2.0
)
 
$
(30.5
)
 
$
(27.4
)
 
$
(1.1
)
 
$
(2.0
)
 
$
(30.5
)




(18) Restructuring Charges

Fiscal 2020 Actions

During the second quarter of fiscal 2020, the Company disposed of its life sciences testing business, which performs research testing for pharmaceutical companies, to the managers of the operations and recorded a $1.3 million charge upon disposition. Separately, in connection with the Cynosure divestiture, the Company accelerated stock compensation expense and other benefits of $2.6 million, partially offset by other adjustments of $2.0 million.

During the second quarter of fiscal 2020, the Company decided to terminate certain positions around various parts of the world and recorded charges of $1.0 million. These charges were recorded pursuant to ASC 712, Compensation-Nonretirement Postemployment Benefits (ASC 712) or ASC 420 Exit or Disposal Cost Obligations (ASC 420) depending on the employee.

In April 2020, in connection with cost cutting measures related to the COVID-19 pandemic, the Company terminated a limited number of personnel across the Company and expects to record severance benefit charges of approximately $1.0 million in the third quarter of fiscal 2020. In addition the Company made the decision to transfer its Perinatal product from its Sunnyvale facility to its San Diego facility. In connection with this decision, the Company will terminate certain manufacturing personnel and expects to record severance benefit charges of $1.3 million through the end calendar 2020.



35


(19) Share Repurchase
On June 13, 2018, the Board of Directors authorized a share repurchase plan to repurchase up to $500.0 million of the Company's outstanding common stock. This share repurchase plan was effective August 1, 2018 and expired on March 27, 2020. Under this authorization, during the second quarter of fiscal 2020, the Company repurchased 2.4 million shares of its common stock for a total consideration of $130.1 million. As of March 28, 2020, the Company had completed this authorization.
On November 19, 2019, the Board of Directors authorized a new share repurchase plan to repurchase up to $500.0 million of the Company's outstanding common stock, effective at the beginning of the third quarter of fiscal 2020. On March 2, 2020 the Board of Directors approved accelerating the effective date of the new share repurchase plan from March 27, 2020 to March 2, 2020. Under this revised authorization, during the second quarter of fiscal 2020, the Company repurchased 3.5 million shares of its common stock for a total consideration of $137.5 million. As of March 28, 2020, $362.6 million remained available under this authorization.
On November 19, 2019, the Board of Directors authorized the Company to repurchase up to $205 million of its outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement. On November 22, 2019, the Company executed the ASR agreement with Goldman Sachs & Co. ("Goldman Sachs") pursuant to which the Company repurchased $205 million of the Company's common stock. The initial delivery, of approximately 80% of the shares under the ASR, was 3.3 million shares for which the Company initially allocated $164.0 million of the $205 million paid to Goldman Sachs during the first quarter of fiscal 2020. The Company evaluated the nature of the forward contract aspect of the ASR under ASC 815 and concluded equity classification was appropriate. Final settlement of the transaction under the ASR occurred in the second quarter of fiscal 2020. At settlement, Goldman Sachs delivered an additional 0.6 million shares of the Company's common stock.

(20) New Accounting Pronouncements

See Note 1 for Recently Adopted Accounting Pronouncements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10, ASU 2019-11 and ASU 2020-03, on its consolidated financial position and results of operations.
    
In November 2019, the FASB issued ASU No. 2019-08, Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606). The guidance identifies, evaluates, and improves areas of GAAP for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided. The amendments in that Update expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. For entities that have adopted the amendments in Update 2018-07, the updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2019-08 on its consolidated financial position and results of operations.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board is issuing this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on its consolidated financial position and results of operations.

In January 2020, FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The Board is issuing this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for

36


investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2020-01 on its consolidated financial position and results of operations.

37


Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
CAUTIONARY STATEMENT
Some of the statements contained in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements regarding:
 
the ongoing and possible future effects of the global COVID-19 pandemic and associated economic disruptions on our business, financial condition, results of operations and cash flows and our ability to further draw down our revolver;
our ability to complete the development, obtain the authorization for, and manufacture and sell a second COVID-19 assay that will run on our Panther instrument on a timely basis, if at all;
the impact of cost-cutting measures we have taken in response to the COVID-19 pandemic;
the effect of the continuing worldwide macroeconomic uncertainty, including the UK's decision to leave the European Union (known as Brexit), on our business and results of operations;
the effect of the current trade war between the U.S. and other nations, most notably China, and the impending impact of tariffs on the sale of our products in those countries and potential increased costs we may incur to purchase materials from our suppliers to manufacture our products;
the development of new competitive technologies and products, and the impact and anticipated benefits of completed acquisitions;
the ability to consolidate certain of our manufacturing and other operations on a timely basis and within budget, without disrupting our business and to achieve anticipated cost synergies related to such actions;
the ability to successfully manage ongoing organizational and strategic changes, including our ability to attract, motivate and retain key employees;
regulatory approvals and clearances for our products, including the implementation of the new European Union Medical Device Regulations;
potential cybersecurity threats and targeted computer crime;
the coverage and reimbursement decisions of third-party payors;
the uncertainty of the impact of cost containment efforts and federal healthcare reform legislation on our business and results of operations;
the guidelines, recommendations, and studies published by various organizations relating to the use of our products;
the effect of consolidation in the healthcare industry;
production schedules for our products;
the anticipated development of markets we sell our products into and the success of our products in these markets;
the anticipated performance and benefits of our products;
business strategies;
estimated asset and liability values;
the impact and costs and expenses of any litigation we may be subject to now or in the future;
our compliance with covenants contained in our debt agreements;
anticipated trends relating to our financial condition or results of operations, including the impact of interest rate and foreign currency exchange fluctuations, including the potential impact of the proposed phase out of LIBOR by the end of 2021; and
our liquidity, capital resources and the adequacy thereof.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “potential” and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or

38


revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. Factors that could cause or contribute to differences in our future financial results include the cautionary statements set forth herein and in our other filings with the Securities and Exchange Commission, including those set forth under "Risk Factors" set forth in Part II, Item 1A of this Quarterly Report, as well as those described in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019 or any other of our subsequently filed reports. We qualify all of our forward-looking statements by these cautionary statements.
OVERVIEW
We are a developer, manufacturer and supplier of premium diagnostics products, medical imaging systems, and surgical products focused on women's health and well-being through early detection and treatment and until recently our product portfolio included light-based aesthetic and medical treatments systems sold by our former Medical Aesthetic business. During the second quarter of fiscal 2020, we operated in four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. We completed the sale of the Medical Aesthetics segment on December 30, 2019 (the beginning of the second quarter of fiscal 2020). We sell and service our products through a combination of direct sales and service personnel and a network of independent distributors and sales representatives.
We offer a wide range of diagnostic products which are used primarily to aid in the diagnosis of human diseases. Our primary diagnostics products include our Aptima family of molecular diagnostic assays, which run on our advanced instrumentation systems (Panther and Tigris), our ThinPrep cytology system, and the Rapid Fetal Fibronectin Test. The Aptima family of molecular diagnostic assays is used to detect, among other things, the infectious microorganisms that cause the common sexually transmitted diseases, or STDs, such as chlamydia and gonorrhea, certain high-risk strains of human papillomavirus, or HPV, and Trichomonas vaginalis, the parasite that causes trichomoniasis. In addition, the Aptima portfolio includes quantitative viral load tests for HIV, Hepatitis C and Hepatitis B. The Aptima portfolio also includes diagnostic tests for a range of acute respiratory ailments that are run on the Panther Fusion system, a field upgradeable instrument addition to the Panther. During the second quarter of fiscal 2020, the U.S. Food and Drug Administration (the "FDA") granted Emergency Use Authorization (EUA) for our Panther Fusion® SARS-CoV-2 assay for testing for the COVID-19 virus. We are in the process of completing development of a second SARS-CoV-2 assay that will run on the Panther instrument, more than 1,800 of which are used by clinical laboratories around the world. Subject to obtaining the required authorizations, we expect to introduce the assay in May. The ThinPrep System is primarily used in cytology applications, such as cervical cancer screening, and the Rapid Fetal Fibronectin Test assists physicians in assessing the risk of pre-term birth.
Our Breast Health products include a broad portfolio of solutions for breast cancer care for radiology, pathology and surgery. These solutions include breast imaging and analytics, such as our 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, ultrasound and connectivity solutions. Our most advanced breast imaging platform, Selenia Dimensions and 3Dimensions, utilizes a technology called tomosynthesis to produce 3D images that show multiple contiguous slice images of the breast, which we refer to as the Genius 3D Mammography exam, as well as conventional 2D full field digital mammography images. Our clinical results for FDA approval demonstrated that conventional 2D digital mammography with the addition of 3D tomosynthesis is superior to 2D digital mammography alone for both screening and diagnostics for women of all ages and breast densities. In addition, through our acquisitions of Faxitron Bioptics, LLC ("Faxitron") and Focal we have expanded our product portfolio to include breast conserving surgery products.
Our GYN Surgical products include our NovaSure Endometrial Ablation System, or NovaSure, and our MyoSure Hysteroscopic Tissue Removal System, or MyoSure, as well as our Fluent Fluid Management system, or Fluent. The NovaSure portfolio is comprised of the NovaSure CLASSIC and NovaSure ADVANCED devices and involves a trans-cervical procedure for the treatment of abnormal uterine bleeding. The MyoSure suite of devices offers four options to provide incision-less removal of fibroids, polyps, and other pathology within the uterus. The Fluent system is a fluid management system that provides liquid distention during diagnostic and operative hysteroscopic procedures.
Our disposed of Medical Aesthetics segment offered a portfolio of aesthetic treatment systems, including SculpSure, PicoSure and MonaLisa Touch, that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve gynecologic health. This segment also marketed our TempSure radio frequency, or RF, energy sourced platform that offered both non-surgical and surgical aesthetic treatments and procedures.

39


On November 20, 2019, we entered into a definitive agreement to sell our Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019 (the beginning of the second quarter of fiscal 2020), and the Company received cash proceeds of $153.4 million. The sales price remains subject to adjustment pursuant to the terms of the definitive agreement, and the Company is in process of evaluating adjustments to the final sales price. As a result, we recorded a $30.2 million impairment charge in the first quarter of fiscal 2020 to record the asset group to its fair value less costs to dispose as it met the assets held-for-sale criteria. For additional information, see Note 6 to our consolidated financial statements included herein. Following the sale of our Medical Aesthetics business, we do not anticipate to receive any further revenue related to this business, although additional expenses will be incurred in connection with indemnification provisions primarily related to legal and tax matters. In addition, we have agreed to provide transition services for a period of up to 15 months.
Our Skeletal Health segment's products includes the Horizon DXA, a dual energy x-ray system, which evaluates bone density and performs body composition assessments, and the Fluoroscan Insight FD mini C-arm, which assists in performing minimally invasive orthopedic surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle.
Unless the context otherwise requires, references to we, us, Hologic or our company refer to Hologic, Inc. and its consolidated subsidiaries.
Trademark Notice
Hologic is a trademark of Hologic, Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 2D Dimensions, 3Dimensions, 3D Mammography, Affirm, Alpha Imaging, Aptima, ATEC, BioZorb, Hologic Clarity HD, Emsor, Eviva, Faxitron, Fluent, Fluoroscan, Focal, Fusion, Health Beacons, Insight FD, Intelligent 2D, Genius 3D Mammography, GYN Surgical, Horizon DXA, MyoSure, NovaSure, Panther, Panther Fusion, Rapid fFN, Selenia, Selenia Dimensions, SmartCurve, SuperSonic Imagine, ThinPrep, and Tigris. Cynosure, MonaLisa Touch, PicoSure, SculpSure, and TempSure remain trademarks of Cynosure, which we no longer own following the sale of our Medical Aesthetics business on December 30, 2019.

40



COVID-19 Considerations
The pandemic caused by the spread of the novel strain of coronavirus disease 2019 ("COVID-19") has created significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate in, primarily the U.S., Europe and Asia-Pacific. In the second quarter of fiscal 2020, the spread of COVID-19 has negatively impacted business and healthcare activity globally. As healthcare systems respond to the increasing demands of managing COVID-19 and the resulting economic uncertainties, governments around the world have imposed measures designed to reduce the transmission of COVID-19, and individuals are responding to the fears of contracting COVID-19. In particular, elective procedures and exams are being delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals are postponing or cancelling capital purchases as well as limiting or eliminating services. As further discussed in this Report, these responses have had, and we believe will continue to have, a negative impact on our operating results and cash flows. While the effects of COVID-19 and the associated economic disruptions were felt primarily in the second half of March in many of our end-markets and earlier in Asia, primarily China, we expect the effect on our financial results in the third fiscal quarter to be significant. While we believe that the impact on our business will begin to lessen in the fourth quarter and continue to do so in subsequent periods the impacts on these periods could be significant.
We believe that COVID-19’s adverse impact on our operating results, cash flows and financial condition will be primarily driven by: the severity and duration of the COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. and international healthcare systems, the U.S. economy and worldwide economy; and the timing, scope and effectiveness of U.S. and international governmental responses to the COVID-19 pandemic and associated economic disruptions.
In addition to adversely affecting demand for our products, COVID-19 and associated economic disruptions could have an adverse impact on our supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. A reduction or interruption in any of our manufacturing processes could have a material adverse effect on our business.
We expect that the uncertainty surrounding world financial markets and deteriorating worldwide macroeconomic conditions resulting from the pandemic have caused and may continue to cause the purchasers of medical equipment to decrease their medical equipment purchasing and procurement activities. Additionally, the pandemic has caused and may further cause constrictions in world credit markets that have and could cause our customers to experience increased difficulty in paying their existing obligations to us or in securing the financing necessary to purchase our products. Economic uncertainty has and may continue to result in cost-conscious consumers focusing on acute care rather than wellness, which would also continue to adversely affect demand for our products.
The terms of our credit facilities require us to satisfy certain financial covenants. Should our future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions over an extended period of time or otherwise, we cannot assure that we will remain in compliance with our current financial covenants. In such event, the factors that adversely affect our business may also similarly adversely affect the capital markets, and we cannot assure that we would be able to negotiate alternative covenants or alternative financing on favorable terms if at all. Our failure to comply with the covenants contained in our credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition.
As we assessed the potential longer term economic and capital market uncertainties resulting from the COVID-19 pandemic, at the end of March 2020 we suspended our accounts receivable securitization program and borrowed $750 million under our revolver. We used $250 million of these proceeds to pay off all amounts then owed under our accounts receivable securitization agreement, and retained the balance as cash reserve. As of March 28, 2020 we had another $750 million available under our revolver.
In response to the negative impact of COVID-19 on our business, in April 2020 we initiated cost-cutting measures, which included not only reducing discretionary and variable spending, such as travel, marketing programs and the use of contractors, consultants and temporary help, but we also implemented employee furloughs, salary cuts primarily in the U.S., reduced hours and in certain instances employee terminations. Further, we have shut down certain manufacturing facilities temporarily and implemented reduced work-week schedules in response to lower near-term demand for many of our products. These actions, as they relate to our manufacturing operations, are expected to reduce the efficiency of our manufacturing operations and could further adversely affect our results of operations. Future cost savings initiatives and other measures related to stopping the spread of COVID-19 could also adversely affect our research and development activities, including our clinical trials.
We have also taken measures to ensure the safety of our employees and to comply with governmental orders. These measures could require that our employees refrain from traveling to their normal workplace for extended periods of time, which in turn could result in a decrease in our commercial and marketing activities.

41


During the second quarter of fiscal 2020, the FDA granted Emergency Use Authorization (EUA) for our Panther Fusion SARS-CoV-2 assay for testing for the COVID-19 virus. We are in the process of completing development of a second SARS-CoV-2 assay which will run on our more widely distributed Panther instrument. We have installed more than 1,800 Panther instruments, which are used by clinical laboratories around the world. Subject to obtaining the required authorizations, we expect to introduce the assay in May. However, we can give no assurance that this assay will be developed and authorized on a timely basis, if at all, or if introduced, will be commercially successful.

ACQUISITIONS

SuperSonic Imagine

On August 1, 2019, we acquired approximately 46% of the outstanding shares of SuperSonic Imagine S. A., or SSI. SSI, headquartered in France, specializes in ultrasound imaging and designs, develops and markets an ultrasound platform used in the non-invasive care path for the characterization of breast, liver or prostate diseases. We initially accounted for this investment as an equity method investment.

On November 21, 2019, we acquired an additional 7.6 million shares of SSI for $12.6 million. As a result, we owned approximately 78% of the outstanding shares of SSI at November 21, 2019 and controlled SSI's voting interest and operations. We performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within our consolidated financial statements. We remeasured the initial investment of 46% of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of $3.2 million in the first quarter of fiscal 2020. The total purchase price was $69.3 million, which consisted of $17.9 million for the equity method investment in SSI, $12.6 million for shares acquired on November 21, 2019, $30.2 million for loans we provided to SSI prior to the acquisition that are considered forgiven, and $8.6 million representing the fair value of the noncontrolling interests as of November 21, 2019. Based on our preliminary purchase price allocation, we have allocated $45.3 million of the purchase price to the preliminary value of intangibles and $22.4 million to goodwill. The allocation of the purchase price is preliminary as we continue to gather information supporting the acquired assets and liabilities.

As of March 28, 2020, we owned approximately 81% of SSI, and accordingly we have recorded an adjustment to our net income for the non-controlling interest we do not own of $1.5 million and $1.8 million, respectively, for the three and six months ended March 28, 2020,

Alpha Imaging

On December 30, 2019, we completed the acquisition of assets from Alpha Imaging, LLC ("Alpha Imaging"), for a purchase price of $18.0 million, which included a hold-back of $1.0 million and contingent consideration which we have estimated at $0.9M. The contingent consideration is payable upon shipment of backlog orders entered into by Alpha Imaging prior to the acquisition. Alpha Imaging was a long-standing distributor of our Breast and Skeletal products in the U.S.

Health Beacons

On February 3, 2020, we completed the acquisition of Health Beacons, Inc. ("Health Beacons"), for a purchase price of $19.3 million, which included hold-backs of $2.3 million that are payable up to eighteen months from the date of acquisition. Health Beacons manufactures the LOCalizer product that is sold by Faxitron Bioptics, LLC ("Faxitron"), which we acquired in July 2018.

RESULTS OF OPERATIONS
All dollar amounts in tables are presented in millions.

42


Product Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
Change
 
March 28, 2020
 
March 30, 2019
 
Change
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
Product Revenues
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diagnostics
$
314.4

 
41.6
%
 
$
290.4

 
35.5
%
 
$
24.0

 
8.3
 %
 
$
620.8

 
38.6
%
 
$
580.5

 
35.2
%
 
$
40.3

 
6.9
 %
Breast Health
187.2

 
24.8
%
 
200.2

 
24.5
%
 
(13.0
)
 
(6.4
)%
 
395.3

 
24.6
%
 
405.9

 
24.6
%
 
(10.6
)
 
(2.6
)%
GYN Surgical
105.0

 
13.9
%
 
101.9

 
12.5
%
 
3.1

 
3.0
 %
 
223.7

 
13.9
%
 
210.1

 
12.7
%
 
13.6

 
6.5
 %
Medical Aesthetics

 
%
 
58.4

 
7.1
%
 
(58.4
)
 
(100.0
)%
 
49.7

 
3.1
%
 
123.2

 
7.5
%
 
(73.5
)
 
(59.7
)%
Skeletal Health
17.0

 
2.2
%
 
16.9

 
2.1
%
 
0.1

 
0.6
 %
 
33.4

 
2.1
%
 
31.2

 
1.9
%
 
2.2

 
7.1
 %
 
$
623.6

 
82.5
%
 
$
667.8

 
81.7
%
 
$
(44.2
)
 
(6.6
)%
 
$
1,322.9

 
82.3
%
 
$
1,350.9

 
81.9
%
 
$
(28.0
)
 
(2.1
)%
We had a reduction in product revenues in both the current three and six month periods of 6.6% and 2.1%, respectively, compared to the corresponding periods in the prior year. The decrease is primarily due to the disposition of the Medical Aesthetics business segment, which was completed on December 30, 2019 and a reduction in Breast Health product revenues primarily due to decreased demand in the second half of March which we attribute to the impact of COVID-19 pandemic as described above.
Diagnostics product revenues increased $24.0 million and $40.3 million or 8.3% and 6.9%, respectively, in the current three and six month periods compared to the corresponding periods in the prior year primarily due to increases in Molecular Diagnostics of $23.7 million and $39.0 million, respectively, a decrease of $2.2 million in the current three month period and an increase of $0.4 million in the current six month period in Cytology & Perinatal, and increases of $2.5 million and $0.9 million, respectively, in blood screening, which we divested in the second quarter of fiscal 2017 but for which we continue to provide long-term access to Panther instrumentation and certain supplies. Molecular Diagnostics product revenue (excluding blood screening) was $189.1 million and $365.7 million, respectively, in the current three and six month periods compared to $165.4 million and $326.7 million in the corresponding periods in the prior year. The increases were primarily attributable to sales volume of our Aptima family of assays, which increased $9.5 million and $18.7 million, respectively, on a worldwide basis in the current three and six month periods primarily due to the increased installed base of our Panther instruments, menu expansion and the adoption of co-testing for cervical cancer screening in Germany. This installed base is driving higher volumes of assay testing, which is partially offset by a slight decline in average selling prices. We also sold more instruments on a worldwide basis in both current year periods compared to the prior year. In addition, we had an increase in worldwide sales of our virology products and our newer Fusion assays. Cytology & Perinatal product revenue decreased in the current quarter primarily due to lower domestic ThinPrep test volumes, which we primarily attribute to screening interval expansion as well as slight declined in average selling prices, partially offset by an increase in international volumes. Cytology & Perinatal product revenue increased in the current six month period due to higher international ThinPrep test volumes partially offset by lower domestic ThinPrep test volumes and slightly lower average selling prices. The increase in ThinPrep volumes internationally is primarily due to increasing our customer base in Europe, which was partially offset by declines in Asia-Pacific, primarily China, which we primarily attribute to the impact of the COVID-19 pandemic. The increase in revenues was partially offset by the negative foreign currency exchange impact of the strengthening U.S. dollar against a number of currencies. We expect a significant decrease in sales of our diagnostic products, except our COVID-19 assay, in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond as the COVID-19 pandemic continues and wellness visits are delayed or cancelled.
Breast Health product revenues decreased $13.0 million and $10.6 million or 6.4% and 2.6%, respectively, in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the impact of the COVID-19 pandemic on sales in the second half of the month of March 2020 resulting in a decrease in sales volume of our 3D Dimensions and 2D systems and related workflow products, consisting of Intelligent 2D, Clarity HD, and SmartCurve upgrades, lower 3D software upgrades, and a slight decline in average selling prices for our 3D systems. We also experienced a decline in sales volume of our Affirm Prone breast biopsy tables. We primarily attribute the decline in revenues to the COVID-19 pandemic in the U.S. as hospitals and imaging centers either slowed down purchases or delayed orders and installations of capital equipment units in order to focus their efforts towards COVID-19 patients and concerns on maintaining their cash and liquidity, as well as from the impact of delayed or cancelled elective imaging exams and procedure as described above. These decreases were partially offset by the inclusion of SSI

43


which contributed $4.9 million and $10.6 million, respectively, of product revenue in the current three and six month periods. We obtained control of SSI and began consolidating their results for the last fiscal month of the first quarter of fiscal 2020. In addition, we had increased sales of our interventional breast solutions ATEC and Eviva disposables. We expect a significant further decrease in sales of our Breast Health products in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and wellness visits and elective medical procedures, and capital expenditures continue to be delayed or cancelled.
GYN Surgical product revenues increased $3.1 million and $13.6 million or 3.0% and 6.5%, respectively, in the current three and six month periods compared to the corresponding periods in the prior year primarily due to increases in the volume of MyoSure system sales of $1.0 million and $7.0 million, respectively, and increases in Fluent systems sales of $3.8 million and $8.0 million, respectively. These increases were partially offset by decreases in NovaSure systems sales of $3.6 million and $5.5 million, respectively, in the current three and six month periods compared to the corresponding periods in the prior year. We attribute the decrease in NovaSure sales primarily to a stagnant market for endometrial ablation in the U.S. We expect a significant decrease in sales of our GYN Surgical products in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and elective medical procedures continue to be delayed or cancelled.
We divested the Medical Aesthetics segment on December 30, 2019, the beginning of our second quarter of fiscal 2020.
Skeletal Health product revenues increased $0.1 million and $2.2 million or 0.6% and 7.1% respectively, in the current three and six month periods compared to the corresponding period in the prior year primarily due to an increase in sales volume of our Horizon DXA systems, which was partially offset by lower sales volume of our Insight FD mini C-arm system. We expect a significant decrease in sales of our Skeletal products in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and wellness and elective medical procedures continue to be delayed or cancelled.
Product revenues by geography as a percentage of total product revenues were as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
United States
74.9
%
 
74.4
%
 
74.2
%
 
74.1
%
Europe
15.6
%
 
12.9
%
 
14.4
%
 
12.7
%
Asia-Pacific
5.6
%
 
8.1
%
 
7.1
%
 
8.4
%
Rest of World
3.9
%
 
4.6
%
 
4.3
%
 
4.8
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%
In the current three and six month periods compared to the corresponding periods in the prior year, the percentage of product revenue derived from Europe increased due to growth in ThinPrep and Molecular Diagnostics as we expanded our customer base and increased sales from the adoption of co-testing for cervical cancer screening in Germany, an increase in digital mammography systems in the UK and the inclusion of SSI. Asia-Pacific product revenue as a percentage of total product revenue decreased primarily due to lower sales in China in the second quarter of fiscal 2020, which we primarily attribute to the effect of the COVID-19 pandemic, and the disposition of Medical Aesthetics.
Service and Other Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
Change
 
March 28, 2020
 
March 30, 2019
 
Change
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
Service and Other Revenues
$
132.5

 
17.5
%
 
$
150.6

 
18.4
%
 
$
(18.1
)
 
(12.0
)%
 
$
283.7

 
17.7
%
 
$
298.2

 
18.1
%
 
$
(14.5
)
 
(4.9
)%
Service and other revenues consist primarily of revenue generated from our field service organization to provide ongoing service, installation and repair of our products. The majority of these revenues are generated within our Breast Health segment, and to a lesser extent, the Medical Aesthetics business prior to its disposition in the beginning of the second quarter of fiscal 2020. The

44


Breast Health business continues to convert a high percentage of our installed base of digital mammography systems to service contracts upon expiration of the warranty period. The Medical Aesthetics business represented 0% and 5.5% of service and other revenues in the current three and six month periods, respectively, and 10.2% of service and other revenues in both of the corresponding periods in the prior year. Excluding Medical Aesthetics, service and other revenues decreased 2% in the current three month period compared to the corresponding period in the prior year primarily due to the prior year period including additional one-time license revenue in Breast Health. Excluding Medical Aesthetics, service and other revenues were consistent in the current six month period compared to the corresponding period in the prior year as we had higher service contract revenue offset by lower license revenue.
Cost of Product Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
Change
 
March 28, 2020
 
March 30, 2019
 
Change
 
Amount
 
% of
Product
Revenue
 
Amount
 
% of
Product
Revenue
 
Amount
 
%
 
Amount
 
% of
Product
Revenue
 
Amount
 
% of
Product
Revenue
 
Amount
 
%
Cost of Product Revenues
$
223.3

 
35.8
%
 
$
232.9

 
34.9
%
 
$
(9.6
)
 
(4.1
)%
 
$
460.8

 
34.8
%
 
$
465.0

 
34.4
%
 
$
(4.2
)
 
(0.9
)%
Amortization of Intangible Assets
62.9

 
10.1
%
 
80.4

 
12.0
%
 
(17.5
)
 
(21.8
)%
 
126.5

 
9.6
%
 
161.4

 
11.9
%
 
(34.9
)
 
(21.6
)%
Impairment of Intangible Assets

 
%
 
374.6

 
56.1
%
 
(374.6
)
 
(100.0
)%
 
25.8

 
2.0
%
 
374.6

 
27.7
%
 
(348.8
)
 
(93.1
)%
 
$
286.2

 
45.9
%
 
$
687.9

 
103.0
%
 
$
(401.7
)
 
(58.4
)%
 
$
613.1

 
46.4
%
 
$
1,001.0

 
74.1
%
 
$
(387.9
)
 
(38.8
)%
Cost of Product Revenues. The cost of product revenues as a percentage of product revenues was 35.8% and 34.8% in the current three and six month periods, respectively, compared to 34.9% and 34.4% in the corresponding periods in the prior year. Cost of product revenues as a percentage of revenue increased in the current three and six month periods primarily due to shifts in product mix for the Diagnostics, Breath Health and GYN Surgical business segments resulting in lower gross margin in fiscal 2020, an increase in inventory reserves and higher freight costs. Partially offsetting these increases was a benefit from the disposition of Medical Aesthetics, which had lower gross margins compared to our remaining businesses. We expect gross margin to deteriorate across our businesses from significantly lower sales volume and manufacturing shut-downs resulting in higher period costs in the third quarter of fiscal 2020 and potentially in the fourth quarter of fiscal 2020 as a result of the economic impact of the COVID-19 pandemic.
Diagnostics' product costs as a percentage of revenue increased in the current three month period compared to the corresponding period in the prior year primarily due to lower gross margin from blood screening based on the increase in sales under our long-term supply agreement with Grifols, lower ThinPrep volumes in the U.S., and an increase in inventory reserves, partially offset by increased volume of Aptima assays and viral assays which generally have higher gross margin. Product costs as a percentage of revenue were consistent in the current six month period compared to the corresponding period in the prior year primarily due to improved molecular diagnostics' gross margin from increased volume of Aptima assays and viral assays offsetting the increased costs noted above.
Breast Health’s product costs as a percentage of revenue increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to decreased sales volume of our 3D Dimensions systems and Affirm Prone breast biopsy tables, a slight decline in average selling prices for our 3D Dimensions systems due to customer mix and higher international sales which have lower average selling prices than the U.S., a decrease in our higher-margin workflow products, consisting of Intelligent 2D, Clarity HD, and SmartCurve upgrades and a decrease in 3D software upgrades. These decreases were primarily due to the COVID-19 pandemic in the U.S. as hospitals and imaging centers either slowed down purchases or delayed orders and installations of capital equipment units in order to focus their efforts towards COVID-19 patients and concerns on maintaining their cash and liquidity, as well as from the impact of delayed or cancelled elective imaging exams, screenings and procedures as described above.
GYN Surgical’s product costs as a percentage of revenue increased in the current three and six month periods compared to the corresponding period in the prior year primarily due to increased sales of Fluent, which is a lower-margin product, and continued product mix shift to higher volumes of MyoSure devices and lower volumes of NovaSure devices, which have higher margins as compared to MyoSure. For the current six month period, this trend was partially offset by an increase in sales volume in the current quarter for the higher margin NovaSure ADVANCED device compared to the Classic device.

45


We divested the Medical Aesthetics segment on December 30, 2019, the beginning of our second quarter of fiscal 2020.
Skeletal Health’s product costs as a percentage of revenue decreased in the current three and six month periods compared to the corresponding periods in the prior year due to increased sales volume of our Horizon DXA systems, which have higher margins than our mini C-arm systems.
Amortization of Intangible Assets. Amortization of intangible assets relates to acquired developed technology, which is generally amortized over its estimated useful life of between 5 and 15 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed. Amortization expense decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to lower amortization of $17.4 million and $33.1 million, respectively, from intangible assets acquired in the Cynosure acquisition as a result of impairment charges (partially offset by shortening lives of certain assets) in fiscal 2019, the classification of the Medical Aesthetic business as assets held-for-sale in November 2019 and its subsequent disposition on December 30, 2019, and lower amortization of intangible assets acquired in the Cytyc acquisition which reduce over time. These decreases were partially offset by amortization expense in the current three and six month periods related to intangible assets acquired in the SSI acquisition of $1.2 million and $1.4 million, respectively.
Impairment of Intangible Assets. As discussed in Note 6 to the consolidated financial statements, we recorded an aggregate impairment charge of $30.2 million during the first quarter of fiscal 2020. The impairment charge was allocated to the Medical Aesthetics long-lived assets, of which $25.8 million was allocated to developed technology assets and written off to cost of revenues. During the second quarter of fiscal 2019, we recorded an aggregate impairment charge of $443.8 million. The impairment charge was allocated to the long-lived assets and $373.3 million of developed technology intangible assets and $1.3 million of equipment was written off to cost of product revenues. See Note 15 to the consolidated financial statements for additional information.
Cost of Service and Other Revenues
 
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
Change
 
March 28, 2020
 
March 30, 2019
 
Change
 
Amount
 
% of
Service
Revenue
 
Amount
 
% of
Service
Revenue
 
Amount
 
%
 
Amount
 
% of
Service
Revenue
 
Amount
 
% of
Service
Revenue
 
Amount
 
%
Cost of Service and Other Revenue
$
74.1

 
55.9
%
 
$
88.1

 
58.5
%
 
$
(14.0
)
 
(15.9
)%
 
$
163.9

 
57.7
%
 
$
171.6

 
57.6
%
 
$
(7.7
)
 
(4.5
)%
Service and other revenues gross margin increased to 44.1% in the current three month period compared to 41.5% in the corresponding period in the prior year and was consistent at 42.3% in the current six month period compared to 42.4% in the corresponding period in the prior year. The increase in the current three month period is primarily due to the disposition of Medical Aesthetics as service margins for Medical Aesthetics were lower compared to the Breast Health business which generates the majority of our service revenues. In addition, in the current three month period, in Breast Health we had lower warranty costs and increased service contracts, which was offset by lower license revenue as the prior year period included additional one-time license revenue in Breast Health. In the current six month period compared to the prior year corresponding period, the disposition of Medical Aesthetics improved service margins in the current year, which was offset by higher field service and parts costs and freight in Breast Health and lower license revenue as the prior year period included additional one-time license revenue in Breast Health.

46


Operating Expenses
 
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
Change
 
March 28, 2020
 
March 30, 2019
 
Change
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
 
Amount
 
% of
Total
Revenue
 
Amount
 
% of
Total
Revenue
 
Amount
 
%
Operating Expenses
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Research and development
$
49.3

 
6.5
%
 
$
57.3

 
7.0
%
 
$
(8.0
)
 
(14.0
)%
 
$
110.4

 
6.9
%
 
$
110.5

 
6.7
%
 
$
(0.1
)
 
(0.1
)%
Selling and marketing
110.6

 
14.6
%
 
133.5

 
16.3
%
 
(22.9
)
 
(17.2
)%
 
255.4

 
15.9
%
 
279.5

 
16.9
%
 
(24.1
)
 
(8.6
)%
General and administrative
66.5

 
8.8
%
 
89.9

 
11.0
%
 
(23.4
)
 
(26.0
)%
 
155.1

 
9.7
%
 
168.5

 
10.2
%
 
(13.4
)
 
(8.0
)%
Amortization of intangible assets
10.1

 
1.3
%
 
14.1

 
1.7
%
 
(4.0
)
 
(28.4
)%
 
19.2

 
1.2
%
 
28.2

 
1.7
%
 
(9.0
)
 
(31.9
)%
Impairment of intangible assets and equipment

 
%
 
69.2

 
8.5
%
 
(69.2
)
 
(100.0
)%
 
4.4

 
0.3
%
 
69.2

 
4.2
%
 
(64.8
)
 
(93.6
)%
Restructuring and Divestiture charges
2.9

 
0.4
%
 
1.6

 
0.2
%
 
1.3

 
81.3
 %
 
3.9

 
0.2
%
 
3.3

 
0.2
%
 
0.6

 
18.2
 %
 
$
239.4

 
31.7
%
 
$
365.6

 
44.7
%
 
$
(126.2
)
 
(34.5
)%
 
$
548.4

 
34.1
%
 
$
659.2

 
40.0
%
 
$
(110.8
)
 
(16.8
)%
Research and Development Expenses. Research and development expenses decreased 14.0% and 0.1% in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the disposition of the Medical Aesthetics business in the beginning of the second quarter of fiscal 2020, which had research and development expenses of $0 and $7.3 million, respectively, in the current three and six month periods and $7.5 million and $14.4 million, respectively, in the corresponding periods in the prior year. In addition, the current three month period had lower compensation and benefits driven by a credit from our deferred compensation plan as the expense is primarily driven by the mark-to-market of the value of the underlying investments, lower bonus expense and a reduction in project spend in Breast Health, partially offset by the addition of $1.0 million of SSI expenses, increased spending to implement the European MDR/IVDR requirements, and increased R&D project spend in Diagnostics and Surgical. The current six month period had lower expense from Medical Aesthetics of $7.1 million, but this was offset by increased R&D consulting and project spend across the businesses, the addition of $1.5 million of SSI expenses and increased spending to implement the European MDR/IVDR requirements. At any point in time, we have a number of different research projects and clinical trials being conducted and the timing of these projects and related costs can vary from period to period.
Selling and Marketing Expenses. Selling and marketing expenses decreased 17.2% and 8.6% in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the disposition of the Medical Aesthetics business in the beginning of the second quarter of fiscal 2020, which had sales and marketing expenses of $0 and $23.7 million, respectively, in the current three and six month periods and $26.1 million and $53.6 million, respectively, in the corresponding periods in the prior year. In addition, the current three and six month periods had reductions in marketing initiatives, trade show expenses, consulting and travel expenses, partially offset by an increase in commissions in Breast Health and the inclusion of SSI expenses in the current three and six month periods of $5.8 million and $8.1 million, respectively. We expect selling and marketing expenses to decline further in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter due to our cost-containment measures implemented in response to the COVID-19 pandemic as described above.
General and Administrative Expenses. General and administrative expenses decreased 26.0% and 8.0% in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the disposition of the Medical Aesthetics business in the beginning of the second quarter of fiscal 2020, which had general and administrative expenses of $0 and $5.5 million, respectively, in the current three and six month periods and $4.8 million and $9.9 million, respectively, in the corresponding periods in the prior year. In addition, the current three and six month periods had lower compensation and benefits principally driven by our deferred compensation plan, lower stock compensation expenses, lower bonus expense, a credit related to services provided under the transition services agreement with Cynosure, lower travel expenses, lower accounting and tax fees, and lower legal expenses as the prior year period included higher litigation and settlement costs related to the Fuji, Enzo and Minerva lawsuits, partially offset by an increase in bad debt expense, acquisition related fees for due diligence and consulting, project expenses related to the Medical Aesthetics disposition including accelerated stock compensation, and the inclusion of SSI. In addition, the current six month period expenses were lower due to acquisition-related holdback and accrual reversals. We expect

47


general and administrative expenses to further decline in the third quarter of fiscal 2020 and a possible further decline in the fourth quarter primarily due to our cost-containment measures implemented in response to the COVID-19 pandemic as described above.
Amortization of Intangible Assets. Amortization of intangible assets results from customer relationships, trade names, distributor relationships and business licenses related to our acquisitions. These intangible assets are generally amortized over their estimated useful lives of between 2 and 30 years using a straight-line method or, if reliably determinable, based on the pattern in which the economic benefits of the assets are expected to be consumed utilizing expected undiscounted future cash flows. Amortization expense decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to lower amortization from intangible assets acquired in the Cynosure acquisition as a result of impairment charges (partially offset by shortening lives of certain assets) in fiscal 2019 and the classification of the Medical Aesthetic business as assets held-for-sale in November 2019 and its subsequent disposition on December 30, 2019.
Impairment of Intangible Assets. As discussed in Note 6 to the consolidated financial statements, we recorded an aggregate impairment charge of $30.2 million during the first quarter of fiscal 2020. The impairment charge was allocated to the Medical Aesthetics long-lived assets of which $4.4 million was written off to operating expenses. During the second quarter of fiscal 2019, we recorded an aggregate impairment charge of $443.8 million. The impairment charge was allocated to the long-lived assets and written off to operating expenses was $14.4 million to customer relationships, $31.5 million to trade names, $17.8 million to distribution agreements and $5.5 million to equipment. See Note 15 to the consolidated financial statements for additional information.
Restructuring and Divestiture Charges. We have implemented various cost reduction initiatives to align our cost structure with our operations and related to integration activities. In addition, we have recorded divestiture charges. These actions have primarily resulted in the termination of employees. As a result, we recorded charges of $2.9 million and $3.9 million in the current three and six month periods, respectively, primarily related to severance benefits. See Note 18 to the consolidated financial statements for additional information.
Interest Expense
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Interest Expense
$
(31.3
)
 
$
(34.8
)
 
$
3.5

 
(10.1
)%
 
$
(64.1
)
 
$
(70.9
)
 
$
6.8

 
(9.6
)%

Interest expense consists primarily of the cash interest costs and the related amortization of the debt discount and deferred issuance costs on our outstanding debt. Interest expense in the current three and six month periods decreased primarily due to a decrease in LIBOR year over year, the basis for determining interest expense under our 2018 Credit Agreement, and overall lower debt balances in the current year, until we borrowed a net of $500 million at the end of March 2020, partially offset by lower proceeds received under our interest rate cap agreements that hedge the variable interest rate under our credit facilities in the current three and six month periods compared to the corresponding periods in the prior year.
Other (Expense) Income, net
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Other (Expense) Income, net
$
(7.5
)
 
$
3.5

 
$
(11.0
)
 
(314.3
)%
 
$
(4.2
)
 
$
2.9

 
$
(7.1
)
 
(244.8
)%

For the current three month period, this account primarily consisted of a loss of $9.0 million on the cash surrender value of life insurance contracts related to our deferred compensation plan driven primarily by stock market losses, partially offset by miscellaneous income and net foreign currency exchange gains were negligible as hedging activities offset realized losses. For the second quarter of fiscal 2019 this account primarily consisted of a gain of $4.5 million on the cash surrender value of life insurance

48


contracts related to our deferred compensation plan driven by stock market gains. partially offset by net foreign currency exchange losses of $0.3 million primarily from the mark-to-market of outstanding forward foreign currency exchange contracts.

For the current six month period, this account primarily consisted of a loss of $6.1 million on the cash surrender value of life insurance contracts related to our deferred compensation plan driven primarily by stock market losses, net foreign currency exchange losses of $1.7 million primarily from mark-to-market of outstanding forward foreign currency and foreign currency option exchange contracts, partially offset by a net gain of $3.2 million to reflect an adjustment to remeasure our initial investment in SSI in connection with purchase accounting. For the prior year corresponding six month period, this account primarily consisted of net foreign currency exchange gains of $3.9 million primarily from the mark-to market of outstanding forward foreign currency exchange contracts, a gain of $0.8 million on the sale of an investment, partially offset by a loss of $1.0 million on the cash surrender value of life insurance contracts related to our deferred compensation plan driven by stock market losses.
Provision (Benefit) for Income Taxes
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Provision (Benefit) for Income Taxes
$
24.1

 
$
(81.1
)
 
$
105.2

 
**
 
$
(264.3
)
 
$
(75.4
)
 
$
(188.9
)
 
**
** Percentage not meaningful

Our effective tax rate for the three and six months ended March 28, 2020 was a provision of 20.3% and a benefit of 122.1%, respectively, compared to a benefit of 22.9% and 30.2%, respectively, for the corresponding periods in the prior year. The effective tax rate for the three months ended March 28, 2020 differed from the statutory tax rate primarily due to taxation of foreign earnings at a tax rate lower than the statutory tax rate including the impact to global intangible low tax income and foreign derived intangible income, partially offset by unbenefited foreign losses. The effective tax rate for the six months ended March 28, 2020 differed from the statutory tax rate primarily due to a $310.9 million discrete net tax benefit related to the loss on the sale of the Medical Aesthetics business.
For the three months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, and earnings in jurisdictions subject to lower tax rates. For the six months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, earnings in jurisdictions subject to lower tax rates, a discrete benefit related to an internal restructuring, and finalizing the impact of the enactment of the Tax Cuts and Jobs Act in the first quarter of fiscal 2019.
Segment Results of Operations
We report our business as five segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. We completed the disposition of the Medical Aesthetics segment on December 30, 2019 (the beginning of the second quarter of fiscal 2020). The accounting policies of the segments are the same as those described in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019. We measure segment performance based on total revenues and operating income (loss). Revenues from product sales of each of these segments are described in further detail above. The discussion that follows is a summary analysis of total revenues and the primary changes in operating income or loss by segment.
Diagnostics
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
319.2

 
$
296.7

 
$
22.5

 
7.6
%
 
$
630.7

 
$
593.3

 
$
37.4

 
6.3
%
Operating Income
$
57.3

 
$
31.1

 
$
26.2

 
84.2
%
 
$
106.8

 
$
74.4

 
$
32.4

 
43.5
%
Operating Income as a % of Segment Revenue
18.0
%
 
10.5
%
 
 
 
 
 
16.9
%
 
12.5
%
 
 
 
 

49


Diagnostics revenues increased in the current three and six month period compared to the corresponding periods in the prior year primarily due to the fluctuations in product revenues discussed above. However, we expect a significant decrease in sales of our products, except our COVID-19 assays, in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and elective medical procedures continue to be delayed or cancelled.

Operating income for this business segment increased in the current three month period compared to the corresponding period in the prior year due to an increase in gross profit from higher revenues and a decrease in operating expenses. Gross margin was 47.4% and 47.3% in the current three month period and corresponding prior year period, respectively. The decrease in operating expenses was primarily due to the corresponding prior year period including a $10.5 million settlement charge related to the Enzo litigation, and in the current year, we had lower compensation and benefits driven by our deferred compensation plan and lower bonus, and a decrease in travel expenses due to COVID-19 restrictions, partially offset by an increase in bad debt expense.

Operating income for this business segment increased in the current six month period compared to the corresponding period in the prior year primarily due to an increase in gross profit from higher revenues with higher gross margins and a decrease in operating expenses. Gross margin was 48.2% and 47.3% in the current six month period and corresponding prior year period, respectively. The increase in gross profit was primarily due to increased sales of our Aptima family of assays and viral products as described above. The decrease in operating expense was primarily due to the $10.5 million settlement charge for the Enzo litigation in the prior year period, partially offset by increased research and development project spend including software development expenses and bad debt expense.
Breast Health
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
307.8

 
$
321.5

 
$
(13.7
)
 
(4.3
)%
 
$
638.9

 
$
646.2

 
$
(7.3
)
 
(1.1
)%
Operating Income
$
75.9

 
$
99.0

 
$
(23.1
)
 
(23.3
)%
 
$
169.8

 
$
196.8

 
$
(27.0
)
 
(13.7
)%
Operating Income as a % of Segment Revenue
24.7
%
 
30.8
%
 
 
 
 
 
26.6
%
 
30.5
%
 
 
 
 
Breast Health revenues decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to a decrease of $12.9 million and $10.6 million in product revenue, respectively, discussed above and a decrease of $0.7 million and an increase of $3.3 million in service revenue, respectively. The decrease in service revenue in the current three month period is primarily due to the prior year period including additional one-time license revenue, partially offset by lower warranty costs and higher service contract revenue. The increase in service revenue in the current six month period is due to continued conversion of a high percentage of the installed base of digital mammography systems to service contracts upon expiration of the warranty period and installation services, partially offset by lower license revenue. We expect a significant further decrease in sales of our products in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and elective medical procedures and capital expenditures continue to be delayed or cancelled.

Operating income for this business segment decreased in the current three and six month periods compared to the corresponding periods in the prior year due to a decrease in gross profit from lower revenues with lower gross margin and an increase in operating expenses. Gross margin was 55.2% and 56.3% in the current three and six month periods, respectively, compared to 56.9% and 57.3% in the corresponding periods in the prior year, respectively. The decrease in gross margin was primarily due to decreased sales volume of our 3D Dimensions systems and Affirm Prone breast biopsy tables, a slight decline in average selling prices for our 3D Dimensions systems due to customer mix and higher international sales which have lower average selling prices than the U.S., a decrease in our higher-margin workflow products, consisting of Intelligent 2D, Clarity HD, and SmartCurve upgrades and a decrease in 3D software upgrades.

Operating expenses increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the prior year periods including a benefit from settling the Fuji litigation, an increase in bad debt expense, an increase in commissions and third party commissions and the inclusion in the current three and six month period of $9.1 million and $12.7 million, respectively, of expenses from the SSI acquisition. These increases were partially offset by a

50


decrease in R&D project spend, a decrease in marketing initiatives, and in the six month period the reversal of acquisition related accruals and a holdback.
GYN Surgical
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
105.4

 
$
102.2

 
$
3.2

 
3.1
%
 
$
224.5

 
$
210.6

 
$
13.9

 
6.6
%
Operating Income
$
23.9

 
$
20.5

 
$
3.4

 
16.6
%
 
$
55.4

 
$
47.6

 
$
7.8

 
16.4
%
Operating Income as a % of Segment Revenue
22.7
%
 
20.1
%
 
 
 
 
 
24.7
%
 
22.6
%
 
 
 
 
GYN Surgical revenues increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the increase in product revenues discussed above. We expect a significant decrease in sales of our products in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and elective medical procedures continued to be delayed or cancelled.
Operating income for this business segment increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to an increase in gross profit from higher revenues with consistent gross margins. Gross margin was 62.3% and 64.4% in the current three and six month periods, respectively, compared to 62.3% and 63.9% in the corresponding periods in the prior year, respectively.
Operating expenses decreased in the current three month period compared to the corresponding period in the prior year primarily due to lower commission and bonus expense, decreased marketing initiative spend and lower legal expenses, partially offset by increased spending on research and development projects. Operating expenses increased in the current six month period compared to the corresponding period in the prior year primarily due to increased spending on research and development projects, consulting expenses and increased commissions, partially offset by decreased marketing initiative spend and lower legal expenses.
Medical Aesthetics

 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$

 
$
73.8

 
$
(73.8
)
 
(100.0
)%
 
$
65.3

 
$
153.6

 
$
(88.3
)
 
(57.5
)%
Operating Loss
$
(2.4
)
 
$
(473.9
)
 
$
471.5

 
(99.5
)%
 
$
(53.4
)
 
$
(499.1
)
 
$
445.7

 
(89.3
)%
Operating Loss as a % of Segment Revenue
(100.0
)%
 
(642.0
)%
 
 
 
 
 
(81.8
)%
 
(324.9
)%
 
 
 
 
Medical Aesthetics revenue and operating loss decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to the divestiture of the Medical Aesthetics segment on December 30, 2019, the beginning of our second quarter of fiscal 2020.
The operating loss in the current six month period and the corresponding period in the prior year included intangible assets and equipment impairment charges of $30.2 million recorded in the first quarter of fiscal 2020 and $443.8 million recorded in the second quarter of fiscal 2019.

51


Skeletal Health
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
Change
 
March 28,
2020
 
March 30,
2019
 
Change
 
Amount
 
Amount
 
Amount
 
%
 
Amount
 
Amount
 
Amount
 
%
Total Revenues
$
23.7

 
$
24.2

 
$
(0.5
)
 
(2.1
)%
 
$
47.2

 
$
45.4

 
$
1.8

 
4.0
%
Operating Income (Loss)
$
1.7

 
$
0.1

 
$
1.6

 
**

 
$
2.6

 
$
(2.4
)
 
$
5.0

 
**

Operating Income (Loss) as a % of Segment Revenue
7.2
%
 
0.2
%
 
 
 
 
 
5.5
%
 
(5.3
)%
 
 
 
 
** Percentage not meaningful
Skeletal Health revenues decreased in the current three month period compared to the corresponding period in the prior year primarily due to a decrease in service and spare parts revenue, partially offset by the increase in product revenues discussed above. Revenues increased in the current six month period compared to the corresponding period in the prior year primarily due to the fluctuations in product revenues discussed above. We expect a significant decrease in sales of our products in the third quarter of fiscal 2020 and to a lesser extent in the fourth quarter and beyond if the COVID-19 pandemic continues and hospitals and healthcare centers continue to restrict access and elective medical procedures continue to be delayed or cancelled.
Operating income for this business segment increased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to higher gross profit and a decrease in operating expenses. Gross margin was 38.7% and 40.4% in the current three and six month periods, respectively, compared to 38.5% and 38.4% in the corresponding periods in the prior year, respectively. The increase in gross margin was primarily due to increased sales volume of our Horizon DXA systems.
Operating expenses decreased in the current three and six month periods compared to the corresponding periods in the prior year primarily due to lower compensation and benefits driven by our deferred compensation plan, lower bonus and lower commissions.

LIQUIDITY AND CAPITAL RESOURCES
At March 28, 2020, we had $455.7 million of working capital and our cash and cash equivalents totaled $799.8 million. Our cash and cash equivalents balance increased by $198.0 million during the first six months of fiscal 2020 primarily due to cash generated from operating and investing activities, partially offset by cash used in financing activities.
As we assessed the potential longer term economic and capital market uncertainties resulting from the COVID-19 pandemic, in March 2020 we suspended our accounts receivable securitization program and borrowed $750.0 million under our revolver. We used $250.0 million of these proceeds to pay off all amounts then owned under our accounts receivable securitization agreement, and retained the balance as cash reserve. As of March 28, 2020 we had another $750.0 million available under our revolver.
In the first six months of fiscal 2020, our operating activities provided cash of $231.6 million, primarily due to net income of $480.7 million, non-cash charges for depreciation and amortization aggregating $188.1 million, the Medical Aesthetics non-cash intangible asset impairment charges of $30.2 million and stock-based compensation expense of $33.8 million. These adjustments to net income were partially offset by a decrease in net deferred tax liabilities of $44.2 million primarily due to the amortization of intangible assets and intangible assets impairment charge. Cash provided by operations was negatively impacted by a net cash outflow of $471.8 million from changes in our operating assets and liabilities. The net cash outflow was driven primarily by an increase in prepaid expenses and other assets of $317.6 million primarily due to recording a $310.9 million tax refund receivable in connection with carrying back the Medical Aesthetics' loss, a decrease in accrued expenses of $50.8 million primarily due to annual bonus and commission payments and payments of professional service fees, a decrease in accounts payable of $47.9 million due to timing of payments, an increase in inventory of $33.3 million primarily due to lower Breast Health sales than anticipated due to the COVID-19 pandemic, increased safety stock and raw materials for new products, and an increase in prepaid taxes primarily due to the timing of payments versus estimates of annual income to record the tax provision.
In the first six months of fiscal 2020, our investing activities provided cash of $32.6 million primarily related to net proceeds received from the sale of the Medical Aesthetics business of $142.7 million. These proceeds were partially offset by capital expenditures of $63.1 million, which primarily consisted of the placement of equipment under customer usage

52


agreements and purchases of manufacturing equipment and computer hardware and software, and net cash payments of $43.2 million related to the SSI, Alpha Imaging and Health Beacons acquisitions.
In the first six months of fiscal 2020, our financing activities used cash of $67.3 million primarily related to executing an accelerated share repurchase agreement for $205.0 million to repurchase of our common stock, $348.5 million for repurchases of our common stock on the open market, $234.0 million for the net repayment of amounts borrowed under the accounts receivable securitization agreement, payments of $24.3 million for holdback and contingent consideration payments related to the Focal, Faxitron and Emsor acquisitions, $18.8 million for scheduled principal payments under our 2018 Credit Agreement, $8.3 million for the repayment of acquired long-term debt from the SSI acquisition, and $12.5 million for the payment of employee taxes withheld for the net share settlement of vested restricted stock units. Partially offsetting these uses of cash were proceeds of $750.0 million under our revolving credit line, and $36.6 million from our equity plans, primarily from the exercise of stock options.
Debt
We had total recorded debt outstanding of $3.56 billion at March 28, 2020, which was comprised of amounts outstanding under our 2018 Credit Agreement of $2.22 billion (principal of $2.23 billion, including $750.0 million on the 2018 Amended Revolver), 2025 Senior Notes of $938.3 million (principal of $950.0 million), 2028 Senior Notes of $394.2 million (principal of $400.0 million).
2018 Credit Agreement
On December 17, 2018, we refinanced our term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement, amended and restated as of October 3, 2017 ("2017 Credit Agreement").

The credit facilities under the 2018 Credit Agreement consisted of:

A $1.5 billion secured term loan ("2018 Amended Term Loan") with a maturity date of December 17, 2023; and
A secured revolving credit facility (the "2018 Amended Revolver") under which the Company may borrow up to $1.5 billion, subject to certain sublimits, with a maturity date of December 17, 2023.

The borrowings of the 2018 Amended Term Loan bear interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate, which was equal to 1.375% as of March 28, 2020. The borrowings of the 2018 Amended Revolver bear interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate, which was equal to 1.375% as of March 28, 2020. At March 28, 2020, borrowings under the 2018 Amended Term Loan were subject to an interest rate of 2.33%.

We are required to make scheduled principal payments under the 2018 Amended Term Loan in increasing amounts ranging from $9.375 million per three-month period commencing with the three-month period ending on December 27, 2019 to $28.125 million per three-month period commencing with the three-month period ending on December 29, 2022 and ending on September 29, 2023. The remaining balance of the 2018 Amended Term Loan after the scheduled principal payments, which was $1.2 billion as of March 28, 2020, and any amount outstanding under the 2018 Amended Revolver, which was $750.0 million at March 28, 2020, are due at maturity. In addition, subject to the terms and conditions set forth in the 2018 Credit Agreement, we may be required to make certain mandatory prepayments from the net proceeds of specified types of asset sales (subject to certain reinvestment rights), debt issuances and insurance recoveries (subject to certain reinvestment rights). These mandatory prepayments are required to be applied by us, first, to the 2018 Amended Term Loan, second, to any outstanding amount under any Swing Line Loans, third, to the 2018 Amended Revolver, fourth to prepay any outstanding reimbursement obligations with respect to Letters of Credit and fifth, to cash collateralize any Letters of Credit. Subject to certain limitations, the Company may voluntarily prepay any of the 2018 Credit Facilities without premium or penalty.
Borrowings are secured by first-priority liens on, and a first-priority security interest in, substantially all of the assets of
the Company and its U.S. subsidiaries, with certain exceptions. For example, borrowings under the 2018 Credit Agreement are not secured by those accounts receivable that are transferred to the special purpose entity under the Company's Accounts Receivable Securitization program (discussed below).
The 2018 Credit Agreement contains affirmative and negative covenants customarily applicable to senior secured credit facilities, including covenants restricting our ability, subject to negotiated exceptions, to incur additional indebtedness and grant

53


additional liens on its assets, engage in mergers or acquisitions or dispose of assets, enter into sale-leaseback transactions, pay dividends or make other distributions, voluntarily prepay other indebtedness, enter into transactions with affiliated persons, make investments, and change the nature of their businesses. In addition, the 2018 Credit Agreement requires us to maintain certain financial ratios. The 2018 Credit Agreement also contains customary representations and warranties and events of default, including payment defaults, breach of representations and warranties, covenant defaults, cross defaults and an event of default upon a change of control of the company.

The 2018 Credit Agreement contains two financial covenants (a total net leverage ratio and an interest coverage ratio) measured as of the last day of each fiscal quarter. As of March 28, 2020, we were in compliance with these covenants.

2025 Senior Notes

The total aggregate principal balance of 2025 Senior Notes is $950.0 million. The 2025 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries. The 2025 Senior Notes were issued pursuant to an indenture, dated as of October 10, 2017 and a supplement to such indenture, dated as of January 19, 2018, each among the Company, the guarantors and Wells Fargo Bank, National Association, as trustee. The 2025 Senior Notes mature on October 15, 2025 and bear interest at the rate of 4.375% per year, payable semi-annually on April 15 and October 15 of each year, commencing on April 15, 2018. We may redeem the 2025 Senior Notes at any time prior to October 15, 2020 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the Indenture. We may also redeem up to 35% of the aggregate principal amount of the 2025 Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before October 15, 2020, at a redemption price equal to 104.375% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. We also have the option to redeem the 2025 Senior Notes on or after: October 15, 2020 through October 14, 2021 at 102.188% of par; October 15, 2021 through October 14, 2022 at 101.094% of par; and October 15, 2022 and thereafter at 100% of par. In addition, if there is a change of control coupled with a decline in ratings, as provided in the indenture, we will be required to make an offer to purchase each holder’s 2025 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date.

2028 Senior Notes

The total aggregate principal balance of the 2028 Senior Notes is $400.0 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain of the Company's domestic subsidiaries. The 2028 Senior Notes were issued pursuant to an indenture, dated as of January 19, 2018, among the Company, the guarantors and Wells Fargo Bank, National Association, as trustee. The 2028 Senior Notes mature on February 1, 2028 and bear interest at the rate of 4.625% per year, payable semi-annually on February 1 and August 1 of each year, commencing on August 1, 2018. We may redeem the 2028 Senior Notes at any time prior to February 1, 2023 at a price equal to 100% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date and a make-whole premium set forth in the indenture. We may also redeem up to 35% of the aggregate principal amount of the 2028 Senior Notes with the net cash proceeds of certain equity offerings at any time and from time to time before February 1, 2021, at a redemption price equal to 104.625% of the aggregate principal amount so redeemed, plus accrued and unpaid interest, if any, to the redemption date. We also have the option to redeem the 2028 Senior Notes on or after: February 1, 2023 through February 1, 2024 at 102.312% of par; February 1, 2024 through February 1, 2025 at 101.541% of par; February 1, 2025 through February 1, 2026 at 100.770% of par; and February 1, 2026 and thereafter at 100% of par. In addition, if there is a change of control coupled with a decline in ratings, as provided in the indenture, we will be required to make an offer to purchase each holder’s 2028 Senior Notes at a price equal to 101% of their principal amount, plus accrued and unpaid interest, if any, to the repurchase date.

Accounts Receivable Securitization Program

On April 25, 2016, we entered into a one-year $200.0 million accounts receivable securitization program (the "Securitization Program") with several of our wholly owned subsidiaries and certain financial institutions. The Securitization Program provides for annual renewals. Under the terms of the Securitization Program, we and certain of our wholly-owned subsidiaries sell our customer receivables to a bankruptcy remote special purpose entity, which is wholly-owned by us. The special purpose entity, as borrower, and we, as servicer, have entered into a Credit and Security Agreement with several lenders pursuant to which the special purpose entity may borrow from the lenders up to the maximum borrowing amount allowed, with the loans secured by the receivables. The amount that the special purpose entity may borrow at a given point in time is determined based on the amount of qualifying receivables that are present in the special purpose entity at such point in time. The assets of the special purpose entity secure the amounts borrowed and cannot be used to pay our other debts or liabilities.

54



Effective April 18, 2019, we entered into an amendment to extend the Securitization Program an additional year to April 17, 2020. Under the amendment, the maximum borrowing amount increased from $225.0 million to $250.0 million. On March 26, 2020, we paid-off the total amount outstanding of $250.0 million previously borrowed under the Securitization Program in response to concerns regarding the potential future impact of the COVID-19 pandemic on the program. As of March 28, 2020, we did not have any borrowings under this program. On April 13, 2020, the Company amended the Credit and Security agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year.
Stock Repurchase Program
On June 13, 2018, the Board of Directors authorized a share repurchase plan to repurchase up to $500.0 million of our outstanding common stock. This share repurchase plan was effective August 1, 2018 and expired on March 27, 2020.
On November 19, 2019, the Board of Directors authorized a new share repurchase plan to repurchase up to $500.0 million of our outstanding common stock, effective at the beginning of the third quarter of fiscal 2020. On March 2, 2020, the Board of Directors approved accelerating the effective date of the new share repurchase plan from March 27, 2020 to March 2, 2020. Under this revised authorization, during the second quarter of fiscal 2020, we repurchased 3.5 million shares of our common stock for a total consideration of $137.5 million. As of March 28, 2020, $362.6 million remained available under this authorization.
On November 19, 2019, the Board of Directors authorized the repurchase of up to $205 million of our outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement. On November 22, 2019, we executed the ASR agreement with Goldman Sachs & Co. ("Goldman Sachs") pursuant to which we repurchased $205 million of our common stock. The initial delivery, of approximately 84% of the shares under the ASR, was 3.3 million shares for which we initially allocated $164.0 million of the $205 million paid to Goldman Sachs during the first quarter of fiscal 2020. Final settlement of the transaction under the ASR occurred in the second quarter of fiscal 2020. At settlement, Goldman Sachs delivered an additional 0.6 million shares of the Company’s common stock.

Legal Contingencies
We are currently involved in several legal proceedings and claims. In connection with these legal proceedings and claims, management periodically reviews estimates of potential costs to be incurred by us in connection with the adjudication or settlement, if any, of these proceedings. These estimates are developed, as applicable in consultation with outside counsel, and are based on an analysis of potential litigation outcomes and settlement strategies. In accordance with ASC 450, Contingencies, loss contingencies are accrued if, in the opinion of management, an adverse outcome is probable and such financial outcome can be reasonably estimated. It is possible that future results for any particular quarter or annual period may be materially affected by changes in our assumptions or the effectiveness of our strategies relating to these proceedings. Information with respect to this disclosure may be found in Note 9 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.

Future Liquidity Considerations

We expect to continue to review and evaluate potential strategic transactions and alliances that we believe will complement our current or future business. Subject to the “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report, as well as those described in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019 or any other of our subsequently filed reports, and the general disclaimers set forth in our Special Note Regarding Forward-Looking Statements at the outset of this MD&A, we believe that our cash and cash equivalents, cash flows from operations, and the cash available under our 2018 Amended Revolver will provide us with sufficient funds in order to fund our expected normal operations and debt payments over the next twelve months. Our longer-term liquidity is contingent upon future operating performance. We may also require additional capital in the future to fund capital expenditures, repayment of debt, acquisitions, strategic transactions or other investments.
As described above, we have significant indebtedness outstanding under our 2018 Credit Agreement, 2025 Senior Notes, and 2028 Senior Notes. These capital requirements could be substantial. The terms of our financing obligations contain covenants that restrict our ability to engage in certain transactions and, if not met, may impair our ability to respond to changing business and economic conditions. Moreover, our credit facilities also require us to satisfy certain financial covenants. Should our future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions or otherwise, we cannot assure that we will remain in compliance with our current financial covenants. In such event, the factors that adversely affect our business may also similarly adversely affect the capital markets, and we cannot

55


assure that we would be able to negotiate alternative covenants or alternative financing on favorable terms if at all. Our failure to comply with the covenants contained in our amended and restated credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition. For a description of risks to our operating performance and our indebtedness, see “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report, as well as those described in Part I, Item 1A in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The discussion and analysis of our financial condition and results of operations are based upon our interim consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP"). The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate our estimates, including those related to revenue recognition for multiple element arrangements, allowance for doubtful accounts, reserves for excess and obsolete inventories, valuations, purchase price allocations and contingent consideration related to business combinations, expected future cash flows including growth rates, discount rates, terminal values and other assumptions used to evaluate the recoverability of long-lived assets and goodwill, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, restructuring and other related charges, stock-based compensation, contingent liabilities, tax reserves and recoverability of our net deferred tax assets and related valuation allowances. We base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ from these estimates if past experience or other assumptions do not turn out to be substantially accurate. Any differences may have a material impact on our financial condition and results of operations. For a discussion of how these and other factors may affect our business, see the “Cautionary Statement” above and “Risk Factors” set forth in Part II, Item 1A of this Quarterly Report as well as those described in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019 or any other of our subsequently filed reports.
The critical accounting estimates that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019. There have been no material changes to our critical accounting policies or estimates from those set forth in our Annual Report on Form 10-K for the fiscal year ended September 28, 2019.

Item 3.    Quantitative and Qualitative Disclosures About Market Risk.
Financial Instruments, Other Financial Instruments, and Derivative Commodity Instruments. Financial instruments consist of cash and cash equivalents, accounts receivable, equity investments, foreign currency contracts, interest rate cap and interest rate swap agreements, insurance contracts, accounts payable and debt obligations. Except for our outstanding 2025 Senior Notes and 2028 Senior Notes, the fair value of these financial instruments approximates their carrying amount. The fair value of our 2025 Senior Notes and 2028 Senior Notes as of March 28, 2020 was approximately $947.6 million and $402.1 million, respectively. Amounts outstanding under our 2018 Credit Agreement of $2.2 billion as of March 28, 2020 are subject to variable rates of interest based on current market rates, and as such, we believe the carrying amount of these obligations approximates fair value.
Primary Market Risk Exposures. Our primary market risk exposure is in the areas of interest rate risk and foreign currency exchange rate risk. We incur interest expense on borrowings outstanding under our 2025 Senior Notes, 2028 Senior Notes, 2018 Credit Agreement and Securitization Program. The 2025 Senior Notes and 2028 Senior Notes have fixed interest rates. Borrowings under our 2018 Credit Agreement currently bear interest at the Eurocurrency Rate (i.e., LIBOR) plus the applicable margin of 1.375% per annum. Borrowings under our Securitization Program currently bear interest at LIBOR plus the applicable margin of 0.71%.
As noted above, as of March 28, 2020, there was $2.23 billion of aggregate principal outstanding under the 2018 Credit Agreement. Since these debt obligations are variable rate instruments, our interest expense associated with these instruments is subject to change. A 10% adverse movement (increase in LIBOR rate) would increase annual interest expense by approximately $5.0 million. We entered into multiple interest rate cap agreements and an interest rate swap agreement to help mitigate the interest rate volatility associated with the variable rate interest on the amounts outstanding. The critical terms of the interest rate caps and interest rate swap were designed to mirror the terms of our LIBOR-based borrowings under the 2018 Credit Agreement and prior credit agreement, and therefore the interest rate caps and interest rate swap are highly effective at

56


offsetting the cash flows being hedged. We designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal. These interest rate cap agreements expire through December 23, 2020, and the interest rate swap contract expires on December 17, 2023.
The UK Financial Conduct Authority announced in 2017 that it intends to phase out LIBOR by the end of 2021. If changes are made to the method of calculating LIBOR or LIBOR ceases to exist, we may need to amend certain contracts, including our 2018 Credit Agreement and related interest rate cap and swap agreements, and we cannot predict what alternative rate or benchmark would be negotiated or the extent to which this would adversely affect our interest rate and the effectiveness of our interest rate hedging activity.
The return from cash and cash equivalents will vary as short-term interest rates change. A hypothetical 10% increase or decrease in interest rates, however, would not have a material adverse effect on our business, financial condition or results of operations.
Foreign Currency Exchange Risk. Our international business is subject to risks, including, but not limited to: unique economic conditions, changes in political climate, differing tax structures, other regulations and restrictions, and foreign exchange rate volatility. Accordingly, our future results could be materially adversely impacted by changes in these or other factors.

We conduct business worldwide and maintain sales and service offices outside the United States as well as manufacturing facilities in Costa Rica and the United Kingdom. Our international sales are denominated in a number of currencies, primarily the Euro, U.S. dollar, UK Pound and Renminbi. The majority of our foreign subsidiaries' functional currency is the local currency, although certain foreign subsidiaries functional currency is the U.S. dollar based on the nature of their operations or functions. Our revenues denominated in foreign currencies are positively affected when the U.S. dollar weakens against them and adversely affected when the U.S. dollar strengthens. Fluctuations in foreign currency rates could affect our sales, cost of goods and operating margins and could result in exchange losses. In addition, currency devaluations can result in a loss if we hold deposits of that currency. We have executed forward foreign currency contracts and foreign currency option contracts to hedge a portion of results denominated in the Euro, UK Pound, Australian dollar, Japanese Yen, Chinese Yuan and Canadian dollar. These contracts do not qualify for hedge accounting. As a result, we may experience volatility in our Consolidated Statements of Income due to (i) the impact of unrealized gains and losses reported in other income, net from the mark-to-market of outstanding contracts and (ii) realized gains and losses recognized in other income, net, whereas the offsetting economic gains and losses are reported in the line item of the underlying cash flow, for example, revenue.
We believe that the operating expenses of our international subsidiaries that are incurred in local currencies will not have a material adverse effect on our business, results of operations or financial condition. Our operating results and certain assets and liabilities that are denominated in foreign currencies are affected by changes in the relative strength of the U.S. dollar against those currencies. Our expenses, denominated in foreign currencies, are positively affected when the U.S. dollar strengthens against them and adversely affected when the U.S. dollar weakens. However, we believe that the foreign currency exchange risk is not significant. A hypothetical 10% increase or decrease in foreign currencies in which we transact would not have a material adverse impact on our business, financial condition or results of operations.

Item 4.    Controls and Procedures.
We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
As of March 28, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of March 28, 2020.

57


An evaluation was also performed under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our latest fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

58


PART II – OTHER INFORMATION
Item 1.    Legal Proceedings.
Information with respect to this Item may be found in Note 9 to the Consolidated Financial Statements in this Quarterly Report on Form 10-Q, which information is incorporated herein by reference.
Additional information on our commitments and contingencies can be found in our Annual Report on Form 10-K for our fiscal year ended September 28, 2019.
Item 1A. Risk Factors.

There are no material changes from the risk factors as previously disclosed in our Annual Report on Form 10-K for our fiscal year ended September 28, 2019 or any of our subsequently filed reports, except for the risk factor described below.

Our results of operations have been adversely affected, and our results of operations, cash flow and financial position could in the future be materially adversely impacted by the coronavirus disease 2019 (COVID-19) pandemic and associated economic disruptions.

The pandemic caused by the spread of the novel strain of coronavirus disease 2019 ("COVID-19") has created significant volatility, uncertainty and economic disruption in the markets we sell our products into and operate in, primarily the U.S, Europe and Asia-Pacific. In the second quarter of fiscal 2020, the spread of COVID-19 has negatively impacted business and healthcare activity globally.

Decreased demand for products. As healthcare systems respond to the increasing demands of managing COVID-19 and the resulting economic uncertainties, governments around the world have imposed measures designed to reduce the transmission of COVID-19 and individuals are responding to the fears of contracting COVID-19. In particular, elective procedures and exams are being delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals are postponing or cancelling capital purchases as well as limiting or eliminating services. As further discussed in this Report, these responses have had, and we believe will continue to have, a negative impact on our operating results, cash flows and financial condition. While the effects of COVID-19 and the associated economic disruptions were felt primarily in the second half of March, in many of our end-markets and earlier in Asia, primarily China, we expect the effect on our financial results in the third fiscal quarter and future periods to be more significant. We believe that COVID-19’s adverse impact on our operating results, cash flows and financial condition will be primarily driven by: the severity and duration of the COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. and international healthcare systems, the U.S. economy and worldwide economy; and the timing, scope and effectiveness of U.S. and international governmental responses to the COVID-19 pandemic and associated economic disruptions.

Potential disruption in manufacturing, distribution and supply chain. In addition to adversely affecting demand for our products, COVID-19 and associated economic disruptions could have an adverse impact on our manufacturing capacity, supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Although we have not experienced significant manufacturing or supply chain difficulties as a result of COVID-19, we may in the future. A reduction or interruption in any of our manufacturing processes could have a material adverse effect on our business.

Potential liquidity and credit impacts. The terms of our financing obligations contain covenants that restrict our ability to engage in certain transactions and, if not met, may impair our ability to respond to changing business and economic conditions. Moreover, our credit facilities also require us to satisfy certain financial covenants. Should our future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions or otherwise, we cannot assure that we will remain in compliance with our current financial covenants. In such event, the factors that adversely affect our business may also similarly adversely affect the capital markets, and we cannot assure that we would be able to negotiate alternative covenants or alternative financing on favorable terms if at all. Our failure to comply with the covenants contained in our amended and restated credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect our results of operations and financial condition.

We refer you to “Management’s Discussion and Analysis of Financial Position and Results of Operations” for a more detailed discussions of the potential impact of the COVID-19 pandemic and associated economic disruptions.


59


We may not realize anticipated revenue from our COVID-19 diagnostic assays, including one assay still under development.

We have developed an assay to detect the virus causing COVID-19 which runs on our Panther Fusion system (PCR assay), and we are in the process of developing another COVID-19 assay to run on our more widely distributed Panther system (TMA assay). Our development of the TMA assay has not yet been completed. We cannot assure that we will be able to complete development or obtain the requisite authorizations for the TMA assay on a timely basis or within budget, if at all. Also, other companies are working to produce or have produced tests for COVID-19 which may lead to the diversion of customers as well as governmental and quasi-governmental funding away from us and toward other companies. Additionally, we are committing financial resources and personnel to the development of the COVID-19 TMA assay and production of both assays. This resource allocation may cause delays in or otherwise negatively impact our other development programs or production capacities. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable and could dissipate; there is no guarantee that current or anticipated demand will continue, or if demand does continue, that we will be able to produce in quantities to meet the demand.


60


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.
Issuer's Purchases of Equity Securities

Period of Repurchase
Total Number of
Shares Purchased
(#) (1)
 
Average Price
Paid Per Share
($) (1)
 
Total Number of
Shares Purchased As Part of Publicly
Announced Plans or Programs 
(#) (2)
 
Average Price Paid Per Share As Part of Publicly Announced Plans or Programs($) (2)
 
Maximum
Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under Our
Programs
(in millions) ($) (2) (3)
December 29, 2019 – January 25, 2020
28,294

 
$
51.96

 
937,274

 
$
53.37

 
$
121.5

January 26, 2020 – February 22, 2020
1,127

 
53.52

 
2,114,235

 
53.86

 
41.5

February 23, 2020 – March 28, 2020
639

 
47.12

 
3,428,057

 
40.11

 
362.5

Total
30,060

 
$
51.91

 
6,479,566

 
$
45.73

 
$
362.5

 ___________________________________
(1)
For the majority of restricted stock units granted, the number of shares issued on the date that the restricted stock units vest is net of the minimum statutory tax withholding requirements that we pay in cash to the appropriate taxing authorities on behalf of our employees. These repurchases of our common stock were to cover employee income tax withholding obligations in connection with the vesting of restricted stock units under our equity incentive plans.

(2)
On June 13, 2018, the Board of Directors authorized another share repurchase plan to repurchase up to $500.0 million of our outstanding common stock. This share repurchase plan, which replaced the prior plan, was effective August 1, 2018 and expires on March 27, 2020. On November 19, 2019, the Board of Directors authorized a new share repurchase plan to repurchase up to $500.0 million of our outstanding common stock, effective at the beginning of the third quarter of fiscal 2020. On March 2, 2020, the Board of Directors approved accelerating the effective date of the new share repurchase plan from March 27, 2020 to March 2, 2020.

(3)
On November 22, 2019, Board of Directors authorized the further repurchase of up to $205 million of our outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement with Goldman Sachs. Under the ASR, Hologic agreed to purchase $205 million of Hologic’s common stock. The initial delivery was 3.3 million shares for which the Company has initially allocated $164.0 million of the $205 million paid to Goldman Sachs, based on the current market price of $50.02. The ASR was completed in the second quarter of fiscal 2020. At settlement, Goldman Sachs delivered an additional 0.6 million shares of the Company’s common stock.



61



Item 6.    Exhibits.
(a) Exhibits
 
 
 
 
 
Incorporated by
Reference
Exhibit
Number
 
Exhibit Description
 
Form
 
Filing Date/
Period End
Date
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31.1*
 
 
 
 
 
 
 
 
 
 
 
 
31.2*
 
 
 
 
 
 
 
 
 
 
 
 
32.1**
 
 
 
 
 
 
 
 
 
 
 
 
32.2**
 
 
 
 
 
 
 
 
 
 
 
 
101.INS*
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
 
 
 
 
 
 
 
 
 
 
 
101.SCH*
 
XBRL Taxonomy Extension Schema Document
 
 
 
 
 
 
 
 
 
 
 
101.CAL*
 
XBRL Taxonomy Extension Calculation Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
101.LAB*
 
XBRL Taxonomy Extension Label Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
101.PRE*
 
XBRL Taxonomy Extension Presentation Linkbase Document
 
 
 
 
 
 
 
 
 
 
 
101.DEF*
 
XBRL Taxonomy Extension Definition
 
 
 
 
_______________


* Filed herewith.
**    Furnished herewith.







62


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 
 
 
Hologic, Inc.
 
 
 
(Registrant)
 
 
 
 
Date:
April 29, 2020
 
/s/    Stephen P. MacMillan        
 
 
 
 
 
 
 
Stephen P. MacMillan
Chairman, President and Chief Executive Officer
(Principal Executive Officer)
 
 
 
 
Date:
April 29, 2020
 
/s/    Karleen M. Oberton        
 
 
 
 
 
 
 
Karleen M. Oberton
 
 
 
Chief Financial Officer
(Principal Financial Officer)


63
EX-31.1 2 holxq2-2020ex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Stephen P. MacMillan, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Hologic, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 29, 2020
 
/s/    Stephen P. MacMillan        
 
Stephen P. MacMillan
 
Chairman, President and Chief Executive Officer
 


EX-31.2 3 holxq2-2020ex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Karleen M. Oberton, certify that:
1.
I have reviewed this quarterly report on Form 10-Q of Hologic, Inc.;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: April 29, 2020
 
/s/    Karleen M. Oberton
 
Karleen M. Oberton
 
Chief Financial Officer
 


EX-32.1 4 holxq2-2020ex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
I, Stephen P. MacMillan, Chief Executive Officer of Hologic, Inc., a Delaware corporation (the “Company”), do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), that:
(1)
The Quarterly Report on Form 10-Q for the quarter ended March 28, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: April 29, 2020
/s/    Stephen P. MacMillan        
 
Stephen P. MacMillan
 
Chairman, President and Chief Executive Officer
A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.


EX-32.2 5 holxq2-2020ex322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
Certification
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)
I, Karleen M. Oberton, Chief Financial Officer of Hologic, Inc., a Delaware corporation (the “Company”), do hereby certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code), that:
(1)
The Quarterly Report on Form 10-Q for the quarter ended March 28, 2020 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated: April 29, 2020
/s/    Karleen M. Oberton
 
Karleen M. Oberton
 
Chief Financial Officer
A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HOLOGIC, INC. AND WILL BE RETAINED BY HOLOGIC, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.


EX-101.SCH 6 holx-20200328.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2421402 - Disclosure - Accumulated Other Comprehensive Income (Detail) link:presentationLink link:calculationLink link:definitionLink 2121100 - Disclosure - Accumulated Other Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 2321301 - Disclosure - Accumulated Other Comprehensive Loss (Tables) link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Basis of Presentation Details (Details) link:presentationLink link:calculationLink link:definitionLink 2110100 - Disclosure - Borrowings and Credit Arrangements link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2410403 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2410402 - Disclosure - Borrowings and Credit Arrangements - Company's Borrowings (Detail) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 2410405 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) link:presentationLink link:calculationLink link:definitionLink 2310301 - Disclosure - Borrowings and Credit Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Business Combination - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Business Combination - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Business Combinations link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Business Combinations (Tables) link:presentationLink link:calculationLink link:definitionLink 2117100 - Disclosure - Business Segments and Geographic Information link:presentationLink link:calculationLink link:definitionLink 2417402 - Disclosure - Business Segments and Geographic Information - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2417404 - Disclosure - Business Segments and Geographic Information - Revenues by Geography (Detail) link:presentationLink link:calculationLink link:definitionLink 2417403 - Disclosure - Business Segments and Geographic Information - Segment Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2317301 - Disclosure - Business Segments and Geographic Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Commitments and Contingencies (Detail) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005000 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1002501 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Derivatives link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Derivatives - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Derivatives - Fair Value of Derivative Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2411405 - Disclosure - Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Derivatives (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Disposition link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Disposition (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Disposition Disposition (Tables) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Disposition - Schedule of Assets and Liabilities Held For Sale (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Disposition - Schedule of Disposition Related Income Statement Information (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Fair Value Measurements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2118100 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2418401 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 2119100 - Disclosure - Intangible Assets and Goodwill link:presentationLink link:calculationLink link:definitionLink 2419404 - Disclosure - Intangible Assets and Goodwill -Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419403 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) link:presentationLink link:calculationLink link:definitionLink 2419402 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) link:presentationLink link:calculationLink link:definitionLink 2319301 - Disclosure - Intangible Assets and Goodwill (Tables) link:presentationLink link:calculationLink link:definitionLink 2403404 - Disclosure - Leases - Additional Lease Information (Details) link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Leases - Lease Liability Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2403405 - Disclosure - Leases - Lease Liability Maturity Schedule (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Leases (Notes) link:presentationLink link:calculationLink link:definitionLink 2403403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) link:presentationLink link:calculationLink link:definitionLink 2303301 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2113100 - Disclosure - Net Income (Loss) Per Share link:presentationLink link:calculationLink link:definitionLink 2413402 - Disclosure - Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) link:presentationLink link:calculationLink link:definitionLink 2313301 - Disclosure - Net Income (Loss) Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2124100 - Disclosure - New Accounting Pronouncements link:presentationLink link:calculationLink link:definitionLink 2224201 - Disclosure - New Accounting Pronouncements (Policies) link:presentationLink link:calculationLink link:definitionLink 2116100 - Disclosure - Other Balance Sheet Information link:presentationLink link:calculationLink link:definitionLink 2416402 - Disclosure - Other Balance Sheet Information - Inventories (Detail) link:presentationLink link:calculationLink link:definitionLink 2416403 - Disclosure - Other Balance Sheet Information - Property, Plant and Equipment (Detail) link:presentationLink link:calculationLink link:definitionLink 2316301 - Disclosure - Other Balance Sheet Information (Tables) link:presentationLink link:calculationLink link:definitionLink 2120100 - Disclosure - Product Warranties link:presentationLink link:calculationLink link:definitionLink 2420402 - Disclosure - Product Warranties - Product Warranty Activity (Detail) link:presentationLink link:calculationLink link:definitionLink 2320301 - Disclosure - Product Warranties (Tables) link:presentationLink link:calculationLink link:definitionLink 2422402 - Disclosure - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 2122100 - Disclosure - Restructuring (Notes) link:presentationLink link:calculationLink link:definitionLink 2322301 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 2102100 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 2402402 - Disclosure - Revenue - Business Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2402403 - Disclosure - Revenue - Geographical Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 2402405 - Disclosure - Revenue - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2402406 - Disclosure - Revenue - Remaining Performance Obligation (Details) link:presentationLink link:calculationLink link:definitionLink 2402404 - Disclosure - Revenue - Revenue by Type (Details) link:presentationLink link:calculationLink link:definitionLink 2302301 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 2123100 - Disclosure - Share Repurchase link:presentationLink link:calculationLink link:definitionLink 2423401 - Disclosure - Share Repurchase Share repurchase (Details) link:presentationLink link:calculationLink link:definitionLink 2114100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2414403 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 2414402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 2314301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2414404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 holx-20200328_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 holx-20200328_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 holx-20200328_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Segment Reporting [Abstract] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Segments [Axis] Segments [Axis] Segments [Domain] Segments [Domain] Diagnostics Diagnostics [Member] Diagnostics. Breast Health Breast Health [Member] Breast health. Medical Aesthetics Medical Aesthetics [Domain] Medical Aesthetics [Domain] GYN Surgical Gyn Surgical [Member] GYN surgical. Skeletal Health Skeletal Health [Member] Skeletal health. Corporate Corporate Segment [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Total revenues Revenues Income (loss) from operations Operating Income (Loss) Depreciation and amortization Depreciation, Amortization and Accretion, Net Capital expenditures Payments to Acquire Productive Assets Identifiable assets Assets Restructuring [Abstract] Restructuring [Abstract] Entity Location [Table] Entity Location [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Disposal Group Name [Domain] Disposal Group Name [Domain] Tepnel [Member] Tepnel [Member] Tepnel [Member] Cynosure Cynosure [Member] Cynosure [Member] Entity by Location [Axis] Entity by Location [Axis] Location [Domain] Location [Domain] COVID-19 [Member] COVID-19 [Member] COVID-19 [Member] Sunnyvale [Member] Sunnyvale [Member] Sunnyvale [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Severance Costs Severance Costs Restructuring Reserve, Translation and Other Adjustment Restructuring Reserve, Translation and Other Adjustment Share Based Compensation Expense Included Other Restructuring Costs Share Based Compensation Expense Included Other Restructuring Costs Share based compensation expense included other restructuring costs. Restructuring Charges Restructuring Charges Estimated severance and benefits future costs Estimated severance and benefits future costs Estimated severance and benefits future costs Derivative Instruments and Hedging Activities Disclosure [Abstract] Schedule of Derivative Assets at Fair Value Schedule of Derivative Assets at Fair Value [Table Text Block] Schedule of Unrealized Loss Recognized in AOCI Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Adjustment to Fair Value within the Consolidated Statements of Income Derivatives Not Designated as Hedging Instruments [Table Text Block] Discontinued Operations and Disposal Groups [Abstract] Assets of Business Held-for-Sale [Abstract] Assets of Business Held-for-Sale [Abstract] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of revenues Cost of Sales [Member] Operating Expense Operating Expense [Member] Disposal Group Classification [Axis] Disposal Group Classification [Axis] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Expenses from disposition Expenses from disposition Expenses from disposition Disposal Group, Including Discontinued Operation, Consideration Disposal Group, Including Discontinued Operation, Consideration Proceeds from Divestiture of Businesses Proceeds from Divestiture of Businesses Intangible asset and equipment impairment charges Asset Impairment Charges Revenue from Contract with Customer [Abstract] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Geographical [Axis] Geographical [Axis] Geographical [Domain] Geographical [Domain] United States UNITED STATES Europe Europe [Member] Asia-Pacific Asia Pacific [Member] Rest of World Rest of World [Member] Rest of World [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Revenues Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Hedging Designation [Axis] Hedging Designation [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Derivative instruments designated as a cash flow hedge Designated as Hedging Instrument [Member] Derivatives not designated as hedging instruments Not Designated as Hedging Instrument [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Derivative Contract [Domain] Derivative Contract [Domain] Interest rate cap agreements Interest Rate Cap [Member] Interest Rate Swap Interest Rate Swap [Member] Forward foreign currency contracts Foreign Exchange Forward [Member] Foreign currency option contracts Foreign Exchange Option [Member] Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Other assets Other Assets [Member] Accrued expenses Accrued Liabilities [Member] Other long-term liabilities Other Noncurrent Liabilities [Member] Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Interest rate swap at fair value Cash Flow Hedge Derivative Instrument Assets at Fair Value Derivative Liability Derivative Liability Derivative Asset, Fair Value, Gross Asset Derivative Asset, Fair Value, Gross Asset Equity [Abstract] Share Repurchase Treasury Stock [Text Block] Basis of Presentation [Abstract] Basis of Presentation [Abstract] Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Product and Service [Axis] Product and Service [Axis] Product and Service [Domain] Product and Service [Domain] Cytology & Perinatal Cytology & Perinatal [Member] Cytology & Perinatal [Member] Molecular Diagnostics Molecular Diagnostics [Member] Molecular Diagnostics [Member] Blood Screening Blood Screening [Member] Blood Screening [Member] Breast Imaging Breast Imaging [Member] Breast Imaging [Member] Interventional Breast Solutions Interventional Breast Solutions [Member] Interventional Breast Solutions [Member] International International [Member] International [Member] Fair Value Disclosures [Abstract] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Statement of Comprehensive Income [Abstract] Net income (loss) Net Income (Loss) Attributable to Parent Changes in foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019. Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax Loss reclassified from accumulated other comprehensive loss to the statements of operations Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive income (loss) Comprehensive Income (Loss), Net of Tax, Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Comprehensive Income Comprehensive Income Comprehensive Income Guarantees [Abstract] Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward] Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward] Balance at Beginning of Period Standard and Extended Product Warranty Accrual Provisions Standard and Extended Product Warranty Accrual, Increase for Warranties Issued Standard and Extended Product Warranty Accrual, Additions from Business Acquisition Standard and Extended Product Warranty Accrual, Additions from Business Acquisition Standard Product Warranty Accrual, Period Increase (Decrease) Standard Product Warranty Accrual, Period Increase (Decrease) Settlements/ Adjustments Standard and Extended Product Warranty Accrual, Decrease for Payments Balance at End of Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Revenue, Remaining Performance Obligation, Percentage Revenue, Remaining Performance Obligation, Percentage Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Revenues by Geography Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Remainder of Fiscal 2020 Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year Fiscal 2021 Finite-Lived Intangible Assets, Amortization Expense, Year Two Fiscal 2022 Finite-Lived Intangible Assets, Amortization Expense, Year Three Fiscal 2023 Finite-Lived Intangible Assets, Amortization Expense, Year Four Fiscal 2024 Finite-Lived Intangible Assets, Amortization Expense, Year Five Debt Disclosure [Abstract] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Term Loan Term Loan [Member] Term Loan [Member] Revolver [Member] Revolver [Member] Revolver [Member] Securitization Program Accounts Receivable Securitization [Member] Accounts Receivable Securitization [Member] SSI [Member] SSI [Member] SSI [Member] 2025 Senior Notes 2025 Senior Notes [Member] 2025 Senior Notes [Member] 2028 Senior Notes 2028 Senior Notes [Member] 2028 Senior Notes [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Current portion of long-term debt Long-term Debt, Current Maturities Long term debt obligations. excluding convertible notes Long Term Debt Obligations Without Convertible Notes Long term debt obligations without convertible notes. Total long-term debt obligations Long-term Debt, Excluding Current Maturities Total debt obligations Long-term Debt Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity File Number Entity File Number Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Emerging Growth Company Entity Emerging Growth Company Entity Small Business Entity Small Business Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Entity Shell Company Entity Shell Company Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current City Area Code City Area Code Local Phone Number Local Phone Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Share-based Payment Arrangement [Abstract] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate Expected life (in years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend Weighted average fair value of options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule Of Geographical Segments [Table] Schedule Of Geographical Segments [Table] Schedule Of Geographical Segments [Table] Rest of World All Other Countries [Member] All other countries. Schedule Of Geographical Segments [Line Items] Schedule Of Geographical Segments [Line Items] Schedule Of Geographical Segments [Line Items] Revenues Percentage Of Revenues Percentage of revenues. Medical Aesthetics [Domain] Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member] Cash Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Accounts Receivable Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Inventory Disposal Group, Including Discontinued Operation, Inventory Prepaid expenses and other current assets Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Property, plant, and equipment Disposal Group, Including Discontinued Operation, Property, Plant and Equipment Intangible assets Disposal Group, Including Discontinued Operation, Intangible Assets Other assets Disposal Group, Including Discontinued Operation, Other Assets Total assets disposed of Disposal Group, Including Discontinued Operation, Assets Accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable Accrued expenses Disposal Group, Including Discontinued Operation, Accrued Liabilities Deferred revenue Disposal Group, Including Discontinued Operation, Deferred Revenue Total liabilities disposed of Disposal Group, Including Discontinued Operation, Liabilities Stock-Based Compensation Expense in Consolidated Statements of Operations Schedule Of Share Based Compensation Expense [Table Text Block] Schedule of share-based compensation expense. Weighted-Average Assumptions Utilized to Value Stock Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Statement of Cash Flows [Abstract] OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income (loss) to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Depreciation Depreciation Amortization of acquired intangibles Amortization Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense Deferred income taxes Deferred Income Tax Expense (Benefit) Other adjustments and non-cash items Other Noncash Income (Expense) Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions: Increase (Decrease) in Operating Capital [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventories Increase (Decrease) in Inventories Prepaid income taxes Increase (Decrease) in Prepaid Taxes Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accounts payable Increase (Decrease) in Accounts Payable Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Acquisition of businesses, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Proceeds From Sale Of Business Proceeds From Sale Of Business Proceeds from sale of business. Capital expenditures Payments to Acquire Property, Plant, and Equipment Increase in equipment under customer usage agreements Payments To Manufacture Equipment Under Customer Usage Agreements The cash outflow related to equipment placed at customer locations for which title is not transferred to the Company's customers. Payments to Acquire Trading Securities Held-for-investment Payments to Acquire Trading Securities Held-for-investment Purchase of insurance contracts Purchase of insurance contracts Purchase of insurance contracts Other activity Increase (Decrease) in Other Noncurrent Assets Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Proceeds from long-term debt Proceeds from (Repayments of) Other Long-term Debt Repayment of long-term debt Repayments of Long-term Debt Proceeds from revolving credit line Proceeds from Lines of Credit Repayments under revolving credit line Repayments of Lines of Credit Proceeds from accounts receivable securitization agreement Proceeds from (Repayments of) Accounts Receivable Securitization Repayments of Accounts Receivable Securitization Repayments of Accounts Receivable Securitization Payments to Noncontrolling Interests Payments to Noncontrolling Interests Payment of deferred acquisition consideration Payment for Contingent Consideration Liability, Financing Activities Repayments of acquired long term debt Repayments of acquired long term debt Repayments of acquired long term debt Payment of debt issuance costs Payments of Debt Issuance Costs Accelerated share repurchase agreement Accelerated share repurchase agreement Accelerated share repurchase agreement Repurchase of common stock Payments for Repurchase of Common Stock Interest Rate Cap Agreements Aggregate Premium Payable Interest Rate Cap Agreements Aggregate Premium Payable Interest rate cap agreements aggregate premium payable. Proceeds from issuance of common stock pursuant to employee stock plans Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised Payments under finance lease obligations Repayments of Long-term Capital Lease Obligations Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Payment of minimum tax withholdings on net share settlements of equity awards Payment For Tax Withholding Related To Vested And Released Restricted Stock Units The payment of minimum statutory tax withholdings to taxing authorities on the behalf of employees from the net share settlement upon vesting of restricted stock units. This payment is not an expense of the Company nor an operating activity. Effect of exchange rate changes on cash and cash equivalents Effect of Exchange Rate on Cash and Cash Equivalents Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash and cash equivalents, beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Quoted Prices in Active Market for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Financial Instrument [Axis] Financial Instrument [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Forward foreign currency contracts Foreign Exchange Contract [Member] Contingent Consideration Type Contingent Consideration Type [Domain] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Assets: Assets, Fair Value Disclosure [Abstract] Assets measured at fair value on a recurring basis Investments, Fair Value Disclosure Liabilities: Liabilities, Fair Value Disclosure [Abstract] Contingent consideration Contingent Consideration Classified as Equity, Fair Value Disclosure Total Obligations, Fair Value Disclosure Business Combinations [Abstract] Business Combinations Business Combination Disclosure [Text Block] Accounts Receivable Securitization Amended Term Loan Amended Term Loan [Member] Amended Term Loan [Member] Senior Notes Senior Notes [Member] Debt Instrument [Axis] Debt Instrument [Axis] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Amended Revolver [Member] Amended Revolver [Member] Amended Revolver [Member] Amended Credit Agreement Amended Credit Agreement [Member] Amended Credit Agreement [Member] Credit Agreement Credit Agreement [Member] Credit agreement. Percentage Added to Eurodollar Rate Percentage Added to Eurodollar Rate [Member] Percentage Added to Eurodollar Rate [Member] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Periodic principal payment period Debt Instrument, Periodic Payment, Principal, Period Debt Instrument, Periodic Payment, Principal, Period Long-term debt Debt extinguishment losses Gain (Loss) on Extinguishment of Debt Maximum range of present value of cash flow percentage Maximum Range of Present Value of Cash Flow Percentage Maximum Range of Present Value of Cash Flow Percentage Direct third party costs interest expense Direct Third Party Costs interest Expense Direct Third Party Costs interest Expense Payment of debt issuance costs Senior notes Senior Notes Stated interest rate Debt Instrument, Interest Rate, Stated Percentage Offering price of principal amount Offering Price of Principal Amount Offering Price of Principal Amount Borrowed principal Principal Amount Of Borrowings Represents the aggregate outstanding principal of amounts borrowed under the Credit Agreement. Senior notes, face amount Debt Instrument, Face Amount Long-term Debt, Current Maturities Repayments of Debt Repayments of Debt Debt Instrument, Unused Borrowing Capacity, Amount Debt Instrument, Unused Borrowing Capacity, Amount Balance Sheet Related Disclosures [Abstract] Other Balance Sheet Information of Inventories Schedule of Inventory, Current [Table Text Block] Other Balance Sheet Information of Property, Plant and Equipment Property, Plant and Equipment [Table Text Block] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Other Income Other Income [Member] Business Acquisition [Axis] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Emsor Emsor [Member] Emsor [Member] Faxitron Faxitron [Member] Faxitron [Member] Focal Therapeutics Focal Therapeutics, Inc. [Member] Focal Therapeutics, Inc. [Member] SuperSonic Imagine SuperSonic Imagine [Member] SuperSonic Imagine [Member] Alpha Imaging [Member] Alpha Imaging [Member] Alpha Imaging [Member] Health Beacons [Member] Health Beacons [Member] Health Beacons [Member] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Developed technology Developed Technology Rights [Member] In-process research and development In Process Research and Development [Member] Customer relationships Customer Relationships [Member] Trade names Trade Names [Member] Statistical Measurement [Axis] Statistical Measurement [Axis] Statistical Measurement [Domain] Statistical Measurement [Domain] Minimum Minimum [Member] Maximum Maximum [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input Type [Domain] Discount Rate Measurement Input, Discount Rate [Member] Business Acquisition [Line Items] Business Acquisition [Line Items] Consideration transferred Business Combination, Consideration Transferred Holdback Holdback Holdback Ownership percentage Business Combination, Ownership Percentage Business Combination, Ownership Percentage Equity interest in acquiree, Percentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Purchase price withheld Business Combination, Contingent Consideration, Liability Period for payment of contingent consideration liabilities Business Combination, Period for Payment of Contingent Consideration Liability Business Combination, Period for Payment of Contingent Consideration Liability Period of cumulative revenue to trigger payment of contingent consideration liability Business Combination, Period for Achievement of Cumulative Revenues For Payment of Contingent Consideration Liability Business Combination, Period for Achievement of Cumulative Revenues For Payment of Contingent Consideration Liability Identifiable intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Goodwill Goodwill Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Intangible assets, fair value (percentage) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value Weighted average period Acquired Finite-lived Intangible Assets, Weighted Average Useful Life Percentage of outstanding shares acquired Business Acquisition, Percentage of Voting Interests Acquired Income (loss) from equity method investments Income (Loss) from Equity Method Investments Cash tender offer price (per share) Business Acquisition, Cash Tender Offer Price Per Share Business Acquisition, Cash Tender Offer Price Per Share Shares acquired Business Combination, Shares Acquired Business Combination, Shares Acquired Equity interest in acquiree, remeasurement gain Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain Consideration related to equity method investment Business Combination, Consideration Transferred, Portion Allocable To Equity Method Investment Business Combination, Consideration Transferred, Portion Allocable To Equity Method Investment Consideration related to newly acquired shares Business Combination, Consideration Transferred, Portion Allocable To Newly Acquired Shares Business Combination, Consideration Transferred, Portion Allocable To Newly Acquired Shares Consideration, portion related to loan repayment Business Combination, Consideration Transferred, Portion Allocable To Loan Repayment Business Combination, Consideration Transferred, Portion Allocable To Loan Repayment Business Combination, Consideration related to fair value of noncontrolling interest Business Combination, Consideration Transferred, Portion Allocable To Fair Value Of Noncontrolling Interest Business Combination, Consideration Transferred, Portion Allocable To Fair Value Of Noncontrolling Interest Discount rate percentage Fair Value Assumption, Discount Rate Fair Value Assumption, Discount Rate Customer relationships Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities Equipment Manufacturing Equipment And Software Gross amount as of the balance sheet date of long-lived, depreciable assets that include manufacturing and other equipment with finite lives used to produce goods and services, and computer equipment and software. Equipment under customer usage agreements Equipment Under Customer Usage Agreements Gross amount at the balance sheet date of long-lived, depreciable asset that are equipment placed at customer locations for which title is not transferred to the Company's customers. Building and improvements Buildings and Improvements, Gross Leasehold improvements Leasehold Improvements, Gross Land Land Furniture and fixtures Furniture and Fixtures, Gross Property, plant and equipment, gross Property, Plant and Equipment, Gross Less – accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, net Property, Plant and Equipment, Net Disposal Group, Including Discontinued Operation, Operating Income (Loss) Disposal Group, Including Discontinued Operation, Operating Income (Loss) Earnings Per Share [Abstract] Net Income (Loss) Per Share Earnings Per Share [Text Block] Revenue Revenue from Contract with Customer [Text Block] Product Warranty Activity Schedule of Product Warranty Liability [Table Text Block] Line of Credit Facility [Table] Line of Credit Facility [Table] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Interest expense Interest Expense, Borrowings Revenue, Remaining Performance Obligation, Amount Revenue, Remaining Performance Obligation, Amount Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Leases [Abstract] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Period with option to terminate lease Lessee, Operating And Finance Lease, Period With Option To Terminate Lessee, Operating And Finance Lease, Period With Option To Terminate Lessee, Operating And Finance Lease, Remaining Lease Term Lessee, Operating And Finance Lease, Remaining Lease Term Lessee, Operating And Finance Lease, Remaining Lease Term Extension period Lessee, Operating And Finance Leases, Extension Period Lessee, Operating And Finance Leases, Extension Period Weighted average discount rate (percentage) Lessee, Operating And Finance Leases, Weighted Average Discount Rate, Percent Lessee, Operating And Finance Leases, Weighted Average Discount Rate, Percent Finance lease liability, current Finance Lease, Liability, Current Finance lease liabilities (non-current) Finance Lease, Liability, Noncurrent Lease revenue as a percentage of total (percentage) Lease Revenue, Percentage Of Total Revenue Lease Revenue, Percentage Of Total Revenue Credit Agreement Weighted average interest rate Line of Credit Facility, Interest Rate During Period Interest rate at end of period Line of Credit Facility, Interest Rate at Period End Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Forward foreign currency contracts Gain (Loss) on Fair Value Hedges Recognized in Earnings Derivative instruments not designated as hedges, gain (loss) Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Schedule of Recognized Identified Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Other assets Finance lease obligations - short term Finance Lease Obligations - Short Term [Member] Finance Lease Obligations - Short Term [Member] Finance lease obligations - long term Finance Lease Obligations - Long Term [Member] Finance Lease Obligations - Long Term [Member] Operating Leases, Lease right-of-use asset Operating Lease, Right-of-Use Asset Operating lease liabilities (current) Operating Lease, Liability, Current Finance lease liabilities (current) Operating lease liabilities (non-current) Operating Lease, Liability, Noncurrent Operating Lease, Weighted Average Remaining Lease Term Operating Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Finance Lease, Weighted Average Remaining Lease Term Operating Leases, Weighted average discount rate Operating Lease, Weighted Average Discount Rate, Percent Financing Leases, Weighted average discount rate Finance Lease, Weighted Average Discount Rate, Percent Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Asset Class [Axis] Asset Class [Axis] Asset Class [Domain] Asset Class [Domain] Developed technology Developed Technology [Member] Developed technology. Distribution agreement Distribution agreement [Member] Distribution agreement [Member] Equipment [Member] Equipment [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Capital equipment, components and software Capital Equipment, Components and Software [Member] Capital Equipment, Components and Software [Member] Consumables Consumables [Member] Consumables [Member] Service Service [Member] Other Other Type of Revenue [Member] Other Type of Revenue [Member] Intangible Assets and Goodwill Intangible Assets Disclosure [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Research and development Research and Development Expense [Member] Selling and marketing Selling and Marketing Expense [Member] General and administrative General and Administrative Expense [Member] Restructuring Charges [Member] Restructuring Charges [Member] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Award Type [Axis] Award Type [Axis] Award Type [Domain] Award Type [Domain] Stock option plans Share-based Payment Arrangement, Option [Member] Restricted stock units Restricted Stock Units (RSUs) [Member] Performance Shares Performance Shares [Member] Market Based Awards Market Based Awards [Member] Market Based Awards [Member] PSU Free Cash Flow [Member] PSU Free Cash Flow [Member] PSU Free Cash Flow [Member] RSU, PSU, MSU RSU, PSU, MSU [Member] RSU, PSU, MSU [Member] Options granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures Weighted-average exercise prices Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based compensation, stock option outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Weighted-average exercise price of options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Shares granted Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted stock units (RSUs), weighted average grant date fair values Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Minimum eligible percentage to receive target number of shares of company's common stock Minimum Target Number Of Shares Issued On Stock Performance In Percent Minimum target number percentage of shares that would be issued based on stock price performance. Maximum eligible percentage to receive target number of shares of company's common stock Maximum Target Number Of Shares Issued Based On Stock Performance In Percent Maximum target number percentage of shares issued based on stock performance. Performance stock units vesting period Shared Based Compensation Arrangement Restricted Stock Vesting Period Period of time that must lapse in order for the restricted stock units to vest. Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Weighted-average period for recognition of unrecognized stock-based compensation, years Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Right of use asset recognized - operating Right of use asset recognized - operating Right of use asset recognized - operating Right of use asset recognized - Finance Lease Right of use asset recognized - Finance Lease Right of use asset recognized - Finance Lease Right of use liability recognized - Operating lease Right of use liability recognized - Operating lease Right of use liability recognized - Operating lease Right of use liability recognized - Finance lease Right of use liability recognized - Finance lease Right of use liability recognized - Finance lease Derecognition of property, plant and equipment Derecognition of property, plant and equipment Derecognition of property, plant and equipment Derecognition of finance leases Derecognition of finance leases Derecognition of finance leases Operating lease cost Operating Lease, Cost Finance lease cost - amortization of right-of-use assets Finance Lease, Right-of-Use Asset, Amortization Finance lease cost - interest cost Finance Lease, Interest Expense Operating cash flows from finance leases Finance Lease, Interest Payment on Liability Operating cash flows from operating leases Operating Lease, Payments Financing cash flows from finance leases Finance Lease, Principal Payments Total cash paid for amounts included in the measurement of lease liabilities Operating And Finance Lease, Total Cash Paid For Amounts Included In Measurement Of Lease Liability Operating And Finance Lease, Total Cash Paid For Amounts Included In Measurement Of Lease Liability ROU assets arising from entering into new operating lease obligations Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Commitments and Contingencies Disclosure [Abstract] Loss Contingencies [Table] Loss Contingencies [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Minerva Minerva [Member] Minerva [Member] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Assessed damages Amount Assessed In Damages Amount assessed in damages. Petitions filed Loss Contingency, New Claims Filed, Number Payment of settlement compensation Litigation Settlement, Amount Awarded to Other Party Consolidation Items [Axis] Consolidation Items [Axis] Consolidation Items [Domain] Consolidation Items [Domain] Intersegment Intersegment Eliminations [Member] Segment Reporting Disclosure [Line Items] Segment Reporting Disclosure [Line Items] Segment Reporting Disclosure [Line Items] Number of reportable segments Number of Reportable Segments Concentration Risk, Customer Concentration Risk, Customer Statement of Financial Position [Abstract] Accounts receivable, reserves Accounts Receivable, Allowance for Credit Loss, Current Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, authorized (in shares) Preferred Stock, Shares Authorized Preferred stock, issued (in shares) Preferred Stock, Shares Issued Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, authorized (in shares) Common Stock, Shares Authorized Common stock, issued (in shares) Common Stock, Shares, Issued Treasury stock (in shares) Treasury Stock, Shares Dispositions Mergers, Acquisitions and Dispositions Disclosures [Text Block] Borrowings and Credit Arrangements Debt Disclosure [Text Block] Customer relationships Customer Relationships Contracts [Member] Customer relationships contracts. Non-competition agreements Noncompete Agreements [Member] Business licenses Business Licenses [Member] Business licenses. Total acquired intangible assets Acquired intangible assets [Member] Acquired intangible assets [Member] Internal-use software Internal-use software [Member] Internal-use software [Member] Capitalized software embedded in products Capitalized software [Member] Capitalized software [Member] Gross Carrying Value Finite-Lived Intangible Assets, Gross Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Derivative [Table] Derivative [Table] Foreign Exchange Option Financial Instrument [Axis] Interest rate caps - derivative Derivative [Line Items] Derivative [Line Items] Interest Rate Cap Agreements Aggregate Premium Payable Loss reclassified from accumulated other comprehensive loss to the statement of income Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Interest Rate Cash Flow Hedge Asset at Fair Value Interest Rate Cash Flow Hedge Asset at Fair Value Derivative notional amount Derivative, Notional Amount Variable interest rate Derivative, Variable Interest Rate Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax Net unrealized loss Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax Notional Amount Notional Amount Notional Amount Stock-Based Compensation Share-based Payment Arrangement [Text Block] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Lessee Lease Assets And Liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] Schedule of Additional Lease Information Lease, Cost [Table Text Block] Schedule of Operating Lease Liability Maturities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of Finance Lease Liability Maturities Finance Lease, Liability, Maturity [Table Text Block] Raw materials Inventory, Raw Materials, Net of Reserves Work-in-process Inventory, Work in Process, Net of Reserves Finished goods Inventory, Finished Goods, Net of Reserves Inventories Inventory, Net Derivatives Derivative Instruments and Hedging Activities Disclosure [Text Block] 2020 remaining Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2021 Lessee, Operating Lease, Liability, Payments, Due Year Two 2022 Lessee, Operating Lease, Liability, Payments, Due Year Three 2023 Lessee, Operating Lease, Liability, Payments, Due Year Four 2024 Lessee, Operating Lease, Liability, Payments, Due Year Five Thereafter Lessee, Operating Lease, Liability, Payments, Due after Year Five Total future minimum lease payments Lessee, Operating Lease, Liability, Payments, Due Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Operating Lease, Liability 2020 remaining Finance Lease, Liability, Payments, Due Next Twelve Months 2021 Finance Lease, Liability, Payments, Due Year Two 2022 Finance Lease, Liability, Payments, Due Year Three 2023 Finance Lease, Liability, Payments, Due Year Four 2024 Finance Lease, Liability, Payments, Due Year Five Thereafter Finance Lease, Liability, Payments, Due after Year Five Total future minimum lease payments Finance Lease, Liability, Payment, Due Less: imputed interest Finance Lease, Liability, Undiscounted Excess Amount Present value of lease liabilities Finance Lease, Liability Changes in unrealized holding gains and losses on available-for-sale securities. tax Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax Changes in pension plans, tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent Changes in value of hedged interest rate caps, tax Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax Purchase Price Allocation [Table] Purchase Price Allocation [Table] Purchase Price Allocation [Table] Purchase Price Allocation [Line Items] Purchase Price Allocation [Line Items] [Line Items] for Purchase Price Allocation [Table] Cash Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Inventory Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Other assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Accounts payable and accrued expenses Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable Deferred revenue Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt Deferred income taxes, net Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Purchase Price Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Reconciliation of Basic and Diluted Share Amounts Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] share repurchase plan [Table] share repurchase plan [Table] share repurchase plan [Table] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] June 13, 2019 Plan [Member] June 13, 2019 Plan [Member] June 13, 2019 Plan [Member] November 19, 2019 Plan [Member] November 19, 2019 Plan [Member] November 19, 2019 Plan [Member] share repurchase plan [Line Items] share repurchase plan [Line Items] [Line Items] for share repurchase plan [Table] Total repurchase authorization Treasury Stock Authorized Treasury Stock Authorized Stock Repurchased During Period, Shares Stock Repurchased During Period, Shares Repurchase of equity Proceeds from (Repurchase of) Equity Stock Repurchase Program, Remaining Authorized Repurchase Amount Stock Repurchase Program, Remaining Authorized Repurchase Amount ASR Authorized ASR Authorized ASR Authorized ASR Shares Repurchased during the period ASR Shares Repurchased during the period ASR Shares Repurchased during the period Amount paid during the period under ASR Agreement Amount paid during the period under ASR Agreement Amount paid during the period under ASR Agreement Accumulated Other Comprehensive Income [Abstract] Accumulated Other Comprehensive Income [Abstract] Changes in Accumulated Other Comprehensive Income Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] ASSETS Assets [Abstract] Current assets: Assets, Current [Abstract] Cash less assets held for sale Accounts receivable, less reserves of $16.0 and $17.8, respectively Accounts Receivable, after Allowance for Credit Loss, Current Inventories Prepaid Income Taxes-Current Prepaid Income Taxes-Current Prepaid Income Taxes-Current Prepaid expenses and other current assets Prepaid Expense, Current Total current assets Assets, Current Property, plant and equipment, net Other assets Other Assets, Noncurrent Total assets LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Current portion of capital lease obligations Capital Lease Obligations, Current Total liabilities and stockholders’ equity Liabilities and Equity Total current liabilities Liabilities, Current Long-term debt, net of current portion Finance lease obligation - long term (capital lease obligation in 2019) Capital Lease Obligations, Noncurrent Deferred Income Tax Liabilities, Net Deferred Income Tax Liabilities, Net Deferred revenue Deferred Revenue, Noncurrent Other long-term liabilities Other Liabilities, Noncurrent Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued Preferred Stock, Value, Issued Common stock, $0.01 par value – 750,000 shares authorized; 294,142 and 292,323 shares issued, respectively Common Stock, Value, Issued Additional paid-in-capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Treasury stock, at cost – 35,941 and 24,638 shares, respectively Treasury Stock, Value Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Total Hologic's stockholders’ equity Stockholders' Equity Attributable to Parent Stockholders' Equity Attributable to Noncontrolling Interest Stockholders' Equity Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Accounting Policies [Abstract] New Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Product Warranties Product Warranty Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Other Tax Expense (Benefit) Other Tax Expense (Benefit) Unrecognized Tax Benefits Unrecognized Tax Benefits Company's effective tax rate Effective Income Tax Rate Reconciliation, Percent Increase to income tax expense adoption of ASU 2016-16 Increase to income tax expense adoption of ASU 2016-16 Increase to income tax expense adoption of ASU 2016-16 Decrease in deferred tax liabilities due to ASC 2016-16 Decrease in deferred tax liabilities due to ASC 2016-16 Decrease in deferred tax liabilities due to ASC 2016-16 Increase to Net Income resulted from adoption of ASU 2016-16 Increase to Net Income resulted from adoption of ASU 2016-16 Increase to Net Income resulted from adoption of ASU 2016-16 Increase to Earnings per Share resulted from adoption of ASC 2016-16 Increase to Earnings per Share resulted from adoption of ASC 2016-16 Increase to Earnings per Share resulted from adoption of ASC 2016-16 Increase in deferred tax assets resulting from adoption of ASCU 2016-16 Increase in deferred tax assets resulting from adoption of ASCU 2016-16 Increase in deferred tax assets resulting from adoption of ASCU 2016-16 Decease in accumulated deficit resulting from adoption of ASCU 2016-16 Decease in accumulated deficit resulting from adoption of ASCU 2016-16 Decease in accumulated deficit resulting from adoption of ASCU 2016-16 Decease to prepaid taxes resulting from adoption of ASCU 2016-16 Decease to prepaid taxes resulting from adoption of ASCU 2016-16 Decease to prepaid taxes resulting from adoption of ASCU 2016-16 Accumulated Other Comprehensive Loss Comprehensive Income (Loss) Note [Text Block] Fair Value Assets and Liabilities Measured on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Interest Rate Swap [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Foreign Currency Translation Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Pension Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Total AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Beginning balance Changes in unrealized holding gains and losses on available-for-sale securities, net of tax of$0.2 for the three months ended December 30, 2017: Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Other Comprehensive Income (Loss) before Reclassifications, Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Amounts reclassified to statement of income Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Accumulated other comprehensive loss Earnings Per Share [Table] Earnings Per Share [Table] Earnings Per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Outstanding Stock Options and stock units Share-based Payment Arrangement [Member] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Earnings Per Share [Line Items] Basic weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements Diluted weighted average common shares outstanding Weighted Average Number of Shares Outstanding, Diluted Weighted-average anti-dilutive shares related to: Weighted Average Number of Shares Outstanding, Basic [Abstract] Weighted-average anti-dilutive shares (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Fair Value, Off-balance Sheet Risks [Table] Schedule of Fair Value, Off-balance Sheet Risks [Table] Acquired intangible assets [Member] Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items] Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Fair value of debt instrument Debt Instrument, Fair Value Disclosure Statement of Stockholders' Equity [Abstract] Statement [Table] Statement [Table] Share Repurchase Program Share Repurchase Program [Member] Share Repurchase Program [Member] Common Stock Common Stock [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Retained Earnings Retained Earnings [Member] Treasury Stock Treasury Stock [Member] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2014-09 Accounting Standards Update 2014-09 [Member] Accounting Standards Update 2016-16 Accounting Standards Update 2016-16 [Member] Accounting Standards Update 2018-01 [Member] Accounting Standards Update 2018-01 [Member] Statement [Line Items] Statement [Line Items] Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount Noncontrolling Interest, Increase from Business Combination Noncontrolling Interest, Increase from Business Combination Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance (in shares) Shares, Issued Accounting standard transition adjustment Cumulative Effect of New Accounting Principle in Period of Adoption Exercise of stock options (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares) Restricted Stock, Shares Issued Net of Shares for Tax Withholdings Vesting of restricted stock units, net of shares withheld for employee taxes Restricted Stock, Value, Shares Issued Net of Tax Withholdings Common stock issued under the employee stock purchase plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Common stock issued under the employee stock purchase plan Stock Issued During Period, Value, Employee Stock Purchase Plan Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Other comprehensive income activity Other Comprehensive Income (Loss), Net of Tax Repurchase of common stock (in shares) Treasury Stock, Shares, Acquired Repurchase of common stock Treasury Stock, Value, Acquired, Par Value Method ASR portion flowing through APIC ASR portion flowing through APIC ASR portion flowing through APIC Balance (in shares) Ending balance Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable Net income Net income Net income attributable to Hologic New Accounting Pronouncements Description of New Accounting Pronouncements Not yet Adopted [Text Block] Leases Lessee, Finance Leases [Text Block] Leases Lessee, Operating Leases [Text Block] Leases Lessor, Operating Leases [Text Block] Leases Lessor, Sales-type Leases [Text Block] Cash Accounts receivable Inventory Other assets Accounts payable and accrued expenses Deferred revenue Short and long-term debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt Other liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities Developed technology Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Technology Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Technology Trade names Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Trade Names Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Trade Names Deferred income taxes, net Amount of loss recognized in other comprehensive income, net of taxes: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Schedule of Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Schedule of Estimated Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Business Segments and Geographic Information Segment Reporting Disclosure [Text Block] Company's Borrowings Schedule of Debt [Table Text Block] Schedule of Line of Credit Facilities Schedule of Line of Credit Facilities [Table Text Block] Schedule Of Interest Expense Under Convertible Notes Schedule Of Interest Expense Under Convertible Notes [Table Text Block] Schedule of interest expense under convertible notes. Disclosure of Long Lived Assets Held-for-sale Disclosure of Long Lived Assets Held-for-sale [Table Text Block] Schedule of Income from Operation of Disposed Business Disposal Groups, Including Discontinued Operations [Table Text Block] Income Statement [Abstract] Revenues: Revenues [Abstract] Product Product Revenue Product Revenue Service and other Service Revenue Service Revenue Revenues Costs of revenues: Cost of Revenue [Abstract] Product Cost of Goods and Services Sold Amortization, Cost of Goods Sold Amortization, Cost of Goods Sold Amortization, Cost of Goods Sold Impairment of intangible assets and equipment Cost Of Goods Sold Impairment Of Intangible Assets and equipment The amount of impairment loss recognized in cost of product sales in the period resulting from the write-down of the carrying amount of an intangible asset to fair value. Service and other Cost of service Cost of service Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research and Development Expense Selling and marketing Selling and Marketing Expense General and administrative General and Administrative Expense Amortization of acquired intangible assets Amortization of Intangible Assets Impairment of intangible assets and equipment Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Restructuring and divestiture charges Operating expenses Operating Expenses Income (loss) from operations Interest income Investment Income, Interest Interest expense Interest Expense Debt extinguishment loss Other (expense) income, net Other Nonoperating Income (Expense) Income (loss) before income taxes Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest Provision (benefit) for income taxes Income Tax Expense (Benefit) Net income (loss) Net income (loss) per common share attributable to Hologic: Basic (in usd per share) Earnings Per Share, Basic Diluted (in usd per share) Earnings Per Share, Diluted Weighted average number of shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic (in shares) Diluted (in shares) Other Balance Sheet Information Details Of Certain Balance Sheet Accounts [Text Block] Details of certain balance sheet accounts. EX-101.PRE 10 holx-20200328_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R82.htm IDEA: XBRL DOCUMENT v3.20.1
Intangible Assets and Goodwill -Narrative (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Dec. 28, 2019
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges   $ 30.2   $ 30.2 $ 443.8
Medical Aesthetics          
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges $ 30.2 30.2 $ 443.8    
Developed technology | Medical Aesthetics          
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges   24.1 373.3    
Customer relationships | Medical Aesthetics          
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges   0.9 14.4    
Trade names | Medical Aesthetics          
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges   2.0 31.5    
Distribution agreement | Medical Aesthetics          
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges   $ 1.2 17.8    
Equipment [Member] | Medical Aesthetics          
Finite-Lived Intangible Assets [Line Items]          
Intangible asset and equipment impairment charges     $ 6.8    
XML 12 R72.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation - Additional Information (Detail) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Stock option plans    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Options granted 0.9 0.9
Weighted-average exercise prices $ 45.82 $ 41.25
Share-based compensation, stock option outstanding 5.3  
Weighted-average exercise price of options outstanding $ 38.74  
Unrecognized compensation expense $ 26.7  
Weighted-average period for recognition of unrecognized stock-based compensation, years 2 years 7 months 6 days  
Restricted stock units    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted 0.8 0.9
Restricted stock units (RSUs), weighted average grant date fair values $ 45.76 $ 41.11
Unrecognized compensation expense $ 70.6  
Weighted-average period for recognition of unrecognized stock-based compensation, years 2 years  
Performance Shares    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted 0.1 0.1
Restricted stock units (RSUs), weighted average grant date fair values $ 45.76 $ 40.97
Market Based Awards    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted 0.1 0.1
Restricted stock units (RSUs), weighted average grant date fair values $ 43.90 $ 55.13
Minimum eligible percentage to receive target number of shares of company's common stock 0.00%  
Maximum eligible percentage to receive target number of shares of company's common stock 200.00%  
Performance stock units vesting period 3 years  
PSU Free Cash Flow [Member]    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted 0.1  
Restricted stock units (RSUs), weighted average grant date fair values $ 45.76  
Maximum eligible percentage to receive target number of shares of company's common stock 200.00%  
RSU, PSU, MSU    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2.5  
XML 13 R76.htm IDEA: XBRL DOCUMENT v3.20.1
Business Segments and Geographic Information - Additional Information (Detail)
3 Months Ended 6 Months Ended
Mar. 28, 2020
USD ($)
Mar. 30, 2019
USD ($)
Mar. 28, 2020
USD ($)
Segment
Mar. 30, 2019
USD ($)
Segment Reporting Disclosure [Line Items]        
Number of reportable segments | Segment     5  
Revenues $ 756,100,000 $ 818,400,000 $ 1,606,600,000 $ 1,649,100,000
Concentration Risk, Customer 0 0 0 0
Intersegment        
Segment Reporting Disclosure [Line Items]        
Revenues $ 0 $ 0 $ 0 $ 0
XML 14 R86.htm IDEA: XBRL DOCUMENT v3.20.1
Share Repurchase Share repurchase (Details) - USD ($)
shares in Millions
3 Months Ended
Nov. 20, 2019
Mar. 28, 2020
Dec. 28, 2019
share repurchase plan [Line Items]      
Total repurchase authorization $ 500,000,000.0    
Stock Repurchase Program, Remaining Authorized Repurchase Amount   $ 362,600,000  
ASR Authorized   205,000,000 $ 205,000,000
ASR Shares Repurchased during the period   $ 600,000 3,300,000
Amount paid during the period under ASR Agreement     $ 164,000,000.0
June 13, 2019 Plan [Member]      
share repurchase plan [Line Items]      
Stock Repurchased During Period, Shares   2.4  
Repurchase of equity   $ 130,100,000  
November 19, 2019 Plan [Member]      
share repurchase plan [Line Items]      
Stock Repurchased During Period, Shares   3.5  
Repurchase of equity   $ 137,500,000  
XML 15 R59.htm IDEA: XBRL DOCUMENT v3.20.1
Disposition - Schedule of Assets and Liabilities Held For Sale (Details) - Medical Aesthetics [Domain] - Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]
Dec. 28, 2019
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]  
Cash $ 10,700
Accounts Receivable 59,600
Inventory 90,600
Prepaid expenses and other current assets 7,700
Property, plant, and equipment 4,000.0
Intangible assets 28,200
Other assets 9,800
Total assets disposed of 210,600
Accounts payable 12,300
Accrued expenses 49,000.0
Deferred revenue 16,600
Total liabilities disposed of $ 77,900
XML 17 R55.htm IDEA: XBRL DOCUMENT v3.20.1
Business Combination - Narrative (Details)
$ / shares in Units, shares in Millions, $ in Millions
1 Months Ended 2 Months Ended 3 Months Ended 6 Months Ended
Dec. 30, 2019
USD ($)
Nov. 21, 2019
USD ($)
shares
Oct. 01, 2019
USD ($)
Aug. 01, 2019
USD ($)
Oct. 01, 2018
USD ($)
Jul. 31, 2018
Dec. 11, 2017
Nov. 30, 2019
USD ($)
Sep. 30, 2019
$ / shares
Sep. 28, 2019
USD ($)
Mar. 28, 2020
USD ($)
Mar. 30, 2019
USD ($)
Nov. 20, 2019
Business Acquisition [Line Items]                          
Consideration transferred   $ 69.3                      
Ownership percentage   78.00%                      
Goodwill                   $ 2,563.7 $ 2,592.0    
Equity interest in acquiree, remeasurement gain   $ 3.2                      
Consideration related to equity method investment   17.9                      
Consideration related to newly acquired shares               $ 12.6          
Consideration, portion related to loan repayment   30.2                      
Business Combination, Consideration related to fair value of noncontrolling interest   8.6                      
Discount rate percentage                       0.120  
Intangible assets, net                   1,459.8 $ 1,328.8    
Emsor                          
Business Acquisition [Line Items]                          
Period of cumulative revenue to trigger payment of contingent consideration liability             2 years            
Faxitron | Developed technology                          
Business Acquisition [Line Items]                          
Weighted average period           9 years              
Faxitron | Customer relationships                          
Business Acquisition [Line Items]                          
Weighted average period           9 years              
Faxitron | Trade names                          
Business Acquisition [Line Items]                          
Weighted average period           8 years 3 months 18 days              
Focal Therapeutics                          
Business Acquisition [Line Items]                          
Consideration transferred     $ 12.5   $ 120.1                
Purchase price withheld         $ 14.0             $ 1.5  
Period for payment of contingent consideration liabilities         1 year                
Goodwill         $ 31.1                
Focal Therapeutics | Developed technology                          
Business Acquisition [Line Items]                          
Identifiable intangible assets         $ 83.1                
Weighted average period         11 years                
Focal Therapeutics | In-process research and development                          
Business Acquisition [Line Items]                          
Identifiable intangible assets         $ 11.4                
Focal Therapeutics | In-process research and development | Minimum | Discount Rate                          
Business Acquisition [Line Items]                          
Intangible assets, fair value (percentage)         15.50%                
Focal Therapeutics | In-process research and development | Maximum | Discount Rate                          
Business Acquisition [Line Items]                          
Intangible assets, fair value (percentage)         16.50%                
Focal Therapeutics | Trade names                          
Business Acquisition [Line Items]                          
Identifiable intangible assets         $ 2.7                
Weighted average period         13 years                
SuperSonic Imagine                          
Business Acquisition [Line Items]                          
Consideration transferred   12.6   $ 18.2                  
Equity interest in acquiree, Percentage       46.00%             81.00%    
Goodwill   22.4                      
Other assets   $ 6.5                      
Percentage of outstanding shares acquired       46.00%                 50.00%
Cash tender offer price (per share) | $ / shares                 $ 1.50        
Shares acquired | shares   7.6                      
Customer relationships   $ 4.0                      
Alpha Imaging [Member]                          
Business Acquisition [Line Items]                          
Consideration transferred $ 18.0                        
Holdback                       1.0  
Purchase price withheld                     $ 0.9    
Customer relationships                       $ 18.1  
Health Beacons [Member]                          
Business Acquisition [Line Items]                          
Consideration transferred                     19.3    
Holdback                     2.3    
Goodwill                     5.7    
Intangible assets, net                     10.7    
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities                     $ 2.9    
Other Income                          
Business Acquisition [Line Items]                          
Income (loss) from equity method investments                   $ 3.3      
XML 18 R51.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Additional Lease Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 28, 2020
Leases [Abstract]    
Operating lease cost $ 6,800 $ 13,800
Finance lease cost - amortization of right-of-use assets 0 300
Finance lease cost - interest cost 300 500
Operating cash flows from finance leases 300 500
Operating cash flows from operating leases 5,700 11,700
Financing cash flows from finance leases 400 900
Total cash paid for amounts included in the measurement of lease liabilities 6,400 13,100
ROU assets arising from entering into new operating lease obligations $ 3,300 $ 4,700
XML 19 R30.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Tables)
6 Months Ended
Mar. 28, 2020
Leases [Abstract]  
Schedule of Lessee Lease Assets And Liabilities
The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
Three Months Ended March 28, 2020
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
5.93

8.14

Weighted average discount rate
 
1.95
%
5.1
%

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
March 28, 2020
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
82.6

$

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.1

$

Finance lease liabilities (current)
 
Finance lease obligations - short term
$

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
68.7

$

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$

$
18.4


Schedule of Additional Lease Information
The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended March 28, 2020
Six Months Ended March 28, 2020
Operating lease cost (a)
$
6.8

$
13.8

Finance lease cost - amortization of right-of-use assets
$

$
0.3

Finance lease cost - interest cost
$
0.3

$
0.5

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from finance leases
$
0.3

$
0.5

 
Operating cash flows from operating leases
$
5.7

$
11.7

 
Financing cash flows from finance leases
$
0.4

$
0.9

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.4

$
13.1

 
 
 
 
ROU assets arising from entering into new operating lease obligations
$
3.3

$
4.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.
Schedule of Operating Lease Liability Maturities
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


Schedule of Finance Lease Liability Maturities
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


XML 20 R34.htm IDEA: XBRL DOCUMENT v3.20.1
Borrowings and Credit Arrangements (Tables)
6 Months Ended
Mar. 28, 2020
Debt Disclosure [Abstract]  
Company's Borrowings
The Company’s borrowings consisted of the following: 
 
March 28,
2020
 
September 28,
2019
Current debt obligations, net of debt discount and deferred issuance costs:
 
 
 
Term Loan
$
56.1

 
$
37.4

Revolver
750.0

 

Securitization Program

 
234.0

Total current debt obligations
$
806.1

 
$
271.4

Long-term debt obligations, net of debt discount and deferred issuance costs:
 
 
 
Term Loan
1,416.2

 
1,452.4

Debt assumed from SSI acquisition
0.6

 

2025 Senior Notes
938.3

 
937.3

2028 Senior Notes
394.2

 
393.9

Total long-term debt obligations
$
2,749.3

 
$
2,783.6

Total debt obligations
$
3,555.4

 
$
3,055.0


Schedule of Line of Credit Facilities

Interest expense, weighted average interest rate, and interest rate at the end of period under the Credit Agreements were as follow
Schedule Of Interest Expense Under Convertible Notes 8.
Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows:
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
 
Interest Rate
 
Interest Expense
 
Interest Expense
 
Interest Expense
 
Interest Expense
2028 Senior Notes
4.625
%
 
$
4.8

 
$
4.8

 
$
9.6

 
$
9.6

2025 Senior Notes
4.375
%
 
10.9

 
10.9

 
21.8

 
21.8

Total
 
 
$
15.7

 
$
15.7

 
$
31.4

 
$
31.4


Accounts Receivable Securitization Program

On March 26, 2020, the Company paid-off the total amount outstanding of $250.0 million previously borrowed under the Accounts Receivable Securitization Program (the "Securitization Program"). As of March 28, 2020, the Company did not have any borrowings under this program. On April 13, 2020, the Company amended the Credit and Security agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year.
XML 21 R38.htm IDEA: XBRL DOCUMENT v3.20.1
Other Balance Sheet Information (Tables)
6 Months Ended
Mar. 28, 2020
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information of Inventories

 
March 28,
2020
 
September 28,
2019
Inventories
 
 
 
Raw materials
$
155.1

 
$
166.1

Work-in-process
56.4

 
54.5

Finished goods
189.8

 
224.3

 
$
401.3

 
$
444.9


Other Balance Sheet Information of Property, Plant and Equipment
Property, plant and equipment
 
 
 
Equipment
$
407.6

 
$
379.2

Equipment under customer usage agreements
452.8

 
435.5

Building and improvements
162.9

 
196.7

Leasehold improvements
42.8

 
61.7

Land
40.6

 
46.3

Furniture and fixtures
15.6

 
17.5

 
1,122.3

 
1,136.9

Less – accumulated depreciation and amortization
(677.0
)
 
(666.0
)
 
$
445.3

 
$
470.9


XML 22 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies
6 Months Ended
Mar. 28, 2020
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Litigation and Related Matters
    
On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses or any reliance on collateral findings regarding invalidity from inter partes review proceedings. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition. On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company $4.8 million in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages continued to accrue as Minerva continues its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions. On March 4, 2016, Minerva filed two petitions at the USPTO for inter partes review of the '348 patent. On September 12, 2016, the PTAB declined both petitions to review patentability of the '348 patent. On April 11, 2016, Minerva filed a petition for inter partes review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018 the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 22, 2020, the Court of Appeals affirmed the district court’s summary judgment ruling in favor of the Company of no invalidity and infringement, and summary judgment that assignor estoppel bars Minerva from challenging the validity of the ‘348 patent. The Court of Appeals also denied the Company’s motion for a permanent injunction and ongoing royalties for infringement of the ‘183 patent. The Court of Appeals denied Minerva’s motion for no damages or, alternatively, a new trial.
    
On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208. Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. The original trial date of July 20, 2020 was vacated and the parties are now waiting for a new trial date to be set by the court. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.
    
On February 3, 2017, bioMérieux, S.A. and bioMérieux, Inc. (collectively “bioMérieux”) filed suit against the Company in the United States District Court for the Middle District of North Carolina ("MDNC"), alleging that the Company’s HIV products, including blood screening products previously manufactured by the Company for its former blood screening partner Grifols Diagnostic Solutions Inc. ("Grifols USA"), infringe U.S. Patent Nos. 8,697,352 and 9,074,262. On January 3, 2018, the MDNC Court granted the parties’ consent motion to transfer the case to Delaware. On June 11, 2019, the Court issued a claim construction ruling regarding the disputed terms in the patents. Motions for summary judgment were filed by the parties on September 30, 2019, and a hearing on these motions was held on December 18, 2019. A six-day trial concluded on February 25, 2020, with the jury finding that all claims of U.S. Patent No. 8,697,352 are invalid (U.S. Patent No. 9,074,262 was dropped from the case by bioMérieux prior to trial). On March 18, 2020, the parties agreed to a settlement under which bioMérieux agreed to dismiss all claims with prejudice and to waive the filing of post-trial motions and pursuing an appeal in exchange for a de minimis payment from the Company and Grifols USA.

As described in Note 6, the Company has agreed to indemnify CD&R for certain legal matters related to the Medical Aesthetics business that existed at the date of disposition. The Company currently has $8.5 million accrued for such matters as of March 28, 2020, but this amount could become greater if some or all of the cases which it is indemnifying have an adverse result.
    
The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal costs are expensed as incurred.
XML 23 R13.htm IDEA: XBRL DOCUMENT v3.20.1
Business Combinations
6 Months Ended
Mar. 28, 2020
Business Combinations [Abstract]  
Business Combinations Business Combinations

Focal Therapeutics

On October 1, 2018, the Company completed the acquisition of Focal Therapeutics, Inc. ("Focal") for a purchase price of $120.1 million, which included hold-backs of $14.0 million payable up to one year from the date of acquisition. In the second quarter of fiscal 2019, $1.5 million of the hold-back was paid, and the remaining $12.5 million was paid on October 1, 2019. Focal, headquartered in California, manufactures and markets its BioZorb marker, which is an implantable three-dimensional marker that helps clinicians overcome certain challenges in breast conserving surgery.

The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below:

Cash
$
2.2

Accounts receivable
2.0

Inventory
7.9

Other assets
0.5

Accounts payable and accrued expenses
(5.6
)
Long-term debt
(2.5
)
Identifiable intangible assets:
 
       Developed technology
83.1

       In-process research and development
11.4

       Trade names
2.7

Deferred income taxes, net
(12.7
)
Goodwill
31.1

Purchase Price
$
120.1



In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Focal's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, in-process research and development ("IPR&D"), and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from 15.5% to 16.5%. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names was 11 years and 13 years, respectively. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the amount of goodwill were based on synergistic benefits that are expected to be realized from this acquisition. Benefits include the expectation of broadening the Company's Breast Health portfolio of products and technology. None of the goodwill is expected to be deductible for income tax purposes.

SuperSonic Imagine

On August 1, 2019, the Company purchased 46% of the outstanding shares of SuperSonic Imagine ("SSI") for $18.2 million. SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares
for a price of €1.50 per share in cash. The Company determined that SSI was a Variable Interest Entity (“VIE”) but it was not the primary beneficiary as it was not a party to the initial design of the entity nor did it have control over SSI's operations until November 21, 2019 when the Company's ownership of SSI's voting stock exceeded 50%. Accordingly, the Company initially accounted for this investment under the equity method of accounting and included its proportionate share of SSI's net loss of $3.3 million for the two months ended September 28, 2019 within Other (expense) income, net.

On November 21, 2019, the Company acquired an additional 7.6 million shares of SSI for $12.6 million. As a result, the Company owned approximately 78% of the outstanding shares of SSI at November 21, 2019 and controlled SSI's voting interest and operations. The Company performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within the Company's consolidated financial statements. The Company remeasured the initial investment of 46% of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of $3.2 million recorded in the first quarter of fiscal 2020. The total accounting purchase price was $69.3 million, which consisted of $17.9 million for the equity method investment in SSI, $12.6 million for shares acquired on November 21, 2019, $30.2 million for loans the Company provided to SSI prior to the acquisition that are considered forgiven, and $8.6 million representing the fair value of the noncontrolling interest as of November 21, 2019. As of March 28, 2020, the Company owned approximately 81% of the outstanding shares of SSI.

The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows:

Cash
$
2.6

Accounts receivable
7.1

Inventory
10.0

Property, plant and equipment
6.5

Other assets
4.4

Accounts payable and accrued expenses
(13.0
)
Deferred revenue
(1.8
)
Short and long-term debt
(8.8
)
Other liabilities
(3.8
)
Identifiable intangible assets:

       Developed technology
38.3

       Customer relationships
4.0

       Trade names
3.0

Deferred income taxes, net
(1.5
)
Goodwill
22.4

Purchase Price
$
69.4



In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of SSI's business. The Company has not yet obtained all of the information related to the fair value of the acquired assets and liabilities, primarily taxes, to finalize the purchase price allocation. 

As part of the preliminary purchase price allocation, the Company has determined the identifiable intangible assets are developed technology, customer relationships, and trade names. The preliminary fair value of the intangible assets has been estimated using the income approach, and the cash flow projections were discounted using a 12.0% rate. The cash flows are based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life for the developed technology is 9 years, customer relationships is 9 years and for trade names it is 8.6 years. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the preliminary amount of goodwill are based on synergistic benefits of SSI's products being complementary to Breast Health's 3D mammography systems and using the Company's existing U.S. sales force as SSI's presence in the U.S. is limited. None of the goodwill is expected to be deductible for income tax purposes.

Alpha Imaging

On December 30, 2019, the Company completed the acquisition of assets from Alpha Imaging, LLC ("Alpha Imaging"), for a purchase price of $18.0 million, which included a hold-back of $1.0 million and contingent consideration which the Company has estimated at $0.9 million. The contingent consideration is payable upon shipment of backlog orders entered into by Alpha Imaging prior to the acquisition. Alpha Imaging was a long-standing distributor of the Company's Breast and Skeletal products in the U.S. Based on the Company's preliminary valuation, it has allocated $18.1 million of the purchase price to a customer relationships intangible asset, which has a useful life of 5 years. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities.

Health Beacons

On February 3, 2020, the Company completed the acquisition of Health Beacons, Inc. ("Health Beacons"), for a purchase price of $19.3 million, which included hold-backs of $2.3 million that are payable up to eighteen months from the date of acquisition. Health Beacons manufactures the LOCalizer product that is sold by Faxitron Bioptics, LLC ("Faxitron"), which the Company acquired in July 2018. Based on the Company's preliminary valuation, it has allocated $10.7 million of the purchase price to the preliminary value of intangible assets and $5.7 million to goodwill. The remaining $2.9 million of the purchase price has been allocated to acquired tangible assets and liabilities. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities.
XML 24 holxq2-2020_htm.xml IDEA: XBRL DOCUMENT 0000859737 2019-09-29 2020-03-28 0000859737 2019-12-29 2020-03-28 0000859737 2020-04-23 0000859737 2018-09-30 2019-03-30 0000859737 2018-12-30 2019-03-30 0000859737 2020-03-28 0000859737 2019-09-28 0000859737 us-gaap:CommonStockMember 2019-03-31 2019-06-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-12-29 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-12-30 2019-03-30 0000859737 us-gaap:TreasuryStockMember 2018-09-30 2018-12-29 0000859737 2019-06-30 2019-09-28 0000859737 us-gaap:CommonStockMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 2019-09-28 0000859737 holx:ShareRepurchaseProgramMember us-gaap:TreasuryStockMember 2019-09-29 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-03-30 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-12-29 0000859737 us-gaap:TreasuryStockMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-09-29 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-06-29 0000859737 2018-12-29 0000859737 us-gaap:CommonStockMember 2019-06-30 2019-09-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-30 2019-03-30 0000859737 us-gaap:RetainedEarningsMember 2019-03-30 0000859737 us-gaap:CommonStockMember 2019-09-28 0000859737 2019-09-29 2019-12-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 2019-09-28 0000859737 2019-03-30 0000859737 us-gaap:AccountingStandardsUpdate201616Member 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-29 0000859737 us-gaap:TreasuryStockMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2019-03-30 0000859737 us-gaap:CommonStockMember 2018-09-30 2018-12-29 0000859737 2018-09-30 2018-12-29 0000859737 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-12-29 0000859737 2019-06-29 0000859737 holx:ShareRepurchaseProgramMember us-gaap:TreasuryStockMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-29 0000859737 us-gaap:CommonStockMember 2019-09-29 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-09-29 2019-12-28 0000859737 us-gaap:AccountingStandardsUpdate201801Member us-gaap:RetainedEarningsMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2019-06-29 0000859737 us-gaap:TreasuryStockMember 2019-03-31 2019-06-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 2019-06-29 0000859737 us-gaap:TreasuryStockMember 2019-12-29 2020-03-28 0000859737 2019-03-31 2019-06-29 0000859737 us-gaap:RetainedEarningsMember 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-09-28 0000859737 us-gaap:RetainedEarningsMember 2018-09-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-29 2019-12-28 0000859737 us-gaap:RetainedEarningsMember 2019-09-28 0000859737 us-gaap:RetainedEarningsMember 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-12-28 0000859737 2019-12-28 0000859737 us-gaap:RetainedEarningsMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2018-09-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-29 0000859737 us-gaap:CommonStockMember 2018-12-30 2019-03-30 0000859737 us-gaap:TreasuryStockMember 2018-09-29 0000859737 2018-09-29 0000859737 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-12-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-28 0000859737 us-gaap:CommonStockMember 2019-12-28 0000859737 us-gaap:TreasuryStockMember 2019-09-28 0000859737 us-gaap:CommonStockMember 2019-12-29 2020-03-28 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-06-29 0000859737 us-gaap:TreasuryStockMember 2018-12-29 0000859737 us-gaap:CommonStockMember 2018-12-29 0000859737 us-gaap:AccountingStandardsUpdate201409Member 2018-12-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2018-09-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 2019-06-29 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-30 0000859737 us-gaap:RetainedEarningsMember 2019-06-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 2018-12-29 0000859737 us-gaap:AdditionalPaidInCapitalMember 2019-03-30 0000859737 holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 country:US holx:MedicalAestheticsDomain 2018-09-30 2019-03-30 0000859737 country:US 2018-09-30 2019-03-30 0000859737 holx:InternationalMember holx:GynSurgicalMember 2019-09-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2018-09-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 country:US holx:GynSurgicalMember 2019-09-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2018-09-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 country:US holx:SkeletalHealthMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 country:US holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 country:US holx:GynSurgicalMember 2018-09-30 2019-03-30 0000859737 holx:GynSurgicalMember 2018-09-30 2019-03-30 0000859737 country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2018-09-30 2019-03-30 0000859737 holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 country:US holx:SkeletalHealthMember 2018-09-30 2019-03-30 0000859737 holx:InternationalMember holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:InternationalMember 2019-09-29 2020-03-28 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 country:US 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 country:US holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:SkeletalHealthMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:InternationalMember 2018-09-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:GynSurgicalMember 2019-09-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 country:US holx:BreastHealthMember 2019-09-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2019-09-29 2020-03-28 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 holx:SkeletalHealthMember 2018-09-30 2019-03-30 0000859737 holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2018-09-30 2019-03-30 0000859737 holx:DiagnosticsMember 2019-09-29 2020-03-28 0000859737 holx:InternationalMember holx:GynSurgicalMember 2018-09-30 2019-03-30 0000859737 country:US holx:MedicalAestheticsDomain 2019-09-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2018-09-30 2019-03-30 0000859737 2024-03-29 2020-03-28 0000859737 2023-03-29 2020-03-28 0000859737 2022-03-29 2020-03-28 0000859737 2021-03-29 2020-03-28 0000859737 2020-03-29 2020-03-28 0000859737 holx:ConsumablesMember 2018-09-30 2019-03-30 0000859737 holx:ConsumablesMember 2019-12-29 2020-03-28 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2019-12-29 2020-03-28 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2018-12-30 2019-03-30 0000859737 holx:ConsumablesMember 2019-09-29 2020-03-28 0000859737 holx:OtherTypeofRevenueMember 2018-12-30 2019-03-30 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2019-09-29 2020-03-28 0000859737 holx:OtherTypeofRevenueMember 2019-09-29 2020-03-28 0000859737 holx:OtherTypeofRevenueMember 2019-12-29 2020-03-28 0000859737 us-gaap:ServiceMember 2019-09-29 2020-03-28 0000859737 us-gaap:ServiceMember 2018-09-30 2019-03-30 0000859737 holx:OtherTypeofRevenueMember 2018-09-30 2019-03-30 0000859737 us-gaap:ServiceMember 2018-12-30 2019-03-30 0000859737 holx:CapitalEquipmentComponentsandSoftwareMember 2018-09-30 2019-03-30 0000859737 us-gaap:ServiceMember 2019-12-29 2020-03-28 0000859737 holx:ConsumablesMember 2018-12-30 2019-03-30 0000859737 srt:AsiaPacificMember 2018-09-30 2019-03-30 0000859737 srt:EuropeMember 2019-12-29 2020-03-28 0000859737 srt:AsiaPacificMember 2019-12-29 2020-03-28 0000859737 holx:RestofWorldMember 2018-12-30 2019-03-30 0000859737 srt:AsiaPacificMember 2019-09-29 2020-03-28 0000859737 country:US 2018-12-30 2019-03-30 0000859737 srt:EuropeMember 2018-09-30 2019-03-30 0000859737 country:US 2019-12-29 2020-03-28 0000859737 holx:RestofWorldMember 2019-12-29 2020-03-28 0000859737 srt:EuropeMember 2018-12-30 2019-03-30 0000859737 srt:EuropeMember 2019-09-29 2020-03-28 0000859737 holx:RestofWorldMember 2019-09-29 2020-03-28 0000859737 holx:RestofWorldMember 2018-09-30 2019-03-30 0000859737 srt:AsiaPacificMember 2018-12-30 2019-03-30 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2019-12-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:GynSurgicalMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:SkeletalHealthMember 2018-12-30 2019-03-30 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 country:US holx:GynSurgicalMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 country:US holx:SkeletalHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember country:US holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember holx:InternationalMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember 2019-12-29 2020-03-28 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 country:US holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:GynSurgicalMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember 2018-12-30 2019-03-30 0000859737 country:US holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:SkeletalHealthMember 2019-12-29 2020-03-28 0000859737 holx:BloodScreeningMember country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 country:US holx:MedicalAestheticsDomain 2019-12-29 2020-03-28 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:MedicalAestheticsDomain 2019-12-29 2020-03-28 0000859737 holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:MolecularDiagnosticsMember holx:InternationalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:BloodScreeningMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:GynSurgicalMember 2019-12-29 2020-03-28 0000859737 country:US holx:GynSurgicalMember 2019-12-29 2020-03-28 0000859737 holx:CytologyPerinatalMember holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:InternationalMember holx:SkeletalHealthMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:GynSurgicalMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 country:US holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 country:US holx:SkeletalHealthMember 2019-12-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember country:US holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:InternationalMember holx:BreastHealthMember 2018-12-30 2019-03-30 0000859737 holx:BreastImagingMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:InterventionalBreastSolutionsMember holx:InternationalMember holx:BreastHealthMember 2019-12-29 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 holx:CytologyPerinatalMember country:US holx:DiagnosticsMember 2019-12-29 2020-03-28 0000859737 holx:MolecularDiagnosticsMember country:US holx:DiagnosticsMember 2018-12-30 2019-03-30 0000859737 srt:MinimumMember 2019-09-29 2020-03-28 0000859737 srt:MaximumMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccruedLiabilitiesMember 2020-03-28 0000859737 holx:FinanceLeaseObligationsLongTermMember 2020-03-28 0000859737 us-gaap:OtherAssetsMember 2020-03-28 0000859737 us-gaap:OtherNoncurrentLiabilitiesMember 2020-03-28 0000859737 holx:FinanceLeaseObligationsShortTermMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member 2020-03-28 0000859737 us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:ForeignExchangeContractMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 us-gaap:FairValueInputsLevel2Member us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:InterestRateSwapMember 2020-03-28 0000859737 holx:FocalTherapeuticsInc.Member 2019-09-29 2020-03-28 0000859737 holx:FaxitronMember 2019-09-29 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 us-gaap:FairValueInputsLevel3Member 2020-03-28 0000859737 us-gaap:FairValueInputsLevel1Member us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 us-gaap:ContingentConsiderationTypeDomain 2020-03-28 0000859737 holx:AcquiredintangibleassetsMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:CreditAgreementMember 2020-03-28 0000859737 us-gaap:EquipmentMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:A2028SeniorNotesMember 2020-03-28 0000859737 holx:A2025SeniorNotesMember 2020-03-28 0000859737 holx:HealthBeaconsMember 2020-03-28 0000859737 holx:FocalTherapeuticsInc.Member 2018-10-01 2018-10-01 0000859737 holx:HealthBeaconsMember 2019-12-29 2020-03-28 0000859737 holx:FocalTherapeuticsInc.Member 2019-10-01 2019-10-01 0000859737 holx:FocalTherapeuticsInc.Member 2019-03-30 0000859737 2019-11-21 2019-11-21 0000859737 holx:SuperSonicImagineMember 2019-11-21 2019-11-21 0000859737 us-gaap:OtherIncomeMember 2019-07-28 2019-09-28 0000859737 holx:SuperSonicImagineMember 2019-09-01 2019-09-30 0000859737 holx:AlphaImagingMember 2020-03-28 0000859737 holx:SuperSonicImagineMember 2019-08-01 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:TradeNamesMember 2018-10-01 2018-10-01 0000859737 holx:AlphaImagingMember 2019-12-30 2019-12-30 0000859737 holx:FocalTherapeuticsInc.Member 2018-10-01 0000859737 2019-11-01 2019-11-30 0000859737 holx:AlphaImagingMember 2019-03-30 0000859737 holx:SuperSonicImagineMember 2019-11-20 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:DevelopedTechnologyRightsMember 2018-10-01 2018-10-01 0000859737 holx:SuperSonicImagineMember 2019-08-01 2019-08-01 0000859737 srt:MaximumMember holx:FocalTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2018-10-01 2018-10-01 0000859737 srt:MinimumMember holx:FocalTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember us-gaap:MeasurementInputDiscountRateMember 2018-10-01 2018-10-01 0000859737 holx:SuperSonicImagineMember 2020-03-28 0000859737 holx:SuperSonicImagineMember 2019-11-21 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:InProcessResearchAndDevelopmentMember 2018-10-01 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:TradeNamesMember 2018-10-01 0000859737 holx:FocalTherapeuticsInc.Member us-gaap:DevelopedTechnologyRightsMember 2018-10-01 0000859737 holx:FaxitronMember us-gaap:CustomerRelationshipsMember 2018-07-31 2018-07-31 0000859737 holx:FaxitronMember us-gaap:DevelopedTechnologyRightsMember 2018-07-31 2018-07-31 0000859737 holx:EmsorMember 2017-12-11 2017-12-11 0000859737 holx:FaxitronMember us-gaap:TradeNamesMember 2018-07-31 2018-07-31 0000859737 us-gaap:CostOfSalesMember 2019-09-29 2019-12-28 0000859737 us-gaap:OperatingExpenseMember 2019-09-29 2019-12-28 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:MedicalAestheticsDomain 2019-11-20 2019-11-20 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:MedicalAestheticsDomain 2019-11-20 0000859737 us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember holx:MedicalAestheticsDomain 2019-12-28 0000859737 holx:TermLoanMember 2019-09-28 0000859737 holx:AccountsReceivableSecuritizationMember 2020-03-28 0000859737 holx:RevolverMember 2019-09-28 0000859737 holx:TermLoanMember 2020-03-28 0000859737 holx:A2025SeniorNotesMember 2019-09-28 0000859737 holx:A2025SeniorNotesMember 2020-03-28 0000859737 holx:A2028SeniorNotesMember 2020-03-28 0000859737 holx:AccountsReceivableSecuritizationMember 2019-09-28 0000859737 holx:RevolverMember 2020-03-28 0000859737 holx:SSIMember 2019-09-28 0000859737 holx:SSIMember 2020-03-28 0000859737 holx:A2028SeniorNotesMember 2019-09-28 0000859737 holx:CreditAgreementMember 2019-03-30 0000859737 holx:CreditAgreementMember 2019-12-29 2020-03-28 0000859737 holx:CreditAgreementMember 2018-09-30 2019-03-30 0000859737 holx:CreditAgreementMember 2019-09-29 2020-03-28 0000859737 holx:CreditAgreementMember 2018-12-30 2019-03-30 0000859737 2018-01-19 0000859737 2017-10-10 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-01-19 0000859737 holx:A2028SeniorNotesMember 2018-01-19 0000859737 holx:AmendedRevolverMember holx:PercentageAddedtoEurodollarRateMember 2019-09-29 2020-03-28 0000859737 holx:AmendedCreditAgreementMember 2019-09-29 2019-12-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2017-10-10 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2018-01-19 0000859737 holx:A2025SeniorNotesMember 2018-01-19 0000859737 holx:AmendedTermLoanMember holx:PercentageAddedtoEurodollarRateMember 2019-09-29 2020-03-28 0000859737 holx:AccountsReceivableSecuritizationMember 2019-12-29 2020-03-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-30 2019-03-30 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-12-30 2019-03-30 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2018-09-30 2019-03-30 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-29 2020-03-28 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2020-03-28 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2019-12-29 2020-03-28 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2018-09-30 2019-03-30 0000859737 holx:A2028SeniorNotesMember us-gaap:SeniorNotesMember 2019-09-29 2020-03-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2020-03-28 0000859737 holx:A2025SeniorNotesMember us-gaap:SeniorNotesMember 2019-09-29 2020-03-28 0000859737 holx:AmendedCreditAgreementMember holx:AmendedTermLoanMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-28 0000859737 us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeOptionMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:OtherAssetsMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2020-03-28 0000859737 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2019-09-28 0000859737 us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2020-03-28 0000859737 us-gaap:ForeignExchangeOptionMember 2019-09-29 2020-03-28 0000859737 us-gaap:ForeignExchangeOptionMember 2020-03-28 0000859737 2018-09-30 2019-09-28 0000859737 us-gaap:ForeignExchangeForwardMember 2019-09-29 2020-03-28 0000859737 us-gaap:ForeignExchangeForwardMember 2019-12-29 2020-03-28 0000859737 us-gaap:ForeignExchangeForwardMember 2018-12-30 2019-03-30 0000859737 us-gaap:ForeignExchangeOptionMember 2019-12-29 2020-03-28 0000859737 us-gaap:ForeignExchangeForwardMember 2018-09-30 2019-03-30 0000859737 us-gaap:ForeignExchangeOptionMember 2018-12-30 2019-03-30 0000859737 us-gaap:ForeignExchangeOptionMember 2018-09-30 2019-03-30 0000859737 us-gaap:InterestRateSwapMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2019-12-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateCapMember 2019-12-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember 2018-09-30 2019-03-30 0000859737 us-gaap:InterestRateSwapMember 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateCapMember 2018-09-30 2019-03-30 0000859737 holx:CynosureMember 2019-09-29 2020-03-28 0000859737 holx:MinervaMember 2016-03-04 2016-03-04 0000859737 holx:MinervaMember 2018-07-27 0000859737 us-gaap:StockCompensationPlanMember 2019-12-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2018-12-30 2019-03-30 0000859737 us-gaap:StockCompensationPlanMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 2019-03-30 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2019-09-29 2020-03-28 0000859737 us-gaap:StockCompensationPlanMember 2018-12-30 2019-03-30 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2019-12-29 2020-03-28 0000859737 us-gaap:StockCompensationPlanMember 2018-09-30 2019-03-30 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2019-12-29 2020-03-28 0000859737 us-gaap:SellingAndMarketingExpenseMember 2018-12-30 2019-03-30 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2019-09-29 2020-03-28 0000859737 us-gaap:CostOfSalesMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestructuringChargesMember 2018-12-30 2019-03-30 0000859737 us-gaap:SellingAndMarketingExpenseMember 2018-09-30 2019-03-30 0000859737 us-gaap:CostOfSalesMember 2018-09-30 2019-03-30 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2019-09-29 2020-03-28 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2018-09-30 2019-03-30 0000859737 us-gaap:RestructuringChargesMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestructuringChargesMember 2019-12-29 2020-03-28 0000859737 us-gaap:RestructuringChargesMember 2018-09-30 2019-03-30 0000859737 us-gaap:CostOfSalesMember 2019-12-29 2020-03-28 0000859737 us-gaap:SellingAndMarketingExpenseMember 2019-12-29 2020-03-28 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2018-12-30 2019-03-30 0000859737 us-gaap:CostOfSalesMember 2018-12-30 2019-03-30 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2019-12-29 2020-03-28 0000859737 us-gaap:ResearchAndDevelopmentExpenseMember 2018-09-30 2019-03-30 0000859737 us-gaap:SellingAndMarketingExpenseMember 2019-09-29 2020-03-28 0000859737 us-gaap:GeneralAndAdministrativeExpenseMember 2018-12-30 2019-03-30 0000859737 us-gaap:PerformanceSharesMember 2019-09-29 2020-03-28 0000859737 us-gaap:PerformanceSharesMember 2018-09-30 2019-03-30 0000859737 holx:RSUPSUMSUMember 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2018-09-30 2019-03-30 0000859737 us-gaap:EmployeeStockOptionMember 2020-03-28 0000859737 holx:MarketBasedAwardsMember 2019-09-29 2020-03-28 0000859737 us-gaap:EmployeeStockOptionMember 2018-09-30 2019-03-30 0000859737 holx:MarketBasedAwardsMember 2018-09-30 2019-03-30 0000859737 holx:PSUFreeCashFlowMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2019-09-29 2020-03-28 0000859737 us-gaap:EmployeeStockOptionMember 2019-09-29 2020-03-28 0000859737 us-gaap:RestrictedStockUnitsRSUMember 2020-03-28 0000859737 holx:AllOtherCountriesMember 2019-09-29 2020-03-28 0000859737 holx:AllOtherCountriesMember 2018-12-30 2019-03-30 0000859737 holx:AllOtherCountriesMember 2018-09-30 2019-03-30 0000859737 holx:AllOtherCountriesMember 2019-12-29 2020-03-28 0000859737 us-gaap:IntersegmentEliminationMember 2019-12-29 2020-03-28 0000859737 holx:DiagnosticsMember 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2020-03-28 0000859737 holx:BreastHealthMember 2019-09-28 0000859737 holx:GynSurgicalMember 2020-03-28 0000859737 holx:MedicalAestheticsDomain 2019-09-28 0000859737 holx:SkeletalHealthMember 2019-09-28 0000859737 us-gaap:CorporateMember 2020-03-28 0000859737 holx:SkeletalHealthMember 2020-03-28 0000859737 holx:BreastHealthMember 2020-03-28 0000859737 us-gaap:CorporateMember 2019-09-28 0000859737 holx:GynSurgicalMember 2019-09-28 0000859737 holx:DiagnosticsMember 2019-09-28 0000859737 us-gaap:CorporateMember 2019-09-29 2020-03-28 0000859737 us-gaap:CorporateMember 2018-09-30 2019-03-30 0000859737 us-gaap:CorporateMember 2018-12-30 2019-03-30 0000859737 us-gaap:CorporateMember 2019-12-29 2020-03-28 0000859737 us-gaap:IntersegmentEliminationMember 2018-09-30 2019-03-30 0000859737 us-gaap:IntersegmentEliminationMember 2019-09-29 2020-03-28 0000859737 us-gaap:IntersegmentEliminationMember 2018-12-30 2019-03-30 0000859737 holx:AcquiredintangibleassetsMember 2019-09-28 0000859737 holx:InternalusesoftwareMember 2020-03-28 0000859737 holx:DevelopedTechnologyMember 2019-09-28 0000859737 holx:InternalusesoftwareMember 2019-09-28 0000859737 holx:DevelopedTechnologyMember 2020-03-28 0000859737 holx:DistributionagreementMember 2020-03-28 0000859737 us-gaap:TradeNamesMember 2020-03-28 0000859737 holx:AcquiredintangibleassetsMember 2020-03-28 0000859737 holx:CapitalizedsoftwareMember 2019-09-28 0000859737 holx:BusinessLicensesMember 2019-09-28 0000859737 holx:DistributionagreementMember 2019-09-28 0000859737 holx:CustomerRelationshipsContractsMember 2020-03-28 0000859737 us-gaap:TradeNamesMember 2019-09-28 0000859737 us-gaap:NoncompeteAgreementsMember 2020-03-28 0000859737 us-gaap:NoncompeteAgreementsMember 2019-09-28 0000859737 holx:CapitalizedsoftwareMember 2020-03-28 0000859737 holx:CustomerRelationshipsContractsMember 2019-09-28 0000859737 holx:BusinessLicensesMember 2020-03-28 0000859737 us-gaap:CustomerRelationshipsMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 holx:DistributionagreementMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 us-gaap:TradeNamesMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 us-gaap:TradeNamesMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 us-gaap:CustomerRelationshipsMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:DevelopedTechnologyMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 holx:DevelopedTechnologyMember holx:MedicalAestheticsDomain 2019-09-29 2019-12-28 0000859737 holx:DistributionagreementMember holx:MedicalAestheticsDomain 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-29 2020-03-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-03-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-28 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-29 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-29 2020-03-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-29 2020-03-28 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateSwapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-29 2020-03-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-03-28 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-28 0000859737 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2019-03-30 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-30 2019-03-30 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 2019-03-30 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-29 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-03-30 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-09-29 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-29 0000859737 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-29 0000859737 us-gaap:InterestRateCapMember us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-29 0000859737 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-29 0000859737 holx:COVID19Member 2019-12-29 2020-03-28 0000859737 holx:SunnyvaleMember 2019-12-29 2020-03-28 0000859737 holx:CynosureMember 2019-12-29 2020-03-28 0000859737 holx:TepnelMember 2019-12-29 2020-03-28 0000859737 2019-11-20 2019-11-20 0000859737 holx:November192019PlanMember 2019-12-29 2020-03-28 0000859737 holx:June132019PlanMember 2019-12-29 2020-03-28 pure iso4217:USD shares shares iso4217:USD holx:Segment holx:petition false --09-28 Q2 2020 0000859737 P2Y P3M P9Y P9Y P8Y3M18D 17800000 16000000 0.01 0.01 750000000 750000000 292323000 294142000 0 0 0 0 0 300000 800000 -8100000 -6400000 0 0.01 0.01 1623000 1623000 0 0 P6M P1Y P1Y P1Y P1Y 0 0 0 0 24638000 35941000 10-Q true 2020-03-28 false 1-36214 HOLOGIC, INC DE 04-2902449 250 Campus Drive, Marlborough, MA 01752 (508) 263-2900 Common Stock, $0.01 par value HOLX NASDAQ Yes Yes Large Accelerated Filer false false false 258205678 623600000 667800000 1322900000 1350900000 132500000 150600000 283700000 298200000 756100000 818400000 1606600000 1649100000 223300000 232900000 460800000 465000000.0 62900000 80400000 126500000 161400000 0 374600000 25800000 374600000 74100000 88100000 163900000 171600000 395800000 42400000 829600000 476500000 49300000 57300000 110400000 110500000 110600000 133500000 255400000 279500000 66500000 89900000 155100000 168500000 10100000 14100000 19200000 28200000 0 69200000 4400000 69200000 2900000 1600000 3900000 3300000 239400000 365600000 548400000 659200000 156400000 -323200000 281200000 -182700000 1300000 800000 3500000 2100000 31300000 34800000 64100000 70900000 0 0 0 -800000 -7500000 3500000 -4200000 2900000 118900000 -353700000 216400000 -249400000 24100000 -81100000 -264300000 -75400000 94800000 -272600000 480700000 -174000000.0 -1500000 0 -1800000 0 96300000 -272600000 482500000 -174000000.0 0.37 -1.01 1.82 -0.64 0.36 -1.01 1.81 -0.64 263238000 269235000 265566000 269913000 264506000 269235000 267114000 269913000 94800000 -272600000 480700000 -174000000.0 -5400000 2400000 2900000 -800000 -25200000 -1500000 -21200000 -5400000 -400000 -500000 -1700000 -1200000 -30200000 1400000 -16600000 -5000000.0 64600000 -271200000 464100000 -179000000.0 1500000 0 1800000 0 1500000 0 1800000 0 66100000 -271200000 465900000 -179000000.0 799800000 601800000 597200000 648700000 401300000 444900000 62600000 34900000 75700000 62800000 1936600000 1793100000 445300000 470900000 1328800000 1459800000 2592000000.0 2563700000 519100000 154600000 6821800000 6442100000 806100000 271400000 134400000 186500000 366000000.0 430900000 172600000 179500000 1800000 1800000 1480900000 1070100000 2749300000 2783600000 18400000 19200000 235900000 275300000 15000000.0 15800000 231100000 162400000 0 0 2900000 2900000 5827600000 5769800000 -2206000000.0 -2688700000 1479500000 926000000.0 -58900000 -42300000 2086100000 2115700000 5100000 0 2091200000 2115700000 6821800000 6442100000 289900000 2900000 5671300000 -2494000000.0 -25500000 19812000 -725900000 0 2428800000 -6400000 -6400000 2500000 2500000 373000 9100000 9100000 575000 11600000 11600000 17100000 17100000 98600000 98600000 -6400000 -6400000 3712000 150100000 150100000 290848000 2900000 5685900000 -2386500000 -31900000 23524000 -876000000.0 0 2394400000 454000 11600000 11600000 33000 400000 400000 226000 7900000 7900000 17500000 17500000 -272600000 -272600000 1400000 1400000 291561000 2900000 5722500000 -2659100000 -30500000 23524000 -876000000.0 0 2159800000 108000 3100000 3100000 21000 500000 500000 13900000 13900000 93900000 93900000 -3700000 -3700000 1114000 50000000.0 50000000.0 291690000 2900000 5739000000.0 -2565200000 -34200000 24638000 -926000000.0 0 2216500000 369000 9000000.0 9000000.0 16000 300000 300000 248000 8600000 8600000 13500000 13500000 -123500000 -123500000 -8100000 -8100000 292323000 2900000 5769800000 -2688700000 -42300000 24638000 -926000000.0 0 2115700000 8600000 8600000 -300000 -300000 540000 13800000 13800000 476000 10900000 10900000 18100000 18100000 386100000 -300000 385800000 13600000 13600000 1545000 80900000 80900000 41000000.0 3279000 -164000000.0 205000000.0 1400000 1400000 293339000 2900000 5749800000 -2302300000 -28700000 29462000 -1170900000 6900000 2257700000 503000 13900000 13900000 86000 1600000 1600000 214000 8800000 8800000 15700000 15700000 96300000 -1500000 94800000 5851000 267600000 267600000 -41000000.0 628000 -41000000.0 0 300000 300000 294142000 2900000 5827600000 -2206000000.0 -58900000 35941000 -1479500000 5100000 2091200000 480700000 -174000000.0 42300000 46800000 145800000 189600000 33800000 34600000 -44200000 -173300000 30200000 443800000 -14800000 -14400000 300000 -18600000 33300000 54000000.0 27700000 8300000 317600000 10400000 -47900000 -27200000 -50800000 -71200000 5800000 8700000 231600000 238100000 43200000 108600000 142700000 0 29600000 23000000.0 33500000 28900000 0 3000000.0 2400000 0 1400000 3600000 32600000 -167100000 0 1500000000.0 18800000 1462500000 750000000.0 480000000.0 0 695000000.0 16000000.0 0 250000000.0 18000000.0 1700000 0 24300000 0 8300000 2500000 0 2700000 205000000.0 0 348500000 150100000 0 1500000 36600000 28800000 12500000 11900000 800000 800000 -67300000 -336200000 1100000 -500000 198000000.0 -265700000 601800000 666700000 799800000 401000000.0 Basis of Presentation<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended </span><span style="font-family:inherit;font-size:10pt;">September 28, 2019</span><span style="font-family:inherit;font-size:10pt;"> included in the Company’s Form 10-K filed with the SEC on November 27, 2019. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending </span><span style="font-family:inherit;font-size:10pt;">September 26, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">COVID-19 Considerations</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The pandemic caused by the spread of the novel strain of coronavirus disease 2019 ("COVID-19") has created significant volatility, uncertainty and economic disruption in the markets the Company sells its products into, primarily the U.S., Europe and Asia-Pacific. In the second quarter of fiscal 2020, the spread of COVID-19 has negatively impacted business activity globally. As healthcare systems respond to the increasing demands of managing COVID-19 and the resulting economic uncertainties, governments around the world have imposed measures designed to reduce the transmission of COVID-19, and individuals are responding to the fears of contracting COVID-19. In particular, elective procedures and exams are being delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals are postponing or cancelling capital purchases as well as limiting or eliminating services. These responses have had, and the Company believes will continue to have, a negative impact on the Company's operating results and cash flows. While the effects of COVID-19 and the associated economic disruptions were felt primarily in the second half of March in many of the Company's end-markets and earlier in Asia, primarily China, the Company expects the effect on its financial results in the third fiscal quarter to be significant. While the Company believes the impact on its business will begin to lessen in the fourth quarter and continue to do so in subsequent periods the impacts on these periods could be significant.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's belief is that COVID-19’s adverse impact on its operating results, cash flows and financial condition will be primarily driven by: the severity and duration of the COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. and international healthcare system, the U.S. economy and worldwide economy; and the timing, scope and effectiveness of U.S. and international governmental responses to the COVID-19 pandemic and associated economic disruptions.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In addition to adversely affecting demand for the Company's products, COVID-19 and associated economic disruptions could have an adverse impact on the Company's supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that it, other businesses and governments are taking. A reduction or interruption in any of the Company's manufacturing processes could have a material adverse effect on its business.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company expects that the uncertainty surrounding world financial markets and deteriorating worldwide macroeconomic conditions resulting from the pandemic have caused and may continue to cause the purchasers of medical equipment to decrease their medical equipment purchasing and procurement activities. Additionally, the pandemic has caused and may further cause constrictions in world credit markets that have and could cause its customers to experience increased difficulty in paying their existing obligations to the Company or in securing the financing necessary to purchase the Company's products. Economic uncertainty has and may continue to result in cost-conscious consumers focusing on acute care rather than wellness, which would also continue to adversely affect demand for the Company's products.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The terms of the Company's credit facilities require it to satisfy certain financial covenants. Should the Company's future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions over an extended period of time or otherwise, the Company cannot assure that it will remain in compliance with its current financial covenants. In such event, the factors that adversely affect the Company's business may also similarly adversely affect the capital markets, and the Company cannot assure that it would be able to negotiate alternative covenants or alternative financing on favorable terms if at all. The Company's failure to comply with the covenants contained in its credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect its results of operations and financial condition.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As the Company assessed the potential longer term economic and capital market uncertainties resulting from the COVID-19 pandemic, at the end of March 2020 the Company suspended its accounts receivable securitization program and borrowed $750.0 million under its revolver. The Company used $250.0 million of these proceeds to pay off all amounts then owed under its accounts receivable securitization agreement, and retained the balance as cash reserve. As of March 28, 2020 the Company had another $750.0 million available under its revolver.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the negative impact of COVID-19 on the Company's business, in April 2020 it initiated cost-cutting measures, which included not only reducing discretionary and variable spend, such as travel, marketing programs and the use of contractors, consultants and temporary help, but the Company also implemented employee furloughs, salary cuts primarily in the U.S., reduced hours and in certain instances employee terminations. Further, the Company has shut down certain manufacturing facilities temporarily and implemented reduced work-week schedules in response to lower near-term demand for many of its products. These actions, as they relate to the Company's manufacturing operations, are expected to reduce the efficiency of its manufacturing operations and could further adversely affect its results of operations. Future cost savings initiatives and other measures related to stopping the spread of COVID-19 could also adversely affect the Company's research and development activities, including its clinical trials.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has also taken measures to ensure the safety of its employees and to comply with governmental orders. These measures could require that the Company's employees refrain from traveling to their normal workplace for extended periods of time, which in turn could result in a decrease in its commercial and marketing activities.</span></div><div style="line-height:120%;padding-top:10px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of fiscal 2020, the FDA granted Emergency Use Authorization (EUA) for the Company's Panther Fusion SARS-CoV-2 assay for testing for the COVID-19 virus. The Company is in the process of completing development of a second SARS-CoV-2 assay which will run on its more widely distributed Panther instrument. The Company has installed more than 1,800 Panther instruments, which are used by clinical laboratories around the world. Subject to obtaining the required authorizations, the Company expects to introduce the assay in May. However, the Company can give no assurance that this assay will be developed and authorized on a timely basis, if at all, or if introduced, will be commercially successful.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), referred to as ASC 842. The purpose of ASU 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">expect to have a significant amount of sales-type leases. Under ASC 840, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$91.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$10.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, and corresponding operating lease liabilities and finance lease liabilities of </span><span style="font-family:inherit;font-size:10pt;"><span>$96.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$21.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. This includes recording the Company’s existing capital lease as a finance lease at transition. In addition, the Company derecognized </span><span style="font-family:inherit;font-size:10pt;"><span>$32.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of property, plant and equipment and </span><span style="font-family:inherit;font-size:10pt;"><span>$35.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> of finance lease obligations recorded in accrued expenses and other long-term liabilities associated with two previously existing build-to-suit lease arrangements. Right-of-use assets and corresponding liabilities for these build-to-suit lease arrangements are included within the total amount recognized upon adoption of the new lease standard. The Company’s adoption of ASC 842 is more fully described in Note 3.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The guidance requires certain changes to the presentation of hedge accounting in the financial statements and also simplifies the application of hedge accounting and expands the strategies that qualify for hedge accounting. The Company adopted the standard in the first quarter of fiscal 2020. The adoption of ASU 2017-12 did not have a material effect on the Company's consolidated financial statements.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Subsequent Events Consideration</span></div><span style="font-family:inherit;font-size:10pt;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events affecting the unaudited consolidated financial statements as of and for the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span>. 91700000 10200000 96600000 21000000.0 32600000 35200000 Revenue<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company accounts for revenue pursuant to ASC Update No. 2014-09, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customer</span><span style="font-family:inherit;font-size:10pt;"> (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays, surgical and interventional breast disposable products and until December 28, 2019 medical aesthetic treatment systems, and related services, which were primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:6%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 30, 2019</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Business (</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">in millions</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cytology &amp; Perinatal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Molecular Diagnostics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Blood Screening</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>238.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Imaging</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Breast Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>615.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:6%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 30, 2019</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Business (in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cytology &amp; Perinatal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>233.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Molecular Diagnostics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Blood Screening</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>454.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Imaging</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>535.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Breast Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>490.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>505.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,207.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,237.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>411.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Geographic Regions (</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">in millions</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>615.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,207.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,237.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia-Pacific</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rest of World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenue recognized by source:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue by type (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital equipment, components and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consumables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>457.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>923.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>863.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company recognizes a receivable when it has an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of stand-alone selling price using average selling prices over 3 to 12 month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Variable Consideration</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts.</span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company's contracts typically do not provide the right to return product. In general, estimates of variable consideration and constraints are not material to the Company's financial statements.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Remaining Performance Obligations</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of March 28, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$583.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. This remaining performance obligation primarily relates to extended warranty and support and maintenance obligations in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately </span><span style="font-family:inherit;font-size:10pt;"><span>23%</span></span><span style="font-family:inherit;font-size:10pt;"> of this amount as revenue in 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>32%</span></span><span style="font-family:inherit;font-size:10pt;"> in 2021, </span><span style="font-family:inherit;font-size:10pt;"><span>24%</span></span><span style="font-family:inherit;font-size:10pt;"> in 2022, </span><span style="font-family:inherit;font-size:10pt;"><span>14%</span></span><span style="font-family:inherit;font-size:10pt;"> in 2023, and </span><span style="font-family:inherit;font-size:10pt;"><span>7%</span></span><span style="font-family:inherit;font-size:10pt;"> thereafter. The Company has applied the practical expedient to not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Contract Assets and Liabilities</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial. </span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and Skeletal Health reportable segments and until recently the divested Medical Aesthetics segment. Contract liabilities are classified as other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The Company recognized revenue of </span><span style="font-family:inherit;font-size:10pt;"><span>$26.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> </span></div><span style="font-family:inherit;font-size:10pt;">and </span><span style="font-family:inherit;font-size:10pt;">$77.5 million</span> in the three and six months ended March 28, 2020 that was included in the contract liability balance at September 28, 2019. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:<div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:6%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 30, 2019</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Business (</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">in millions</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics:</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cytology &amp; Perinatal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.9</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>115.5</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Molecular Diagnostics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>149.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>190.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>136.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>167.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Blood Screening</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>238.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>81.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>226.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Imaging</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>186.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>250.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>206.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Breast Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>48.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>253.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>86.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>84.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>181.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>615.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>202.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:6%;"/><td style="width:27%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 30, 2019</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Business (in millions)</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">United States</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">International</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cytology &amp; Perinatal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.7</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.4</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>233.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Molecular Diagnostics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>291.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>369.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>270.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>332.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Blood Screening</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>469.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>160.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>454.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>139.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Imaging</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>395.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>129.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>412.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>122.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>535.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interventional Breast Solutions</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>95.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>113.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>92.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>110.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>490.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>148.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>505.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>140.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>185.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>39.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>175.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>78.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,207.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,237.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>411.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Geographic Regions (</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;font-style:italic;">in millions</span><span style="font-family:inherit;font-size:9pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>574.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>615.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,207.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,237.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>221.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>203.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia-Pacific</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>64.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>111.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>134.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rest of World</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>36.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>66.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides revenue recognized by source:</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Revenue by type (in millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital equipment, components and software</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>239.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>399.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>487.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Consumables</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>457.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>428.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>923.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>863.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Service</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>127.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>141.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>272.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>283.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 73200000 40200000 113400000 76600000 38900000 115500000 149800000 40800000 190600000 136800000 31000000.0 167800000 15200000 0 15200000 13400000 0 13400000 238200000 81000000.0 319200000 226800000 69900000 296700000 186000000.0 64200000 250200000 206200000 59700000 265900000 48400000 9200000 57600000 46800000 8800000 55600000 234400000 73400000 307800000 253000000.0 68500000 321500000 86700000 18700000 105400000 84100000 18100000 102200000 0 0 0 37600000 36200000 73800000 15600000 8100000 23700000 14000000.0 10200000 24200000 574900000 181200000 756100000 615500000 202900000 818400000 150700000 83700000 234400000 155800000 77800000 233600000 291900000 77200000 369100000 270900000 61200000 332100000 27200000 0 27200000 27600000 0 27600000 469800000 160900000 630700000 454300000 139000000.0 593300000 395400000 129600000 525000000.0 412700000 122900000 535600000 95500000 18400000 113900000 92900000 17700000 110600000 490900000 148000000.0 638900000 505600000 140600000 646200000 185500000 39000000.0 224500000 175200000 35400000 210600000 30900000 34400000 65300000 74900000 78700000 153600000 30500000 16700000 47200000 27200000 18200000 45400000 1207600000 399000000.0 1606600000 1237200000 411900000 1649100000 574900000 615500000 1207600000 1237200000 111800000 102100000 221200000 203200000 41700000 64300000 111800000 134000000.0 27700000 36500000 66000000.0 74700000 756100000 818400000 1606600000 1649100000 166600000 239400000 399500000 487800000 457000000.0 428400000 923400000 863100000 127200000 141100000 272200000 283000000.0 5300000 9500000 11500000 15200000 756100000 818400000 1606600000 1649100000 583500000 0.23 0.32 0.24 0.14 0.07 26200000 Leases<div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessee Activity - Leases where Hologic is the Lessee</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;"> and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>2.59%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease right-of-use assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - short term</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - long term</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.93</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.14</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:3%;"/><td style="width:59%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets arising from entering into new operating lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessor Activity - Leases where Hologic is the Lessor</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s consolidated revenue for both the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.</span></div> Leases<div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessee Activity - Leases where Hologic is the Lessee</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;"> and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>2.59%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease right-of-use assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - short term</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - long term</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.93</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.14</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:3%;"/><td style="width:59%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets arising from entering into new operating lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessor Activity - Leases where Hologic is the Lessor</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s consolidated revenue for both the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.</span></div> Leases<div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessee Activity - Leases where Hologic is the Lessee</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;"> and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>2.59%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease right-of-use assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - short term</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - long term</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.93</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.14</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:3%;"/><td style="width:59%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets arising from entering into new operating lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessor Activity - Leases where Hologic is the Lessor</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s consolidated revenue for both the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.</span></div> Leases<div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessee Activity - Leases where Hologic is the Lessee</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;">. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> to approximately </span><span style="font-family:inherit;font-size:10pt;"><span>15 years</span></span><span style="font-family:inherit;font-size:10pt;">, some of which may include options to extend the leases for up to </span><span style="font-family:inherit;font-size:10pt;"><span>20 years</span></span><span style="font-family:inherit;font-size:10pt;"> and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> was </span><span style="font-family:inherit;font-size:10pt;"><span>2.59%</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease right-of-use assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - short term</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - long term</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were </span><span style="font-family:inherit;font-size:10pt;"><span>$1.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.93</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.14</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:3%;"/><td style="width:59%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets arising from entering into new operating lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.</span></div><div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Lessor Activity - Leases where Hologic is the Lessor</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately </span><span style="font-family:inherit;font-size:10pt;"><span>3%</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company’s consolidated revenue for both the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.</span></div> P1Y P1Y P15Y P20Y 0.0259 82600 22100 1800 68700 18400 1800000 19200000 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:60.546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/><td style="width:22%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average remaining lease term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.93</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.14</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average discount rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.95</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents supplemental balance sheet information related to the Company's operating and finance leases:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:36%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Balance Sheet Location</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Lease right-of-use assets </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>82.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accrued expenses</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - short term</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other long-term liabilities</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>68.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease liabilities (non-current)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Finance lease obligations - long term</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> P5Y11M4D P8Y1M20D 0.0195 0.051 <div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table provides information related to the Company’s operating and finance leases:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:3%;"/><td style="width:59%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating lease cost (a)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - amortization of right-of-use assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finance lease cost - interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from finance leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financing cash flows from finance leases</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total cash paid for amounts included in the measurement of lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">ROU assets arising from entering into new operating lease obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.</span></div> 6800 13800 0 300 300 500 300 500 5700 11700 400 900 6400 13100 3300 4700 <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:16px;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.3828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Fiscal Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating Leases</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Finance Lease</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2020 remaining</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2022</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Total future minimum lease payments</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>96.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less: imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Present value of lease liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 11900 1400 22500 2900 17800 3000.0 11400 3000.0 9300 3000.0 23900 11400 96800 24700 6000.0 4500 90800 20200 0.03 Fair Value Measurements<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company has investments in derivative instruments consisting of interest rate caps, interest rate swaps and foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 8 for further discussion and information on derivative instruments. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:12pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value at Reporting Date Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Market for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs (Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs (Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency option contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps - derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets Measured and Recorded at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had contingent consideration liabilities related to its Emsor S.A. and Faxitron Bioptics, LLC acquisitions. The remeasurement of these liabilities in the second quarter of fiscal 2020 was insignificant, and the Company settled these obligations for </span><span style="font-family:inherit;font-size:10pt;"><span>$9.8 million</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;padding-top:24px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Assets Measured and Recorded at Fair Value on a Nonrecurring Basis</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. There were no such remeasurements for equity investments in the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. During the first quarter of fiscal 2020, the Company's Medical Aesthetics division met the criteria to be classified as assets-held-for sale and the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> loss to record the asset group at its fair value less costs to sell. This is a level 1 measurement. See Note 6 for additional information. During the second quarter of fiscal 2019, the Company identified indicators of impairment related to its long-lived assets of its Medical Aesthetics reportable segment and recorded impairment charges of </span><span style="font-family:inherit;font-size:10pt;"><span>$443.8 million</span></span><span style="font-family:inherit;font-size:10pt;">, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$437.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to intangible assets and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to equipment. This was a level 3 measurement. See Note 15.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Disclosure of Fair Value of Financial Instruments</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, interest rate caps, interest rate swaps, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts are recorded at </span></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">fair value. The carrying amount of the insurance contracts is recorded at the cash surrender value, as required by GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amounts outstanding under the Company’s 2018 Credit Agreement (as defined below) of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.2 billion</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> are subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2025 Senior Notes and 2028 Senior Notes had fair values of </span><span style="font-family:inherit;font-size:10pt;"><span>$947.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$402.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> based on their trading prices, representing Level 1 measurements. Refer to Note 7 for the carrying amounts of the various components of the Company’s debt.</span></div> <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">:</span><span style="font-family:inherit;font-size:12pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:38%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Fair Value at Reporting Date Using</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance as of March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Quoted Prices in</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Active Market for</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Identical Assets</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">(Level 1)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Observable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs (Level 2)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Significant</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Unobservable</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Inputs (Level 3)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency option contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Contingent consideration</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swaps - derivative</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 900000 0 900000 0 1900000 0 1900000 0 2800000 0 2800000 0 900000 0 0 900000 22900000 0 22900000 0 23800000 0 22900000 900000 9800000 30200000 443800000 437000000.0 6800000 2200000000 947600000 402100000 Business Combinations<div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Focal Therapeutics</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 1, 2018, the Company completed the acquisition of Focal Therapeutics, Inc. ("Focal") for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$120.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, which included hold-backs of </span><span style="font-family:inherit;font-size:10pt;"><span>$14.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> payable up to </span><span style="font-family:inherit;font-size:10pt;"><span>one year</span></span><span style="font-family:inherit;font-size:10pt;"> from the date of acquisition. In the second quarter of fiscal 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the hold-back was paid, and the remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$12.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> was paid on October 1, 2019. Focal, headquartered in California, manufactures and markets its BioZorb marker, which is an implantable three-dimensional marker that helps clinicians overcome certain challenges in breast conserving surgery. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.5390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing the purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of Focal's business. As part of the purchase price allocation, the Company determined the identifiable intangible assets were developed technology, in-process research and development ("IPR&amp;D"), and trade names. The fair value of the intangible assets was estimated using the income approach, and the cash flow projections were discounted using rates ranging from </span><span style="font-family:inherit;font-size:10pt;"><span>15.5%</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>16.5%</span></span><span style="font-family:inherit;font-size:10pt;">. The cash flows were based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life of developed technology and trade names was </span><span style="font-family:inherit;font-size:10pt;"><span>11</span></span><span style="font-family:inherit;font-size:10pt;"> years and </span><span style="font-family:inherit;font-size:10pt;"><span>13</span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively. The calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the amount of goodwill were based on synergistic benefits that are expected to be realized from this acquisition. Benefits include the expectation of broadening the Company's Breast Health portfolio of products and technology. None of the goodwill is expected to be deductible for income tax purposes.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">SuperSonic Imagine</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On August 1, 2019, the Company purchased </span><span style="font-family:inherit;font-size:10pt;"><span>46%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of SuperSonic Imagine ("SSI") for </span><span style="font-family:inherit;font-size:10pt;"><span>$18.2 million</span></span><span style="font-family:inherit;font-size:10pt;">. SSI is a public company located in Aix-en-Provence, France that manufactures and markets ultrasound medical imaging equipment. In September 2019, the Company launched a cash tender offer to acquire the remaining outstanding shares </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">for a price of </span><span style="font-family:inherit;font-size:10pt;"><span>€1.50</span></span><span style="font-family:inherit;font-size:10pt;"> per share in cash. The Company determined that SSI was a Variable Interest Entity (“VIE”) but it was not the primary beneficiary as it was not a party to the initial design of the entity nor did it have control over SSI's operations until November 21, 2019 when the Company's ownership of SSI's voting stock exceeded </span><span style="font-family:inherit;font-size:10pt;"><span>50%</span></span><span style="font-family:inherit;font-size:10pt;">. Accordingly, the Company initially accounted for this investment under the equity method of accounting and included its proportionate share of SSI's net loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the two months ended September 28, 2019 within Other (expense) income, net. </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 21, 2019, the Company acquired an additional </span><span style="font-family:inherit;font-size:10pt;"><span>7.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of SSI for </span><span style="font-family:inherit;font-size:10pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. As a result, the Company owned approximately </span><span style="font-family:inherit;font-size:10pt;"><span>78%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of SSI at November 21, 2019 and controlled SSI's voting interest and operations. The Company performed purchase accounting as of November 21, 2019 and beginning on that date the financial results of SSI are included within the Company's consolidated financial statements. The Company remeasured the initial investment of </span><span style="font-family:inherit;font-size:10pt;"><span>46%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of SSI to its fair value at the acquisition date, resulting in a gain of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> recorded in the first quarter of fiscal 2020. The total accounting purchase price was </span><span style="font-family:inherit;font-size:10pt;"><span>$69.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, which consisted of </span><span style="font-family:inherit;font-size:10pt;"><span>$17.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> for the equity method investment in SSI, </span><span style="font-family:inherit;font-size:10pt;"><span>$12.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> for shares acquired on November 21, 2019, </span><span style="font-family:inherit;font-size:10pt;"><span>$30.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> for loans the Company provided to SSI prior to the acquisition that are considered forgiven, and </span><span style="font-family:inherit;font-size:10pt;"><span>$8.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> representing the fair value of the noncontrolling interest as of November 21, 2019. As of March 28, 2020, the Company owned approximately </span><span style="font-family:inherit;font-size:10pt;"><span>81%</span></span><span style="font-family:inherit;font-size:10pt;"> of the outstanding shares of SSI.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.5390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short and long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable intangible assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In performing the preliminary purchase price allocation, the Company considered, among other factors, the intended future use of acquired assets, analysis of historical financial performance and estimates of future performance of SSI's business. The Company has not yet obtained all of the information related to the fair value of the acquired assets and liabilities, primarily taxes, to finalize the purchase price allocation. </span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As part of the preliminary purchase price allocation, the Company has determined the identifiable intangible assets are developed technology, customer relationships, and trade names. The preliminary fair value of the intangible assets has been estimated using the income approach, and the cash flow projections were discounted using a </span><span style="font-family:inherit;font-size:10pt;"><span>12.0%</span></span><span style="font-family:inherit;font-size:10pt;"> rate. The cash flows are based on estimates used to price the transaction, and the discount rates applied were benchmarked with reference to the implied rate of return from the transaction model and the weighted average cost of capital. The weighted average life for the developed technology is </span><span style="font-family:inherit;font-size:10pt;">9 years</span><span style="font-family:inherit;font-size:10pt;">, customer relationships is </span><span style="font-family:inherit;font-size:10pt;">9 years</span><span style="font-family:inherit;font-size:10pt;"> and for trade names it is </span><span style="font-family:inherit;font-size:10pt;">8.6 years</span><span style="font-family:inherit;font-size:10pt;">. The preliminary calculation of the excess of the purchase price over the estimated fair value of the tangible net assets and intangible assets acquired was recorded to goodwill. The factors contributing to the recognition of the preliminary amount of goodwill are based on synergistic benefits of SSI's products being complementary to Breast Health's 3D mammography systems and using the Company's existing U.S. sales force as SSI's presence in the U.S. is limited. None of the goodwill is expected to be deductible for income tax purposes.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Alpha Imaging</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 30, 2019, the Company completed the acquisition of assets from Alpha Imaging, LLC ("Alpha Imaging"), for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$18.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, which included a hold-back of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and contingent consideration which the Company has estimated at </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">. The contingent consideration is payable upon shipment of backlog orders entered into by Alpha Imaging prior to the acquisition. Alpha Imaging was a long-standing distributor of the Company's Breast and Skeletal products in the U.S. Based on the Company's preliminary valuation, it has allocated </span><span style="font-family:inherit;font-size:10pt;"><span>$18.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the purchase price to a customer relationships intangible asset, which has a useful life of 5 years. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities.</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Health Beacons</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 3, 2020, the Company completed the acquisition of Health Beacons, Inc. ("Health Beacons"), for a purchase price of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.3 million</span></span><span style="font-family:inherit;font-size:10pt;">, which included hold-backs of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> that are payable up to eighteen months from the date of acquisition. Health Beacons manufactures the LOCalizer product that is sold by Faxitron Bioptics, LLC ("Faxitron"), which the Company acquired in July 2018. Based on the Company's preliminary valuation, it has allocated </span><span style="font-family:inherit;font-size:10pt;"><span>$10.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the purchase price to the preliminary value of intangible assets and </span><span style="font-family:inherit;font-size:10pt;"><span>$5.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> to goodwill. The remaining </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the purchase price has been allocated to acquired tangible assets and liabilities. The allocation of the purchase price is preliminary as the Company continues to gather information supporting the acquired assets and liabilities.</span></div> 120100000 14000000.0 P1Y 1500000 12500000 <div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.5390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>83.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       In-process research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>11.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(12.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>120.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2200000 2000000.0 7900000 500000 5600000 2500000 83100000 11400000 2700000 12700000 31100000 120100000 0.155 0.165 P11Y P13Y 0.46 18200000 1.50 0.50 3300000 7600000 12600000 0.78 0.46 3200000 69300000 17900000 12600000 30200000 8600000 0.81 <div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows:</span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.5390625%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:75%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts receivable</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(13.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Short and long-term debt</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(8.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable intangible assets:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">—</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Developed technology</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>38.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">       Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred income taxes, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Purchase Price</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>69.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2600000 7100000 10000000.0 6500000 4400000 13000000.0 1800000 8800000 3800000 38300000 4000000.0 3000000.0 1500000 22400000 69400000 0.120 18000000.0 1000000.0 900000 18100000 19300000 2300000 10700000 5700000 2900000 Disposition<div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Sale of Medical Aesthetics</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier &amp; Rice ("CD&amp;R") for a sales price of </span><span style="font-family:inherit;font-size:10pt;"><span>$205.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of </span><span style="font-family:inherit;font-size:10pt;"><span>$153.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. The sale price remains subject to adjustment pursuant to the terms of the definitive agreement. The Company agreed to provide certain transition services for three to fifteen months, depending on the nature of the service. The Company also agreed to indemnify CD&amp;R for certain legal and tax matters that existed as of the date of disposition. In connection with its accounting for the sale, the Company recorded indemnification liabilities of $10.9 million within accrued expenses associated with its obligations under the sale agreement.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, asset groups under this designation are required to be recorded at fair value less costs to sell. The Company determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or will have a major effect on the Company's operations and financial results. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services and the amount that must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&amp;R, the Company recorded an impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$30.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which </span><span style="font-family:inherit;font-size:10pt;"><span>$25.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> was allocated to cost of product revenues and </span><span style="font-family:inherit;font-size:10pt;"><span>$4.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> to operating expenses. The Company is currently in the process of evaluating adjustments to the final sales price.</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The assets and liabilities of the disposed business at the date of disposition were as follows:</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.3671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts Receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets disposed of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities disposed of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations of the disposed business presented below represents the operating loss of the business as it was operated prior to the date of disposition. The operating expenses include only those that were incurred directly by and were retained by the disposed business. As noted above, the Company is performing a number of transition services and the financial impact from these services are not included in the amounts presented below. In addition, the Company will continue to incur expenses related to this business under the indemnification provisions primarily related to legal and tax matters that existed as of the date of disposition, which it will continued to report in the Medical Aesthetic reportable segment. In the second quarter of fiscal 2020, the Company recorded accelerated stock compensation in connection with the disposition, legal expenses for retained cases and other adjustments totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$2.4 million</span></span><span style="font-family:inherit;font-size:10pt;">, which is not included below. Loss from operations of the disposed business for the three and six month periods ended March 28, 2020 and March 30, 2019 was as follows:</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(468.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(488.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 205000000.0 153400000 30200000 25800000 4400000 <div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.3671875%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cash</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts Receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Inventory</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>90.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Property, plant, and equipment</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total assets disposed of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>49.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Deferred revenue</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total liabilities disposed of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>77.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 10700 59600 90600 7700 4000.0 28200 9800 210600 12300 49000.0 16600 77900 2400000 from operations of the disposed business for the three and six month periods ended March 28, 2020 and March 30, 2019 was as follows:<div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="6" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Loss from operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(468.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(46.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(488.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 -468300 -46500 -488700 Borrowings and Credit Arrangements<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s borrowings consisted of the following:</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current debt obligations, net of debt discount and deferred issuance costs:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolver</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securitization Program</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current debt obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>806.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt obligations, net of debt discount and deferred issuance costs:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,416.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,452.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt assumed from SSI acquisition </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>938.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>937.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2028 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>393.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,749.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,783.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,555.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,055.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2018 Amended and Restated Credit Agreement</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On December 17, 2018, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement dated as of October 3, 2017 (the "2017 Credit Agreement"). The borrowings of the 2018 Amended Term Loan bear interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate, which was equal to </span><span style="font-family:inherit;font-size:10pt;"><span>1.375%</span></span><span style="font-family:inherit;font-size:10pt;"> as of March 28, 2020. The borrowings of the 2018 Amended Revolver bear interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate equal to </span><span style="font-family:inherit;font-size:10pt;"><span>1.375%</span></span><span style="font-family:inherit;font-size:10pt;">. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Pursuant to ASC 470, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Debt </span><span style="font-family:inherit;font-size:10pt;">(ASC 470), the accounting related to entering into the 2018 Credit Agreement and using the proceeds to pay off the 2017 Credit Agreement was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2017 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in the first quarter of fiscal 2019. For the remainder of the creditors, this transaction was accounted for as a modification because on a creditor-by-creditor basis the present value of the cash flows between the two debt instruments before and after the transaction was less than </span><span style="font-family:inherit;font-size:10pt;"><span>10%</span></span><span style="font-family:inherit;font-size:10pt;">. Pursuant to ASC 470, subtopic 50-40, third-party costs of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> related to this transaction were recorded as interest expense and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> was recorded as a reduction to debt representing deferred issuance costs and debt discount for fees paid directly to the lenders.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In response to the current market uncertainties created by the COVID-19 pandemic, in March 2020, the Company borrowed </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> under its revolver, which it intends to repay within one year, </span><span style="font-family:inherit;font-size:10pt;"><span>$250 million</span></span><span style="font-family:inherit;font-size:10pt;"> of which was used to pay off amounts outstanding under the asset securitization agreement, in order to have sufficient cash on hand. The Company has another </span><span style="font-family:inherit;font-size:10pt;"><span>$750 million</span></span><span style="font-family:inherit;font-size:10pt;"> available under its revolver as of March 28, 2020.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense, weighted average interest rate, and interest rate at the end of period under the Credit Agreements were as follows: </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;text-indent:30px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.86</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.93</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.84</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate at end of period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The 2018 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2018 Credit Agreement. As of March 28, 2020, the Company was in compliance with these covenants.</span></div><div style="line-height:120%;padding-left:96px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Senior Notes</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 10, 2017, the Company completed a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>$350 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of its </span><span style="font-family:inherit;font-size:10pt;"><span>4.375%</span></span><span style="font-family:inherit;font-size:10pt;"> Senior Notes due 2025 (the "2025 Senior Notes") at an offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the 2025 Senior Notes.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On January 19, 2018, the Company completed a private placement of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amount of senior notes, allocated between (i) an additional </span><span style="font-family:inherit;font-size:10pt;"><span>$600 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amounts of its 2025 Senior Notes pursuant to a supplement to the indenture governing the Company's existing 2025 Senior Notes at an offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the 2025 Senior Notes and (ii) </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;"> aggregate principal amounts of its </span><span style="font-family:inherit;font-size:10pt;"><span>4.625%</span></span><span style="font-family:inherit;font-size:10pt;"> Senior Notes due 2028 (the "2028 Senior Notes") at an offering price of </span><span style="font-family:inherit;font-size:10pt;"><span>100%</span></span><span style="font-family:inherit;font-size:10pt;"> of the aggregate principal amount of the 2028 Senior Notes. </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2025 Senior Notes</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The total aggregate principal balance of 2025 Senior Notes is </span><span style="font-family:inherit;font-size:10pt;"><span>$950 million</span></span><span style="font-family:inherit;font-size:10pt;">. The 2025 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on October 15, 2025.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">2028 Senior Notes</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate principal balance of the 2028 Senior Notes is </span><span style="font-family:inherit;font-size:10pt;"><span>$400 million</span></span><span style="font-family:inherit;font-size:10pt;">. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on February 1, 2028. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:27%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2028 Senior Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.625</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 Senior Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable Securitization Program</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 26, 2020, the Company paid-off the total amount outstanding of </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> previously borrowed under the Accounts Receivable Securitization Program (the "Securitization Program"). As of March 28, 2020, the Company did not have any borrowings under this program. On April 13, 2020, the Company amended the Credit and Security agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:12pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s borrowings consisted of the following:</span><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Current debt obligations, net of debt discount and deferred issuance costs:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>37.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revolver</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>750.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Securitization Program</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>234.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total current debt obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>806.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>271.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Long-term debt obligations, net of debt discount and deferred issuance costs:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Term Loan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,416.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,452.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Debt assumed from SSI acquisition </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>938.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>937.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2028 Senior Notes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>394.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>393.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total long-term debt obligations</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,749.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,783.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total debt obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,555.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,055.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 56100000 37400000 750000000.0 0 0 234000000.0 806100000 271400000 1416200000 1452400000 600000 0 938300000 937300000 394200000 393900000 2749300000 2783600000 3555400000 3055000000.0 0.01375 0.01375 800000 0.10 800000 1900000 750000000 250000000 750000000 <div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div>Interest expense, weighted average interest rate, and interest rate at the end of period under the Credit Agreements were as follow 13000000.0 16800000 26600000 35500000 0.0275 0.0386 0.0293 0.0384 0.0233 0.0387 0.0233 0.0387 350000000 0.04375 1 1000000000.0 600000000 1 400000000 0.04625 1 950000000 400000000 8. <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows:</span></div><div style="line-height:120%;padding-top:16px;text-align:center;text-indent:32px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:90.625%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"/></tr><tr><td style="width:27%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2028 Senior Notes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.625</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>9.6</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">2025 Senior Notes</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.375</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Accounts Receivable Securitization Program</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On March 26, 2020, the Company paid-off the total amount outstanding of </span><span style="font-family:inherit;font-size:10pt;"><span>$250.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> previously borrowed under the Accounts Receivable Securitization Program (the "Securitization Program"). As of March 28, 2020, the Company did not have any borrowings under this program. On April 13, 2020, the Company amended the Credit and Security agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year.</span></div> 0.04625 4800000 4800000 9600000 9600000 0.04375 10900000 10900000 21800000 21800000 15700000 15700000 31400000 31400000 250000000.0 Derivatives<div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Cap - Cash Flow Hedge</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Operations.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable interest rate on amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was </span><span style="font-family:inherit;font-size:10pt;"><span>$3.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was the initial fair value of the instruments recorded in the Company's financial statements. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was </span><span style="font-family:inherit;font-size:10pt;"><span>$1.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, which was the initial fair value of the instruments recorded in the Company’s financial statements.    </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under its Credit Agreement, that has been amended multiple times, and therefore are highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of principal, which ended on December 27, 2019 for the contracts entered into in fiscal 2018, and which will end on December 23, 2020 for the interest rate cap agreements entered into in fiscal 2019.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, all changes in the fair value of the interest rate caps were recorded in the Consolidated Statements of Comprehensive Income (Loss).</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, the Company reclassified </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.7 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively and $0.5 million and $1.2 million, respectively from AOCI to the Consolidated Statements of Operations related to the interest rate cap agreements. The Company expects to similarly reclassify a loss of approximately </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> from AOCI to the Consolidated Statements of Operations in the next nine months.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The aggregate fair value of these interest rate caps was </span><span style="font-family:inherit;font-size:10pt;"><span>$0.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> at </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">September 28, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, and is included in prepaid expenses and other current assets on the Company’s Consolidated Balance Sheet. Refer to Note 4 “Fair Value Measurements” above for related fair value disclosures.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Interest Rate Swap - Cash Flow Hedge</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In fiscal 2019, in order to hedge a portion of its variable rate debt beyond the contracted period under interest cap agreements, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The notional amount of this swap is </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;">. The interest rate swap effectively fixes the LIBOR component of the variable interest rate on </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of the notional amount under the 2018 Credit Agreement at </span><span style="font-family:inherit;font-size:10pt;"><span>1.23%</span></span><span style="font-family:inherit;font-size:10pt;">. The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the LIBOR-based interest payments on </span><span style="font-family:inherit;font-size:10pt;"><span>$1.0 billion</span></span><span style="font-family:inherit;font-size:10pt;"> of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of this derivative was in a liability position of </span><span style="font-family:inherit;font-size:10pt;"><span>$22.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Forward Foreign Currency Contracts and Foreign Currency Option Contracts</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these forward foreign currency contracts and foreign currency option contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, for the forward foreign currency exchange contracts the </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company recorded net realized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> in both periods from settling forward foreign currency exchange contracts and net unrealized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended March 30, 2019, the Company recorded net realized gains of </span><span style="font-family:inherit;font-size:10pt;">$1.8 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$3.5 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, from settling forward foreign currency contracts and net unrealized loss of </span><span style="font-family:inherit;font-size:10pt;">$1.4 million</span><span style="font-family:inherit;font-size:10pt;"> and net realized gain of </span><span style="font-family:inherit;font-size:10pt;">$2.0 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, for the foreign currency option contracts the Company recorded net unrealized gains of </span><span style="font-family:inherit;font-size:10pt;"><span>$1.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and net unrealized losses of </span><span style="font-family:inherit;font-size:10pt;">$0.4 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, on outstanding option contracts. During the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, for the foreign currency option contracts, the Company recorded net realized losses of </span><span style="font-family:inherit;font-size:10pt;">$0.5 million</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">$0.7 million</span><span style="font-family:inherit;font-size:10pt;">, respectively, on outstanding option contracts. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Australian dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$51.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, the Company had outstanding foreign currency option contracts that were not designated for hedge accounting and are used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro and UK Pound with a notional amount of </span><span style="font-family:inherit;font-size:10pt;"><span>$80.6 million</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financial Instrument Presentation</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:49%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments designated as a cash flow hedge:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate cap agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contract</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency option contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments designated as a cash flow hedge:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contract</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contract</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount of loss recognized in other comprehensive income, net of taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate cap agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives not classified as hedging instruments</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of (Loss) Gain Recognized in Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency option contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3700000 1500000 1000000000.0 -400000 -1700000 -1100000 0.0 100000 1000000000.0 1000000000.0 0.0123 1000000000.0 22900000 -100000 2600000 1100000 1100000 51000000.0 80600000 <div style="line-height:120%;padding-top:8px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">: </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:49%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance Sheet Location</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Assets:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments designated as a cash flow hedge:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate cap agreements</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contract</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency option contracts</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivative instruments designated as a cash flow hedge:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contract</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap contract</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Other long-term liabilities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Accrued expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0 100000 0 4700000 0 4800000 1900000 900000 900000 2000000.0 2800000 2900000 2400000 0 20500000 0 22900000 0 0 100000 <div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:53%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Amount of loss recognized in other comprehensive income, net of taxes:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate swap</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(20.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Interest rate cap agreements</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(25.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(21.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -25200000 0 -20800000 0 -100000 -1500000 -400000 -5400000 -25300000 -1500000 -21200000 -5400000 <div style="line-height:120%;padding-top:24px;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:</span></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:33%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Derivatives not classified as hedging instruments</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount of (Loss) Gain Recognized in Income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Forward foreign currency contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Foreign currency option contracts</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 2700000 400000 1300000 5500000 600000 0 -1100000 0 3300000 400000 200000 5500000 Commitments and Contingencies<div style="line-height:120%;padding-top:8px;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Litigation and Related Matters</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 6, 2015, the Company filed a suit against Minerva Surgical, Inc. (“Minerva”) in the United States District Court for the District of Delaware, alleging that Minerva’s endometrial ablation device infringes U.S. Patent 6,872,183 (the '183 patent), U.S. Patent 8,998,898 and U.S. Patent 9,095,348 (the '348 patent). On January 25, 2016, the Company amended the complaint to include claims against Minerva for unfair competition, deceptive trade practices and tortious interference with business relationships. On February 5, 2016, the Company filed a second amended complaint to additionally allege that Minerva’s endometrial ablation device infringes U.S. Patent 9,247,989 (the '989 patent). On March 4, 2016, Minerva filed an answer and counterclaims against the Company, seeking declaratory judgment on the Company’s claims and asserting claims against the Company for unfair competition, deceptive trade practices, interference with contractual relationships, breach of contract and trade libel. On June 2, 2016, the Court denied the Company’s motion for a preliminary injunction on its patent claims and denied Minerva’s request for preliminary injunction related to the Company’s alleged false and deceptive statements regarding the Minerva product. On June 28, 2018, the Court granted the Company's summary judgment motions on infringement and no invalidity with respect to the ‘183 and ‘348 patents. The Court also granted the Company’s motion for summary judgment on assignor estoppel, which bars Minerva’s invalidity defenses or any reliance on collateral findings regarding invalidity from </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review proceedings. The Court also denied all of Minerva’s defenses, including its motions for summary judgment on invalidity, non-infringement, no willfulness, and no unfair competition.</span><span style="font-family:inherit;font-size:10pt;color:#0000ff;"> </span><span style="font-family:inherit;font-size:10pt;">On July 27, 2018, after a two-week trial, a jury returned a verdict that: (1) awarded the Company </span><span style="font-family:inherit;font-size:10pt;"><span>$4.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> in damages for Minerva’s infringement; (2) found that Minerva’s infringement was not willful; and (3) found for the Company regarding Minerva’s counterclaims. Damages continued to accrue as Minerva continues its infringing conduct. On May 2, 2019, the Court issued rulings that denied the parties' post-trial motions, including the Company's motion for a permanent injunction seeking to prohibit Minerva from selling infringing devices. Both parties appealed the Court's rulings regarding the post-trial motions. On March 4, 2016, Minerva filed </span><span style="font-family:inherit;font-size:10pt;"><span>two</span></span><span style="font-family:inherit;font-size:10pt;"> petitions at the USPTO for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review of the '348 patent. On September 12, 2016, the PTAB declined both petitions to review patentability of the '348 patent. On April 11, 2016, Minerva filed a petition for </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">inter partes</span><span style="font-family:inherit;font-size:10pt;"> review of the '183 patent. On October 6, 2016, the PTAB granted the petition and instituted a review of the '183 patent. On December 15, 2017, the PTAB issued a final written decision invalidating all claims of the ‘183 patent. On February 9, 2018 the Company appealed this decision to the United States Court of Appeals for the Federal Circuit ("Court of Appeals"). On April 19, 2019, the Court of Appeals affirmed the PTAB's final written decision regarding the '183 patent. On July 16, 2019, the Court of Appeals denied the Company’s petition for rehearing in the appeal regarding the '183 patent. On April 22, 2020, the Court of Appeals affirmed the district court’s summary judgment ruling in favor of the Company of no invalidity and infringement, and summary judgment that assignor estoppel bars Minerva from challenging the validity of the ‘348 patent. The Court of Appeals also denied the Company’s motion for a permanent injunction and ongoing royalties for infringement of the ‘183 patent. The Court of Appeals denied Minerva’s motion for no damages or, alternatively, a new trial.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On April 11, 2017, Minerva filed suit against the Company and Cytyc Surgical Products, LLC (“Cytyc”) in the United States District Court for the Northern District of California alleging that the Company’s and Cytyc’s NovaSure ADVANCED endometrial ablation device infringes Minerva’s U.S. patent 9,186,208. Minerva is seeking a preliminary and permanent injunction against the Company and Cytyc from selling this NovaSure device as well as enhanced damages and interest, including lost profits, price erosion and/or royalty. On January 5, 2018, the Court denied Minerva's motion for a preliminary injunction. On February 2, 2018, at the parties’ joint request, this action was transferred to the District of Delaware. On March 26, 2019, the Magistrate Judge issued a claims construction ruling regarding the disputed terms in the patent, which the District Court Judge adopted in all respects on October 21, 2019. The original trial date of July 20, 2020 was vacated and the parties are now waiting for a new trial date to be set by the court. At this time, based on available information regarding this litigation, the Company is unable to reasonably assess the ultimate outcome of this case or determine an estimate, or a range of estimates, of potential losses.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On February 3, 2017, bioMérieux, S.A. and bioMérieux, Inc. (collectively “bioMérieux”) filed suit against the Company in the United States District Court for the Middle District of North Carolina ("MDNC"), alleging that the Company’s HIV products, including blood screening products previously manufactured by the Company for its former blood screening partner Grifols Diagnostic Solutions Inc. ("Grifols USA"), infringe U.S. Patent Nos. 8,697,352 and 9,074,262. On January 3, 2018, the MDNC Court granted the parties’ consent motion to transfer the case to Delaware. On June 11, 2019, the Court issued a claim construction ruling regarding the disputed terms in the patents. Motions for summary judgment were filed by the parties on September 30, 2019, and a hearing on these motions was held on December 18, 2019. A six-day trial concluded on February 25, 2020, with the jury finding that all claims of U.S. Patent No. 8,697,352 are invalid (U.S. Patent No. 9,074,262 was dropped from the case by bioMérieux prior to trial). On March 18, 2020, the parties agreed to a settlement under which bioMérieux agreed to dismiss all claims with prejudice and to waive the filing of post-trial motions and pursuing an appeal in exchange for a de minimis payment from the Company and Grifols USA.</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">As described in Note 6, the Company has agreed to indemnify CD&amp;R for certain legal matters related to the Medical Aesthetics business that existed at the date of disposition. The Company currently has </span><span style="font-family:inherit;font-size:10pt;"><span>$8.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> accrued for such matters as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, but this amount could become greater if some or all of the cases which it is indemnifying have an adverse result.</span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is a party to various other legal proceedings and claims arising out of the ordinary course of its business. The Company believes that except for those matters described above there are no other proceedings or claims pending against it the ultimate resolution of which could have a material adverse effect on its financial condition or results of operations. In all cases, at each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450,</span><span style="font-family:inherit;font-size:10pt;font-style:italic;"> Contingencies</span><span style="font-family:inherit;font-size:10pt;">. Legal costs are expensed as incurred.</span></div> 4800000 2 8500000 Net Income Per Share<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of basic and diluted share amounts is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic weighted average common shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265,566</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted weighted average common shares outstanding</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267,114</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average anti-dilutive shares related to:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div>In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock options’ combined exercise price and average unrecognized stock compensation expense upon exercise is greater than the average stock price. In those reporting periods in which the Company has a net loss, anti-dilutive shares are comprised of the impact of those number of shares that would have been dilutive had the Company had net income plus the number of common stock equivalents that would be anti-dilutive had the company had net income. <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">A reconciliation of basic and diluted share amounts is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Basic weighted average common shares outstanding</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>263,238</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,235</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>265,566</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,913</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,548</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diluted weighted average common shares outstanding</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>264,506</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,235</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>267,114</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269,913</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted-average anti-dilutive shares related to:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Outstanding stock options</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,677</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,031</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,483</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,578</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Stock Units</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 263238000 269235000 265566000 269913000 1268000 0 1548000 0 264506000 269235000 267114000 269913000 1677000 4031000 1483000 4578000 10000 0 6000 0 Stock-Based Compensation<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company granted options to purchase </span><span style="font-family:inherit;font-size:10pt;"><span>0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock during the </span><span style="font-family:inherit;font-size:10pt;">six months ended</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, with weighted-average exercise prices of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.82</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$41.25</span></span><span style="font-family:inherit;font-size:10pt;">, respectively. There were </span><span style="font-family:inherit;font-size:10pt;"><span>5.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> options outstanding at </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> with a weighted-average exercise price of </span><span style="font-family:inherit;font-size:10pt;"><span>$38.74</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>0.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> restricted stock units (RSUs) during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, with weighted-average grant date fair values of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.76</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$41.11</span></span><span style="font-family:inherit;font-size:10pt;"> per unit, respectively. In addition, the Company granted </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> performance stock units (PSUs) during the </span><span style="font-family:inherit;font-size:10pt;">six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively, to members of its senior management team, which have a weighted-average grant date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.76</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$40.97</span></span><span style="font-family:inherit;font-size:10pt;"> per unit, respectively. Each recipient of PSUs is eligible to receive between </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>200%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target number of shares of the Company’s common stock at the end of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> of PSUs based on a one-year free cash flow measure (FCF) to its senior management team, which had a grant date fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$45.76</span></span><span style="font-family:inherit;font-size:10pt;">. Each recipient of FCF PSUs is eligible to receive between zero and </span><span style="font-family:inherit;font-size:10pt;"><span>200%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target number of shares of the Company's common stock at the end of the one-year measurement period, but the FCF PSUs vest at the end of the three year service period. The Company is recognizing compensation expense for PSUs and FCF PSUs ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company cumulatively adjusts compensation expense in the period that the change in estimate is made. The Company also granted </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>0.1 million</span></span><span style="font-family:inherit;font-size:10pt;"> market-based awards (MSUs) to its senior management team during the six months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">, respectively. Each recipient of MSUs is eligible to receive between </span><span style="font-family:inherit;font-size:10pt;"><span>zero</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>200%</span></span><span style="font-family:inherit;font-size:10pt;"> of the target number of shares of the Company’s common stock at the end of </span><span style="font-family:inherit;font-size:10pt;"><span>three years</span></span><span style="font-family:inherit;font-size:10pt;"> based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at </span><span style="font-family:inherit;font-size:10pt;"><span>$43.90</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$55.13</span></span><span style="font-family:inherit;font-size:10pt;"> per share using the Monte Carlo simulation model. The Company is recognizing compensation expense for the MSUs ratably over the service period. At </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>2.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> in aggregate RSUs, PSUs, FCF PSUs and MSUs outstanding. </span></div><div style="line-height:120%;padding-bottom:24px;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">At </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;">, there was </span><span style="font-family:inherit;font-size:10pt;"><span>$26.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>$70.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of </span><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span><span style="font-family:inherit;font-size:10pt;"> years, respectively.</span></div> <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Cost of revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Selling and marketing</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">General and administrative</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>19.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Restructuring</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 1700000 2000000.0 3800000 4000000.0 2300000 2700000 4600000 5400000 2800000 2700000 5600000 5400000 6500000 10100000 17400000 19800000 2400000 0 2400000 0 15700000 17500000 33800000 34600000 900000 900000 45.82 41.25 5300000 38.74 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:</span></div><div style="line-height:120%;text-align:center;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Risk-free interest rate</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected volatility</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>33.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>34.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Expected life (in years)</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Dividend yield</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Weighted average fair value of options granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.87</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.50</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 17000 0.030 0.017 0.030 0.336 0.343 0.336 0.343 P4Y9M18D P4Y9M18D P4Y9M18D P4Y9M18D 0 0 0 0 14.45 15.33 13.87 13.50 800000 900000 45.76 41.11 100000 100000 45.76 40.97 0 2 P3Y 100000 45.76 2 100000 100000 0 2 P3Y 43.90 55.13 2500000 26700000 70600000 P2Y7M6D P2Y Other Balance Sheet Information<div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>189.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>444.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, plant and equipment</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment under customer usage agreements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Building and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,136.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less – accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(677.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(666.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventories</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>155.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>166.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Work-in-process</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>56.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>54.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>189.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>401.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>444.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 155100000 166100000 56400000 54500000 189800000 224300000 401300000 444900000 <div style="line-height:120%;padding-bottom:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, plant and equipment</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>407.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>379.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Equipment under customer usage agreements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>452.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>435.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Building and improvements</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>162.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Leasehold improvements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Land</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>40.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>46.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,122.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,136.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Less – accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(677.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(666.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>445.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>470.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 407600000 379200000 452800000 435500000 162900000 196700000 42800000 61700000 40600000 46300000 15600000 17500000 1122300000 1136900000 677000000.0 666000000.0 445300000 470900000 Business Segments and Geographic Information<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the first fiscal quarter of 2020 and during fiscal 2019, the Company had </span><span style="font-family:inherit;font-size:10pt;"><span>five</span></span><span style="font-family:inherit;font-size:10pt;"> reportable segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. The Company completed the sale of its Medical Aesthetics business on December 30, 2019, but will continue to have operating expenses related to indemnifying CD&amp;R for legal and tax matters that existed as of the date of disposition. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were </span><span style="font-family:inherit;font-size:10pt;"><span>no</span></span><span style="font-family:inherit;font-size:10pt;"> inter-segment revenues during the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">. Segment information is as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(473.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(499.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital expenditures:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,193.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,243.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,328.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,069.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,821.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,442.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company had no customers that represented greater than 10% of consolidated revenues during the </span><span style="font-family:inherit;font-size:10pt;">three and six</span><span style="font-family:inherit;font-size:10pt;"> months ended </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.</span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues by geography as a percentage of total revenues were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia-Pacific</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rest of World</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 5 0 egment information is as follows:<div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>319.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>296.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>630.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>593.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>307.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>321.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>638.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>646.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>105.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>102.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>224.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>210.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>73.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>65.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>153.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>24.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>45.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>756.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>818.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,606.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,649.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Income (loss) from operations:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>57.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>106.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>74.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>99.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>169.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>196.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>20.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>55.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>47.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(473.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(53.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(499.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(2.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>156.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(323.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>281.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(182.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Depreciation and amortization:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>59.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>61.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>118.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>123.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>23.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>21.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>42.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>25.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>50.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>93.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>117.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>188.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>236.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capital expenditures:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>17.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>16.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>35.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>10.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>31.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>29.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>63.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">September 28, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Identifiable assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Diagnostics</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,193.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,276.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Breast Health</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,243.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,127.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">GYN Surgical</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,284.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,328.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Medical Aesthetics</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>159.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Skeletal Health</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>30.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Corporate</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,069.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1,522.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,821.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6,442.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div> 319200000 296700000 630700000 593300000 307800000 321500000 638900000 646200000 105400000 102200000 224500000 210600000 0 73800000 65300000 153600000 23700000 24200000 47200000 45400000 756100000 818400000 1606600000 1649100000 57300000 31100000 106800000 74400000 75900000 99000000.0 169800000 196800000 23900000 20500000 55400000 47600000 -2400000 -473900000 -53400000 -499100000 1700000 100000 2600000 -2400000 156400000 -323200000 281200000 -182700000 59300000 61600000 118400000 123400000 13100000 8900000 23100000 18200000 21100000 21900000 42100000 43900000 0 25100000 4100000 50600000 200000 100000 400000 300000 93700000 117600000 188100000 236400000 17100000 16000000.0 35300000 30400000 8100000 4700000 14500000 6800000 5300000 3100000 10600000 6600000 0 3400000 1400000 4500000 100000 300000 200000 600000 1100000 1800000 1100000 3000000.0 31700000 29300000 63100000 51900000 2193800000 2276600000 1243900000 1127800000 1284400000 1328600000 0 159300000 30200000 27300000 2069500000 1522500000 6821800000 6442100000 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Revenues by geography as a percentage of total revenues were as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-bottom:24px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:45%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Six Months Ended</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 28, <br/>2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">March 30, <br/>2019</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">United States</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>76.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>75.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>12.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Asia-Pacific</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Rest of World</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>100.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 0.760 0.751 0.751 0.750 0.148 0.125 0.138 0.123 0.055 0.079 0.070 0.081 0.037 0.045 0.041 0.046 1.000 1.000 1.000 1.000 Income Taxes<div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In accordance with ASC 740, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes</span><span style="font-family:inherit;font-size:10pt;"> (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company’s effective tax rate for the three and six months ended March 28, 2020 was a provision of </span><span style="font-family:inherit;font-size:10pt;"><span>20.3%</span></span><span style="font-family:inherit;font-size:10pt;"> and a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>122.1%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, compared to a benefit of </span><span style="font-family:inherit;font-size:10pt;"><span>22.9%</span></span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;"><span>30.2%</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, for the corresponding periods in the prior year. The effective tax rate for the three months ended March 28, 2020 differed from the statutory tax rate primarily due to taxation of foreign earnings at a tax rate lower than the statutory tax rate including the impact to global intangible low tax income and foreign derived intangible income, partially offset by unbenefited foreign losses. The effective tax rate for the six months ended March 28, 2020 differed from the statutory tax rate primarily due to a </span><span style="font-family:inherit;font-size:10pt;"><span>$310.9 million</span></span><span style="font-family:inherit;font-size:10pt;"> discrete net tax benefit related to the loss on the sale of the Medical Aesthetics business.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">For the three months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, and earnings in jurisdictions subject to lower tax rates. For the six months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, earnings in jurisdictions subject to lower tax rates, a discrete benefit related to an internal restructuring, and finalizing the impact of the enactment of the Tax Cuts and Jobs Act in the first quarter of fiscal 2019.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the six months ended March 28, 2020, the Company's gross unrecognized tax benefits excluding interest increased from </span><span style="font-family:inherit;font-size:10pt;"><span>$101.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> to </span><span style="font-family:inherit;font-size:10pt;"><span>$212.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> primarily as a result of uncertain tax positions related to the divestiture of the Medical Aesthetics business, and to a lesser extent intercompany transfer pricing related to ordinary business operations. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Other Tax Accounting Pronouncements</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. Under ASU 2016-16, the selling (transferring) entity is required to recognize a current tax expense or benefit upon transfer of the asset. Similarly, the purchasing (receiving) entity is required to recognize a deferred tax asset or deferred tax liability, as well as the related deferred tax benefit or expense, upon receipt of the asset.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis through a cumulative-</span></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">effect adjustment to decrease the opening balance of accumulated deficit within stockholders' equity as of September 30, 2018, the first day of fiscal 2019. This change in accounting principle resulted in an increase in deferred tax assets of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, a decrease in accumulated deficit of </span><span style="font-family:inherit;font-size:10pt;"><span>$2.5 million</span></span><span style="font-family:inherit;font-size:10pt;">, and a decrease in prepaid taxes of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of the beginning of the Company’s fiscal year beginning September 30, 2018.</span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company was required to account for the internal restructuring discussed above under ASU 2016-16 and recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$29.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> increase to income tax expense and income tax liabilities and a decrease of </span><span style="font-family:inherit;font-size:10pt;"><span>$48.7 million</span></span><span style="font-family:inherit;font-size:10pt;"> to deferred tax expense and net deferred tax liabilities for the six months ended March 30, 2019. The net result was an increase to net income of </span><span style="font-family:inherit;font-size:10pt;"><span>$19.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, or an earnings per share increase of </span><span style="font-family:inherit;font-size:10pt;"><span>$0.07</span></span><span style="font-family:inherit;font-size:10pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Non-Income Tax Matters</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:justify;text-indent:29px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The Company is subject to tax examinations for value added, sales-based, payroll, and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates pursuant to ASC 450. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.</span></div> 0.203 1.221 0.229 0.302 310900000 101600000 212700000 2900000 2500000 400000 29500000 48700000 19200000 0.07 Intangible Assets<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 28, 2019</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,925.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,779.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,927.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,654.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>546.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>461.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-competition agreements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total acquired intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,720.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,420.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,704.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,276.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internal-use software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized software embedded in products</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,799.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,471.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,786.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,326.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"/><span style="font-family:inherit;font-size:10pt;">In the first quarter of fiscal 2020, the Company's Medical Aesthetics business met the criteria to be designated as assets held-for-sale. As a result, the Company recorded a </span><span style="font-family:inherit;font-size:10pt;"><span>$30.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> charge to record the asset group at fair value less costs to sell. In addition, developed technology, customer lists, tradenames, and distribution agreement related to Medical Aesthetics of </span><span style="font-family:inherit;font-size:10pt;"><span>$24.1 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$0.9 million</span></span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;"><span>$2.0 million</span></span><span style="font-family:inherit;font-size:10pt;">, and </span><span style="font-family:inherit;font-size:10pt;"><span>$1.2 million</span></span><span style="font-family:inherit;font-size:10pt;">, respectively, were reclassified accordingly in the Company's Consolidated Balance Sheet to assets held-for-sale as of December 28, 2019 and subsequently disposed of in the second quarter of fiscal 2020.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In the second quarter of fiscal 2020, the Company reviewed its long-lived assets for indicators of impairment as a result of lowering its expectations for revenue and operating income in the short term from the impact of COVID-19 on its business as discussed in Note 1. The Company updated its long-term forecasts and performed an undiscounted cash flow analysis which indicated that the estimated future cash flows are sufficient to recover the carrying values of its asset groups. In addition, the Company had significant cushion from its most recent goodwill impairment test in each of its reporting units and believes, based on its procedures, current facts and expectations, that as of the date of this report it is it not more likely than not that the fair value of each of its reporting units is below their respective carrying values. Given the current uncertainty of the duration and scope of the COVID-19 pandemic, the related economic impact, and the potential longer term impact on the </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Company's business, financial condition and results of operations, in the future the Company may be required to perform an interim impairment test, in addition to its annual test, and record an impairment charge.</span></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;">Medical Aesthetics Impairment - Fiscal 2019</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">During the second quarter of fiscal 2019, in connection with commencing its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Medical Aesthetics reporting unit (comprised solely of the Cynosure business), the Company reduced its short term and long term revenue and operating income forecasts. The updated forecast reflected reduced volume and market penetration projections primarily in the Body Contouring business due to increased competition in the non-invasive fat reduction category, and lower Women's Health product sales primarily from reduced sales volume of the MonaLisa Touch device, which the Company believed was primarily driven by the FDA's public letter in the fourth quarter of fiscal 2018 challenging various medical aesthetics companies marketing of devices for so called "vaginal rejuvenation" procedures relative to their FDA approvals. As a result of the revised forecasts in the second quarter of fiscal 2019, the Company determined indicators of impairment existed and performed an undiscounted cash flow analysis pursuant to ASC 360, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant, and Equipment - Overall,</span><span style="font-family:inherit;font-size:10pt;"> to determine if the cash flows expected to be generated by this asset group over the estimated remaining useful life of the primary assets were sufficient to recover the carrying value of the asset group, which was determined to be at the reporting unit level. Based on this analysis, which included evaluating various cash flow scenarios, the undiscounted cash flows were not sufficient to recover the carrying value of the asset group. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculates the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company's most recent strategic plan and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used is intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 11.0%. As a result of this analysis, the fair value of the Medical Aesthetics asset group was below its carrying value, and the Company recorded an impairment charge of </span><span style="font-family:inherit;font-size:10pt;"><span>$443.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> during the second quarter of fiscal 2019. The impairment charge was allocated to the long-lived assets as follows: </span><span style="font-family:inherit;font-size:10pt;"><span>$373.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> to developed technology, </span><span style="font-family:inherit;font-size:10pt;"><span>$14.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> to customer relationships, </span><span style="font-family:inherit;font-size:10pt;"><span>$31.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> to trade names, </span><span style="font-family:inherit;font-size:10pt;"><span>$17.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to distribution agreements and </span><span style="font-family:inherit;font-size:10pt;"><span>$6.8 million</span></span><span style="font-family:inherit;font-size:10pt;"> to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. The Company completed the sale of the Medical Aesthetics business in the second quarter of fiscal 2020. Please refer to Note 6 for additional details. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated remaining amortization expense of the Company's acquired intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> for each of the five succeeding fiscal years is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of Fiscal 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Intangible assets consisted of the following:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;text-decoration:underline;">Description</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">As of September 28, 2019</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Gross</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Carrying</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Amortization</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Acquired intangible assets:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Developed technology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,925.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,779.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,927.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2,654.8</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Customer relationships</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>546.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>461.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>525.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>447.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Trade names</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>244.0</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>176.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>245.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>171.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Distribution agreement</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Non-competition agreements</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Business licenses</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total acquired intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,720.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,420.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,704.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,276.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Internal-use software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>51.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>41.7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>53.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>43.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Capitalized software embedded in products</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>28.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>6.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Total intangible assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,799.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,471.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>4,786.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>3,326.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 3925600000 2779600000 3927700000 2654800000 546800000 461400000 525500000 447500000 244000000.0 176100000 245400000 171100000 0 0 2500000 0 1500000 1100000 1400000 900000 2300000 2200000 2300000 2200000 4720200000 3420400000 4704800000 3276500000 51400000 41700000 53900000 43400000 28200000 8900000 27900000 6900000 4799800000 3471000000.0 4786600000 3326800000 30200000 24100000 900000 2000000.0 1200000 443800000 373300000 14400000 31500000 17800000 6800000 <div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The estimated remaining amortization expense of the Company's acquired intangible assets as of </span><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span><span style="font-family:inherit;font-size:10pt;"> for each of the five succeeding fiscal years is as follows:</span></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Remainder of Fiscal 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>145.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>269.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>258.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>161.2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Fiscal 2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>150.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 145100000 269100000 258700000 161200000 150400000 Product Warranties<div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product warranty activity was as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-bottom:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Provisions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Divested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Settlements/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Product warranty activity was as follows:</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:inherit;font-size:12pt;"> </span></div><div style="line-height:120%;padding-bottom:24px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Beginning of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Provisions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Divested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Settlements/</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">Balance at</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;font-weight:bold;">End of Period</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Six Months Ended:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>13.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>7.6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>15.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>5.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>(6.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><span>14.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div> 13900000 5500000 500000 -6100000 6200000 7600000 15900000 5400000 0 0 6900000 14400000 Accumulated Other Comprehensive Loss<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="39"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="18" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Swaps</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Beginning Balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(33.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(41.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(42.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(25.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(30.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(21.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(18.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Amounts reclassified to statement of income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Ending Balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(58.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(58.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Three Months Ended March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Six Months Ended March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Beginning Balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(31.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(25.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Amounts reclassified to statement of income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Ending Balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(27.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(27.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> <div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="39"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Three Months Ended March 28, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="18" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Six Months Ended March 28, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Swaps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Swaps</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Beginning Balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(33.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(28.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(41.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2.7</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(42.3</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(25.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(30.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(21.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(18.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Amounts reclassified to statement of income</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.4</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Ending Balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(58.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(38.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(17.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(58.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="32"/></tr><tr><td style="width:29%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Three Months Ended March 30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Six Months Ended March 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Foreign Currency Translation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Hedged Interest Rate Caps</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;font-weight:bold;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Beginning Balance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(29.8</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.0</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(31.9</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(26.6</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(25.5</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Other comprehensive income (loss) before reclassifications</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(0.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(5.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(6.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Amounts reclassified to statement of income</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>0.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>—</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>1.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">Ending Balance</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(27.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(27.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(1.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(2.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"> </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;"><span>(30.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:inherit;font-size:7pt;">)</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div> -33100000 -1700000 -1400000 7500000 -28700000 -41400000 -1700000 -2700000 3500000 -42300000 -5400000 0 -100000 -25100000 -30600000 2900000 0 -100000 -21100000 -18300000 0 0 400000 0 400000 0 0 1700000 0 1700000 -38500000 -1700000 -1100000 -17600000 -58900000 -38500000 -1700000 -1100000 -17600000 -58900000 -29800000 -1100000 -1000000.0 -31900000 -26600000 -1100000 2200000 -25500000 2400000 0 -1500000 900000 -800000 0 -5400000 -6200000 0 0 500000 500000 0 0 1200000 1200000 -27400000 -1100000 -2000000.0 -30500000 -27400000 -1100000 -2000000.0 -30500000 1300000 2600000 2000000.0 1000000.0 1000000.0 1300000 Share Repurchase<div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On June 13, 2018, the Board of Directors authorized a share repurchase plan to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's outstanding common stock. This share repurchase plan was effective August 1, 2018 and expired on March 27, 2020. Under this authorization, during the second quarter of fiscal 2020, the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>2.4 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$130.1 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of March 28, 2020, the Company had completed this authorization. </span></div><div style="line-height:120%;padding-top:16px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 19, 2019, the Board of Directors authorized a new share repurchase plan to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$500.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's outstanding common stock, effective at the beginning of the third quarter of fiscal 2020. On March 2, 2020 the Board of Directors approved accelerating the effective date of the new share repurchase plan from March 27, 2020 to March 2, 2020. Under this revised authorization, during the second quarter of fiscal 2020, the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>3.5 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of its common stock for a total consideration of </span><span style="font-family:inherit;font-size:10pt;"><span>$137.5 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of March 28, 2020, </span><span style="font-family:inherit;font-size:10pt;"><span>$362.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> remained available under this authorization.</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">On November 19, 2019, the Board of Directors authorized the Company to repurchase up to </span><span style="font-family:inherit;font-size:10pt;"><span>$205 million</span></span><span style="font-family:inherit;font-size:10pt;"> of its outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement. On November 22, 2019, the Company executed the ASR agreement with Goldman Sachs &amp; Co. ("Goldman Sachs") pursuant to which the Company repurchased </span><span style="font-family:inherit;font-size:10pt;"><span>$205 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the Company's common stock. The initial delivery, of approximately 80% of the shares under the ASR, was </span><span style="font-family:inherit;font-size:10pt;"><span>3.3 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares for which the Company initially allocated </span><span style="font-family:inherit;font-size:10pt;"><span>$164.0 million</span></span><span style="font-family:inherit;font-size:10pt;"> of the </span><span style="font-family:inherit;font-size:10pt;"><span>$205 million</span></span><span style="font-family:inherit;font-size:10pt;"> paid to Goldman Sachs during the first quarter of fiscal 2020. The Company evaluated the nature of the forward contract aspect of the ASR under ASC 815 and concluded equity classification was appropriate. Final settlement of the transaction under the ASR occurred in the second quarter of fiscal 2020. At settlement, Goldman Sachs delivered an additional </span><span style="font-family:inherit;font-size:10pt;"><span>0.6 million</span></span><span style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock.</span></div> 500000000.0 2400000 130100000 500000000.0 3500000 137500000 362600000 205000000 205000000 3300000 164000000.0 205000000 600000 New Accounting Pronouncements<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 1 for Recently Adopted Accounting Pronouncements.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:inherit;font-size:10pt;"> and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10, ASU 2019-11 and ASU 2020-03, on its consolidated financial position and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In November 2019, the FASB issued ASU No. 2019-08, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606)</span><span style="font-family:inherit;font-size:10pt;">. The guidance identifies, evaluates, and improves areas of GAAP for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided. The amendments in that Update expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. For entities that have adopted the amendments in Update 2018-07, the updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2019-08 on its consolidated financial position and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes.</span><span style="font-family:inherit;font-size:10pt;"> The Board is issuing this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on its consolidated financial position and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In January 2020, FASB issued ASU No. 2020-01, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)</span><span style="font-family:inherit;font-size:10pt;">. The Board is issuing this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2020-01 on its consolidated financial position and results of operations.</span></div> New Accounting Pronouncements<div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">See Note 1 for Recently Adopted Accounting Pronouncements.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="font-family:inherit;font-size:10pt;font-style:italic;">Financial Instruments - Credit Losses (Topic 326)</span><span style="font-family:inherit;font-size:10pt;"> and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10, ASU 2019-11 and ASU 2020-03, on its consolidated financial position and results of operations.</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">    </span></div> XML 25 R9999.htm IDEA: XBRL DOCUMENT v3.20.1
Label Element Value
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]  
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity $ (1,700,000)
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity (1,100,000)
AOCI Attributable to Parent [Member]  
Accumulated Other Comprehensive Income (Loss), Net of Tax us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax (25,500,000)
Accumulated Other Comprehensive Income (Loss), Net of Tax us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax (31,900,000)
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]  
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity (27,400,000)
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity (38,500,000)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Interest Rate Cap [Member]  
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity (1,100,000)
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity (2,000,000.0)
AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] | Interest Rate Swap [Member]  
Stockholders' Equity Attributable to Parent us-gaap_StockholdersEquity $ (17,600,000)
XML 26 R29.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue (Tables)
6 Months Ended
Mar. 28, 2020
Revenue from Contract with Customer [Abstract]  
Disaggregation of Revenue The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:

 
 
Three Months Ended March 28, 2020
 
Three Months Ended March 30, 2019
Business (in millions)
United States
International
Total
 
United States
International
Total
Diagnostics:
 
 
 
 
 
 
 
 
Cytology & Perinatal
$
73.2

$
40.2

$
113.4

 
$
76.6

$
38.9

$
115.5

 
Molecular Diagnostics
149.8

40.8

190.6

 
136.8

31.0

167.8

 
Blood Screening
15.2


15.2

 
13.4


13.4

Total
$
238.2

$
81.0

$
319.2

 
$
226.8

$
69.9

$
296.7

 
 
 
 
 
 
 
 
 
Breast Health:
 
 
 
 
 
 
 
 
Breast Imaging
$
186.0

$
64.2

$
250.2

 
$
206.2

$
59.7

$
265.9

 
Interventional Breast Solutions
48.4

9.2

57.6

 
46.8

8.8

55.6

Total
$
234.4

$
73.4

$
307.8

 
$
253.0

$
68.5

$
321.5

 
 
 
 
 
 
 
 
 
GYN Surgical
$
86.7

$
18.7

$
105.4

 
$
84.1

$
18.1

$
102.2

 
 
 
 
 
 
 
 
 
Medical Aesthetics
$

$

$

 
$
37.6

$
36.2

$
73.8

 
 
 
 
 
 
 
 
Skeletal Health
$
15.6

$
8.1

$
23.7

 
$
14.0

$
10.2

$
24.2

 
 
$
574.9

$
181.2

$
756.1

 
$
615.5

$
202.9

$
818.4


 
 
Six Months Ended March 28, 2020
 
Six Months Ended March 30, 2019
Business (in millions)
United States
International
Total
 
United States
International
Total
Diagnostics:
 
 
 
 
 
 
 
 
Cytology & Perinatal
$
150.7

$
83.7

$
234.4

 
$
155.8

$
77.8

$
233.6

 
Molecular Diagnostics
291.9

77.2

369.1

 
270.9

61.2

332.1

 
Blood Screening
27.2


27.2

 
27.6


27.6

Total
$
469.8

$
160.9

$
630.7

 
$
454.3

$
139.0

$
593.3

 
 
 
 
 
 
 
 
 
Breast Health:
 
 
 
 
 
 
 
 
Breast Imaging
$
395.4

$
129.6

$
525.0

 
$
412.7

$
122.9

$
535.6

 
Interventional Breast Solutions
95.5

18.4

113.9

 
92.9

17.7

110.6

Total
$
490.9

$
148.0

$
638.9

 
$
505.6

$
140.6

$
646.2

 
 
 
 
 
 
 
 
 
GYN Surgical
$
185.5

$
39.0

$
224.5

 
$
175.2

$
35.4

$
210.6

 
 
 
 
 
 
 
 
 
Medical Aesthetics
$
30.9

$
34.4

$
65.3

 
$
74.9

$
78.7

$
153.6

 
 
 
 
 
 
 
 
Skeletal Health
$
30.5

$
16.7

$
47.2

 
$
27.2

$
18.2

$
45.4

 
 
$
1,207.6

$
399.0

$
1,606.6

 
$
1,237.2

$
411.9

$
1,649.1


 
 
Three Months Ended
 
Six Months Ended
Geographic Regions (in millions)
 
March 28, 2020
March 30, 2019
 
March 28, 2020
March 30, 2019
United States
 
$
574.9

$
615.5

 
$
1,207.6

$
1,237.2

Europe
 
111.8

102.1

 
221.2

203.2

Asia-Pacific
 
41.7

64.3

 
111.8

134.0

Rest of World
 
27.7

36.5

 
66.0

74.7

 
 
$
756.1

$
818.4

 
$
1,606.6

$
1,649.1


The following table provides revenue recognized by source:

 
 
Three Months Ended
 
Six Months Ended
Revenue by type (in millions)
 
March 28, 2020
March 30, 2019
 
March 28, 2020
March 30, 2019
Capital equipment, components and software
 
$
166.6

$
239.4

 
$
399.5

$
487.8

Consumables
 
457.0

428.4

 
923.4

863.1

Service
 
127.2

141.1

 
272.2

283.0

Other
 
5.3

9.5

 
11.5

15.2

 
 
$
756.1

$
818.4

 
$
1,606.6

$
1,649.1


XML 27 R7.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Stockholders' Equity - USD ($)
shares in Thousands, $ in Thousands
Total
Common Stock
Additional Paid-in Capital
Retained Earnings
Total
Treasury Stock
Share Repurchase Program
Treasury Stock
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount $ 0            
Balance (in shares) at Sep. 29, 2018   289,900       19,812  
Beginning balance at Sep. 29, 2018 2,428,800 $ 2,900 $ 5,671,300 $ (2,494,000) $ (25,500) $ (725,900)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)   373          
Exercise of stock options 9,100   9,100        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)   575          
Vesting of restricted stock units, net of shares withheld for employee taxes (11,600)   (11,600)        
Stock-based compensation expense 17,100   17,100        
Net income (loss) 98,600            
Other comprehensive income activity (6,400)       (6,400)    
Repurchase of common stock (in shares)           3,712  
Repurchase of common stock (150,100)         $ (150,100)  
Balance (in shares) at Dec. 29, 2018   290,848       23,524  
Ending balance at Dec. 29, 2018 2,394,400 $ 2,900 5,685,900 (2,386,500) (31,900) $ (876,000)  
Balance (in shares) at Sep. 29, 2018   289,900       19,812  
Beginning balance at Sep. 29, 2018 2,428,800 $ 2,900 5,671,300 (2,494,000) (25,500) $ (725,900)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) (174,000)            
Balance (in shares) at Mar. 30, 2019   291,561       23,524  
Ending balance at Mar. 30, 2019 2,159,800 $ 2,900 5,722,500 (2,659,100) (30,500) $ (876,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable 0            
Net income (174,000)            
Accelerated share repurchase agreement 0            
Payments to Noncontrolling Interests 0            
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount 0            
Accounting standard transition adjustment | Accounting Standards Update 2014-09 6,400     6,400      
Accounting standard transition adjustment | Accounting Standards Update 2016-16 (2,500)     (2,500)      
Balance (in shares) at Dec. 29, 2018   290,848       23,524  
Beginning balance at Dec. 29, 2018 2,394,400 $ 2,900 5,685,900 (2,386,500) (31,900) $ (876,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)   454          
Exercise of stock options 11,600   11,600        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)   33          
Vesting of restricted stock units, net of shares withheld for employee taxes (400)   (400)        
Common stock issued under the employee stock purchase plan (in shares)   226          
Common stock issued under the employee stock purchase plan 7,900   7,900        
Stock-based compensation expense 17,500   17,500        
Net income (loss) (272,600)            
Other comprehensive income activity 1,400       1,400    
Balance (in shares) at Mar. 30, 2019   291,561       23,524  
Ending balance at Mar. 30, 2019 2,159,800 $ 2,900 5,722,500 (2,659,100) (30,500) $ (876,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (272,600)            
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount 0            
Exercise of stock options (in shares)   108          
Exercise of stock options 3,100   3,100        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)   21          
Vesting of restricted stock units, net of shares withheld for employee taxes (500)   (500)        
Stock-based compensation expense 13,900   13,900        
Net income (loss) 93,900            
Other comprehensive income activity (3,700)       (3,700)    
Repurchase of common stock (in shares)           1,114  
Repurchase of common stock (50,000)         $ (50,000)  
Balance (in shares) at Jun. 29, 2019   291,690       24,638  
Ending balance at Jun. 29, 2019 2,216,500 $ 2,900 5,739,000 (2,565,200) (34,200) $ (926,000)  
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount 0            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)   369          
Exercise of stock options     9,000        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)   16          
Vesting of restricted stock units, net of shares withheld for employee taxes     (300)        
Common stock issued under the employee stock purchase plan (in shares)   248          
Common stock issued under the employee stock purchase plan     8,600        
Stock-based compensation expense     13,500        
Net income (loss) (123,500)            
Other comprehensive income activity         (8,100)    
Balance (in shares) at Sep. 28, 2019   292,323       24,638  
Ending balance at Sep. 28, 2019 2,115,700 $ 2,900 5,769,800 (2,688,700) (42,300) $ (926,000)  
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount 0            
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2,115,700            
Noncontrolling Interest, Increase from Business Combination 8,600            
Exercise of stock options (in shares)   540          
Exercise of stock options     13,800        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)   476          
Vesting of restricted stock units, net of shares withheld for employee taxes     (10,900)        
Stock-based compensation expense     18,100        
Net income (loss) 385,800            
Other comprehensive income activity         13,600    
Repurchase of common stock (in shares)           1,545 3,279
Repurchase of common stock (80,900)         $ (80,900) $ 164,000
ASR portion flowing through APIC           $ (41,000)  
Balance (in shares) at Dec. 28, 2019   293,339       29,462  
Ending balance at Dec. 28, 2019   $ 2,900 5,749,800 (2,302,300) (28,700) $ (1,170,900)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable (300)            
Net income 386,100            
Accelerated share repurchase agreement (205,000)            
Payments to Noncontrolling Interests (1,400)            
Balance (in shares) at Sep. 28, 2019   292,323       24,638  
Beginning balance at Sep. 28, 2019 2,115,700 $ 2,900 5,769,800 (2,688,700) (42,300) $ (926,000)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 480,700            
Balance (in shares) at Mar. 28, 2020   294,142       35,941  
Ending balance at Mar. 28, 2020 2,086,100 $ 2,900 5,827,600 (2,206,000) (58,900) $ (1,479,500)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable (1,800)            
Net income 482,500            
Accelerated share repurchase agreement (205,000)            
Payments to Noncontrolling Interests (1,700)            
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount 6,900            
Accounting standard transition adjustment | Accounting Standards Update 2018-01 [Member]       300      
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2,257,700            
Balance (in shares) at Dec. 28, 2019   293,339       29,462  
Beginning balance at Dec. 28, 2019   $ 2,900 5,749,800 (2,302,300) (28,700) $ (1,170,900)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options (in shares)   503          
Exercise of stock options     13,900        
Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)   86          
Vesting of restricted stock units, net of shares withheld for employee taxes     (1,600)        
Common stock issued under the employee stock purchase plan (in shares)   214          
Common stock issued under the employee stock purchase plan     8,800        
Stock-based compensation expense     15,700        
Net income (loss) 94,800            
Repurchase of common stock (in shares)           5,851 628
Repurchase of common stock           $ (267,600) $ 41,000
ASR portion flowing through APIC           $ 41,000  
Balance (in shares) at Mar. 28, 2020   294,142       35,941  
Ending balance at Mar. 28, 2020 2,086,100 $ 2,900 $ 5,827,600 $ (2,206,000) $ (58,900) $ (1,479,500)  
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable (1,500)            
Net income 96,300            
Accelerated share repurchase agreement 0            
Payments to Noncontrolling Interests (300)            
Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount 5,100            
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $ 2,091,200            
XML 28 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net income (loss) $ 94.8 $ (272.6) $ 480.7 $ (174.0)
Changes in foreign currency translation adjustment (5.4) 2.4 2.9 (0.8)
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019. (25.2) (1.5) (21.2) (5.4)
Loss reclassified from accumulated other comprehensive loss to the statements of operations 0.4 0.5 1.7 1.2
Other comprehensive income (loss) (30.2) 1.4 (16.6) (5.0)
Comprehensive income (loss) 64.6 (271.2) 464.1 (179.0)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest 1.5 0.0 1.8 0.0
Comprehensive Income $ 66.1 $ (271.2) $ 465.9 $ (179.0)
XML 29 R25.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Loss
6 Months Ended
Mar. 28, 2020
Accumulated Other Comprehensive Income [Abstract]  
Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Loss

The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:

 
Three Months Ended March 28, 2020
 
Six Months Ended March 28, 2020
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Hedged Interest Rate Swaps
 
Total
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Hedged Interest Rate Swaps
Total
Beginning Balance
$
(33.1
)
 
$
(1.7
)
 
$
(1.4
)
 
$
7.5

 
$
(28.7
)
 
$
(41.4
)
 
$
(1.7
)
 
$
(2.7
)
 
$
3.5

$
(42.3
)
Other comprehensive income (loss) before reclassifications
(5.4
)
 

 
(0.1
)
 
(25.1
)
 
(30.6
)
 
2.9

 

 
(0.1
)
 
(21.1
)
(18.3
)
Amounts reclassified to statement of income

 

 
0.4

 

 
0.4

 

 

 
1.7

 

1.7

Ending Balance
$
(38.5
)
 
$
(1.7
)
 
$
(1.1
)
 
$
(17.6
)
 
$
(58.9
)
 
$
(38.5
)
 
$
(1.7
)
 
$
(1.1
)
 
$
(17.6
)
$
(58.9
)

 
Three Months Ended March 30, 2019
 
Six Months Ended March 30, 2019
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(29.8
)
 
$
(1.1
)
 
$
(1.0
)
 
$
(31.9
)
 
$
(26.6
)
 
$
(1.1
)
 
$
2.2

 
$
(25.5
)
Other comprehensive income (loss) before reclassifications
2.4

 

 
(1.5
)
 
0.9

 
(0.8
)
 

 
(5.4
)
 
(6.2
)
Amounts reclassified to statement of income

 

 
0.5

 
0.5

 

 

 
1.2

 
1.2

Ending Balance
$
(27.4
)
 
$
(1.1
)
 
$
(2.0
)
 
$
(30.5
)
 
$
(27.4
)
 
$
(1.1
)
 
$
(2.0
)
 
$
(30.5
)



XML 30 R21.htm IDEA: XBRL DOCUMENT v3.20.1
Business Segments and Geographic Information
6 Months Ended
Mar. 28, 2020
Segment Reporting [Abstract]  
Business Segments and Geographic Information Business Segments and Geographic Information
During the first fiscal quarter of 2020 and during fiscal 2019, the Company had five reportable segments: Diagnostics, Breast Health, GYN Surgical, Medical Aesthetics and Skeletal Health. The Company completed the sale of its Medical Aesthetics business on December 30, 2019, but will continue to have operating expenses related to indemnifying CD&R for legal and tax matters that existed as of the date of disposition. The Company measures and evaluates its reportable segments based on segment revenues and operating income adjusted to exclude the effect of non-cash charges, such as intangible asset amortization expense, intangible asset and goodwill impairment charges, acquisition related fair value adjustments and integration expenses, restructuring, divestiture and facility consolidation charges and other one-time or unusual items.
Identifiable assets for the reportable segments consist of inventories, intangible assets, goodwill, and property, plant and equipment. The Company fully allocates depreciation expense to its reportable segments. The Company has presented all other identifiable assets as corporate assets. There were no inter-segment revenues during the three and six months ended March 28, 2020 and March 30, 2019. Segment information is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Total revenues:
 
 
 
 
 
 
 
Diagnostics
$
319.2

 
$
296.7

 
$
630.7

 
$
593.3

Breast Health
307.8

 
321.5

 
638.9

 
646.2

GYN Surgical
105.4

 
102.2

 
224.5

 
210.6

Medical Aesthetics

 
73.8

 
65.3

 
153.6

Skeletal Health
23.7

 
24.2

 
47.2

 
45.4

 
$
756.1


$
818.4


$
1,606.6


$
1,649.1

Income (loss) from operations:
 
 
 
 
 
 
 
Diagnostics
$
57.3

 
$
31.1

 
$
106.8

 
$
74.4

Breast Health
75.9

 
99.0

 
169.8

 
196.8

GYN Surgical
23.9

 
20.5

 
55.4

 
47.6

Medical Aesthetics
(2.4
)
 
(473.9
)
 
(53.4
)
 
(499.1
)
Skeletal Health
1.7

 
0.1

 
2.6

 
(2.4
)
 
$
156.4


$
(323.2
)
 
$
281.2

 
$
(182.7
)
Depreciation and amortization:
 
 
 
 
 
 
 
Diagnostics
$
59.3

 
$
61.6

 
$
118.4

 
$
123.4

Breast Health
13.1

 
8.9

 
23.1

 
18.2

GYN Surgical
21.1

 
21.9

 
42.1

 
43.9

Medical Aesthetics

 
25.1

 
4.1

 
50.6

Skeletal Health
0.2

 
0.1

 
0.4

 
0.3

 
$
93.7


$
117.6


$
188.1


$
236.4

Capital expenditures:
 
 
 
 
 
 
 
Diagnostics
$
17.1

 
$
16.0

 
$
35.3

 
$
30.4

Breast Health
8.1

 
4.7

 
14.5

 
6.8

GYN Surgical
5.3

 
3.1

 
10.6

 
6.6

Medical Aesthetics

 
3.4

 
1.4

 
4.5

Skeletal Health
0.1

 
0.3

 
0.2

 
0.6

Corporate
1.1

 
1.8

 
1.1

 
3.0

 
$
31.7


$
29.3


$
63.1


$
51.9

 
 
March 28,
2020
 
September 28,
2019
Identifiable assets:
 
 
 
Diagnostics
$
2,193.8

 
$
2,276.6

Breast Health
1,243.9

 
1,127.8

GYN Surgical
1,284.4

 
1,328.6

Medical Aesthetics

 
159.3

Skeletal Health
30.2

 
27.3

Corporate
2,069.5

 
1,522.5

 
$
6,821.8

 
$
6,442.1

The Company had no customers that represented greater than 10% of consolidated revenues during the three and six months ended March 28, 2020 and March 30, 2019.
The Company operates in the major geographic areas noted in the below chart. Revenue data is based upon customer location. Other than the United States, no single country accounted for more than 10% of consolidated revenues. The Company’s sales in Europe are predominantly derived from France, Germany and the United Kingdom. The Company’s sales in Asia-Pacific are predominantly derived from China, Australia and Japan. The “Rest of World” designation includes Canada, Latin America and the Middle East.
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
United States
76.0
%
 
75.1
%
 
75.1
%
 
75.0
%
Europe
14.8
%
 
12.5
%
 
13.8
%
 
12.3
%
Asia-Pacific
5.5
%
 
7.9
%
 
7.0
%
 
8.1
%
Rest of World
3.7
%
 
4.5
%
 
4.1
%
 
4.6
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%

XML 31 R67.htm IDEA: XBRL DOCUMENT v3.20.1
Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of loss recognized in other comprehensive income, net of taxes: $ (25.3) $ (1.5) $ (21.2) $ (5.4)
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019. (25.2) (1.5) (21.2) (5.4)
Interest Rate Swap        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of loss recognized in other comprehensive income, net of taxes: (25.2) 0.0 (20.8) 0.0
Interest rate cap agreements        
Derivative Instruments, Gain (Loss) [Line Items]        
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019. $ (0.1) $ (1.5) $ (0.4) $ (5.4)
XML 32 R63.htm IDEA: XBRL DOCUMENT v3.20.1
Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Line of Credit Facility [Line Items]        
Interest expense $ 15.7 $ 15.7 $ 31.4 $ 31.4
Credit Agreement        
Line of Credit Facility [Line Items]        
Interest expense $ 13.0 $ 16.8 $ 26.6 $ 35.5
Weighted average interest rate 2.75% 3.86% 2.93% 3.84%
Interest rate at end of period 2.33% 3.87% 2.33% 3.87%
XML 34 R40.htm IDEA: XBRL DOCUMENT v3.20.1
Intangible Assets and Goodwill (Tables)
6 Months Ended
Mar. 28, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Intangible Assets
Intangible assets consisted of the following:
 
Description
As of March 28, 2020
 
As of September 28, 2019
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Acquired intangible assets:
 
 
 
 
 
 
 
Developed technology
$
3,925.6

 
$
2,779.6

 
$
3,927.7

 
$
2,654.8

Customer relationships
546.8

 
461.4

 
525.5

 
447.5

Trade names
244.0

 
176.1

 
245.4

 
171.1

Distribution agreement

 

 
2.5

 

Non-competition agreements
1.5

 
1.1

 
1.4

 
0.9

Business licenses
2.3

 
2.2

 
2.3

 
2.2

Total acquired intangible assets
$
4,720.2

 
$
3,420.4

 
$
4,704.8

 
$
3,276.5

 
 
 
 
 
 
 
 
Internal-use software
51.4

 
41.7

 
53.9

 
43.4

Capitalized software embedded in products
28.2

 
8.9

 
27.9

 
6.9

Total intangible assets
$
4,799.8


$
3,471.0


$
4,786.6


$
3,326.8


Schedule of Estimated Amortization Expense
The estimated remaining amortization expense of the Company's acquired intangible assets as of March 28, 2020 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2020
$
145.1

Fiscal 2021
$
269.1

Fiscal 2022
$
258.7

Fiscal 2023
$
161.2

Fiscal 2024
$
150.4


XML 35 R44.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Business Revenue (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Disaggregation of Revenue [Line Items]        
Revenues $ 756.1 $ 818.4 $ 1,606.6 $ 1,649.1
United States        
Disaggregation of Revenue [Line Items]        
Revenues 574.9 615.5 1,207.6 1,237.2
International        
Disaggregation of Revenue [Line Items]        
Revenues 181.2 202.9 399.0 411.9
Diagnostics        
Disaggregation of Revenue [Line Items]        
Revenues 319.2 296.7 630.7 593.3
Diagnostics | United States        
Disaggregation of Revenue [Line Items]        
Revenues 238.2 226.8 469.8 454.3
Diagnostics | International        
Disaggregation of Revenue [Line Items]        
Revenues 81.0 69.9 160.9 139.0
Diagnostics | Cytology & Perinatal        
Disaggregation of Revenue [Line Items]        
Revenues 113.4 115.5 234.4 233.6
Diagnostics | Cytology & Perinatal | United States        
Disaggregation of Revenue [Line Items]        
Revenues 73.2 76.6 150.7 155.8
Diagnostics | Cytology & Perinatal | International        
Disaggregation of Revenue [Line Items]        
Revenues 40.2 38.9 83.7 77.8
Diagnostics | Molecular Diagnostics        
Disaggregation of Revenue [Line Items]        
Revenues 190.6 167.8 369.1 332.1
Diagnostics | Molecular Diagnostics | United States        
Disaggregation of Revenue [Line Items]        
Revenues 149.8 136.8 291.9 270.9
Diagnostics | Molecular Diagnostics | International        
Disaggregation of Revenue [Line Items]        
Revenues 40.8 31.0 77.2 61.2
Diagnostics | Blood Screening        
Disaggregation of Revenue [Line Items]        
Revenues 15.2 13.4 27.2 27.6
Diagnostics | Blood Screening | United States        
Disaggregation of Revenue [Line Items]        
Revenues 15.2 13.4 27.2 27.6
Diagnostics | Blood Screening | International        
Disaggregation of Revenue [Line Items]        
Revenues 0.0 0.0 0.0 0.0
Breast Health        
Disaggregation of Revenue [Line Items]        
Revenues 307.8 321.5 638.9 646.2
Breast Health | United States        
Disaggregation of Revenue [Line Items]        
Revenues 234.4 253.0 490.9 505.6
Breast Health | International        
Disaggregation of Revenue [Line Items]        
Revenues 73.4 68.5 148.0 140.6
Breast Health | Breast Imaging        
Disaggregation of Revenue [Line Items]        
Revenues 250.2 265.9 525.0 535.6
Breast Health | Breast Imaging | United States        
Disaggregation of Revenue [Line Items]        
Revenues 186.0 206.2 395.4 412.7
Breast Health | Breast Imaging | International        
Disaggregation of Revenue [Line Items]        
Revenues 64.2 59.7 129.6 122.9
Breast Health | Interventional Breast Solutions        
Disaggregation of Revenue [Line Items]        
Revenues 57.6 55.6 113.9 110.6
Breast Health | Interventional Breast Solutions | United States        
Disaggregation of Revenue [Line Items]        
Revenues 48.4 46.8 95.5 92.9
Breast Health | Interventional Breast Solutions | International        
Disaggregation of Revenue [Line Items]        
Revenues 9.2 8.8 18.4 17.7
GYN Surgical        
Disaggregation of Revenue [Line Items]        
Revenues 105.4 102.2 224.5 210.6
GYN Surgical | United States        
Disaggregation of Revenue [Line Items]        
Revenues 86.7 84.1 185.5 175.2
GYN Surgical | International        
Disaggregation of Revenue [Line Items]        
Revenues 18.7 18.1 39.0 35.4
Medical Aesthetics        
Disaggregation of Revenue [Line Items]        
Revenues 0.0 73.8 65.3 153.6
Medical Aesthetics | United States        
Disaggregation of Revenue [Line Items]        
Revenues 0.0 37.6 30.9 74.9
Medical Aesthetics | International        
Disaggregation of Revenue [Line Items]        
Revenues 0.0 36.2 34.4 78.7
Skeletal Health        
Disaggregation of Revenue [Line Items]        
Revenues 23.7 24.2 47.2 45.4
Skeletal Health | United States        
Disaggregation of Revenue [Line Items]        
Revenues 15.6 14.0 30.5 27.2
Skeletal Health | International        
Disaggregation of Revenue [Line Items]        
Revenues $ 8.1 $ 10.2 $ 16.7 $ 18.2
XML 36 R48.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Remaining Performance Obligation (Details)
Mar. 28, 2020
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2020-03-29  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 23.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 6 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-03-29  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 32.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-03-29  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 24.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-03-29  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 14.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-03-29  
Disaggregation of Revenue [Line Items]  
Revenue, Remaining Performance Obligation, Percentage 7.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 1 year
XML 37 R24.htm IDEA: XBRL DOCUMENT v3.20.1
Product Warranties
6 Months Ended
Mar. 28, 2020
Guarantees [Abstract]  
Product Warranties Product Warranties
Product warranty activity was as follows:
 
 
Balance at
Beginning of
Period
 
Provisions
 
Acquired
 
Divested
 
Settlements/
Adjustments
 
Balance at
End of Period
Six Months Ended:
 
 
 
 
 
 
 
 
 
 
 
March 28, 2020
$
13.9

 
$
5.5

 
$
0.5

 
$
(6.1
)
 
$
(6.2
)
 
$
7.6

March 30, 2019
$
15.9

 
$
5.4

 
$

 
$

 
$
(6.9
)
 
$
14.4


XML 38 R20.htm IDEA: XBRL DOCUMENT v3.20.1
Other Balance Sheet Information
6 Months Ended
Mar. 28, 2020
Balance Sheet Related Disclosures [Abstract]  
Other Balance Sheet Information Other Balance Sheet Information

 
March 28,
2020
 
September 28,
2019
Inventories
 
 
 
Raw materials
$
155.1

 
$
166.1

Work-in-process
56.4

 
54.5

Finished goods
189.8

 
224.3

 
$
401.3

 
$
444.9


Property, plant and equipment
 
 
 
Equipment
$
407.6

 
$
379.2

Equipment under customer usage agreements
452.8

 
435.5

Building and improvements
162.9

 
196.7

Leasehold improvements
42.8

 
61.7

Land
40.6

 
46.3

Furniture and fixtures
15.6

 
17.5

 
1,122.3

 
1,136.9

Less – accumulated depreciation and amortization
(677.0
)
 
(666.0
)
 
$
445.3

 
$
470.9


XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.1
New Accounting Pronouncements (Policies)
6 Months Ended
Mar. 28, 2020
Accounting Policies [Abstract]  
New Accounting Pronouncements New Accounting Pronouncements

See Note 1 for Recently Adopted Accounting Pronouncements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10, ASU 2019-11 and ASU 2020-03, on its consolidated financial position and results of operations.
    
XML 40 R6.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Statement of Financial Position [Abstract]    
Accounts receivable, reserves $ 16.0 $ 17.8
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, authorized (in shares) 1,623,000 1,623,000
Preferred stock, issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, authorized (in shares) 750,000,000 750,000,000
Common stock, issued (in shares) 294,142,000 292,323,000
Treasury stock (in shares) 35,941,000 24,638,000
XML 41 R2.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Revenues:        
Product $ 623.6 $ 667.8 $ 1,322.9 $ 1,350.9
Service and other 132.5 150.6 283.7 298.2
Revenues 756.1 818.4 1,606.6 1,649.1
Costs of revenues:        
Product 223.3 232.9 460.8 465.0
Amortization, Cost of Goods Sold 62.9 80.4 126.5 161.4
Impairment of intangible assets and equipment 0.0 374.6 25.8 374.6
Service and other 74.1 88.1 163.9 171.6
Gross profit 395.8 42.4 829.6 476.5
Operating expenses:        
Research and development 49.3 57.3 110.4 110.5
Selling and marketing 110.6 133.5 255.4 279.5
General and administrative 66.5 89.9 155.1 168.5
Amortization of acquired intangible assets 10.1 14.1 19.2 28.2
Impairment of intangible assets and equipment 0.0 69.2 4.4 69.2
Restructuring and divestiture charges 2.9 1.6 3.9 3.3
Operating expenses 239.4 365.6 548.4 659.2
Income (loss) from operations 156.4 (323.2) 281.2 (182.7)
Interest income 1.3 0.8 3.5 2.1
Interest expense (31.3) (34.8) (64.1) (70.9)
Debt extinguishment loss 0.0 0.0 0.0 (0.8)
Other (expense) income, net (7.5) 3.5 (4.2) 2.9
Income (loss) before income taxes 118.9 (353.7) 216.4 (249.4)
Provision (benefit) for income taxes 24.1 (81.1) (264.3) (75.4)
Net income (loss) 94.8 (272.6) 480.7 (174.0)
Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable (1.5)   (1.8) 0.0
Net income $ 96.3 $ (272.6) $ 482.5 $ (174.0)
Net income (loss) per common share attributable to Hologic:        
Basic (in usd per share) $ 0.37 $ (1.01) $ 1.82 $ (0.64)
Diluted (in usd per share) $ 0.36 $ (1.01) $ 1.81 $ (0.64)
Weighted average number of shares outstanding:        
Basic (in shares) 263,238 269,235 265,566 269,913
Diluted (in shares) 264,506 269,235 267,114 269,913
EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 44 R66.htm IDEA: XBRL DOCUMENT v3.20.1
Derivatives - Fair Value of Derivative Financial Instruments (Details) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative Liability $ 22.9 $ 0.0
Interest Rate Swap    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 22.9  
Derivative instruments designated as a cash flow hedge | Interest rate cap agreements    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 0.0 4.8
Derivative instruments designated as a cash flow hedge | Interest rate cap agreements | Prepaid expenses and other current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 0.0 0.1
Derivative instruments designated as a cash flow hedge | Interest Rate Swap | Other assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative Asset, Fair Value, Gross Asset 0.0 4.7
Derivatives not designated as hedging instruments    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative Asset, Fair Value, Gross Asset 2.8 2.9
Derivatives not designated as hedging instruments | Interest Rate Swap | Accrued expenses    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 2.4 0.0
Derivatives not designated as hedging instruments | Interest Rate Swap | Other long-term liabilities    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 20.5 0.0
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Prepaid expenses and other current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 1.9 0.9
Derivatives not designated as hedging instruments | Forward foreign currency contracts | Accrued expenses    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Interest rate swap at fair value 0.0 0.1
Derivatives not designated as hedging instruments | Foreign currency option contracts | Prepaid expenses and other current assets    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Derivative Asset, Fair Value, Gross Asset $ 0.9 $ 2.0

XML 45 R62.htm IDEA: XBRL DOCUMENT v3.20.1
Borrowings and Credit Arrangements - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
Mar. 28, 2020
Dec. 28, 2019
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Sep. 28, 2019
Jan. 19, 2018
Oct. 10, 2017
Debt Instrument [Line Items]                
Long-term debt $ 3,555,400,000     $ 3,555,400,000   $ 3,055,000,000.0    
Debt extinguishment losses 0   $ 0 0 $ 800,000      
Payment of debt issuance costs       0 $ 2,700,000      
Senior notes             $ 1,000,000,000.0 $ 350,000,000
Borrowed principal 1,000,000,000.0     1,000,000,000.0        
Long-term Debt, Current Maturities 806,100,000     $ 806,100,000   271,400,000    
Amended Revolver [Member] | Percentage Added to Eurodollar Rate                
Debt Instrument [Line Items]                
Basis spread on variable rate       1.375%        
Amended Term Loan | Percentage Added to Eurodollar Rate                
Debt Instrument [Line Items]                
Basis spread on variable rate       1.375%        
Amended Credit Agreement                
Debt Instrument [Line Items]                
Debt extinguishment losses   $ (800,000)            
Maximum range of present value of cash flow percentage   10.00%            
Direct third party costs interest expense   $ 800,000            
Payment of debt issuance costs   $ 1,900,000            
Credit Agreement                
Debt Instrument [Line Items]                
Borrowed principal $ 2,200,000,000     $ 2,200,000,000        
2025 Senior Notes                
Debt Instrument [Line Items]                
Stated interest rate 4.375%     4.375%        
Revolver [Member]                
Debt Instrument [Line Items]                
Long-term Debt, Current Maturities $ 750,000,000     $ 750,000,000   0    
Debt Instrument, Unused Borrowing Capacity, Amount 750,000,000     750,000,000        
Accounts Receivable Securitization                
Debt Instrument [Line Items]                
Long-term Debt, Current Maturities 0     $ 0   $ 234,000,000.0    
Repayments of Debt $ 250,000,000              
Amended Term Loan | Amended Credit Agreement                
Debt Instrument [Line Items]                
Periodic principal payment period       3 months        
Senior Notes | 2025 Senior Notes                
Debt Instrument [Line Items]                
Stated interest rate 4.375%     4.375%        
Offering price of principal amount             $ 1 $ 1
Senior Notes | 2028 Senior Notes                
Debt Instrument [Line Items]                
Stated interest rate 4.625%     4.625%     4.625%  
Offering price of principal amount             $ 1  
2025 Senior Notes                
Debt Instrument [Line Items]                
Borrowed principal             600,000,000  
Senior notes, face amount $ 950,000,000     $ 950,000,000        
2028 Senior Notes                
Debt Instrument [Line Items]                
Borrowed principal             $ 400,000,000  
Senior notes, face amount $ 400,000,000     $ 400,000,000        
XML 46 R49.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Details)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 28, 2020
Sep. 28, 2019
USD ($)
Lessee, Lease, Description [Line Items]      
Period with option to terminate lease   1 year  
Extension period   20 years  
Weighted average discount rate (percentage)   0.0259  
Finance lease liability, current     $ 1.8
Finance lease liabilities (non-current)     $ 19.2
Lease revenue as a percentage of total (percentage) 0.03    
Minimum      
Lessee, Lease, Description [Line Items]      
Lessee, Operating And Finance Lease, Remaining Lease Term   1 year  
Maximum      
Lessee, Lease, Description [Line Items]      
Lessee, Operating And Finance Lease, Remaining Lease Term 15 years    
XML 47 R41.htm IDEA: XBRL DOCUMENT v3.20.1
Product Warranties (Tables)
6 Months Ended
Mar. 28, 2020
Guarantees [Abstract]  
Product Warranty Activity
Product warranty activity was as follows:
 
 
Balance at
Beginning of
Period
 
Provisions
 
Acquired
 
Divested
 
Settlements/
Adjustments
 
Balance at
End of Period
Six Months Ended:
 
 
 
 
 
 
 
 
 
 
 
March 28, 2020
$
13.9

 
$
5.5

 
$
0.5

 
$
(6.1
)
 
$
(6.2
)
 
$
7.6

March 30, 2019
$
15.9

 
$
5.4

 
$

 
$

 
$
(6.9
)
 
$
14.4


XML 48 R45.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Geographical Revenue (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Disaggregation of Revenue [Line Items]        
Revenues $ 756.1 $ 818.4 $ 1,606.6 $ 1,649.1
United States        
Disaggregation of Revenue [Line Items]        
Revenues 574.9 615.5 1,207.6 1,237.2
Europe        
Disaggregation of Revenue [Line Items]        
Revenues 111.8 102.1 221.2 203.2
Asia-Pacific        
Disaggregation of Revenue [Line Items]        
Revenues 41.7 64.3 111.8 134.0
Rest of World        
Disaggregation of Revenue [Line Items]        
Revenues $ 27.7 $ 36.5 $ 66.0 $ 74.7
XML 49 R83.htm IDEA: XBRL DOCUMENT v3.20.1
Product Warranties - Product Warranty Activity (Detail) - USD ($)
$ in Millions
6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]    
Balance at Beginning of Period $ 13.9 $ 15.9
Provisions 5.5 5.4
Standard and Extended Product Warranty Accrual, Additions from Business Acquisition 0.5 0.0
Standard Product Warranty Accrual, Period Increase (Decrease) (6.1) 0.0
Settlements/ Adjustments (6.2) (6.9)
Balance at End of Period $ 7.6 $ 14.4
XML 50 R73.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) - USD ($)
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Share-based Payment Arrangement [Abstract]        
Risk-free interest rate 1700000.00% 3.00% 1.70% 3.00%
Expected volatility 33.60% 34.30% 33.60% 34.30%
Expected life (in years) 4 years 9 months 18 days 4 years 9 months 18 days 4 years 9 months 18 days 4 years 9 months 18 days
Dividend yield $ 0 $ 0 $ 0 $ 0
Weighted average fair value of options granted $ 14.45 $ 15.33 $ 13.87 $ 13.50
XML 51 R77.htm IDEA: XBRL DOCUMENT v3.20.1
Business Segments and Geographic Information - Segment Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Sep. 28, 2019
Segment Reporting Information [Line Items]          
Total revenues $ 756.1 $ 818.4 $ 1,606.6 $ 1,649.1  
Income (loss) from operations 156.4 (323.2) 281.2 (182.7)  
Depreciation and amortization 93.7 117.6 188.1 236.4  
Capital expenditures 31.7 29.3 63.1 51.9  
Identifiable assets 6,821.8   6,821.8   $ 6,442.1
Diagnostics          
Segment Reporting Information [Line Items]          
Total revenues 319.2 296.7 630.7 593.3  
Income (loss) from operations 57.3 31.1 106.8 74.4  
Depreciation and amortization 59.3 61.6 118.4 123.4  
Capital expenditures 17.1 16.0 35.3 30.4  
Identifiable assets 2,193.8   2,193.8   2,276.6
Breast Health          
Segment Reporting Information [Line Items]          
Total revenues 307.8 321.5 638.9 646.2  
Income (loss) from operations 75.9 99.0 169.8 196.8  
Depreciation and amortization 13.1 8.9 23.1 18.2  
Capital expenditures 8.1 4.7 14.5 6.8  
Identifiable assets 1,243.9   1,243.9   1,127.8
Medical Aesthetics          
Segment Reporting Information [Line Items]          
Total revenues 0.0 73.8 65.3 153.6  
Income (loss) from operations (2.4) (473.9) (53.4) (499.1)  
Depreciation and amortization 0.0 25.1 4.1 50.6  
Capital expenditures 0.0 3.4 1.4 4.5  
Identifiable assets 0.0   0.0   159.3
GYN Surgical          
Segment Reporting Information [Line Items]          
Total revenues 105.4 102.2 224.5 210.6  
Income (loss) from operations 23.9 20.5 55.4 47.6  
Depreciation and amortization 21.1 21.9 42.1 43.9  
Capital expenditures 5.3 3.1 10.6 6.6  
Identifiable assets 1,284.4   1,284.4   1,328.6
Skeletal Health          
Segment Reporting Information [Line Items]          
Total revenues 23.7 24.2 47.2 45.4  
Income (loss) from operations 1.7 0.1 2.6 (2.4)  
Depreciation and amortization 0.2 0.1 0.4 0.3  
Capital expenditures 0.1 0.3 0.2 0.6  
Identifiable assets 30.2   30.2   27.3
Corporate          
Segment Reporting Information [Line Items]          
Capital expenditures 1.1 $ 1.8 1.1 $ 3.0  
Identifiable assets $ 2,069.5   $ 2,069.5   $ 1,522.5
XML 52 R54.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Additional Information (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Dec. 28, 2019
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability $ 9.8        
Intangible asset and equipment impairment charges   $ 30.2   $ 30.2 $ 443.8
Borrowed principal 1,000.0     1,000.0  
Credit Agreement          
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Borrowed principal 2,200.0     2,200.0  
2025 Senior Notes          
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Fair value of debt instrument 947.6     947.6  
2028 Senior Notes          
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Fair value of debt instrument 402.1     $ 402.1  
Medical Aesthetics          
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Intangible asset and equipment impairment charges $ 30.2 $ 30.2 $ 443.8    
Acquired intangible assets [Member] | Medical Aesthetics          
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Intangible asset and equipment impairment charges     437.0    
Equipment [Member] | Medical Aesthetics          
Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]          
Intangible asset and equipment impairment charges     $ 6.8    
XML 53 R50.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Supplemental Balance Sheet Information (Details) - USD ($)
Mar. 28, 2020
Sep. 28, 2019
Lessee, Lease, Description [Line Items]    
Finance lease liabilities (current)   $ 1,800,000
Finance lease liabilities (non-current)   $ 19,200,000
Operating Lease, Weighted Average Remaining Lease Term 5 years 11 months 4 days  
Finance Lease, Weighted Average Remaining Lease Term 8 years 1 month 20 days  
Operating Leases, Weighted average discount rate 1.95%  
Financing Leases, Weighted average discount rate 5.10%  
Other assets    
Lessee, Lease, Description [Line Items]    
Operating Leases, Lease right-of-use asset $ 82,600  
Accrued expenses    
Lessee, Lease, Description [Line Items]    
Operating lease liabilities (current) 22,100  
Finance lease obligations - short term    
Lessee, Lease, Description [Line Items]    
Finance lease liabilities (current) 1,800  
Other long-term liabilities    
Lessee, Lease, Description [Line Items]    
Operating lease liabilities (non-current) 68,700  
Finance lease obligations - long term    
Lessee, Lease, Description [Line Items]    
Finance lease liabilities (non-current) $ 18,400  
XML 54 R58.htm IDEA: XBRL DOCUMENT v3.20.1
Disposition (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Nov. 20, 2019
Mar. 28, 2020
Dec. 28, 2019
Mar. 28, 2020
Mar. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Expenses from disposition   $ 2.4      
Intangible asset and equipment impairment charges     $ 30.2 $ 30.2 $ 443.8
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Medical Aesthetics          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Disposal Group, Including Discontinued Operation, Consideration $ 205.0        
Proceeds from Divestiture of Businesses $ 153.4        
Cost of revenues          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Intangible asset and equipment impairment charges     25.8    
Operating Expense          
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]          
Intangible asset and equipment impairment charges     $ 4.4    
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.20.1
Business Segments and Geographic Information (Tables)
6 Months Ended
Mar. 28, 2020
Segment Reporting [Abstract]  
Segment Information egment information is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Total revenues:
 
 
 
 
 
 
 
Diagnostics
$
319.2

 
$
296.7

 
$
630.7

 
$
593.3

Breast Health
307.8

 
321.5

 
638.9

 
646.2

GYN Surgical
105.4

 
102.2

 
224.5

 
210.6

Medical Aesthetics

 
73.8

 
65.3

 
153.6

Skeletal Health
23.7

 
24.2

 
47.2

 
45.4

 
$
756.1


$
818.4


$
1,606.6


$
1,649.1

Income (loss) from operations:
 
 
 
 
 
 
 
Diagnostics
$
57.3

 
$
31.1

 
$
106.8

 
$
74.4

Breast Health
75.9

 
99.0

 
169.8

 
196.8

GYN Surgical
23.9

 
20.5

 
55.4

 
47.6

Medical Aesthetics
(2.4
)
 
(473.9
)
 
(53.4
)
 
(499.1
)
Skeletal Health
1.7

 
0.1

 
2.6

 
(2.4
)
 
$
156.4


$
(323.2
)
 
$
281.2

 
$
(182.7
)
Depreciation and amortization:
 
 
 
 
 
 
 
Diagnostics
$
59.3

 
$
61.6

 
$
118.4

 
$
123.4

Breast Health
13.1

 
8.9

 
23.1

 
18.2

GYN Surgical
21.1

 
21.9

 
42.1

 
43.9

Medical Aesthetics

 
25.1

 
4.1

 
50.6

Skeletal Health
0.2

 
0.1

 
0.4

 
0.3

 
$
93.7


$
117.6


$
188.1


$
236.4

Capital expenditures:
 
 
 
 
 
 
 
Diagnostics
$
17.1

 
$
16.0

 
$
35.3

 
$
30.4

Breast Health
8.1

 
4.7

 
14.5

 
6.8

GYN Surgical
5.3

 
3.1

 
10.6

 
6.6

Medical Aesthetics

 
3.4

 
1.4

 
4.5

Skeletal Health
0.1

 
0.3

 
0.2

 
0.6

Corporate
1.1

 
1.8

 
1.1

 
3.0

 
$
31.7


$
29.3


$
63.1


$
51.9

 
 
March 28,
2020
 
September 28,
2019
Identifiable assets:
 
 
 
Diagnostics
$
2,193.8

 
$
2,276.6

Breast Health
1,243.9

 
1,127.8

GYN Surgical
1,284.4

 
1,328.6

Medical Aesthetics

 
159.3

Skeletal Health
30.2

 
27.3

Corporate
2,069.5

 
1,522.5

 
$
6,821.8

 
$
6,442.1

Revenues by Geography
Revenues by geography as a percentage of total revenues were as follows:
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
United States
76.0
%
 
75.1
%
 
75.1
%
 
75.0
%
Europe
14.8
%
 
12.5
%
 
13.8
%
 
12.3
%
Asia-Pacific
5.5
%
 
7.9
%
 
7.0
%
 
8.1
%
Rest of World
3.7
%
 
4.5
%
 
4.1
%
 
4.6
%
 
100.0
%
 
100.0
%
 
100.0
%
 
100.0
%

XML 56 R31.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements (Tables)
6 Months Ended
Mar. 28, 2020
Fair Value Disclosures [Abstract]  
Fair Value Assets and Liabilities Measured on Recurring Basis
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 28, 2020: 
 
 
 
Fair Value at Reporting Date Using
 
Balance as of March 28, 2020
 
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Foreign currency option contracts
0.9

 

 
0.9

 

Forward foreign currency contracts
1.9

 

 
1.9

 

Total
$
2.8

 
$

 
$
2.8

 
$

Liabilities:
 
 
 
 
 
 
 
Contingent consideration
$
0.9

 
$

 
$

 
$
0.9

Interest rate swaps - derivative
$
22.9

 
$

 
$
22.9

 
$

Total
$
23.8

 
$

 
$
22.9

 
$
0.9


XML 57 R35.htm IDEA: XBRL DOCUMENT v3.20.1
Derivatives (Tables)
6 Months Ended
Mar. 28, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Derivative Assets at Fair Value
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 28, 2020:
 
Balance Sheet Location
 
March 28, 2020
 
September 28, 2019
Assets:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate cap agreements
Prepaid expenses and other current assets
 
$

 
$
0.1

Interest rate swap contract
Other assets
 

 
4.7

 
 
 
$

 
$
4.8

 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Prepaid expenses and other current assets
 
$
1.9

 
$
0.9

Foreign currency option contracts
Prepaid expenses and other current assets
 
0.9

 
2.0

 
 
 
$
2.8

 
$
2.9

 
 
 
 
 
 
Liabilities:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate swap contract
Accrued expenses
 
$
2.4

 
$

Interest rate swap contract
Other long-term liabilities
 
20.5

 

Total
 
 
$
22.9

 
$

Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Accrued expenses
 
$

 
$
0.1


Schedule of Unrealized Loss Recognized in AOCI
The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods:
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
Amount of loss recognized in other comprehensive income, net of taxes:
 
 
 
 
 
 
 
Interest rate swap
$
(25.2
)
 
$

 
$
(20.8
)
 
$

Interest rate cap agreements
(0.1
)
 
(1.5
)
 
(0.4
)
 
(5.4
)
Total
$
(25.3
)
 
$
(1.5
)
 
$
(21.2
)
 
$
(5.4
)

Schedule of Adjustment to Fair Value within the Consolidated Statements of Income
The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:
Derivatives not classified as hedging instruments
Amount of (Loss) Gain Recognized in Income
 
Three Months Ended March 28, 2020
 
Three Months Ended March 30, 2019
 
Six Months Ended March 28, 2020
 
Six Months Ended March 30, 2019
Forward foreign currency contracts
$
2.7

 
$
0.4

 
$
1.3

 
$
5.5

Foreign currency option contracts
0.6

 

 
(1.1
)
 

Total
$
3.3

 
$
0.4

 
$
0.2

 
$
5.5


XML 58 R16.htm IDEA: XBRL DOCUMENT v3.20.1
Derivatives
6 Months Ended
Mar. 28, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Derivatives Derivatives
Interest Rate Cap - Cash Flow Hedge
The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company manages its exposure to some of its interest rate risk through the use of interest rate caps, which are derivative financial instruments. The Company does not use derivatives for speculative purposes. For a derivative that is designated as a cash flow hedge, changes in the fair value of the derivative are recognized in accumulated other comprehensive income ("AOCI") to the extent the derivative is effective at offsetting the changes in the cash flows being hedged until the hedged item affects earnings. To the extent there is any hedge ineffectiveness, changes in fair value relating to the ineffective portion are immediately recognized in earnings in other income (expense), net in the Consolidated Statements of Operations.
During fiscal 2018, the Company entered into separate interest rate cap agreements with multiple counter-parties to help mitigate the interest rate volatility associated with the variable interest rate on amounts borrowed under the term loan feature of its credit facilities (see Note 7). Interest rate cap agreements provide the right to receive cash if the reference interest rate rises above a contractual rate. The aggregate premium paid for these interest rate cap agreements was $3.7 million, which was the initial fair value of the instruments recorded in the Company's financial statements.
During fiscal 2019, the Company entered into additional separate interest rate cap agreements with multiple counter-parties to extend the expiration date of its hedges by an additional year. The aggregate premium paid for these interest cap agreements was $1.5 million, which was the initial fair value of the instruments recorded in the Company’s financial statements.    
The critical terms of the interest rate caps were designed to mirror the terms of the Company’s LIBOR-based borrowings under its Credit Agreement, that has been amended multiple times, and therefore are highly effective at offsetting the cash flows being hedged. The Company designated these derivatives as cash flow hedges of the variability of the LIBOR-based interest payments on $1.0 billion of principal, which ended on December 27, 2019 for the contracts entered into in fiscal 2018, and which will end on December 23, 2020 for the interest rate cap agreements entered into in fiscal 2019.
As of March 28, 2020, all changes in the fair value of the interest rate caps were recorded in the Consolidated Statements of Comprehensive Income (Loss).
During the three and six months ended March 28, 2020 and March 30, 2019, the Company reclassified $0.4 million and $1.7 million, respectively and $0.5 million and $1.2 million, respectively from AOCI to the Consolidated Statements of Operations related to the interest rate cap agreements. The Company expects to similarly reclassify a loss of approximately $1.1 million from AOCI to the Consolidated Statements of Operations in the next nine months.
The aggregate fair value of these interest rate caps was $0.0 million and $0.1 million at March 28, 2020 and September 28, 2019, respectively, and is included in prepaid expenses and other current assets on the Company’s Consolidated Balance Sheet. Refer to Note 4 “Fair Value Measurements” above for related fair value disclosures.
Interest Rate Swap - Cash Flow Hedge
In fiscal 2019, in order to hedge a portion of its variable rate debt beyond the contracted period under interest cap agreements, the Company entered into an interest rate swap contract with an effective date of December 23, 2020 and a termination date of December 17, 2023. The notional amount of this swap is $1.0 billion. The interest rate swap effectively fixes the LIBOR component of the variable interest rate on $1.0 billion of the notional amount under the 2018 Credit Agreement at 1.23%. The critical terms of the interest rate swap are designed to mirror the terms of the Company’s LIBOR-based borrowings under its credit agreement and therefore are highly effective at offsetting the cash flows being hedged. The Company designated this derivative as a cash flow hedge of the variability of the LIBOR-based interest payments on $1.0 billion of principal. Therefore, changes in the fair value of the swap are recorded in AOCI. The fair value of this derivative was in a liability position of $22.9 million as of March 28, 2020.
Forward Foreign Currency Contracts and Foreign Currency Option Contracts
The Company enters into forward foreign currency exchange contracts and foreign currency option contracts to mitigate certain operational exposures from the impact of changes in foreign currency exchange rates. Such exposures result from the portion of the Company's operations that are denominated in currencies other than the U.S. dollar, primarily the Euro, the UK Pound, the Australian dollar, the Canadian dollar, the Chinese Yuan and the Japanese Yen. These foreign currency exchange contracts are entered into to support transactions made in the ordinary course of business and are not speculative in nature. The contracts are generally for periods of one year or less. The Company did not elect hedge accounting for these forward foreign currency contracts and foreign currency option contracts; however, the Company may seek to apply hedge accounting in future scenarios. The change in the fair value of these contracts is recognized directly in earnings as a component of other income (expense), net. During the three and six months ended March 28, 2020, for the forward foreign currency exchange contracts the
Company recorded net realized gains of $0.1 million in both periods from settling forward foreign currency exchange contracts and net unrealized gains of $2.6 million and $1.1 million, respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the three and six months ended March 30, 2019, the Company recorded net realized gains of $1.8 million and $3.5 million, respectively, from settling forward foreign currency contracts and net unrealized loss of $1.4 million and net realized gain of $2.0 million, respectively, on the mark-to-market for its outstanding forward foreign currency contracts. During the three and six months ended March 28, 2020, for the foreign currency option contracts the Company recorded net unrealized gains of $1.1 million and net unrealized losses of $0.4 million, respectively, on outstanding option contracts. During the three and six months ended March 28, 2020, for the foreign currency option contracts, the Company recorded net realized losses of $0.5 million and $0.7 million, respectively, on outstanding option contracts.
As of March 28, 2020, the Company had outstanding forward foreign currency contracts that were not designated for hedge accounting and were used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Australian dollar, Canadian Dollar, Chinese Yuan and Japanese Yen with an aggregate notional amount of $51.0 million. As of March 28, 2020, the Company had outstanding foreign currency option contracts that were not designated for hedge accounting and are used to hedge fluctuations in the U.S. dollar of forecasted transactions denominated in the Euro and UK Pound with a notional amount of $80.6 million.
Financial Instrument Presentation
The table below presents the fair value of the Company's derivative financial instruments as well as their classification on the balance sheet as of March 28, 2020:
 
Balance Sheet Location
 
March 28, 2020
 
September 28, 2019
Assets:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate cap agreements
Prepaid expenses and other current assets
 
$

 
$
0.1

Interest rate swap contract
Other assets
 

 
4.7

 
 
 
$

 
$
4.8

 
 
 
 
 
 
Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Prepaid expenses and other current assets
 
$
1.9

 
$
0.9

Foreign currency option contracts
Prepaid expenses and other current assets
 
0.9

 
2.0

 
 
 
$
2.8

 
$
2.9

 
 
 
 
 
 
Liabilities:
 
 
 
 
 
Derivative instruments designated as a cash flow hedge:
 
 
 
 
 
Interest rate swap contract
Accrued expenses
 
$
2.4

 
$

Interest rate swap contract
Other long-term liabilities
 
20.5

 

Total
 
 
$
22.9

 
$

Derivatives not designated as hedging instruments:
 
 
 
 
 
Forward foreign currency contracts
Accrued expenses
 
$

 
$
0.1


The following table presents the unrealized gain (loss) recognized in AOCI related to the interest rate caps and interest rate swap for the following reporting periods:
 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
Amount of loss recognized in other comprehensive income, net of taxes:
 
 
 
 
 
 
 
Interest rate swap
$
(25.2
)
 
$

 
$
(20.8
)
 
$

Interest rate cap agreements
(0.1
)
 
(1.5
)
 
(0.4
)
 
(5.4
)
Total
$
(25.3
)
 
$
(1.5
)
 
$
(21.2
)
 
$
(5.4
)

The following table presents the adjustment to fair value (realized and unrealized) recorded within the Consolidated Statements of Income for derivative instruments for which the Company did not elect hedge accounting:
Derivatives not classified as hedging instruments
Amount of (Loss) Gain Recognized in Income
 
Three Months Ended March 28, 2020
 
Three Months Ended March 30, 2019
 
Six Months Ended March 28, 2020
 
Six Months Ended March 30, 2019
Forward foreign currency contracts
$
2.7

 
$
0.4

 
$
1.3

 
$
5.5

Foreign currency option contracts
0.6

 

 
(1.1
)
 

Total
$
3.3

 
$
0.4

 
$
0.2

 
$
5.5


XML 59 R12.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements
6 Months Ended
Mar. 28, 2020
Fair Value Disclosures [Abstract]  
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] Fair Value Measurements
Assets/Liabilities Measured and Recorded at Fair Value on a Recurring Basis
The Company has investments in derivative instruments consisting of interest rate caps, interest rate swaps and foreign currency contracts, which are valued using analyses obtained from independent third party valuation specialists based on market observable inputs, representing Level 2 assets. The fair values of the Company's interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts represent the estimated amounts the Company would receive or pay to terminate the contracts. Refer to Note 8 for further discussion and information on derivative instruments.
Assets and liabilities measured and recorded at fair value on a recurring basis consisted of the following at March 28, 2020: 
 
 
 
Fair Value at Reporting Date Using
 
Balance as of March 28, 2020
 
Quoted Prices in
Active Market for
Identical Assets
(Level 1)
 
Significant
Other
Observable
Inputs (Level 2)
 
Significant
Unobservable
Inputs (Level 3)
Assets:
 
 
 
 
 
 
 
Foreign currency option contracts
0.9

 

 
0.9

 

Forward foreign currency contracts
1.9

 

 
1.9

 

Total
$
2.8

 
$

 
$
2.8

 
$

Liabilities:
 
 
 
 
 
 
 
Contingent consideration
$
0.9

 
$

 
$

 
$
0.9

Interest rate swaps - derivative
$
22.9

 
$

 
$
22.9

 
$

Total
$
23.8

 
$

 
$
22.9

 
$
0.9


Assets Measured and Recorded at Fair Value on a Recurring Basis
The Company had contingent consideration liabilities related to its Emsor S.A. and Faxitron Bioptics, LLC acquisitions. The remeasurement of these liabilities in the second quarter of fiscal 2020 was insignificant, and the Company settled these obligations for $9.8 million.
Assets Measured and Recorded at Fair Value on a Nonrecurring Basis
The Company remeasures the fair value of certain assets and liabilities upon the occurrence of certain events. Such assets consist of equity investments and long-lived assets, including property, plant and equipment, intangible assets and goodwill. There were no such remeasurements for equity investments in the three and six months ended March 28, 2020 and March 30, 2019. During the first quarter of fiscal 2020, the Company's Medical Aesthetics division met the criteria to be classified as assets-held-for sale and the Company recorded a $30.2 million loss to record the asset group at its fair value less costs to sell. This is a level 1 measurement. See Note 6 for additional information. During the second quarter of fiscal 2019, the Company identified indicators of impairment related to its long-lived assets of its Medical Aesthetics reportable segment and recorded impairment charges of $443.8 million, of which $437.0 million was allocated to intangible assets and $6.8 million was allocated to equipment. This was a level 3 measurement. See Note 15.
Disclosure of Fair Value of Financial Instruments
The Company’s financial instruments mainly consist of cash and cash equivalents, accounts receivable, equity investments, interest rate caps, interest rate swaps, forward foreign currency contracts, foreign currency option contracts, insurance contracts, accounts payable and debt obligations. The carrying amounts of the Company’s cash equivalents, accounts receivable and accounts payable approximate their fair value due to the short-term nature of these instruments. The Company’s interest rate caps, interest rate swaps, forward foreign currency contracts and foreign currency option contracts are recorded at
fair value. The carrying amount of the insurance contracts is recorded at the cash surrender value, as required by GAAP, which approximates fair value. The Company believes the carrying amounts of its equity investments approximate fair value.
Amounts outstanding under the Company’s 2018 Credit Agreement (as defined below) of $2.2 billion aggregate principal as of March 28, 2020 are subject to variable interest rates, which are based on current market rates, and as such, the Company believes the carrying amount of these obligations approximates fair value. The Company’s 2025 Senior Notes and 2028 Senior Notes had fair values of $947.6 million and $402.1 million, respectively, as of March 28, 2020 based on their trading prices, representing Level 1 measurements. Refer to Note 7 for the carrying amounts of the various components of the Company’s debt.
XML 60 R26.htm IDEA: XBRL DOCUMENT v3.20.1
Share Repurchase
6 Months Ended
Mar. 28, 2020
Equity [Abstract]  
Share Repurchase Share Repurchase
On June 13, 2018, the Board of Directors authorized a share repurchase plan to repurchase up to $500.0 million of the Company's outstanding common stock. This share repurchase plan was effective August 1, 2018 and expired on March 27, 2020. Under this authorization, during the second quarter of fiscal 2020, the Company repurchased 2.4 million shares of its common stock for a total consideration of $130.1 million. As of March 28, 2020, the Company had completed this authorization.
On November 19, 2019, the Board of Directors authorized a new share repurchase plan to repurchase up to $500.0 million of the Company's outstanding common stock, effective at the beginning of the third quarter of fiscal 2020. On March 2, 2020 the Board of Directors approved accelerating the effective date of the new share repurchase plan from March 27, 2020 to March 2, 2020. Under this revised authorization, during the second quarter of fiscal 2020, the Company repurchased 3.5 million shares of its common stock for a total consideration of $137.5 million. As of March 28, 2020, $362.6 million remained available under this authorization.
On November 19, 2019, the Board of Directors authorized the Company to repurchase up to $205 million of its outstanding shares pursuant to an accelerated share repurchase ("ASR") agreement. On November 22, 2019, the Company executed the ASR agreement with Goldman Sachs & Co. ("Goldman Sachs") pursuant to which the Company repurchased $205 million of the Company's common stock. The initial delivery, of approximately 80% of the shares under the ASR, was 3.3 million shares for which the Company initially allocated $164.0 million of the $205 million paid to Goldman Sachs during the first quarter of fiscal 2020. The Company evaluated the nature of the forward contract aspect of the ASR under ASC 815 and concluded equity classification was appropriate. Final settlement of the transaction under the ASR occurred in the second quarter of fiscal 2020. At settlement, Goldman Sachs delivered an additional 0.6 million shares of the Company's common stock.
XML 61 R8.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Cash Flows - USD ($)
$ in Millions
6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
OPERATING ACTIVITIES    
Net income (loss) $ 480.7 $ (174.0)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:    
Depreciation 42.3 46.8
Amortization of acquired intangibles 145.8 189.6
Stock-based compensation expense 33.8 34.6
Deferred income taxes (44.2) (173.3)
Intangible asset and equipment impairment charges 30.2 443.8
Other adjustments and non-cash items 14.8 14.4
Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:    
Accounts receivable (0.3) 18.6
Inventories (33.3) (54.0)
Prepaid income taxes (27.7) (8.3)
Prepaid expenses and other assets (317.6) (10.4)
Accounts payable (47.9) (27.2)
Accrued expenses and other liabilities (50.8) (71.2)
Deferred revenue 5.8 8.7
Net cash provided by operating activities 231.6 238.1
INVESTING ACTIVITIES    
Acquisition of businesses, net of cash acquired (43.2) (108.6)
Proceeds From Sale Of Business 142.7 0.0
Capital expenditures (29.6) (23.0)
Increase in equipment under customer usage agreements (33.5) (28.9)
Payments to Acquire Trading Securities Held-for-investment 0.0 3.0
Purchase of insurance contracts 2.4 0.0
Other activity (1.4) (3.6)
Net cash provided by (used in) investing activities 32.6 (167.1)
FINANCING ACTIVITIES    
Proceeds from long-term debt 0.0 1,500.0
Repayment of long-term debt (18.8) (1,462.5)
Proceeds from revolving credit line 750.0 480.0
Repayments under revolving credit line 0.0 (695.0)
Proceeds from accounts receivable securitization agreement 16.0 0.0
Repayments of Accounts Receivable Securitization 250.0 18.0
Payments to Noncontrolling Interests (1.7) 0.0
Payment of deferred acquisition consideration (24.3) 0.0
Repayments of acquired long term debt 8.3 2.5
Payment of debt issuance costs 0.0 (2.7)
Accelerated share repurchase agreement (205.0) 0.0
Repurchase of common stock (348.5) (150.1)
Interest Rate Cap Agreements Aggregate Premium Payable 0.0 1.5
Proceeds from issuance of common stock pursuant to employee stock plans 36.6 28.8
Payments under finance lease obligations (0.8) (0.8)
Net cash used in financing activities (67.3) (336.2)
Payment of minimum tax withholdings on net share settlements of equity awards (12.5) (11.9)
Effect of exchange rate changes on cash and cash equivalents 1.1 (0.5)
Net increase (decrease) in cash and cash equivalents 198.0 (265.7)
Cash and cash equivalents, beginning of period 601.8 666.7
Cash and cash equivalents, end of period $ 799.8 $ 401.0
JSON 62 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "holxq2-2020.htm": { "axisCustom": 0, "axisStandard": 27, "contextCount": 523, "dts": { "calculationLink": { "local": [ "holx-20200328_cal.xml" ] }, "definitionLink": { "local": [ "holx-20200328_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml", "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml" ] }, "inline": { "local": [ "holxq2-2020.htm" ] }, "labelLink": { "local": [ "holx-20200328_lab.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "holx-20200328_pre.xml" ] }, "referenceLink": { "remote": [ "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml", "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "holx-20200328.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd", "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd", "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 676, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2019-01-31": 38, "http://www.hologic.com/20200328": 2, "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 45 }, "keyCustom": 77, "keyStandard": 414, "memberCustom": 53, "memberStandard": 55, "nsprefix": "holx", "nsuri": "http://www.hologic.com/20200328", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://www.hologic.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "dei:Security12bTitle", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2102100 - Disclosure - Revenue", "role": "http://www.hologic.com/role/Revenue", "shortName": "Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103100 - Disclosure - Leases (Notes)", "role": "http://www.hologic.com/role/LeasesNotes", "shortName": "Leases (Notes)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock", "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2104100 - Disclosure - Fair Value Measurements", "role": "http://www.hologic.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105100 - Disclosure - Business Combinations", "role": "http://www.hologic.com/role/BusinessCombinations", "shortName": "Business Combinations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107100 - Disclosure - Disposition", "role": "http://www.hologic.com/role/Disposition", "shortName": "Disposition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2110100 - Disclosure - Borrowings and Credit Arrangements", "role": "http://www.hologic.com/role/BorrowingsAndCreditArrangements", "shortName": "Borrowings and Credit Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111100 - Disclosure - Derivatives", "role": "http://www.hologic.com/role/Derivatives", "shortName": "Derivatives", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2112100 - Disclosure - Commitments and Contingencies", "role": "http://www.hologic.com/role/CommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113100 - Disclosure - Net Income (Loss) Per Share", "role": "http://www.hologic.com/role/NetIncomeLossPerShare", "shortName": "Net Income (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2114100 - Disclosure - Stock-Based Compensation", "role": "http://www.hologic.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "holx:ProductRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001000 - Statement - Consolidated Statements of Income", "role": "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "shortName": "Consolidated Statements of Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "holx:ProductRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:DetailsOfCertainBalanceSheetAccountsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116100 - Disclosure - Other Balance Sheet Information", "role": "http://www.hologic.com/role/OtherBalanceSheetInformation", "shortName": "Other Balance Sheet Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:DetailsOfCertainBalanceSheetAccountsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2117100 - Disclosure - Business Segments and Geographic Information", "role": "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformation", "shortName": "Business Segments and Geographic Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2118100 - Disclosure - Income Taxes", "role": "http://www.hologic.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2119100 - Disclosure - Intangible Assets and Goodwill", "role": "http://www.hologic.com/role/IntangibleAssetsAndGoodwill", "shortName": "Intangible Assets and Goodwill", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120100 - Disclosure - Product Warranties", "role": "http://www.hologic.com/role/ProductWarranties", "shortName": "Product Warranties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ProductWarrantyDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2121100 - Disclosure - Accumulated Other Comprehensive Loss", "role": "http://www.hologic.com/role/AccumulatedOtherComprehensiveLoss", "shortName": "Accumulated Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2123100 - Disclosure - Share Repurchase", "role": "http://www.hologic.com/role/ShareRepurchase", "shortName": "Share Repurchase", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:TreasuryStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124100 - Disclosure - New Accounting Pronouncements", "role": "http://www.hologic.com/role/NewAccountingPronouncements", "shortName": "New Accounting Pronouncements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2224201 - Disclosure - New Accounting Pronouncements (Policies)", "role": "http://www.hologic.com/role/NewAccountingPronouncementsPolicies", "shortName": "New Accounting Pronouncements (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:DescriptionOfNewAccountingPronouncementsNotYetAdopted", "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2302301 - Disclosure - Revenue (Tables)", "role": "http://www.hologic.com/role/RevenueTables", "shortName": "Revenue (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2303301 - Disclosure - Leases (Tables)", "role": "http://www.hologic.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.hologic.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_holx_FaxitronMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2305301 - Disclosure - Business Combinations (Tables)", "role": "http://www.hologic.com/role/BusinessCombinationsTables", "shortName": "Business Combinations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD_us-gaap_BusinessAcquisitionAxis_holx_FaxitronMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2307301 - Disclosure - Disposition Disposition (Tables)", "role": "http://www.hologic.com/role/DispositionDispositionTables", "shortName": "Disposition Disposition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310301 - Disclosure - Borrowings and Credit Arrangements (Tables)", "role": "http://www.hologic.com/role/BorrowingsAndCreditArrangementsTables", "shortName": "Borrowings and Credit Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2311301 - Disclosure - Derivatives (Tables)", "role": "http://www.hologic.com/role/DerivativesTables", "shortName": "Derivatives (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2313301 - Disclosure - Net Income (Loss) Per Share (Tables)", "role": "http://www.hologic.com/role/NetIncomeLossPerShareTables", "shortName": "Net Income (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314301 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.hologic.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2316301 - Disclosure - Other Balance Sheet Information (Tables)", "role": "http://www.hologic.com/role/OtherBalanceSheetInformationTables", "shortName": "Other Balance Sheet Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317301 - Disclosure - Business Segments and Geographic Information (Tables)", "role": "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationTables", "shortName": "Business Segments and Geographic Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1002501 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)", "role": "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical", "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2319301 - Disclosure - Intangible Assets and Goodwill (Tables)", "role": "http://www.hologic.com/role/IntangibleAssetsAndGoodwillTables", "shortName": "Intangible Assets and Goodwill (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2320301 - Disclosure - Product Warranties (Tables)", "role": "http://www.hologic.com/role/ProductWarrantiesTables", "shortName": "Product Warranties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321301 - Disclosure - Accumulated Other Comprehensive Loss (Tables)", "role": "http://www.hologic.com/role/AccumulatedOtherComprehensiveLossTables", "shortName": "Accumulated Other Comprehensive Loss (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2401401 - Disclosure - Basis of Presentation Details (Details)", "role": "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "shortName": "Basis of Presentation Details (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q1", "decimals": "-5", "lang": null, "name": "holx:Rightofuseassetrecognizedoperating", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402402 - Disclosure - Revenue - Business Revenue (Details)", "role": "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "shortName": "Revenue - Business Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD_srt_StatementGeographicalAxis_holx_InternationalMember", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402403 - Disclosure - Revenue - Geographical Revenue (Details)", "role": "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "shortName": "Revenue - Geographical Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD_srt_StatementGeographicalAxis_srt_EuropeMember", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402404 - Disclosure - Revenue - Revenue by Type (Details)", "role": "http://www.hologic.com/role/RevenueRevenueByTypeDetails", "shortName": "Revenue - Revenue by Type (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD_srt_ProductOrServiceAxis_holx_CapitalEquipmentComponentsandSoftwareMember", "decimals": "-5", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402405 - Disclosure - Revenue - Narrative (Details)", "role": "http://www.hologic.com/role/RevenueNarrativeDetails", "shortName": "Revenue - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-03-29", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402406 - Disclosure - Revenue - Remaining Performance Obligation (Details)", "role": "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails", "shortName": "Revenue - Remaining Performance Obligation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain_2020-03-29", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:RevenueRemainingPerformanceObligationPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:LesseeOperatingAndFinanceLeasePeriodWithOptionToTerminate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403402 - Disclosure - Leases (Details)", "role": "http://www.hologic.com/role/LeasesDetails", "shortName": "Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "holx:LesseeOperatingAndFinanceLeasePeriodWithOptionToTerminate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003000 - Statement - Consolidated Balance Sheets", "role": "http://www.hologic.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FinanceLeaseLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)", "role": "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails", "shortName": "Leases - Supplemental Balance Sheet Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": null, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403404 - Disclosure - Leases - Additional Lease Information (Details)", "role": "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails", "shortName": "Leases - Additional Lease Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2403405 - Disclosure - Leases - Lease Liability Maturity Schedule (Details)", "role": "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails", "shortName": "Leases - Lease Liability Maturity Schedule (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404402 - Disclosure - Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)", "role": "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail", "shortName": "Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InvestmentsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2404403 - Disclosure - Fair Value Measurements - Additional Information (Detail)", "role": "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "shortName": "Fair Value Measurements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "D2020Q1Nov21-21", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405402 - Disclosure - Business Combination - Narrative (Details)", "role": "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "shortName": "Business Combination - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "D2020Q1Nov21-21", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405403 - Disclosure - Business Combination - Purchase Price Allocation (Details)", "role": "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "shortName": "Business Combination - Purchase Price Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "I2019Q1Oct01_us-gaap_BusinessAcquisitionAxis_holx_FocalTherapeuticsInc.Member", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405404 - Disclosure - Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details)", "role": "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails", "shortName": "Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "I2020Q1Nov21_us-gaap_BusinessAcquisitionAxis_holx_SuperSonicImagineMember", "decimals": "-5", "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "holx:Expensesfromdisposition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Disposition (Details)", "role": "http://www.hologic.com/role/DispositionDetails", "shortName": "Disposition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "holx:Expensesfromdisposition", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q1_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_holx_MedicalAestheticsDomain", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407403 - Disclosure - Disposition - Schedule of Assets and Liabilities Held For Sale (Details)", "role": "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails", "shortName": "Disposition - Schedule of Assets and Liabilities Held For Sale (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q1_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_holx_MedicalAestheticsDomain", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R60": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407404 - Disclosure - Disposition - Schedule of Disposition Related Income Statement Information (Details)", "role": "http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails", "shortName": "Disposition - Schedule of Disposition Related Income Statement Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-2", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410402 - Disclosure - Borrowings and Credit Arrangements - Company's Borrowings (Detail)", "role": "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "shortName": "Borrowings and Credit Arrangements - Company's Borrowings (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2_us-gaap_LongtermDebtTypeAxis_holx_TermLoanMember", "decimals": "-5", "lang": null, "name": "us-gaap:LongTermDebtCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:LongTermDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410403 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail)", "role": "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "shortName": "Borrowings and Credit Arrangements - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "I2018Q1SD", "decimals": "-8", "lang": null, "name": "us-gaap:SeniorNotes", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpenseBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details)", "role": "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "shortName": "Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD_us-gaap_DebtInstrumentAxis_holx_CreditAgreementMember", "decimals": "-5", "lang": null, "name": "us-gaap:InterestExpenseBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InterestExpenseBorrowings", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410405 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details)", "role": "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails", "shortName": "Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD_us-gaap_DebtInstrumentAxis_holx_A2028SeniorNotesMember_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember", "decimals": "-5", "lang": null, "name": "us-gaap:InterestExpenseBorrowings", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "holx:InterestRateCapAgreementsAggregatePremiumPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411402 - Disclosure - Derivatives - Additional Information (Details)", "role": "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "shortName": "Derivatives - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "holx:InterestRateCapAgreementsAggregatePremiumPayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411403 - Disclosure - Derivatives - Fair Value of Derivative Financial Instruments (Details)", "role": "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "shortName": "Derivatives - Fair Value of Derivative Financial Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:DerivativeLiabilities", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details)", "role": "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails", "shortName": "Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411405 - Disclosure - Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details)", "role": "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails", "shortName": "Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "I2018Q3Jul27_dei_LegalEntityAxis_holx_MinervaMember", "decimals": "-5", "first": true, "lang": null, "name": "holx:AmountAssessedInDamages", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412401 - Disclosure - Commitments and Contingencies (Detail)", "role": "http://www.hologic.com/role/CommitmentsAndContingenciesDetail", "shortName": "Commitments and Contingencies (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "I2018Q3Jul27_dei_LegalEntityAxis_holx_MinervaMember", "decimals": "-5", "first": true, "lang": null, "name": "holx:AmountAssessedInDamages", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RedeemableNoncontrollingInterestEquityOtherCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004000 - Statement - Consolidated Statements of Stockholders' Equity", "role": "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "shortName": "Consolidated Statements of Stockholders' Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2018Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:RedeemableNoncontrollingInterestEquityOtherCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413402 - Disclosure - Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail)", "role": "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail", "shortName": "Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-3", "lang": null, "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "holx:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)", "role": "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail", "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "holx:ScheduleOfShareBasedCompensationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414403 - Disclosure - Stock-Based Compensation - Additional Information (Detail)", "role": "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "shortName": "Stock-Based Compensation - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)", "role": "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail", "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416402 - Disclosure - Other Balance Sheet Information - Inventories (Detail)", "role": "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail", "shortName": "Other Balance Sheet Information - Inventories (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "holx:ManufacturingEquipmentAndSoftware", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416403 - Disclosure - Other Balance Sheet Information - Property, Plant and Equipment (Detail)", "role": "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail", "shortName": "Other Balance Sheet Information - Property, Plant and Equipment (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "holx:ManufacturingEquipmentAndSoftware", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417402 - Disclosure - Business Segments and Geographic Information - Additional Information (Detail)", "role": "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail", "shortName": "Business Segments and Geographic Information - Additional Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "Segment", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417403 - Disclosure - Business Segments and Geographic Information - Segment Information (Detail)", "role": "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "shortName": "Business Segments and Geographic Information - Segment Information (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "lang": null, "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "INF", "first": true, "lang": null, "name": "holx:PercentageOfRevenues", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417404 - Disclosure - Business Segments and Geographic Information - Revenues by Geography (Detail)", "role": "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail", "shortName": "Business Segments and Geographic Information - Revenues by Geography (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "INF", "first": true, "lang": null, "name": "holx:PercentageOfRevenues", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418401 - Disclosure - Income Taxes (Details)", "role": "http://www.hologic.com/role/IncomeTaxesDetails", "shortName": "Income Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2019Q4", "decimals": "-5", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005000 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": "-5", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419402 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail)", "role": "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail", "shortName": "Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419403 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)", "role": "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail", "shortName": "Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q1QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419404 - Disclosure - Intangible Assets and Goodwill -Narrative (Details)", "role": "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "shortName": "Intangible Assets and Goodwill -Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q1QTD_us-gaap_FairValueByAssetClassAxis_holx_DevelopedTechnologyMember_us-gaap_StatementBusinessSegmentsAxis_holx_MedicalAestheticsDomain", "decimals": "-5", "lang": null, "name": "us-gaap:AssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420402 - Disclosure - Product Warranties - Product Warranty Activity (Detail)", "role": "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail", "shortName": "Product Warranties - Product Warranty Activity (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfProductWarrantyLiabilityTableTextBlock", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2019Q4", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:ProductWarrantyAccrual", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2019Q1", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421402 - Disclosure - Accumulated Other Comprehensive Income (Detail)", "role": "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "shortName": "Accumulated Other Comprehensive Income (Detail)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember", "decimals": "-5", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422402 - Disclosure - Restructuring (Details)", "role": "http://www.hologic.com/role/RestructuringDetails", "shortName": "Restructuring (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2QTD", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:SeveranceCosts1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "D2020Q1Nov20-20", "decimals": "INF", "first": true, "lang": null, "name": "holx:TreasuryStockAuthorized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423401 - Disclosure - Share Repurchase Share repurchase (Details)", "role": "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails", "shortName": "Share Repurchase Share repurchase (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "div", "ix:continuation", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "D2020Q1Nov20-20", "decimals": "INF", "first": true, "lang": null, "name": "holx:TreasuryStockAuthorized", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101100 - Disclosure - Basis of Presentation", "role": "http://www.hologic.com/role/BasisOfPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FD2020Q2YTD", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "span", "div", "td", "tr", "table", "div", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "div", "body", "html" ], "baseRef": "holxq2-2020.htm", "contextRef": "FI2020Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember", "decimals": "-5", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - holxq2-2020.htm", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - holxq2-2020.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 122, "tag": { "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2017-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r454" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r455" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityByLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity by Location [Axis]", "terseLabel": "Entity by Location [Axis]" } } }, "localname": "EntityByLocationAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r457" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityLocationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The Entity location table associates entities with primary and other locations. The domain members may be countries, states, provinces and groupings of these and other geographic codes.", "label": "Entity Location [Table]", "terseLabel": "Entity Location [Table]" } } }, "localname": "EntityLocationTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r456" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_LocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A domain representing all geographic locations. Depending on the axis, it may contain members that are specific geographies, or synthetic entity-specific geographical groups.", "label": "Location [Domain]", "terseLabel": "Location [Domain]" } } }, "localname": "LocationDomain", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r452" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r453" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.hologic.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "holx_A2025SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2025 Senior Notes [Member]", "label": "2025 Senior Notes [Member]", "terseLabel": "2025 Senior Notes" } } }, "localname": "A2025SeniorNotesMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_A2028SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2028 Senior Notes [Member]", "label": "2028 Senior Notes [Member]", "terseLabel": "2028 Senior Notes" } } }, "localname": "A2028SeniorNotesMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_ASRAuthorized": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "ASR Authorized", "label": "ASR Authorized", "terseLabel": "ASR Authorized" } } }, "localname": "ASRAuthorized", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "holx_ASRSharesRepurchasedduringtheperiod": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "ASR Shares Repurchased during the period", "label": "ASR Shares Repurchased during the period", "terseLabel": "ASR Shares Repurchased during the period" } } }, "localname": "ASRSharesRepurchasedduringtheperiod", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "holx_ASRportionflowingthroughAPIC": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "ASR portion flowing through APIC", "label": "ASR portion flowing through APIC", "negatedTerseLabel": "ASR portion flowing through APIC" } } }, "localname": "ASRportionflowingthroughAPIC", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "holx_Acceleratedsharerepurchaseagreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Accelerated share repurchase agreement", "label": "Accelerated share repurchase agreement", "negatedTerseLabel": "Accelerated share repurchase agreement" } } }, "localname": "Acceleratedsharerepurchaseagreement", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "holx_AccountsReceivableSecuritizationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accounts Receivable Securitization [Member]", "label": "Accounts Receivable Securitization [Member]", "terseLabel": "Accounts Receivable Securitization", "verboseLabel": "Securitization Program" } } }, "localname": "AccountsReceivableSecuritizationMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "domainItemType" }, "holx_AccumulatedOtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accumulated Other Comprehensive Income [Abstract]", "label": "Accumulated Other Comprehensive Income [Abstract]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeAbstract", "nsuri": "http://www.hologic.com/20200328", "xbrltype": "stringItemType" }, "holx_AcquiredintangibleassetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Acquired intangible assets [Member]", "label": "Acquired intangible assets [Member]", "terseLabel": "Total acquired intangible assets", "verboseLabel": "Acquired intangible assets [Member]" } } }, "localname": "AcquiredintangibleassetsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_AllOtherCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "All other countries.", "label": "All Other Countries [Member]", "terseLabel": "Rest of World" } } }, "localname": "AllOtherCountriesMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail" ], "xbrltype": "domainItemType" }, "holx_AlphaImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alpha Imaging [Member]", "label": "Alpha Imaging [Member]", "terseLabel": "Alpha Imaging [Member]" } } }, "localname": "AlphaImagingMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "holx_AmendedCreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended Credit Agreement [Member]", "label": "Amended Credit Agreement [Member]", "terseLabel": "Amended Credit Agreement" } } }, "localname": "AmendedCreditAgreementMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_AmendedRevolverMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended Revolver [Member]", "label": "Amended Revolver [Member]", "terseLabel": "Amended Revolver [Member]" } } }, "localname": "AmendedRevolverMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_AmendedTermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Amended Term Loan [Member]", "label": "Amended Term Loan [Member]", "terseLabel": "Amended Term Loan" } } }, "localname": "AmendedTermLoanMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_AmortizationCostofGoodsSold": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization, Cost of Goods Sold", "label": "Amortization, Cost of Goods Sold", "terseLabel": "Amortization, Cost of Goods Sold" } } }, "localname": "AmortizationCostofGoodsSold", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "holx_AmountAssessedInDamages": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount assessed in damages.", "label": "Amount Assessed In Damages", "terseLabel": "Assessed damages" } } }, "localname": "AmountAssessedInDamages", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "holx_AmountpaidduringtheperiodunderASRAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount paid during the period under ASR Agreement", "label": "Amount paid during the period under ASR Agreement", "terseLabel": "Amount paid during the period under ASR Agreement" } } }, "localname": "AmountpaidduringtheperiodunderASRAgreement", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "holx_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets And Liabilities, Lessee [Table Text Block]", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "Schedule of Lessee Lease Assets And Liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "holx_AssetsofBusinessHeldforSaleAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Assets of Business Held-for-Sale [Abstract]", "label": "Assets of Business Held-for-Sale [Abstract]" } } }, "localname": "AssetsofBusinessHeldforSaleAbstract", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/DispositionDetails" ], "xbrltype": "stringItemType" }, "holx_BasisofPresentationAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Basis of Presentation [Abstract]", "label": "Basis of Presentation [Abstract]" } } }, "localname": "BasisofPresentationAbstract", "nsuri": "http://www.hologic.com/20200328", "xbrltype": "stringItemType" }, "holx_BloodScreeningMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Blood Screening [Member]", "label": "Blood Screening [Member]", "terseLabel": "Blood Screening" } } }, "localname": "BloodScreeningMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_BreastHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Breast health.", "label": "Breast Health [Member]", "terseLabel": "Breast Health" } } }, "localname": "BreastHealthMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_BreastImagingMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Breast Imaging [Member]", "label": "Breast Imaging [Member]", "terseLabel": "Breast Imaging" } } }, "localname": "BreastImagingMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_BusinessAcquisitionCashTenderOfferPricePerShare": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Acquisition, Cash Tender Offer Price Per Share", "label": "Business Acquisition, Cash Tender Offer Price Per Share", "terseLabel": "Cash tender offer price (per share)" } } }, "localname": "BusinessAcquisitionCashTenderOfferPricePerShare", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "holx_BusinessCombinationConsiderationTransferredPortionAllocableToEquityMethodInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Portion Allocable To Equity Method Investment", "label": "Business Combination, Consideration Transferred, Portion Allocable To Equity Method Investment", "terseLabel": "Consideration related to equity method investment" } } }, "localname": "BusinessCombinationConsiderationTransferredPortionAllocableToEquityMethodInvestment", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationConsiderationTransferredPortionAllocableToFairValueOfNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Portion Allocable To Fair Value Of Noncontrolling Interest", "label": "Business Combination, Consideration Transferred, Portion Allocable To Fair Value Of Noncontrolling Interest", "terseLabel": "Business Combination, Consideration related to fair value of noncontrolling interest" } } }, "localname": "BusinessCombinationConsiderationTransferredPortionAllocableToFairValueOfNoncontrollingInterest", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationConsiderationTransferredPortionAllocableToLoanRepayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Portion Allocable To Loan Repayment", "label": "Business Combination, Consideration Transferred, Portion Allocable To Loan Repayment", "terseLabel": "Consideration, portion related to loan repayment" } } }, "localname": "BusinessCombinationConsiderationTransferredPortionAllocableToLoanRepayment", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationConsiderationTransferredPortionAllocableToNewlyAcquiredShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Consideration Transferred, Portion Allocable To Newly Acquired Shares", "label": "Business Combination, Consideration Transferred, Portion Allocable To Newly Acquired Shares", "terseLabel": "Consideration related to newly acquired shares" } } }, "localname": "BusinessCombinationConsiderationTransferredPortionAllocableToNewlyAcquiredShares", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationOwnershipPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Ownership Percentage", "label": "Business Combination, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "BusinessCombinationOwnershipPercentage", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "percentItemType" }, "holx_BusinessCombinationPeriodforAchievementofCumulativeRevenuesForPaymentofContingentConsiderationLiability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Period for Achievement of Cumulative Revenues For Payment of Contingent Consideration Liability", "label": "Business Combination, Period for Achievement of Cumulative Revenues For Payment of Contingent Consideration Liability", "terseLabel": "Period of cumulative revenue to trigger payment of contingent consideration liability" } } }, "localname": "BusinessCombinationPeriodforAchievementofCumulativeRevenuesForPaymentofContingentConsiderationLiability", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "durationItemType" }, "holx_BusinessCombinationPeriodforPaymentofContingentConsiderationLiability": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Period for Payment of Contingent Consideration Liability", "label": "Business Combination, Period for Payment of Contingent Consideration Liability", "terseLabel": "Period for payment of contingent consideration liabilities" } } }, "localname": "BusinessCombinationPeriodforPaymentofContingentConsiderationLiability", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "durationItemType" }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCustomerRelationships": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 11.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Customer Relationships", "terseLabel": "Customer relationships" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedCustomerRelationships", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDebt": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Debt", "negatedTerseLabel": "Short and long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDebt", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDevelopedTechnology": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 10.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Technology", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Developed Technology", "terseLabel": "Developed technology" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedDevelopedTechnology", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Fair Value", "terseLabel": "Intangible assets, fair value (percentage)" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedIntangibleAssetsFairValue", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "percentItemType" }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherLiabilities": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Liabilities", "negatedTerseLabel": "Other liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedOtherLiabilities", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTradeNames": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 12.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Trade Names", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Trade Names", "terseLabel": "Trade names" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedTradeNames", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "holx_BusinessCombinationSharesAcquired": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business Combination, Shares Acquired", "label": "Business Combination, Shares Acquired", "terseLabel": "Shares acquired" } } }, "localname": "BusinessCombinationSharesAcquired", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "holx_BusinessLicensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Business licenses.", "label": "Business Licenses [Member]", "terseLabel": "Business licenses" } } }, "localname": "BusinessLicensesMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_COVID19Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "COVID-19 [Member]", "label": "COVID-19 [Member]", "terseLabel": "COVID-19 [Member]" } } }, "localname": "COVID19Member", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "holx_CapitalEquipmentComponentsandSoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capital Equipment, Components and Software [Member]", "label": "Capital Equipment, Components and Software [Member]", "terseLabel": "Capital equipment, components and software" } } }, "localname": "CapitalEquipmentComponentsandSoftwareMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "holx_CapitalizedsoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Capitalized software [Member]", "label": "Capitalized software [Member]", "terseLabel": "Capitalized software embedded in products" } } }, "localname": "CapitalizedsoftwareMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_ComprehensiveIncome": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Comprehensive Income", "label": "Comprehensive Income", "terseLabel": "Comprehensive Income" } } }, "localname": "ComprehensiveIncome", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "holx_ConsumablesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Consumables [Member]", "label": "Consumables [Member]", "terseLabel": "Consumables" } } }, "localname": "ConsumablesMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "holx_CostOfGoodsSoldImpairmentOfIntangibleAssetsandequipment": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in cost of product sales in the period resulting from the write-down of the carrying amount of an intangible asset to fair value.", "label": "Cost Of Goods Sold Impairment Of Intangible Assets and equipment", "terseLabel": "Impairment of intangible assets and equipment" } } }, "localname": "CostOfGoodsSoldImpairmentOfIntangibleAssetsandequipment", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "holx_Costofservice": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Cost of service", "label": "Cost of service", "terseLabel": "Service and other" } } }, "localname": "Costofservice", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "holx_CreditAgreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Credit agreement.", "label": "Credit Agreement [Member]", "terseLabel": "Credit Agreement", "verboseLabel": "Credit Agreement" } } }, "localname": "CreditAgreementMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_CustomerRelationshipsContractsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customer relationships contracts.", "label": "Customer Relationships Contracts [Member]", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsContractsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_CynosureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cynosure [Member]", "label": "Cynosure [Member]", "terseLabel": "Cynosure" } } }, "localname": "CynosureMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail", "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "holx_CytologyPerinatalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cytology & Perinatal [Member]", "label": "Cytology & Perinatal [Member]", "terseLabel": "Cytology & Perinatal" } } }, "localname": "CytologyPerinatalMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_DebtInstrumentPeriodicPaymentPrincipalPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Debt Instrument, Periodic Payment, Principal, Period", "label": "Debt Instrument, Periodic Payment, Principal, Period", "terseLabel": "Periodic principal payment period" } } }, "localname": "DebtInstrumentPeriodicPaymentPrincipalPeriod", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "holx_DeceaseinaccumulateddeficitresultingfromadoptionofASCU201616": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decease in accumulated deficit resulting from adoption of ASCU 2016-16", "label": "Decease in accumulated deficit resulting from adoption of ASCU 2016-16", "terseLabel": "Decease in accumulated deficit resulting from adoption of ASCU 2016-16" } } }, "localname": "DeceaseinaccumulateddeficitresultingfromadoptionofASCU201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "holx_DeceasetoprepaidtaxesresultingfromadoptionofASCU201616": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decease to prepaid taxes resulting from adoption of ASCU 2016-16", "label": "Decease to prepaid taxes resulting from adoption of ASCU 2016-16", "terseLabel": "Decease to prepaid taxes resulting from adoption of ASCU 2016-16" } } }, "localname": "DeceasetoprepaidtaxesresultingfromadoptionofASCU201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "holx_DecreaseindeferredtaxliabilitiesduetoASC201616": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in deferred tax liabilities due to ASC 2016-16", "label": "Decrease in deferred tax liabilities due to ASC 2016-16", "terseLabel": "Decrease in deferred tax liabilities due to ASC 2016-16" } } }, "localname": "DecreaseindeferredtaxliabilitiesduetoASC201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "holx_Derecognitionoffinanceleases": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derecognition of finance leases", "label": "Derecognition of finance leases", "terseLabel": "Derecognition of finance leases" } } }, "localname": "Derecognitionoffinanceleases", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails" ], "xbrltype": "monetaryItemType" }, "holx_Derecognitionofpropertyplantandequipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Derecognition of property, plant and equipment", "label": "Derecognition of property, plant and equipment", "terseLabel": "Derecognition of property, plant and equipment" } } }, "localname": "Derecognitionofpropertyplantandequipment", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails" ], "xbrltype": "monetaryItemType" }, "holx_DetailsOfCertainBalanceSheetAccountsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Details of certain balance sheet accounts.", "label": "Details Of Certain Balance Sheet Accounts [Text Block]", "terseLabel": "Other Balance Sheet Information" } } }, "localname": "DetailsOfCertainBalanceSheetAccountsTextBlock", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformation" ], "xbrltype": "textBlockItemType" }, "holx_DevelopedTechnologyMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Developed technology.", "label": "Developed Technology [Member]", "verboseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_DiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Diagnostics.", "label": "Diagnostics [Member]", "terseLabel": "Diagnostics" } } }, "localname": "DiagnosticsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_DirectThirdPartyCostsinterestExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Direct Third Party Costs interest Expense", "label": "Direct Third Party Costs interest Expense", "terseLabel": "Direct third party costs interest expense" } } }, "localname": "DirectThirdPartyCostsinterestExpense", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "holx_DistributionagreementMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Distribution agreement [Member]", "label": "Distribution agreement [Member]", "verboseLabel": "Distribution agreement" } } }, "localname": "DistributionagreementMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_EarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings Per Share [Line Items]", "label": "Earnings Per Share [Line Items]", "terseLabel": "Earnings Per Share [Line Items]" } } }, "localname": "EarningsPerShareLineItems", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "stringItemType" }, "holx_EarningsPerShareTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Earnings Per Share [Table]", "label": "Earnings Per Share [Table]", "terseLabel": "Earnings Per Share [Table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "stringItemType" }, "holx_EmsorMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Emsor [Member]", "label": "Emsor [Member]", "terseLabel": "Emsor" } } }, "localname": "EmsorMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "holx_EquipmentUnderCustomerUsageAgreements": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount at the balance sheet date of long-lived, depreciable asset that are equipment placed at customer locations for which title is not transferred to the Company's customers.", "label": "Equipment Under Customer Usage Agreements", "terseLabel": "Equipment under customer usage agreements" } } }, "localname": "EquipmentUnderCustomerUsageAgreements", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "holx_Estimatedseveranceandbenefitsfuturecosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Estimated severance and benefits future costs", "label": "Estimated severance and benefits future costs", "terseLabel": "Estimated severance and benefits future costs" } } }, "localname": "Estimatedseveranceandbenefitsfuturecosts", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "holx_Expensesfromdisposition": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Expenses from disposition", "label": "Expenses from disposition", "terseLabel": "Expenses from disposition" } } }, "localname": "Expensesfromdisposition", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/DispositionDetails" ], "xbrltype": "monetaryItemType" }, "holx_FairValueAssumptionDiscountRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fair Value Assumption, Discount Rate", "label": "Fair Value Assumption, Discount Rate", "terseLabel": "Discount rate percentage" } } }, "localname": "FairValueAssumptionDiscountRate", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "pureItemType" }, "holx_FaxitronMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Faxitron [Member]", "label": "Faxitron [Member]", "verboseLabel": "Faxitron" } } }, "localname": "FaxitronMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "domainItemType" }, "holx_FinanceLeaseObligationsLongTermMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease Obligations - Long Term [Member]", "label": "Finance Lease Obligations - Long Term [Member]", "terseLabel": "Finance lease obligations - long term" } } }, "localname": "FinanceLeaseObligationsLongTermMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "holx_FinanceLeaseObligationsShortTermMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Finance Lease Obligations - Short Term [Member]", "label": "Finance Lease Obligations - Short Term [Member]", "terseLabel": "Finance lease obligations - short term" } } }, "localname": "FinanceLeaseObligationsShortTermMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "holx_FocalTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Focal Therapeutics, Inc. [Member]", "label": "Focal Therapeutics, Inc. [Member]", "terseLabel": "Focal Therapeutics" } } }, "localname": "FocalTherapeuticsInc.Member", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "domainItemType" }, "holx_GynSurgicalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "GYN surgical.", "label": "Gyn Surgical [Member]", "terseLabel": "GYN Surgical" } } }, "localname": "GynSurgicalMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_HealthBeaconsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Health Beacons [Member]", "label": "Health Beacons [Member]", "terseLabel": "Health Beacons [Member]" } } }, "localname": "HealthBeaconsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "holx_Holdback": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Holdback", "label": "Holdback", "terseLabel": "Holdback" } } }, "localname": "Holdback", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "holx_IncreaseindeferredtaxassetsresultingfromadoptionofASCU201616": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase in deferred tax assets resulting from adoption of ASCU 2016-16", "label": "Increase in deferred tax assets resulting from adoption of ASCU 2016-16", "terseLabel": "Increase in deferred tax assets resulting from adoption of ASCU 2016-16" } } }, "localname": "IncreaseindeferredtaxassetsresultingfromadoptionofASCU201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "holx_IncreasetoEarningsperShareresultedfromadoptionofASC201616": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Increase to Earnings per Share resulted from adoption of ASC 2016-16", "label": "Increase to Earnings per Share resulted from adoption of ASC 2016-16", "terseLabel": "Increase to Earnings per Share resulted from adoption of ASC 2016-16" } } }, "localname": "IncreasetoEarningsperShareresultedfromadoptionofASC201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "perShareItemType" }, "holx_IncreasetoNetIncomeresultedfromadoptionofASU201616": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase to Net Income resulted from adoption of ASU 2016-16", "label": "Increase to Net Income resulted from adoption of ASU 2016-16", "terseLabel": "Increase to Net Income resulted from adoption of ASU 2016-16" } } }, "localname": "IncreasetoNetIncomeresultedfromadoptionofASU201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "holx_IncreasetoincometaxexpenseadoptionofASU201616": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Increase to income tax expense adoption of ASU 2016-16", "label": "Increase to income tax expense adoption of ASU 2016-16", "terseLabel": "Increase to income tax expense adoption of ASU 2016-16" } } }, "localname": "IncreasetoincometaxexpenseadoptionofASU201616", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "holx_InterestRateCapAgreementsAggregatePremiumPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Interest rate cap agreements aggregate premium payable.", "label": "Interest Rate Cap Agreements Aggregate Premium Payable", "terseLabel": "Interest Rate Cap Agreements Aggregate Premium Payable", "verboseLabel": "Interest Rate Cap Agreements Aggregate Premium Payable" } } }, "localname": "InterestRateCapAgreementsAggregatePremiumPayable", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "holx_InternalusesoftwareMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Internal-use software [Member]", "label": "Internal-use software [Member]", "terseLabel": "Internal-use software" } } }, "localname": "InternalusesoftwareMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "holx_InternationalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "International" } } }, "localname": "InternationalMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_InterventionalBreastSolutionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Interventional Breast Solutions [Member]", "label": "Interventional Breast Solutions [Member]", "terseLabel": "Interventional Breast Solutions" } } }, "localname": "InterventionalBreastSolutionsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_June132019PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "June 13, 2019 Plan [Member]", "label": "June 13, 2019 Plan [Member]", "terseLabel": "June 13, 2019 Plan [Member]" } } }, "localname": "June132019PlanMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "domainItemType" }, "holx_LeaseRevenuePercentageOfTotalRevenue": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lease Revenue, Percentage Of Total Revenue", "label": "Lease Revenue, Percentage Of Total Revenue", "terseLabel": "Lease revenue as a percentage of total (percentage)" } } }, "localname": "LeaseRevenuePercentageOfTotalRevenue", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "pureItemType" }, "holx_LesseeOperatingAndFinanceLeasePeriodWithOptionToTerminate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating And Finance Lease, Period With Option To Terminate", "label": "Lessee, Operating And Finance Lease, Period With Option To Terminate", "terseLabel": "Period with option to terminate lease" } } }, "localname": "LesseeOperatingAndFinanceLeasePeriodWithOptionToTerminate", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "holx_LesseeOperatingAndFinanceLeaseRemainingLeaseTerm": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating And Finance Lease, Remaining Lease Term", "label": "Lessee, Operating And Finance Lease, Remaining Lease Term", "terseLabel": "Lessee, Operating And Finance Lease, Remaining Lease Term" } } }, "localname": "LesseeOperatingAndFinanceLeaseRemainingLeaseTerm", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "holx_LesseeOperatingAndFinanceLeasesExtensionPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating And Finance Leases, Extension Period", "label": "Lessee, Operating And Finance Leases, Extension Period", "terseLabel": "Extension period" } } }, "localname": "LesseeOperatingAndFinanceLeasesExtensionPeriod", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "durationItemType" }, "holx_LesseeOperatingAndFinanceLeasesWeightedAverageDiscountRatePercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lessee, Operating And Finance Leases, Weighted Average Discount Rate, Percent", "label": "Lessee, Operating And Finance Leases, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (percentage)" } } }, "localname": "LesseeOperatingAndFinanceLeasesWeightedAverageDiscountRatePercent", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "pureItemType" }, "holx_LongTermDebtObligationsWithoutConvertibleNotes": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Long term debt obligations without convertible notes.", "label": "Long Term Debt Obligations Without Convertible Notes", "terseLabel": "Long term debt obligations. excluding convertible notes" } } }, "localname": "LongTermDebtObligationsWithoutConvertibleNotes", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "monetaryItemType" }, "holx_ManufacturingEquipmentAndSoftware": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount as of the balance sheet date of long-lived, depreciable assets that include manufacturing and other equipment with finite lives used to produce goods and services, and computer equipment and software.", "label": "Manufacturing Equipment And Software", "terseLabel": "Equipment" } } }, "localname": "ManufacturingEquipmentAndSoftware", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "holx_MarketBasedAwardsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Market Based Awards [Member]", "label": "Market Based Awards [Member]", "terseLabel": "Market Based Awards" } } }, "localname": "MarketBasedAwardsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_MaximumRangeofPresentValueofCashFlowPercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum Range of Present Value of Cash Flow Percentage", "label": "Maximum Range of Present Value of Cash Flow Percentage", "terseLabel": "Maximum range of present value of cash flow percentage" } } }, "localname": "MaximumRangeofPresentValueofCashFlowPercentage", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "holx_MaximumTargetNumberOfSharesIssuedBasedOnStockPerformanceInPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Maximum target number percentage of shares issued based on stock performance.", "label": "Maximum Target Number Of Shares Issued Based On Stock Performance In Percent", "terseLabel": "Maximum eligible percentage to receive target number of shares of company's common stock" } } }, "localname": "MaximumTargetNumberOfSharesIssuedBasedOnStockPerformanceInPercent", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "holx_MedicalAestheticsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Medical Aesthetics [Domain]", "label": "Medical Aesthetics [Domain]", "terseLabel": "Medical Aesthetics [Domain]", "verboseLabel": "Medical Aesthetics" } } }, "localname": "MedicalAestheticsDomain", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IncomeTaxesDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_MinervaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minerva [Member]", "label": "Minerva [Member]", "terseLabel": "Minerva" } } }, "localname": "MinervaMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "domainItemType" }, "holx_MinimumTargetNumberOfSharesIssuedOnStockPerformanceInPercent": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Minimum target number percentage of shares that would be issued based on stock price performance.", "label": "Minimum Target Number Of Shares Issued On Stock Performance In Percent", "terseLabel": "Minimum eligible percentage to receive target number of shares of company's common stock" } } }, "localname": "MinimumTargetNumberOfSharesIssuedOnStockPerformanceInPercent", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "holx_MolecularDiagnosticsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Molecular Diagnostics [Member]", "label": "Molecular Diagnostics [Member]", "terseLabel": "Molecular Diagnostics" } } }, "localname": "MolecularDiagnosticsMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_Netincome": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Net income attributable to Hologic", "label": "Net income", "terseLabel": "Net income" } } }, "localname": "Netincome", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "holx_NotionalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Notional Amount", "label": "Notional Amount", "terseLabel": "Notional Amount" } } }, "localname": "NotionalAmount", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "holx_November192019PlanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "November 19, 2019 Plan [Member]", "label": "November 19, 2019 Plan [Member]", "terseLabel": "November 19, 2019 Plan [Member]" } } }, "localname": "November192019PlanMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "domainItemType" }, "holx_OfferingPriceofPrincipalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Offering Price of Principal Amount", "label": "Offering Price of Principal Amount", "terseLabel": "Offering price of principal amount" } } }, "localname": "OfferingPriceofPrincipalAmount", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "holx_OperatingAndFinanceLeaseTotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiability": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Operating And Finance Lease, Total Cash Paid For Amounts Included In Measurement Of Lease Liability", "label": "Operating And Finance Lease, Total Cash Paid For Amounts Included In Measurement Of Lease Liability", "totalLabel": "Total cash paid for amounts included in the measurement of lease liabilities" } } }, "localname": "OperatingAndFinanceLeaseTotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiability", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "holx_OtherTypeofRevenueMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Type of Revenue [Member]", "label": "Other Type of Revenue [Member]", "terseLabel": "Other" } } }, "localname": "OtherTypeofRevenueMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "holx_PSUFreeCashFlowMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "PSU Free Cash Flow [Member]", "label": "PSU Free Cash Flow [Member]", "terseLabel": "PSU Free Cash Flow [Member]" } } }, "localname": "PSUFreeCashFlowMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The payment of minimum statutory tax withholdings to taxing authorities on the behalf of employees from the net share settlement upon vesting of restricted stock units. This payment is not an expense of the Company nor an operating activity.", "label": "Payment For Tax Withholding Related To Vested And Released Restricted Stock Units", "negatedTerseLabel": "Payment of minimum tax withholdings on net share settlements of equity awards" } } }, "localname": "PaymentForTaxWithholdingRelatedToVestedAndReleasedRestrictedStockUnits", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "holx_PaymentsToManufactureEquipmentUnderCustomerUsageAgreements": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow related to equipment placed at customer locations for which title is not transferred to the Company's customers.", "label": "Payments To Manufacture Equipment Under Customer Usage Agreements", "negatedLabel": "Increase in equipment under customer usage agreements" } } }, "localname": "PaymentsToManufactureEquipmentUnderCustomerUsageAgreements", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "holx_PercentageAddedtoEurodollarRateMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage Added to Eurodollar Rate [Member]", "label": "Percentage Added to Eurodollar Rate [Member]", "terseLabel": "Percentage Added to Eurodollar Rate" } } }, "localname": "PercentageAddedtoEurodollarRateMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_PercentageOfRevenues": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of revenues.", "label": "Percentage Of Revenues", "terseLabel": "Revenues" } } }, "localname": "PercentageOfRevenues", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail" ], "xbrltype": "percentItemType" }, "holx_PrepaidIncomeTaxesCurrent": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Prepaid Income Taxes-Current", "label": "Prepaid Income Taxes-Current", "terseLabel": "Prepaid Income Taxes-Current" } } }, "localname": "PrepaidIncomeTaxesCurrent", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "holx_PrincipalAmountOfBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the aggregate outstanding principal of amounts borrowed under the Credit Agreement.", "label": "Principal Amount Of Borrowings", "verboseLabel": "Borrowed principal" } } }, "localname": "PrincipalAmountOfBorrowings", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "holx_ProceedsFromSaleOfBusiness": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from sale of business.", "label": "Proceeds From Sale Of Business", "terseLabel": "Proceeds From Sale Of Business" } } }, "localname": "ProceedsFromSaleOfBusiness", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "holx_ProductRevenue": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Product Revenue", "label": "Product Revenue", "terseLabel": "Product" } } }, "localname": "ProductRevenue", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "holx_PurchasePriceAllocationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Purchase Price Allocation [Table]", "label": "Purchase Price Allocation [Line Items]", "terseLabel": "Purchase Price Allocation [Line Items]" } } }, "localname": "PurchasePriceAllocationLineItems", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "holx_PurchasePriceAllocationTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Purchase Price Allocation [Table]", "label": "Purchase Price Allocation [Table]", "terseLabel": "Purchase Price Allocation [Table]" } } }, "localname": "PurchasePriceAllocationTable", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails" ], "xbrltype": "stringItemType" }, "holx_Purchaseofinsurancecontracts": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Purchase of insurance contracts", "label": "Purchase of insurance contracts", "terseLabel": "Purchase of insurance contracts" } } }, "localname": "Purchaseofinsurancecontracts", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "holx_RSUPSUMSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RSU, PSU, MSU [Member]", "label": "RSU, PSU, MSU [Member]", "terseLabel": "RSU, PSU, MSU" } } }, "localname": "RSUPSUMSUMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "holx_Repaymentsofacquiredlongtermdebt": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Repayments of acquired long term debt", "label": "Repayments of acquired long term debt", "terseLabel": "Repayments of acquired long term debt" } } }, "localname": "Repaymentsofacquiredlongtermdebt", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "holx_RestofWorldMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Rest of World [Member]", "label": "Rest of World [Member]", "terseLabel": "Rest of World" } } }, "localname": "RestofWorldMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RevenueGeographicalRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_RestructuringAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring [Abstract]", "label": "Restructuring [Abstract]" } } }, "localname": "RestructuringAbstract", "nsuri": "http://www.hologic.com/20200328", "xbrltype": "stringItemType" }, "holx_RevolverMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Revolver [Member]", "label": "Revolver [Member]", "terseLabel": "Revolver [Member]" } } }, "localname": "RevolverMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "domainItemType" }, "holx_RightofuseassetrecognizedFinanceLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Right of use asset recognized - Finance Lease", "label": "Right of use asset recognized - Finance Lease", "terseLabel": "Right of use asset recognized - Finance Lease" } } }, "localname": "RightofuseassetrecognizedFinanceLease", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails" ], "xbrltype": "monetaryItemType" }, "holx_Rightofuseassetrecognizedoperating": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Right of use asset recognized - operating", "label": "Right of use asset recognized - operating", "terseLabel": "Right of use asset recognized - operating" } } }, "localname": "Rightofuseassetrecognizedoperating", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails" ], "xbrltype": "monetaryItemType" }, "holx_RightofuseliabilityrecognizedFinancelease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Right of use liability recognized - Finance lease", "label": "Right of use liability recognized - Finance lease", "terseLabel": "Right of use liability recognized - Finance lease" } } }, "localname": "RightofuseliabilityrecognizedFinancelease", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails" ], "xbrltype": "monetaryItemType" }, "holx_RightofuseliabilityrecognizedOperatinglease": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Right of use liability recognized - Operating lease", "label": "Right of use liability recognized - Operating lease", "terseLabel": "Right of use liability recognized - Operating lease" } } }, "localname": "RightofuseliabilityrecognizedOperatinglease", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails" ], "xbrltype": "monetaryItemType" }, "holx_SSIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SSI [Member]", "label": "SSI [Member]", "terseLabel": "SSI [Member]" } } }, "localname": "SSIMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "domainItemType" }, "holx_ScheduleOfGeographicalSegmentsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Geographical Segments [Line Items]", "label": "Schedule Of Geographical Segments [Line Items]", "terseLabel": "Schedule Of Geographical Segments [Line Items]" } } }, "localname": "ScheduleOfGeographicalSegmentsLineItems", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail" ], "xbrltype": "stringItemType" }, "holx_ScheduleOfGeographicalSegmentsTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule Of Geographical Segments [Table]", "label": "Schedule Of Geographical Segments [Table]", "terseLabel": "Schedule Of Geographical Segments [Table]" } } }, "localname": "ScheduleOfGeographicalSegmentsTable", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail" ], "xbrltype": "stringItemType" }, "holx_ScheduleOfInterestExpenseUnderConvertibleNotesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of interest expense under convertible notes.", "label": "Schedule Of Interest Expense Under Convertible Notes [Table Text Block]", "terseLabel": "Schedule Of Interest Expense Under Convertible Notes" } } }, "localname": "ScheduleOfInterestExpenseUnderConvertibleNotesTableTextBlock", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "holx_ScheduleOfShareBasedCompensationExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule of share-based compensation expense.", "label": "Schedule Of Share Based Compensation Expense [Table Text Block]", "terseLabel": "Stock-Based Compensation Expense in Consolidated Statements of Operations" } } }, "localname": "ScheduleOfShareBasedCompensationExpenseTableTextBlock", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "holx_SegmentReportingDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Segment Reporting Disclosure [Line Items]", "label": "Segment Reporting Disclosure [Line Items]", "terseLabel": "Segment Reporting Disclosure [Line Items]" } } }, "localname": "SegmentReportingDisclosureLineItems", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "holx_ServiceRevenue": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Service Revenue", "label": "Service Revenue", "terseLabel": "Service and other" } } }, "localname": "ServiceRevenue", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "holx_ShareBasedCompensationExpenseIncludedOtherRestructuringCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Share based compensation expense included other restructuring costs.", "label": "Share Based Compensation Expense Included Other Restructuring Costs", "terseLabel": "Share Based Compensation Expense Included Other Restructuring Costs" } } }, "localname": "ShareBasedCompensationExpenseIncludedOtherRestructuringCosts", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "holx_ShareRepurchaseProgramMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share Repurchase Program [Member]", "label": "Share Repurchase Program [Member]", "terseLabel": "Share Repurchase Program" } } }, "localname": "ShareRepurchaseProgramMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "holx_SharedBasedCompensationArrangementRestrictedStockVestingPeriod": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Period of time that must lapse in order for the restricted stock units to vest.", "label": "Shared Based Compensation Arrangement Restricted Stock Vesting Period", "verboseLabel": "Performance stock units vesting period" } } }, "localname": "SharedBasedCompensationArrangementRestrictedStockVestingPeriod", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "holx_SharerepurchaseplanLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for share repurchase plan [Table]", "label": "share repurchase plan [Line Items]", "terseLabel": "share repurchase plan [Line Items]" } } }, "localname": "SharerepurchaseplanLineItems", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "stringItemType" }, "holx_SharerepurchaseplanTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "share repurchase plan [Table]", "label": "share repurchase plan [Table]", "terseLabel": "share repurchase plan [Table]" } } }, "localname": "SharerepurchaseplanTable", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "stringItemType" }, "holx_SkeletalHealthMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Skeletal health.", "label": "Skeletal Health [Member]", "terseLabel": "Skeletal Health" } } }, "localname": "SkeletalHealthMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "holx_SunnyvaleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sunnyvale [Member]", "label": "Sunnyvale [Member]", "terseLabel": "Sunnyvale [Member]" } } }, "localname": "SunnyvaleMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "holx_SuperSonicImagineMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "SuperSonic Imagine [Member]", "label": "SuperSonic Imagine [Member]", "terseLabel": "SuperSonic Imagine" } } }, "localname": "SuperSonicImagineMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "domainItemType" }, "holx_TepnelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tepnel [Member]", "label": "Tepnel [Member]", "terseLabel": "Tepnel [Member]" } } }, "localname": "TepnelMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "holx_TermLoanMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Term Loan [Member]", "label": "Term Loan [Member]", "terseLabel": "Term Loan" } } }, "localname": "TermLoanMember", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "domainItemType" }, "holx_TreasuryStockAuthorized": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Treasury Stock Authorized", "label": "Treasury Stock Authorized", "terseLabel": "Total repurchase authorization" } } }, "localname": "TreasuryStockAuthorized", "nsuri": "http://www.hologic.com/20200328", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia-Pacific" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r152", "r161" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r162", "r262", "r264", "r446", "r447" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/LeasesDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r164", "r262", "r265", "r448", "r449", "r450" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201409Member": { "auth_ref": [ "r266" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).", "label": "Accounting Standards Update 2014-09 [Member]", "terseLabel": "Accounting Standards Update 2014-09" } } }, "localname": "AccountingStandardsUpdate201409Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201616Member": { "auth_ref": [ "r308", "r309" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2016-16 Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory.", "label": "Accounting Standards Update 2016-16 [Member]", "terseLabel": "Accounting Standards Update 2016-16" } } }, "localname": "AccountingStandardsUpdate201616Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201801Member": { "auth_ref": [ "r396" ], "lang": { "en-US": { "role": { "documentation": "Accounting Standards Update 2018-01 Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842.", "label": "Accounting Standards Update 2018-01 [Member]", "terseLabel": "Accounting Standards Update 2018-01 [Member]" } } }, "localname": "AccountingStandardsUpdate201801Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r53" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r20", "r35", "r166", "r167", "r263" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, less reserves of $16.0 and $17.8, respectively" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r56" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r56" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r76", "r82", "r85", "r270", "r340" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Pension Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r205" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less \u2013 accumulated depreciation and amortization" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r73", "r74", "r75", "r82", "r85" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r79", "r81", "r82" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Accumulated other comprehensive loss", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r78", "r82", "r85", "r340" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Total" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r71", "r82", "r85", "r340" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Foreign Currency Translation" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r190" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average period" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r36" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in-capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r121", "r195" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization of acquired intangibles" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r132" ], "lang": { "en-US": { "role": { "documentation": "Information by new accounting pronouncement.", "label": "Adjustments for New Accounting Pronouncements [Axis]", "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r272", "r274", "r294", "r295" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income (loss) to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r41", "r168", "r171" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, reserves" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r121", "r188", "r195" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of Intangible Assets", "terseLabel": "Amortization of acquired intangible assets" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Weighted-average anti-dilutive shares (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_AssetImpairmentCharges": { "auth_ref": [ "r121", "r200" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.", "label": "Asset Impairment Charges", "terseLabel": "Intangible asset and equipment impairment charges" } } }, "localname": "AssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r157", "r422", "r436" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Identifiable assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r22", "r24", "r66" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r10", "r12", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total assets disposed of" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r275", "r291" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r350", "r355" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Balance Sheet Related Disclosures [Abstract]" } } }, "localname": "BalanceSheetRelatedDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_BuildingsAndImprovementsGross": { "auth_ref": [ "r26", "r204" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 3.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.", "label": "Buildings and Improvements, Gross", "terseLabel": "Building and improvements" } } }, "localname": "BuildingsAndImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails", "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r316", "r317" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails", "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails", "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r314" ], "lang": { "en-US": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "terseLabel": "Percentage of outstanding shares acquired" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r327", "r328", "r330" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r120", "r332" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r326", "r329", "r331" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "terseLabel": "Purchase price withheld" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r333" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Business Combinations" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinations" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash", "verboseLabel": "Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable", "verboseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable", "negatedTerseLabel": "Accounts payable and accrued expenses", "verboseLabel": "Accounts payable and accrued expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedTerseLabel": "Deferred revenue", "terseLabel": "Deferred revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r299", "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 13.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedLabel": "Deferred income taxes, net", "negatedTerseLabel": "Deferred income taxes, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "verboseLabel": "Identifiable intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventory", "verboseLabel": "Inventory" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": { "auth_ref": [ "r319" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities", "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt", "negatedTerseLabel": "Long-term debt" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Other assets", "verboseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r318", "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Other assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r319" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Purchase Price" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage", "terseLabel": "Equity interest in acquiree, Percentage" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain": { "auth_ref": [ "r315" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "In a business combination achieved in stages, this element represents the amount of gain recognized by the entity as a result of remeasuring to fair value the equity interest in the acquiree it held before the business combination.", "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Remeasurement Gain", "terseLabel": "Equity interest in acquiree, remeasurement gain" } } }, "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeRemeasurementGain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CapitalLeaseObligationsCurrent": { "auth_ref": [ "r30", "r394", "r395" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of capital lease obligation due within one year or the normal operating cycle, if longer.", "label": "Capital Lease Obligations, Current", "terseLabel": "Current portion of capital lease obligations" } } }, "localname": "CapitalLeaseObligationsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalLeaseObligationsNoncurrent": { "auth_ref": [ "r60", "r394", "r395" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.", "label": "Capital Lease Obligations, Noncurrent", "terseLabel": "Finance lease obligation - long term (capital lease obligation in 2019)" } } }, "localname": "CapitalLeaseObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r18", "r49", "r123" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period", "terseLabel": "Cash less assets held for sale" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r118", "r386" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowHedgeDerivativeInstrumentAssetsAtFairValue": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of all asset derivatives designated as cash flow hedging instruments.", "label": "Cash Flow Hedge Derivative Instrument Assets at Fair Value", "terseLabel": "Interest rate swap at fair value" } } }, "localname": "CashFlowHedgeDerivativeInstrumentAssetsAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r221", "r230" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r34" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r34" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.01 par value \u2013 750,000 shares authorized; 294,142 and 292,323 shares issued, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r88", "r90", "r91" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income (loss)" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r106" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Accumulated Other Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCustomer": { "auth_ref": [ "r146", "r147", "r148" ], "lang": { "en-US": { "role": { "documentation": "Description of risks that arise due to the volume of business transacted with a particular customer. At a minimum, the description informs financial statement users of the general nature of the risk, but excludes \"Information about Major Customers\" that may be disclosed elsewhere (for instance, segment disclosures).", "label": "Concentration Risk, Customer", "terseLabel": "Concentration Risk, Customer" } } }, "localname": "ConcentrationRiskCustomer", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.", "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure", "terseLabel": "Contingent consideration" } } }, "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "auth_ref": [ "r259" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied.", "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized" } } }, "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateMember": { "auth_ref": [ "r149" ], "lang": { "en-US": { "role": { "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items.", "label": "Corporate Segment [Member]", "terseLabel": "Corporate" } } }, "localname": "CorporateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r102" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Product" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Costs of revenues:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of revenues" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.", "label": "Cumulative Effect of New Accounting Principle in Period of Adoption", "negatedTerseLabel": "Accounting standard transition adjustment" } } }, "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerRelationshipsMember": { "auth_ref": [ "r324" ], "lang": { "en-US": { "role": { "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.", "label": "Customer Relationships [Member]", "verboseLabel": "Customer relationships" } } }, "localname": "CustomerRelationshipsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Borrowings and Credit Arrangements" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r30", "r31", "r32", "r423", "r424", "r435" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r389", "r391" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Senior notes, face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of debt instrument" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r58" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Stated interest rate" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r60", "r125", "r250", "r251", "r252", "r253", "r388", "r389", "r391", "r434" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentUnusedBorrowingCapacityAmount": { "auth_ref": [ "r59" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unused borrowing capacity under the long-term financing arrangement that is available to the entity as of the balance sheet date.", "label": "Debt Instrument, Unused Borrowing Capacity, Amount", "terseLabel": "Debt Instrument, Unused Borrowing Capacity, Amount" } } }, "localname": "DebtInstrumentUnusedBorrowingCapacityAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r121", "r124", "r306", "r310" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r300", "r305" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred Income Tax Liabilities, Net" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue, Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue, Noncurrent", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r121", "r203" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "auth_ref": [ "r121" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Depreciation, Amortization and Accretion, Net", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAmortizationAndAccretionNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "auth_ref": [ "r67", "r70", "r353", "r419" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.", "label": "Derivative Asset, Fair Value, Gross Asset", "terseLabel": "Derivative Asset, Fair Value, Gross Asset" } } }, "localname": "DerivativeFairValueOfDerivativeAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r351", "r354", "r361", "r366" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "auth_ref": [ "r376" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "terseLabel": "Derivatives" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/Derivatives" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r347", "r351", "r361", "r366", "r367", "r371", "r373" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r375" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "terseLabel": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r360", "r362" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "terseLabel": "Derivative instruments not designated as hedges, gain (loss)" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r68", "r69", "r383" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "terseLabel": "Derivative Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r344", "r346" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Derivative notional amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r130", "r343", "r345", "r346", "r347", "r349", "r356", "r361", "r369", "r370", "r373" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeVariableInterestRate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Variable interest rate in effect as of the balance sheet date related to the interest rate derivative.", "label": "Derivative, Variable Interest Rate", "terseLabel": "Variable interest rate" } } }, "localname": "DerivativeVariableInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DescriptionOfNewAccountingPronouncementsNotYetAdopted": { "auth_ref": [ "r134" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for a new accounting pronouncement that has been issued but not yet adopted.", "label": "Description of New Accounting Pronouncements Not yet Adopted [Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "DescriptionOfNewAccountingPronouncementsNotYetAdopted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NewAccountingPronouncements" ], "xbrltype": "textBlockItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivative instruments designated as a cash flow hedge" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r325" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Developed technology" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails", "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails", "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r296" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfLongLivedAssetsHeldForSaleTextBlock": { "auth_ref": [ "r210" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of long lived assets held for sale. Disclosure may include the description of the facts and circumstances leading to the expected disposal, manner and timing of disposal, the carrying value of the assets held for sale, the gain (loss) recognized in the income statement and the income statement caption that includes that gain (loss).", "label": "Disclosure of Long Lived Assets Held-for-sale [Table Text Block]", "terseLabel": "Disclosure of Long Lived Assets Held-for-sale" } } }, "localname": "DisclosureOfLongLivedAssetsHeldForSaleTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDispositionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r12" ], "lang": { "en-US": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]", "terseLabel": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.", "label": "Disposal Group Classification [Domain]", "terseLabel": "Disposal Group Classification [Domain]" } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": { "auth_ref": [ "r201", "r210" ], "lang": { "en-US": { "role": { "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.", "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]", "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations", "verboseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]" } } }, "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "terseLabel": "Accounts Receivable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayable": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "terseLabel": "Cash" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Consideration", "terseLabel": "Disposal Group, Including Discontinued Operation, Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredRevenue": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as deferred revenue attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 6.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "terseLabel": "Intangible assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventory1": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as inventory attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Inventory", "terseLabel": "Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventory1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss": { "auth_ref": [ "r9" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of operating income (loss) attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)", "terseLabel": "Disposal Group, Including Discontinued Operation, Operating Income (Loss)" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 7.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Other Assets", "terseLabel": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r0", "r1", "r10", "r202", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment": { "auth_ref": [ "r0", "r1", "r10", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment", "terseLabel": "Property, plant, and equipment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of disposal group.", "label": "Disposal Group Name [Domain]", "terseLabel": "Disposal Group Name [Domain]" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net income (loss) per common share attributable to Hologic:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r97", "r133", "r137", "r139", "r140", "r141", "r144", "r431", "r445" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in usd per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r97", "r133", "r137", "r139", "r140", "r141", "r144", "r431", "r445" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in usd per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Income (Loss) Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r386" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r129", "r302", "r303" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Company's effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r290" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average period for recognition of unrecognized stock-based compensation, years" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r289" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock option plans" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_EquipmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property used to produce goods and services.", "label": "Equipment [Member]", "terseLabel": "Equipment [Member]" } } }, "localname": "EquipmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r380" ], "lang": { "en-US": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r377", "r381" ], "lang": { "en-US": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r377", "r384", "r385" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value, by Balance Sheet Grouping [Table]", "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r268", "r269", "r271", "r378", "r415" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r268", "r269", "r271", "r378", "r416" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Quoted Prices in Active Market for Identical Assets (Level 1)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r268", "r269", "r271", "r378", "r417" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Significant Other Observable Inputs (Level 2)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r268", "r269", "r271", "r378", "r418" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Significant Unobservable Inputs (Level 3)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisObligations": { "auth_ref": [ "r377", "r378" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of obligations measured on a recurring basis.", "label": "Obligations, Fair Value Disclosure", "terseLabel": "Total" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "auth_ref": [ "r382" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.", "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]" } } }, "localname": "FairValueMeasurementInputsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]", "terseLabel": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]" } } }, "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r350", "r356", "r371" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinanceLeaseInterestExpense": { "auth_ref": [ "r399", "r404", "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of interest expense on finance lease liability.", "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease cost - interest cost" } } }, "localname": "FinanceLeaseInterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "auth_ref": [ "r401", "r406" ], "calculation": { "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails": { "order": 1.0, "parentTag": "holx_OperatingAndFinanceLeaseTotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of interest paid on finance lease liability.", "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases" } } }, "localname": "FinanceLeaseInterestPaymentOnLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiability": { "auth_ref": [ "r398", "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.", "label": "Finance Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "FinanceLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityCurrent": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.", "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liability, current", "verboseLabel": "Finance lease liabilities (current)" } } }, "localname": "FinanceLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.", "label": "Finance Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Finance Lease Liability Maturities" } } }, "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.", "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities (non-current)" } } }, "localname": "FinanceLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "FinanceLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due after fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in next fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020 remaining" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fifth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in fourth fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in third fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease, due in second fiscal year following latest fiscal year.", "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.", "label": "Finance Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r400", "r406" ], "calculation": { "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails": { "order": 3.0, "parentTag": "holx_OperatingAndFinanceLeaseTotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r399", "r404", "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Finance lease cost - amortization of right-of-use assets" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r409", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for finance lease calculated at point in time.", "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Financing Leases, Weighted average discount rate" } } }, "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r408", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Finance Lease, Weighted Average Remaining Lease Term" } } }, "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r172", "r173", "r174", "r175", "r176", "r177", "r178", "r179", "r180" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]", "verboseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "auth_ref": [ "r194" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "terseLabel": "Accumulated Amortization" } } }, "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "Remainder of Fiscal 2020" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five", "terseLabel": "Fiscal 2024" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four", "terseLabel": "Fiscal 2023" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "Fiscal 2022" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "Fiscal 2021" } } }, "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r189", "r191", "r194", "r197", "r421" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "auth_ref": [ "r194", "r421" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Gross", "terseLabel": "Gross Carrying Value" } } }, "localname": "FiniteLivedIntangibleAssetsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r189", "r193" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r268", "r364" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Forward foreign currency contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeForwardMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.", "label": "Foreign Exchange Forward [Member]", "terseLabel": "Forward foreign currency contracts" } } }, "localname": "ForeignExchangeForwardMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).", "label": "Foreign Exchange Option [Member]", "terseLabel": "Foreign currency option contracts", "verboseLabel": "Foreign Exchange Option" } } }, "localname": "ForeignExchangeOptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesGross": { "auth_ref": [ "r204" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 6.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures, Gross", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.", "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings", "terseLabel": "Forward foreign currency contracts" } } }, "localname": "GainLossOnFairValueHedgesRecognizedInEarnings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": { "auth_ref": [ "r351", "r360" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.", "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "terseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments", "verboseLabel": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments" } } }, "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r121", "r242", "r243" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 4.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedLabel": "Debt extinguishment losses", "terseLabel": "Debt extinguishment loss" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r103" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r184", "r185" ], "calculation": { "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails": { "order": 9.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails": { "order": 14.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails", "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r100" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_GuaranteesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Guarantees [Abstract]" } } }, "localname": "GuaranteesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r347", "r367" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "auth_ref": [ "r121", "r198" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "terseLabel": "Impairment of intangible assets and equipment" } } }, "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InProcessResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.", "label": "In Process Research and Development [Member]", "terseLabel": "In-process research and development" } } }, "localname": "InProcessResearchAndDevelopmentMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r127" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest", "totalLabel": "Income (loss) before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r95", "r121", "r155", "r170", "r429", "r443" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income (Loss) from Equity Method Investments", "terseLabel": "Income (loss) from equity method investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by name of disposal group.", "label": "Disposal Group Name [Axis]", "terseLabel": "Disposal Group Name [Axis]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails", "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r3", "r4", "r5", "r6", "r7", "r8", "r11", "r13", "r14", "r15", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]", "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r207" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/DispositionDetails", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r124", "r156", "r312" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision (benefit) for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventories" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities, excluding the effect of acquisitions and dispositions:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other activity" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Taxes", "negatedTerseLabel": "Prepaid income taxes" } } }, "localname": "IncreaseDecreaseInPrepaidTaxes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "auth_ref": [ "r138", "r143" ], "calculation": { "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements", "terseLabel": "Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units" } } }, "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible Assets and Goodwill" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwill" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r187", "r192" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r93", "r154", "r387", "r390", "r433" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 3.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpenseBorrowings": { "auth_ref": [ "r432" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Aggregate amount of interest expense on all borrowings.", "label": "Interest Expense, Borrowings", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenseBorrowings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateCapMember": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount.", "label": "Interest Rate Cap [Member]", "terseLabel": "Interest rate caps - derivative", "verboseLabel": "Interest rate cap agreements" } } }, "localname": "InterestRateCapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateCashFlowHedgeAssetAtFairValue": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value as of the balance sheet date of all interest rate derivative assets designated as cash flow hedging instruments.", "label": "Interest Rate Cash Flow Hedge Asset at Fair Value", "terseLabel": "Interest Rate Cash Flow Hedge Asset at Fair Value" } } }, "localname": "InterestRateCashFlowHedgeAssetAtFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r363" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest Rate Swap [Member]", "verboseLabel": "Interest Rate Swap" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_IntersegmentEliminationMember": { "auth_ref": [ "r159" ], "lang": { "en-US": { "role": { "documentation": "Eliminating entries used in operating segment consolidation.", "label": "Intersegment Eliminations [Member]", "terseLabel": "Intersegment" } } }, "localname": "IntersegmentEliminationMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "auth_ref": [ "r43", "r182" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "order": 3.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.", "label": "Inventory, Finished Goods, Net of Reserves", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoodsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r19", "r65", "r181" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "totalLabel": "Inventories" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "auth_ref": [ "r45", "r182" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "order": 1.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.", "label": "Inventory, Raw Materials, Net of Reserves", "terseLabel": "Raw materials" } } }, "localname": "InventoryRawMaterialsNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "auth_ref": [ "r44", "r182" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail": { "order": 2.0, "parentTag": "us-gaap_InventoryNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.", "label": "Inventory, Work in Process, Net of Reserves", "terseLabel": "Work-in-process" } } }, "localname": "InventoryWorkInProcessNetOfReserves", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r104", "r153" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsFairValueDisclosure": { "auth_ref": [ "r377" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.", "label": "Investments, Fair Value Disclosure", "terseLabel": "Assets measured at fair value on a recurring basis" } } }, "localname": "InvestmentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_Land": { "auth_ref": [ "r25", "r50" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 5.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.", "label": "Land", "terseLabel": "Land" } } }, "localname": "Land", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r410" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Additional Lease Information" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsGross": { "auth_ref": [ "r26", "r204" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 4.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements, Gross", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeFinanceLeasesTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.", "label": "Lessee, Finance Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeFinanceLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Lessee, Lease, Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r403" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r411" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Operating Lease Liability Maturities" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetailsCalc2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2020 remaining" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.", "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2021" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r411" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetailsCalc2": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LessorSalesTypeLeasesTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of lessor's sales-type leases.", "label": "Lessor, Sales-type Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LessorSalesTypeLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r40", "r426", "r440" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r57" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r10", "r12", "r208" ], "calculation": { "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "totalLabel": "Total liabilities disposed of" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate at the end of the reporting period.", "label": "Line of Credit Facility, Interest Rate at Period End", "terseLabel": "Interest rate at end of period" } } }, "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": { "auth_ref": [ "r54" ], "lang": { "en-US": { "role": { "documentation": "The effective interest rate during the reporting period.", "label": "Line of Credit Facility, Interest Rate During Period", "terseLabel": "Weighted average interest rate" } } }, "localname": "LineOfCreditFacilityInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r54", "r125" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Payment of settlement compensation" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r32", "r241", "r424", "r437" ], "calculation": { "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "terseLabel": "Long-term debt", "totalLabel": "Total debt obligations" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r55" ], "calculation": { "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "terseLabel": "Long-term Debt, Current Maturities", "verboseLabel": "Current portion of long-term debt" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r60" ], "calculation": { "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 }, "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt, net of current portion", "verboseLabel": "Total long-term debt obligations" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r60" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r60", "r240" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r222", "r223", "r224", "r226", "r227", "r228", "r229", "r231", "r232" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyNewClaimsFiledNumber": { "auth_ref": [ "r225" ], "lang": { "en-US": { "role": { "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.", "label": "Loss Contingency, New Claims Filed, Number", "terseLabel": "Petitions filed" } } }, "localname": "LossContingencyNewClaimsFiledNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/CommitmentsAndContingenciesDetail" ], "xbrltype": "integerItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r379" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r16", "r333" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Dispositions" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/Disposition" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r64", "r425", "r439" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]", "terseLabel": "Movement in Standard and Extended Product Warranty, Increase (Decrease) [Roll Forward]" } } }, "localname": "MovementInStandardAndExtendedProductWarrantyIncreaseDecreaseRollForward", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "INVESTING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r118", "r119", "r122" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r86", "r89", "r96", "r122", "r143", "r430", "r444" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net income (loss)", "verboseLabel": "Net income (loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "New Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NewAccountingPronouncementsPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r323" ], "lang": { "en-US": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-competition agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable": { "auth_ref": [ "r101" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of income (loss) attributable to other redeemable noncontrolling equity holder.", "label": "Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable", "terseLabel": "Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, Redeemable" } } }, "localname": "NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": { "auth_ref": [ "r255", "r320", "r338" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in noncontrolling interest from a business combination.", "label": "Noncontrolling Interest, Increase from Business Combination", "terseLabel": "Noncontrolling Interest, Increase from Business Combination" } } }, "localname": "NoncontrollingInterestIncreaseFromBusinessCombination", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r347" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives not designated as hedging instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenseMember": { "auth_ref": [ "r365" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.", "label": "Operating Expense [Member]", "terseLabel": "Operating Expense" } } }, "localname": "OperatingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Income (loss) from operations", "verboseLabel": "Income (loss) from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r405", "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r398" ], "calculation": { "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetailsCalc2": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Present value of lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities (current)" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r398" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities (non-current)" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r402", "r406" ], "calculation": { "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails": { "order": 2.0, "parentTag": "holx_OperatingAndFinanceLeaseTotalCashPaidForAmountsIncludedInMeasurementOfLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r397" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating Leases, Lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r409", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating Leases, Weighted average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r408", "r412" ], "lang": { "en-US": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating Lease, Weighted Average Remaining Lease Term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": { "auth_ref": [ "r392", "r393", "r414" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for lessor's operating leases.", "label": "Lessor, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "OperatingLeasesOfLessorDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesNotes" ], "xbrltype": "textBlockItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r17", "r342" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r350", "r371" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other assets", "verboseLabel": "Other assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r52" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r77", "r79", "r336", "r339" ], "calculation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent": { "auth_ref": [ "r336", "r337", "r339" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent", "negatedTerseLabel": "Changes in pension plans, tax" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r336", "r337", "r339" ], "calculation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax", "weight": -1.0 }, "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Changes in foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r73", "r74", "r79" ], "calculation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax", "terseLabel": "Changes in unrealized holding gains and losses on available-for-sale securities, net of tax of$0.2 for the three months ended December 30, 2017:" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r80", "r311" ], "calculation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "totalLabel": "Other Comprehensive Income (Loss) before Reclassifications, Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax", "terseLabel": "Net unrealized loss" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r72", "r79", "r352", "r358", "r372" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of loss recognized in other comprehensive income, net of taxes:" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax": { "auth_ref": [ "r72", "r80" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax", "terseLabel": "Changes in value of hedged interest rate caps, tax" } } }, "localname": "OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r87", "r90", "r92", "r249" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income activity" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r87", "r90", "r336", "r337", "r339" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "terseLabel": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r87", "r90", "r336", "r337", "r339" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax": { "auth_ref": [ "r79", "r83", "r84", "r348" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income of accumulated gain (loss) realized from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI on Derivatives, Net of Tax", "negatedTerseLabel": "Loss reclassified from accumulated other comprehensive loss to the statements of operations", "terseLabel": "Loss reclassified from accumulated other comprehensive loss to the statement of income" } } }, "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIOnDerivativesNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax": { "auth_ref": [ "r72", "r79", "r374" ], "calculation": { "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax", "weight": -1.0 }, "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated gain (loss) from derivative instruments designated and qualifying as the effective portion of cash flow hedges and an entity's share of an equity investee's increase (decrease) in deferred hedging gain (loss).", "label": "Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax", "terseLabel": "Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019." } } }, "localname": "OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss", "http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": { "auth_ref": [ "r74", "r80" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.", "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax", "terseLabel": "Changes in unrealized holding gains and losses on available-for-sale securities. tax" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeMember": { "auth_ref": [ "r368" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other revenue.", "label": "Other Income [Member]", "terseLabel": "Other Income" } } }, "localname": "OtherIncomeMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r61" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r122" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedTerseLabel": "Other adjustments and non-cash items" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other long-term liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails", "http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r105" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 5.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other (expense) income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherTaxExpenseBenefit": { "auth_ref": [ "r128", "r301", "r307" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other income tax expense (benefit).", "label": "Other Tax Expense (Benefit)", "terseLabel": "Other Tax Expense (Benefit)" } } }, "localname": "OtherTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": { "auth_ref": [ "r116" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.", "label": "Payment for Contingent Consideration Liability, Financing Activities", "negatedTerseLabel": "Payment of deferred acquisition consideration" } } }, "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r113" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "auth_ref": [ "r115" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.", "label": "Payments of Debt Issuance Costs", "negatedLabel": "Payment of debt issuance costs", "verboseLabel": "Payment of debt issuance costs" } } }, "localname": "PaymentsOfDebtIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r108" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of businesses, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r109" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "terseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r109" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireTradingSecuritiesHeldforinvestment": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to acquire securities classified as trading securities and held for investment purposes. Excludes payments for trading securities purchased and held principally for the purpose of selling them in the near term (thus held for only a short period of time).", "label": "Payments to Acquire Trading Securities Held-for-investment", "terseLabel": "Payments to Acquire Trading Securities Held-for-investment" } } }, "localname": "PaymentsToAcquireTradingSecuritiesHeldforinvestment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToMinorityShareholders": { "auth_ref": [ "r117" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.", "label": "Payments to Noncontrolling Interests", "negatedTerseLabel": "Payments to Noncontrolling Interests" } } }, "localname": "PaymentsToMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Shares" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r33" ], "lang": { "en-US": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r33" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.01 par value \u2013 1,623 shares authorized; 0 shares issued" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r21", "r23", "r183" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "auth_ref": [ "r107" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.", "label": "Proceeds from Divestiture of Businesses", "terseLabel": "Proceeds from Divestiture of Businesses" } } }, "localname": "ProceedsFromDivestitureOfBusinesses", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r111", "r292" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from issuance of common stock pursuant to employee stock plans" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLinesOfCredit": { "auth_ref": [ "r112", "r126" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Proceeds from Lines of Credit", "terseLabel": "Proceeds from revolving credit line" } } }, "localname": "ProceedsFromLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfAccountsReceivableSecuritization": { "auth_ref": [ "r131" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Proceeds from (repayments of) securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.", "label": "Proceeds from (Repayments of) Accounts Receivable Securitization", "terseLabel": "Proceeds from accounts receivable securitization agreement" } } }, "localname": "ProceedsFromRepaymentsOfAccountsReceivableSecuritization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfOtherLongTermDebt": { "auth_ref": [ "r131" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from other long-term debt.", "label": "Proceeds from (Repayments of) Other Long-term Debt", "terseLabel": "Proceeds from long-term debt" } } }, "localname": "ProceedsFromRepaymentsOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepurchaseOfEquity": { "auth_ref": [ "r131" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow resulting from the entity's share transaction.", "label": "Proceeds from (Repurchase of) Equity", "terseLabel": "Repurchase of equity" } } }, "localname": "ProceedsFromRepurchaseOfEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrual": { "auth_ref": [ "r236", "r237", "r427" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.", "label": "Standard and Extended Product Warranty Accrual", "periodEndLabel": "Balance at End of Period", "periodStartLabel": "Balance at Beginning of Period" } } }, "localname": "ProductWarrantyAccrual", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualAdditionsFromBusinessAcquisition": { "auth_ref": [ "r235" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from a business acquisition.", "label": "Standard and Extended Product Warranty Accrual, Additions from Business Acquisition", "terseLabel": "Standard and Extended Product Warranty Accrual, Additions from Business Acquisition" } } }, "localname": "ProductWarrantyAccrualAdditionsFromBusinessAcquisition", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualPayments": { "auth_ref": [ "r233" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in the standard and extended product warranty accrual from payments made in cash or in kind to satisfy claims under the terms of the standard and extended product warranty.", "label": "Standard and Extended Product Warranty Accrual, Decrease for Payments", "negatedLabel": "Settlements/ Adjustments" } } }, "localname": "ProductWarrantyAccrualPayments", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyAccrualWarrantiesIssued": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in the standard and extended product warranty accrual from warranties issued.", "label": "Standard and Extended Product Warranty Accrual, Increase for Warranties Issued", "terseLabel": "Provisions" } } }, "localname": "ProductWarrantyAccrualWarrantiesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductWarrantyDisclosureTextBlock": { "auth_ref": [ "r239" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for standard and extended product warranties and other product guarantee contracts, including a tabular reconciliation of the changes in the guarantor's aggregate product warranty liability for the reporting period.", "label": "Product Warranty Disclosure [Text Block]", "terseLabel": "Product Warranties" } } }, "localname": "ProductWarrantyDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarranties" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r50", "r204" ], "calculation": { "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "totalLabel": "Property, plant and equipment, gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r28", "r29", "r206", "r441" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, plant and equipment, net", "totalLabel": "Property, plant and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r28", "r206" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Other Balance Sheet Information of Property, Plant and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "auth_ref": [ "r82", "r85", "r92" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "negatedTerseLabel": "Amounts reclassified to statement of income" } } }, "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RedeemableNoncontrollingInterestEquityOtherCarryingAmount": { "auth_ref": [ "r245", "r246", "r247", "r248" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of noncontrolling interests which are redeemable by the parent entity, classified as other equity.", "label": "Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount", "terseLabel": "Redeemable Noncontrolling Interest, Equity, Other, Carrying Amount" } } }, "localname": "RedeemableNoncontrollingInterestEquityOtherCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfAccountsReceivableSecuritization": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Repayments of securitizations of receivables treated as collateralized borrowings, which are classified as financing transactions.", "label": "Repayments of Accounts Receivable Securitization", "terseLabel": "Repayments of Accounts Receivable Securitization" } } }, "localname": "RepaymentsOfAccountsReceivableSecuritization", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfDebt": { "auth_ref": [ "r114" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.", "label": "Repayments of Debt", "terseLabel": "Repayments of Debt" } } }, "localname": "RepaymentsOfDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BasisOfPresentationDetailsDetails", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r114", "r126" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "negatedLabel": "Repayments under revolving credit line" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": { "auth_ref": [ "r114" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).", "label": "Repayments of Long-term Capital Lease Obligations", "negatedTerseLabel": "Payments under finance lease obligations" } } }, "localname": "RepaymentsOfLongTermCapitalLeaseObligations", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r114" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Repayment of long-term debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r297", "r451" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Vesting of restricted stock units, net of shares withheld for employee taxes ( in shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail", "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "negatedTerseLabel": "Vesting of restricted stock units, net of shares withheld for employee taxes" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r121", "r212", "r216", "r218" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "terseLabel": "Restructuring and divestiture charges", "verboseLabel": "Restructuring Charges" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r214", "r216", "r219" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring Charges [Member]" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": { "auth_ref": [ "r213", "r217" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).", "label": "Restructuring Reserve, Translation and Other Adjustment", "terseLabel": "Restructuring Reserve, Translation and Other Adjustment" } } }, "localname": "RestructuringReserveTranslationAndOtherAdjustment", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r37", "r254", "r438" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/Revenue" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r260" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Revenue, Remaining Performance Obligation, Amount" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.", "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r261" ], "lang": { "en-US": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Percentage", "terseLabel": "Revenue, Remaining Performance Obligation, Percentage" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r94", "r151", "r152", "r160" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Revenues", "totalLabel": "Revenues", "verboseLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail", "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/RevenueBusinessRevenueDetails", "http://www.hologic.com/role/RevenueGeographicalRevenueDetails", "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r407", "r412" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets arising from entering into new operating lease obligations" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r82" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "verboseLabel": "Changes in Accumulated Other Comprehensive Income" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r316", "r317" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails", "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r359" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Unrealized Loss Recognized in AOCI" } } }, "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDebtTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.", "label": "Schedule of Debt [Table Text Block]", "terseLabel": "Company's Borrowings" } } }, "localname": "ScheduleOfDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative assets at fair value.", "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]", "terseLabel": "Schedule of Derivative Assets at Fair Value" } } }, "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r3", "r4", "r5", "r6", "r7", "r8", "r11", "r13", "r14", "r15", "r210", "r211" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "terseLabel": "Schedule of Income from Operation of Disposed Business" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DispositionDispositionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Reconciliation of Basic and Diluted Share Amounts" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r377", "r378" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Fair Value Assets and Liabilities Measured on Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": { "auth_ref": [ "r383", "r384" ], "lang": { "en-US": { "role": { "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.", "label": "Schedule of Fair Value, Off-balance Sheet Risks [Table]", "terseLabel": "Schedule of Fair Value, Off-balance Sheet Risks [Table]" } } }, "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r189", "r193" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r189", "r193" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r27", "r46", "r47", "r48" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Other Balance Sheet Information of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/OtherBalanceSheetInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "auth_ref": [ "r54", "r125" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Schedule of Line of Credit Facilities" } } }, "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r360", "r362" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Schedule of Adjustment to Fair Value within the Consolidated Statements of Income" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductWarrantyLiabilityTableTextBlock": { "auth_ref": [ "r238" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the changes in the guarantor's aggregate product warranty liability, including the beginning balance of the aggregate product warranty liability, the aggregate reductions in that liability for payments made (in cash or in kind) under the warranty, the aggregate changes in the liability for accruals related to product warranties issued during the reporting period, the aggregate changes in the liability for accruals related to preexisting warranties (including adjustments related to changes in estimates), and the ending balance of the aggregate product warranty liability.", "label": "Schedule of Product Warranty Liability [Table Text Block]", "terseLabel": "Product Warranty Activity" } } }, "localname": "ScheduleOfProductWarrantyLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r321" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r99", "r163" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Revenues by Geography" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r150", "r157", "r158", "r159", "r186" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail", "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r150", "r157", "r158", "r159", "r186" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Segment Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r275", "r291" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Weighted-Average Assumptions Utilized to Value Stock Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "auth_ref": [ "r193" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of Estimated Amortization Expense" } } }, "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IntangibleAssetsAndGoodwillTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IncomeTaxesDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Business Segments and Geographic Information" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfIncome": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "terseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r98" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling and Marketing Expense [Member]", "terseLabel": "Selling and marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_SeniorNotes": { "auth_ref": [ "r428", "r442" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer). Senior note holders are paid off in full before any payments are made to junior note holders.", "label": "Senior Notes", "terseLabel": "Senior notes" } } }, "localname": "SeniorNotes", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_SeniorNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.", "label": "Senior Notes [Member]", "terseLabel": "Senior Notes" } } }, "localname": "SeniorNotesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ServiceMember": { "auth_ref": [ "r264" ], "lang": { "en-US": { "role": { "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.", "label": "Service [Member]", "terseLabel": "Service" } } }, "localname": "ServiceMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RevenueRevenueByTypeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeveranceCosts1": { "auth_ref": [ "r121", "r212", "r216", "r218" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.", "label": "Severance Costs", "terseLabel": "Severance Costs" } } }, "localname": "SeveranceCosts1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/RestructuringDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r120" ], "calculation": { "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r282" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Restricted stock units (RSUs), weighted average grant date fair values" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r281" ], "lang": { "en-US": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r288" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend": { "auth_ref": [ "r287" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend", "terseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": { "auth_ref": [ "r286" ], "lang": { "en-US": { "role": { "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail", "http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-US": { "role": { "documentation": "Net number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r278", "r291" ], "lang": { "en-US": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "terseLabel": "Share-based compensation, stock option outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r277" ], "lang": { "en-US": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise price of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r273", "r276" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted-average exercise prices" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareRepurchaseProgramAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by share repurchase program.", "label": "Share Repurchase Program [Axis]", "terseLabel": "Share Repurchase Program [Axis]" } } }, "localname": "ShareRepurchaseProgramAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareRepurchaseProgramDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the share repurchase program.", "label": "Share Repurchase Program [Domain]", "terseLabel": "Share Repurchase Program [Domain]" } } }, "localname": "ShareRepurchaseProgramDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity", "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r285", "r293" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected life (in years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail" ], "xbrltype": "durationItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r249" ], "lang": { "en-US": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StandardProductWarrantyAccrualPeriodIncreaseDecrease": { "auth_ref": [ "r235" ], "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the standard product warranty accrual. Excludes extended product warranties.", "label": "Standard Product Warranty Accrual, Period Increase (Decrease)", "terseLabel": "Standard Product Warranty Accrual, Period Increase (Decrease)" } } }, "localname": "StandardProductWarrantyAccrualPeriodIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail" ], "xbrltype": "monetaryItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r2", "r157", "r186", "r209", "r215", "r220", "r446" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail", "http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail", "http://www.hologic.com/role/IncomeTaxesDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/RevenueBusinessRevenueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r63", "r249" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r142" ], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "terseLabel": "Outstanding Stock Options and stock units" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r33", "r34", "r249", "r254" ], "lang": { "en-US": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Common stock issued under the employee stock purchase plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r33", "r34", "r249", "r254", "r280" ], "lang": { "en-US": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercise of stock options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r33", "r34", "r249", "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Common stock issued under the employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r63", "r249", "r254" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of stock options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount remaining of a stock repurchase plan authorized.", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "terseLabel": "Stock Repurchase Program, Remaining Authorized Repurchase Amount" } } }, "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRepurchasedDuringPeriodShares": { "auth_ref": [ "r33", "r34", "r249", "r254" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.", "label": "Stock Repurchased During Period, Shares", "terseLabel": "Stock Repurchased During Period, Shares" } } }, "localname": "StockRepurchasedDuringPeriodShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r34", "r38", "r39", "r169" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total Hologic's stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r334", "r335", "r341" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets", "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r322" ], "lang": { "en-US": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "verboseLabel": "Trade names" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/BusinessCombinationNarrativeDetails", "http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails", "http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r420" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail", "http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail", "http://www.hologic.com/role/DerivativesAdditionalInformationDetails", "http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r62", "r256" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r62", "r256" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury stock (in shares)" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r34", "r249", "r254" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Repurchase of common stock (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockTextBlock": { "auth_ref": [ "r258" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.", "label": "Treasury Stock [Text Block]", "terseLabel": "Share Repurchase" } } }, "localname": "TreasuryStockTextBlock", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ShareRepurchase" ], "xbrltype": "textBlockItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r62", "r256", "r257" ], "calculation": { "http://www.hologic.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "negatedTerseLabel": "Treasury stock, at cost \u2013 35,941 and 24,638 shares, respectively" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredParValueMethod": { "auth_ref": [ "r249", "r254", "r256" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.", "label": "Treasury Stock, Value, Acquired, Par Value Method", "negatedTerseLabel": "Repurchase of common stock" } } }, "localname": "TreasuryStockValueAcquiredParValueMethod", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.", "label": "Type of Adoption [Domain]", "terseLabel": "Type of Adoption [Domain]" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": { "auth_ref": [ "r358" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.", "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax", "verboseLabel": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax" } } }, "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/DerivativesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r298", "r304" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized Tax Benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r136", "r141" ], "calculation": { "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average number of shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r135", "r141" ], "calculation": { "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic (in shares)", "verboseLabel": "Basic weighted average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/ConsolidatedStatementsOfIncome", "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]", "terseLabel": "Weighted-average anti-dilutive shares related to:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2019-01-31", "presentation": [ "http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail" ], "xbrltype": "stringItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1)(i))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(n)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "28A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1500-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8657-108599" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599" }, "r165": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r17": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.BB)", "Topic": "330", "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68074540&loc=d3e5879-108316" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r221": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6787-107765" }, "r230": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(2))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "((c)(3))", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(5)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249" }, "r239": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "460", "URI": "http://asc.fasb.org/topic&trid=2155896" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r244": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(12)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(16)(c)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "14", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "15", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=SL6540498-122764" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r258": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/subtopic&trid=2208821" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130551-203045" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048" }, "r267": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=117331771&loc=SL96870463-158277" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324" }, "r313": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5333-128473" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479" }, "r333": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686" }, "r342": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "c", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "4F", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624186-113959" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=109978405&loc=d3e80720-113993" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80845-113994" }, "r376": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "815", "URI": "http://asc.fasb.org/topic&trid=2229140" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r382": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "820", "URI": "http://asc.fasb.org/topic&trid=2155941" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "Note 1", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "Note 3", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164758&loc=d3e45023-112735" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "840", "URI": "http://asc.fasb.org/extlink&oid=84164817&loc=d3e45280-112737" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888252" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=SL51823488-111719" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.16)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.7,8)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.16(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r452": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r453": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r454": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r455": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r456": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r457": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227" } }, "version": "2.1" } XML 63 R22.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes
6 Months Ended
Mar. 28, 2020
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes

In accordance with ASC 740, Income Taxes (ASC 740), each interim period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.

The Company’s effective tax rate for the three and six months ended March 28, 2020 was a provision of 20.3% and a benefit of 122.1%, respectively, compared to a benefit of 22.9% and 30.2%, respectively, for the corresponding periods in the prior year. The effective tax rate for the three months ended March 28, 2020 differed from the statutory tax rate primarily due to taxation of foreign earnings at a tax rate lower than the statutory tax rate including the impact to global intangible low tax income and foreign derived intangible income, partially offset by unbenefited foreign losses. The effective tax rate for the six months ended March 28, 2020 differed from the statutory tax rate primarily due to a $310.9 million discrete net tax benefit related to the loss on the sale of the Medical Aesthetics business.

For the three months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, and earnings in jurisdictions subject to lower tax rates. For the six months ended March 30, 2019, the effective tax rate differed from the statutory tax rate primarily due to the impact of the Medical Aesthetics impairment charge, earnings in jurisdictions subject to lower tax rates, a discrete benefit related to an internal restructuring, and finalizing the impact of the enactment of the Tax Cuts and Jobs Act in the first quarter of fiscal 2019.

During the six months ended March 28, 2020, the Company's gross unrecognized tax benefits excluding interest increased from $101.6 million to $212.7 million primarily as a result of uncertain tax positions related to the divestiture of the Medical Aesthetics business, and to a lesser extent intercompany transfer pricing related to ordinary business operations.

Other Tax Accounting Pronouncements

On October 24, 2016, the FASB issued ASU 2016-16, which removes the prohibition in ASC 740 against the immediate recognition of the current and deferred income tax effects of intra-entity transfers of assets other than inventory. Under ASU 2016-16, the selling (transferring) entity is required to recognize a current tax expense or benefit upon transfer of the asset. Similarly, the purchasing (receiving) entity is required to recognize a deferred tax asset or deferred tax liability, as well as the related deferred tax benefit or expense, upon receipt of the asset.

This ASU is effective for annual periods beginning after December 15, 2017, and interim periods within those annual periods. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis through a cumulative-
effect adjustment to decrease the opening balance of accumulated deficit within stockholders' equity as of September 30, 2018, the first day of fiscal 2019. This change in accounting principle resulted in an increase in deferred tax assets of $2.9 million, a decrease in accumulated deficit of $2.5 million, and a decrease in prepaid taxes of $0.4 million as of the beginning of the Company’s fiscal year beginning September 30, 2018.

The Company was required to account for the internal restructuring discussed above under ASU 2016-16 and recorded a $29.5 million increase to income tax expense and income tax liabilities and a decrease of $48.7 million to deferred tax expense and net deferred tax liabilities for the six months ended March 30, 2019. The net result was an increase to net income of $19.2 million, or an earnings per share increase of $0.07.

Non-Income Tax Matters

The Company is subject to tax examinations for value added, sales-based, payroll, and other non-income tax items. A number of these examinations are ongoing in various jurisdictions. The Company takes certain non-income tax positions in the jurisdictions in which it operates pursuant to ASC 450. In the normal course of business, the Company's positions and conclusions related to its non-income tax positions could be challenged, resulting in assessments by governmental authorities. While the Company believes estimated losses previously recorded are reasonable, certain audits are still ongoing and additional charges could be recorded in the future.
XML 64 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Statement of Comprehensive Income [Abstract]        
Changes in unrealized holding gains and losses on available-for-sale securities. tax       $ 0.0
Changes in pension plans, tax       0.0
Changes in value of hedged interest rate caps, tax $ (8.1) $ 0.3 $ (6.4) $ 0.8
ZIP 65 0000859737-20-000018-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000859737-20-000018-xbrl.zip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�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�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end XML 66 R43.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation Details (Details) - USD ($)
$ in Millions
Mar. 28, 2020
Dec. 28, 2019
Sep. 28, 2019
Debt Instrument [Line Items]      
Long-term Debt, Current Maturities $ 806.1   $ 271.4
Right of use asset recognized - operating   $ 91.7  
Right of use asset recognized - Finance Lease   10.2  
Right of use liability recognized - Operating lease   96.6  
Right of use liability recognized - Finance lease   21.0  
Derecognition of property, plant and equipment   32.6  
Derecognition of finance leases   $ 35.2  
Revolver [Member]      
Debt Instrument [Line Items]      
Long-term Debt, Current Maturities $ 750.0   $ 0.0

XML 67 R47.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Narrative (Details)
$ in Millions
6 Months Ended
Mar. 28, 2020
USD ($)
Revenue from Contract with Customer [Abstract]  
Revenue, Remaining Performance Obligation, Amount $ 583.5
Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized $ 26.2
XML 68 R68.htm IDEA: XBRL DOCUMENT v3.20.1
Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]        
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments $ (0.1)      
Derivative instruments not designated as hedges, gain (loss) 3.3 $ 0.4 $ 0.2 $ 5.5
Forward foreign currency contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Forward foreign currency contracts 2.7 0.4 1.3 5.5
Foreign currency option contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Derivative instruments not designated as hedges, gain (loss) $ 0.6 $ 0.0 $ (1.1) $ 0.0
XML 69 R64.htm IDEA: XBRL DOCUMENT v3.20.1
Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Jan. 19, 2018
Line of Credit Facility [Line Items]          
Interest expense $ 15.7 $ 15.7 $ 31.4 $ 31.4  
2025 Senior Notes          
Line of Credit Facility [Line Items]          
Stated interest rate 4.375%   4.375%    
Senior Notes | 2028 Senior Notes          
Line of Credit Facility [Line Items]          
Stated interest rate 4.625%   4.625%   4.625%
Interest expense $ 4.8 4.8 $ 9.6 9.6  
Senior Notes | 2025 Senior Notes          
Line of Credit Facility [Line Items]          
Stated interest rate 4.375%   4.375%    
Interest expense $ 10.9 $ 10.9 $ 21.8 $ 21.8  
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.20.1
Disposition - Schedule of Disposition Related Income Statement Information (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Discontinued Operations and Disposal Groups [Abstract]        
Disposal Group, Including Discontinued Operation, Operating Income (Loss) $ 0 $ (468,300) $ (46,500) $ (488,700)
XML 71 R56.htm IDEA: XBRL DOCUMENT v3.20.1
Business Combination - Purchase Price Allocation (Details) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Oct. 01, 2018
Purchase Price Allocation [Line Items]      
Goodwill $ 2,592.0 $ 2,563.7  
Focal Therapeutics      
Purchase Price Allocation [Line Items]      
Cash     $ 2.2
Accounts receivable     2.0
Inventory     7.9
Other assets     0.5
Accounts payable and accrued expenses     (5.6)
Long-term debt     (2.5)
Deferred income taxes, net     (12.7)
Goodwill     31.1
Purchase Price     120.1
Focal Therapeutics | Developed technology      
Purchase Price Allocation [Line Items]      
Identifiable intangible assets     83.1
Focal Therapeutics | In-process research and development      
Purchase Price Allocation [Line Items]      
Identifiable intangible assets     11.4
Focal Therapeutics | Trade names      
Purchase Price Allocation [Line Items]      
Identifiable intangible assets     $ 2.7
XML 72 R52.htm IDEA: XBRL DOCUMENT v3.20.1
Leases - Lease Liability Maturity Schedule (Details)
Mar. 28, 2020
USD ($)
Leases [Abstract]  
2020 remaining $ 11,900
2021 22,500
2022 17,800
2023 11,400
2024 9,300
Thereafter 23,900
Total future minimum lease payments 96,800
Less: imputed interest (6,000.0)
Present value of lease liabilities 90,800
2020 remaining 1,400
2021 2,900
2022 3,000.0
2023 3,000.0
2024 3,000.0
Thereafter 11,400
Total future minimum lease payments 24,700
Less: imputed interest (4,500)
Present value of lease liabilities $ 20,200
XML 73 R81.htm IDEA: XBRL DOCUMENT v3.20.1
Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail)
$ in Millions
Mar. 28, 2020
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
Remainder of Fiscal 2020 $ 145.1
Fiscal 2021 269.1
Fiscal 2022 258.7
Fiscal 2023 161.2
Fiscal 2024 $ 150.4
XML 74 R71.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 15.7 $ 17.5 $ 33.8 $ 34.6
Cost of revenues        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 1.7 2.0 3.8 4.0
Research and development        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 2.3 2.7 4.6 5.4
Selling and marketing        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 2.8 2.7 5.6 5.4
General and administrative        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense 6.5 10.1 17.4 19.8
Restructuring Charges [Member]        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Stock-based compensation expense $ 2.4 $ 0.0 $ 2.4 $ 0.0
XML 75 R75.htm IDEA: XBRL DOCUMENT v3.20.1
Other Balance Sheet Information - Property, Plant and Equipment (Detail) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Balance Sheet Related Disclosures [Abstract]    
Equipment $ 407.6 $ 379.2
Equipment under customer usage agreements 452.8 435.5
Building and improvements 162.9 196.7
Leasehold improvements 42.8 61.7
Land 40.6 46.3
Furniture and fixtures 15.6 17.5
Property, plant and equipment, gross 1,122.3 1,136.9
Less – accumulated depreciation and amortization (677.0) (666.0)
Property, plant and equipment, net $ 445.3 $ 470.9
XML 76 R85.htm IDEA: XBRL DOCUMENT v3.20.1
Restructuring (Details) - USD ($)
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Restructuring Cost and Reserve [Line Items]        
Severance Costs $ 1,000,000.0      
Restructuring Charges 2,900,000 $ 1,600,000 $ 3,900,000 $ 3,300,000
COVID-19 [Member]        
Restructuring Cost and Reserve [Line Items]        
Estimated severance and benefits future costs 1,000,000.0      
Sunnyvale [Member]        
Restructuring Cost and Reserve [Line Items]        
Estimated severance and benefits future costs 1,300,000      
Tepnel [Member]        
Restructuring Cost and Reserve [Line Items]        
Restructuring Charges 1,300,000      
Cynosure        
Restructuring Cost and Reserve [Line Items]        
Restructuring Reserve, Translation and Other Adjustment 2,000,000.0      
Share Based Compensation Expense Included Other Restructuring Costs $ 2,600,000      
XML 77 R79.htm IDEA: XBRL DOCUMENT v3.20.1
Income Taxes (Details) - USD ($)
$ / shares in Units, $ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Dec. 29, 2018
Mar. 28, 2020
Mar. 30, 2019
Sep. 28, 2019
Segment Reporting Information [Line Items]            
Unrecognized Tax Benefits $ 212.7     $ 212.7   $ 101.6
Company's effective tax rate 20.30% 22.90%   122.10% 30.20%  
Increase to income tax expense adoption of ASU 2016-16   $ 29.5        
Decrease in deferred tax liabilities due to ASC 2016-16   48.7        
Increase to Net Income resulted from adoption of ASU 2016-16   $ 19.2        
Increase to Earnings per Share resulted from adoption of ASC 2016-16   $ 0.07        
Increase in deferred tax assets resulting from adoption of ASCU 2016-16     $ 2.9      
Decease in accumulated deficit resulting from adoption of ASCU 2016-16     2.5      
Decease to prepaid taxes resulting from adoption of ASCU 2016-16     $ 0.4      
Medical Aesthetics [Domain]            
Segment Reporting Information [Line Items]            
Other Tax Expense (Benefit)       $ 310.9    
XML 78 R18.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share
6 Months Ended
Mar. 28, 2020
Earnings Per Share [Abstract]  
Net Income (Loss) Per Share Net Income Per Share
A reconciliation of basic and diluted share amounts is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Basic weighted average common shares outstanding
263,238

 
269,235

 
265,566

 
269,913

Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units
1,268

 

 
1,548

 

Diluted weighted average common shares outstanding
264,506

 
269,235

 
267,114

 
269,913

Weighted-average anti-dilutive shares related to:
 
 
 
 
 
 
 
Outstanding stock options
1,677

 
4,031

 
1,483

 
4,578

Stock Units
10

 

 
6

 


In those reporting periods in which the Company has reported net income, anti-dilutive shares generally are comprised of those stock options that either have an exercise price above the average stock price for the period or the stock options’ combined exercise price and average unrecognized stock compensation expense upon exercise is greater than the average stock price. In those reporting periods in which the Company has a net loss, anti-dilutive shares are comprised of the impact of those number of shares that would have been dilutive had the Company had net income plus the number of common stock equivalents that would be anti-dilutive had the company had net income.
XML 79 R14.htm IDEA: XBRL DOCUMENT v3.20.1
Disposition
6 Months Ended
Mar. 28, 2020
Discontinued Operations and Disposal Groups [Abstract]  
Dispositions Disposition
Sale of Medical Aesthetics

On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of $153.4 million. The sale price remains subject to adjustment pursuant to the terms of the definitive agreement. The Company agreed to provide certain transition services for three to fifteen months, depending on the nature of the service. The Company also agreed to indemnify CD&R for certain legal and tax matters that existed as of the date of disposition. In connection with its accounting for the sale, the Company recorded indemnification liabilities of $10.9 million within accrued expenses associated with its obligations under the sale agreement.

As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, asset groups under this designation are required to be recorded at fair value less costs to sell. The Company determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or will have a major effect on the Company's operations and financial results. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services and the amount that must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&R, the Company recorded an impairment charge of $30.2 million in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which $25.8 million was allocated to cost of product revenues and $4.4 million to operating expenses. The Company is currently in the process of evaluating adjustments to the final sales price.

The assets and liabilities of the disposed business at the date of disposition were as follows:

Assets:
 
 
Cash
 
$
10.7

Accounts Receivable
 
59.6

Inventory
 
90.6

Prepaid expenses and other current assets
 
7.7

Property, plant, and equipment
 
4.0

Intangible assets
 
28.2

Other assets
 
9.8

Total assets disposed of
 
$
210.6

 
 
 
Liabilities:
 
 
Accounts payable
 
$
12.3

Accrued expenses
 
49.0

Deferred revenue
 
16.6

Total liabilities disposed of
 
$
77.9



Loss from operations of the disposed business presented below represents the operating loss of the business as it was operated prior to the date of disposition. The operating expenses include only those that were incurred directly by and were retained by the disposed business. As noted above, the Company is performing a number of transition services and the financial impact from these services are not included in the amounts presented below. In addition, the Company will continue to incur expenses related to this business under the indemnification provisions primarily related to legal and tax matters that existed as of the date of disposition, which it will continued to report in the Medical Aesthetic reportable segment. In the second quarter of fiscal 2020, the Company recorded accelerated stock compensation in connection with the disposition, legal expenses for retained cases and other adjustments totaling $2.4 million, which is not included below. Loss from operations of the disposed business for the three and six month periods ended March 28, 2020 and March 30, 2019 was as follows:

 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
March 30, 2019
 
 
 
 
 
 
 
Loss from operations
$

 
(468.3
)
 
$
(46.5
)
$
(488.7
)

XML 80 R10.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue
6 Months Ended
Mar. 28, 2020
Revenue from Contract with Customer [Abstract]  
Revenue Revenue

The Company accounts for revenue pursuant to ASC Update No. 2014-09, Revenue from Contracts with Customer (ASC 606) and generates revenue from the sale of its products, primarily medical imaging systems and related components and software, diagnostic tests and assays, surgical and interventional breast disposable products and until December 28, 2019 medical aesthetic treatment systems, and related services, which were primarily support and maintenance services on its medical imaging systems, and to a lesser extent installation, training and repairs. The Company's products are sold primarily through a direct sales force, and within international markets, there is more reliance on distributors and resellers. Revenue is recorded net of sales tax. The following tables provide revenue from contracts with customers by business and geographic region on a disaggregated basis:

 
 
Three Months Ended March 28, 2020
 
Three Months Ended March 30, 2019
Business (in millions)
United States
International
Total
 
United States
International
Total
Diagnostics:
 
 
 
 
 
 
 
 
Cytology & Perinatal
$
73.2

$
40.2

$
113.4

 
$
76.6

$
38.9

$
115.5

 
Molecular Diagnostics
149.8

40.8

190.6

 
136.8

31.0

167.8

 
Blood Screening
15.2


15.2

 
13.4


13.4

Total
$
238.2

$
81.0

$
319.2

 
$
226.8

$
69.9

$
296.7

 
 
 
 
 
 
 
 
 
Breast Health:
 
 
 
 
 
 
 
 
Breast Imaging
$
186.0

$
64.2

$
250.2

 
$
206.2

$
59.7

$
265.9

 
Interventional Breast Solutions
48.4

9.2

57.6

 
46.8

8.8

55.6

Total
$
234.4

$
73.4

$
307.8

 
$
253.0

$
68.5

$
321.5

 
 
 
 
 
 
 
 
 
GYN Surgical
$
86.7

$
18.7

$
105.4

 
$
84.1

$
18.1

$
102.2

 
 
 
 
 
 
 
 
 
Medical Aesthetics
$

$

$

 
$
37.6

$
36.2

$
73.8

 
 
 
 
 
 
 
 
Skeletal Health
$
15.6

$
8.1

$
23.7

 
$
14.0

$
10.2

$
24.2

 
 
$
574.9

$
181.2

$
756.1

 
$
615.5

$
202.9

$
818.4


 
 
Six Months Ended March 28, 2020
 
Six Months Ended March 30, 2019
Business (in millions)
United States
International
Total
 
United States
International
Total
Diagnostics:
 
 
 
 
 
 
 
 
Cytology & Perinatal
$
150.7

$
83.7

$
234.4

 
$
155.8

$
77.8

$
233.6

 
Molecular Diagnostics
291.9

77.2

369.1

 
270.9

61.2

332.1

 
Blood Screening
27.2


27.2

 
27.6


27.6

Total
$
469.8

$
160.9

$
630.7

 
$
454.3

$
139.0

$
593.3

 
 
 
 
 
 
 
 
 
Breast Health:
 
 
 
 
 
 
 
 
Breast Imaging
$
395.4

$
129.6

$
525.0

 
$
412.7

$
122.9

$
535.6

 
Interventional Breast Solutions
95.5

18.4

113.9

 
92.9

17.7

110.6

Total
$
490.9

$
148.0

$
638.9

 
$
505.6

$
140.6

$
646.2

 
 
 
 
 
 
 
 
 
GYN Surgical
$
185.5

$
39.0

$
224.5

 
$
175.2

$
35.4

$
210.6

 
 
 
 
 
 
 
 
 
Medical Aesthetics
$
30.9

$
34.4

$
65.3

 
$
74.9

$
78.7

$
153.6

 
 
 
 
 
 
 
 
Skeletal Health
$
30.5

$
16.7

$
47.2

 
$
27.2

$
18.2

$
45.4

 
 
$
1,207.6

$
399.0

$
1,606.6

 
$
1,237.2

$
411.9

$
1,649.1


 
 
Three Months Ended
 
Six Months Ended
Geographic Regions (in millions)
 
March 28, 2020
March 30, 2019
 
March 28, 2020
March 30, 2019
United States
 
$
574.9

$
615.5

 
$
1,207.6

$
1,237.2

Europe
 
111.8

102.1

 
221.2

203.2

Asia-Pacific
 
41.7

64.3

 
111.8

134.0

Rest of World
 
27.7

36.5

 
66.0

74.7

 
 
$
756.1

$
818.4

 
$
1,606.6

$
1,649.1


The following table provides revenue recognized by source:

 
 
Three Months Ended
 
Six Months Ended
Revenue by type (in millions)
 
March 28, 2020
March 30, 2019
 
March 28, 2020
March 30, 2019
Capital equipment, components and software
 
$
166.6

$
239.4

 
$
399.5

$
487.8

Consumables
 
457.0

428.4

 
923.4

863.1

Service
 
127.2

141.1

 
272.2

283.0

Other
 
5.3

9.5

 
11.5

15.2

 
 
$
756.1

$
818.4

 
$
1,606.6

$
1,649.1



The Company considers revenue to be earned when all of the following criteria are met: the Company has a contract with a customer that creates enforceable rights and obligations; promised products or services are identified; the transaction price, or the amount the Company expects to receive, including an estimate of uncertain amounts subject to a constraint to ensure revenue is not recognized in an amount that would result in a significant reversal upon resolution of the uncertainty, is determinable; and the Company has transferred control of the promised items to the customer. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the contract. The transaction price for the contract is measured as the amount of consideration the Company expects to receive in exchange for the goods and services expected to be transferred. A contract's transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, control of the distinct good or service is transferred. Transfer of control for the Company's products is generally at shipment or delivery, depending on contractual terms, but occurs when title and risk of loss transfers to the customer which represents the
point in time when the customer obtains the use of and substantially all of the remaining benefit of the product. As such, the Company's performance obligation related to product sales is satisfied at a point in time. Revenue from support and maintenance contracts, extended warranty and professional services for installation, training and repairs is recognized over time based on the period contracted or as the services are performed as these methods represent a faithful depiction of the transfer of goods and services.

The Company recognizes a receivable when it has an unconditional right to payment. Payment terms are typically 30 days in the U.S. but may be longer in international markets. The Company treats shipping and handling costs performed after a customer obtains control of the good as a fulfillment cost and records these costs within costs of product revenue when the corresponding revenue is recognized.

The Company also places instruments (or equipment) at customer sites but retains title to the instrument. The customer has the right to use the instrument for a period of time, and the Company recovers the cost of providing the instrument through the sales of disposables, namely tests and assays in Diagnostics and handpieces in GYN Surgical. These types of agreements include an embedded lease, which is generally an operating lease, for the right to use an instrument and no instrument revenue is recognized at the time of instrument delivery. The Company recognizes a portion of the revenue allocated to the embedded lease concurrent with the sale of disposables over the term of the agreement.

Some of the Company's contracts have multiple performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price to each performance obligation using its best estimate of the standalone selling price of each distinct good or service in the contract. The Company determines its best estimate of stand-alone selling price using average selling prices over 3 to 12 month periods of data depending on the products or nature of the services coupled with current market considerations. If the product or service does not have a history of sales or if sales volume is not sufficient, the Company relies on prices set by its pricing committees or applicable marketing department adjusted for expected discounts.

Variable Consideration

The Company exercises judgment in estimating variable consideration, which includes volume discounts, sales rebates, product returns and other adjustments. These amounts are recorded as a reduction to revenue and classified as a current liability. The Company bases its estimates for volume discounts and sales rebates on historical information to the extent it is reasonable to be used as a predictive tool of expected future rebates. To the extent the transaction price includes variable consideration, the Company applies judgment in constraining the estimated variable consideration due to factors that may cause reversal of revenue recognized. The Company evaluates constraints based on its historical and projected experience with similar customer contracts.
    
The Company's contracts typically do not provide the right to return product. In general, estimates of variable consideration and constraints are not material to the Company's financial statements.

Remaining Performance Obligations

As of March 28, 2020, the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied was approximately $583.5 million. This remaining performance obligation primarily relates to extended warranty and support and maintenance obligations in the Company's Breast Health and Skeletal Health reportable segments. The Company expects to recognize approximately 23% of this amount as revenue in 2020, 32% in 2021, 24% in 2022, 14% in 2023, and 7% thereafter. The Company has applied the practical expedient to not include remaining performance obligations related to contracts with original expected durations of one year or less in the amounts above.

Contract Assets and Liabilities

The Company discloses accounts receivable separately in the Consolidated Balance Sheets at their net realizable value. Contract assets primarily relate to the Company's conditional right to consideration for work completed but not billed at the reporting date. Contract assets at the beginning and end of the period, as well as the changes in the balance, were immaterial.

Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. The Company records a contract liability, or deferred revenue, when it has an obligation to provide service, and to a much lesser extent product, to the customer and payment is received or due in advance of performance. Deferred revenue primarily relates to support and maintenance contracts and extended warranty obligations within the Company's Breast Health and Skeletal Health reportable segments and until recently the divested Medical Aesthetics segment. Contract liabilities are classified as other current liabilities and other long-term liabilities on the Consolidated Balance Sheets. The Company recognized revenue of $26.2 million
and $77.5 million in the three and six months ended March 28, 2020 that was included in the contract liability balance at September 28, 2019.
XML 81 R33.htm IDEA: XBRL DOCUMENT v3.20.1
Disposition Disposition (Tables)
6 Months Ended
Mar. 28, 2020
Discontinued Operations and Disposal Groups [Abstract]  
Disclosure of Long Lived Assets Held-for-sale

Assets:
 
 
Cash
 
$
10.7

Accounts Receivable
 
59.6

Inventory
 
90.6

Prepaid expenses and other current assets
 
7.7

Property, plant, and equipment
 
4.0

Intangible assets
 
28.2

Other assets
 
9.8

Total assets disposed of
 
$
210.6

 
 
 
Liabilities:
 
 
Accounts payable
 
$
12.3

Accrued expenses
 
49.0

Deferred revenue
 
16.6

Total liabilities disposed of
 
$
77.9


Schedule of Income from Operation of Disposed Business from operations of the disposed business for the three and six month periods ended March 28, 2020 and March 30, 2019 was as follows:

 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
March 30, 2019
 
 
 
 
 
 
 
Loss from operations
$

 
(468.3
)
 
$
(46.5
)
$
(488.7
)

XML 82 R37.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation (Tables)
6 Months Ended
Mar. 28, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Expense in Consolidated Statements of Operations
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Cost of revenues
$
1.7

 
$
2.0

 
$
3.8

 
$
4.0

Research and development
2.3

 
2.7

 
4.6

 
5.4

Selling and marketing
2.8

 
2.7

 
5.6

 
5.4

General and administrative
6.5

 
10.1

 
17.4

 
19.8

Restructuring
2.4

 

 
2.4

 

 
$
15.7

 
$
17.5

 
$
33.8

 
$
34.6


Weighted-Average Assumptions Utilized to Value Stock Options
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Risk-free interest rate
1.7
%
 
3.0
%
 
1.7
%
 
3.0
%
Expected volatility
33.6
%
 
34.3
%
 
33.6
%
 
34.3
%
Expected life (in years)
4.8

 
4.8

 
4.8

 
4.8

Dividend yield

 

 

 

Weighted average fair value of options granted
$
14.45

 
$
15.33

 
$
13.87

 
$
13.50


XML 83 R57.htm IDEA: XBRL DOCUMENT v3.20.1
Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details) - USD ($)
$ in Millions
Mar. 28, 2020
Nov. 21, 2019
Sep. 28, 2019
Business Acquisition [Line Items]      
Goodwill $ 2,592.0   $ 2,563.7
SuperSonic Imagine      
Business Acquisition [Line Items]      
Cash   $ 2.6  
Accounts receivable   7.1  
Inventory   10.0  
Other assets   6.5  
Other assets   4.4  
Accounts payable and accrued expenses   13.0  
Deferred revenue   1.8  
Short and long-term debt   (8.8)  
Other liabilities   (3.8)  
Developed technology   38.3  
Customer relationships   4.0  
Trade names   3.0  
Deferred income taxes, net   (1.5)  
Goodwill   22.4  
Purchase Price   $ 69.4  
XML 84 R53.htm IDEA: XBRL DOCUMENT v3.20.1
Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail)
$ in Millions
Mar. 28, 2020
USD ($)
Assets:  
Assets measured at fair value on a recurring basis $ 2.8
Liabilities:  
Total 23.8
Foreign currency option contracts  
Assets:  
Assets measured at fair value on a recurring basis 0.9
Forward foreign currency contracts  
Assets:  
Assets measured at fair value on a recurring basis 1.9
Contingent Consideration Type  
Liabilities:  
Contingent consideration 0.9
Interest Rate Swap  
Assets:  
Assets measured at fair value on a recurring basis 22.9
Quoted Prices in Active Market for Identical Assets (Level 1)  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Liabilities:  
Total 0.0
Quoted Prices in Active Market for Identical Assets (Level 1) | Foreign currency option contracts  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Quoted Prices in Active Market for Identical Assets (Level 1) | Forward foreign currency contracts  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Quoted Prices in Active Market for Identical Assets (Level 1) | Contingent Consideration Type  
Liabilities:  
Contingent consideration 0.0
Quoted Prices in Active Market for Identical Assets (Level 1) | Interest Rate Swap  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Significant Other Observable Inputs (Level 2)  
Assets:  
Assets measured at fair value on a recurring basis 2.8
Liabilities:  
Total 22.9
Significant Other Observable Inputs (Level 2) | Foreign currency option contracts  
Assets:  
Assets measured at fair value on a recurring basis 0.9
Significant Other Observable Inputs (Level 2) | Forward foreign currency contracts  
Assets:  
Assets measured at fair value on a recurring basis 1.9
Significant Other Observable Inputs (Level 2) | Contingent Consideration Type  
Liabilities:  
Contingent consideration 0.0
Significant Other Observable Inputs (Level 2) | Interest Rate Swap  
Assets:  
Assets measured at fair value on a recurring basis 22.9
Significant Unobservable Inputs (Level 3)  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Liabilities:  
Total 0.9
Significant Unobservable Inputs (Level 3) | Foreign currency option contracts  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Significant Unobservable Inputs (Level 3) | Forward foreign currency contracts  
Assets:  
Assets measured at fair value on a recurring basis 0.0
Significant Unobservable Inputs (Level 3) | Contingent Consideration Type  
Liabilities:  
Contingent consideration 0.9
Significant Unobservable Inputs (Level 3) | Interest Rate Swap  
Assets:  
Assets measured at fair value on a recurring basis $ 0.0
XML 85 R78.htm IDEA: XBRL DOCUMENT v3.20.1
Business Segments and Geographic Information - Revenues by Geography (Detail)
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Schedule Of Geographical Segments [Line Items]        
Revenues 100.00% 100.00% 100.00% 100.00%
United States        
Schedule Of Geographical Segments [Line Items]        
Revenues 76.00% 75.10% 75.10% 75.00%
Europe        
Schedule Of Geographical Segments [Line Items]        
Revenues 14.80% 12.50% 13.80% 12.30%
Asia-Pacific        
Schedule Of Geographical Segments [Line Items]        
Revenues 5.50% 7.90% 7.00% 8.10%
Rest of World        
Schedule Of Geographical Segments [Line Items]        
Revenues 3.70% 4.50% 4.10% 4.60%
XML 86 R80.htm IDEA: XBRL DOCUMENT v3.20.1
Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value $ 4,799.8 $ 4,786.6
Accumulated Amortization 3,471.0 3,326.8
Developed technology    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 3,925.6 3,927.7
Accumulated Amortization 2,779.6 2,654.8
Customer relationships    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 546.8 525.5
Accumulated Amortization 461.4 447.5
Trade names    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 244.0 245.4
Accumulated Amortization 176.1 171.1
Distribution agreement    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 0.0 2.5
Accumulated Amortization 0.0 0.0
Non-competition agreements    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 1.5 1.4
Accumulated Amortization 1.1 0.9
Business licenses    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 2.3 2.3
Accumulated Amortization 2.2 2.2
Total acquired intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 4,720.2 4,704.8
Accumulated Amortization 3,420.4 3,276.5
Internal-use software    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 51.4 53.9
Accumulated Amortization 41.7 43.4
Capitalized software embedded in products    
Finite-Lived Intangible Assets [Line Items]    
Gross Carrying Value 28.2 27.9
Accumulated Amortization $ 8.9 $ 6.9
XML 87 R70.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) - shares
shares in Thousands
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Earnings Per Share [Line Items]        
Basic weighted average common shares outstanding 263,238 269,235 265,566 269,913
Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units 1,268 0 1,548 0
Diluted weighted average common shares outstanding 264,506 269,235 267,114 269,913
Outstanding Stock Options and stock units        
Weighted-average anti-dilutive shares related to:        
Weighted-average anti-dilutive shares (in shares) 1,677 4,031 1,483 4,578
Restricted stock units        
Weighted-average anti-dilutive shares related to:        
Weighted-average anti-dilutive shares (in shares) 10 0 6 0
XML 88 R74.htm IDEA: XBRL DOCUMENT v3.20.1
Other Balance Sheet Information - Inventories (Detail) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Balance Sheet Related Disclosures [Abstract]    
Raw materials $ 155.1 $ 166.1
Work-in-process 56.4 54.5
Finished goods 189.8 224.3
Inventories $ 401.3 $ 444.9
XML 89 R84.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Income (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance   $ 2,394.4 $ 2,115.7 $ 2,428.8
Changes in foreign currency translation adjustment $ (5.4) 2.4 2.9 (0.8)
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019. (25.2) (1.5) (21.2) (5.4)
Accumulated other comprehensive loss (58.9)   (58.9)  
Foreign Currency Translation        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance (33.1) (29.8) (41.4) (26.6)
Changes in foreign currency translation adjustment (5.4) 2.4 2.9 (0.8)
Amounts reclassified to statement of income 0.0 0.0 0.0 0.0
Pension Plans        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance (1.7) (1.1) (1.7) (1.1)
Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent 0.0 0.0 0.0 0.0
Amounts reclassified to statement of income 0.0 0.0 0.0 0.0
Total        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance (28.7) (31.9) (42.3) (25.5)
Other Comprehensive Income (Loss) before Reclassifications, Tax (30.6) 0.9 (18.3) (6.2)
Amounts reclassified to statement of income (0.4) (0.5) (1.7) (1.2)
Accumulated other comprehensive loss   (30.5)   (30.5)
Interest rate caps - derivative | AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance (1.4) (1.0) (2.7) 2.2
Changes in value of hedged interest rate swaps and interest rate caps, net of tax of ($8.1) and ($6.4) for the three and six months ended March 28, 2020 and $0.3 and $0.8 for the three and six months ended March 30, 2019. (0.1) (1.5) (0.1) (5.4)
Amounts reclassified to statement of income (0.4) $ (0.5) (1.7) $ (1.2)
Interest Rate Swap [Member] | AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]        
Accumulated Other Comprehensive Income (Loss) [Line Items]        
Beginning balance 7.5   3.5  
Changes in unrealized holding gains and losses on available-for-sale securities, net of tax of$0.2 for the three months ended December 30, 2017: (25.1)   (21.1)  
Amounts reclassified to statement of income $ 0.0   $ 0.0  
XML 90 R15.htm IDEA: XBRL DOCUMENT v3.20.1
Borrowings and Credit Arrangements
6 Months Ended
Mar. 28, 2020
Debt Disclosure [Abstract]  
Borrowings and Credit Arrangements Borrowings and Credit Arrangements
The Company’s borrowings consisted of the following: 
 
March 28,
2020
 
September 28,
2019
Current debt obligations, net of debt discount and deferred issuance costs:
 
 
 
Term Loan
$
56.1

 
$
37.4

Revolver
750.0

 

Securitization Program

 
234.0

Total current debt obligations
$
806.1

 
$
271.4

Long-term debt obligations, net of debt discount and deferred issuance costs:
 
 
 
Term Loan
1,416.2

 
1,452.4

Debt assumed from SSI acquisition
0.6

 

2025 Senior Notes
938.3

 
937.3

2028 Senior Notes
394.2

 
393.9

Total long-term debt obligations
$
2,749.3

 
$
2,783.6

Total debt obligations
$
3,555.4

 
$
3,055.0


2018 Amended and Restated Credit Agreement
On December 17, 2018, the Company and certain of its subsidiaries refinanced its term loan and revolving credit facility by entering into an Amended and Restated Credit and Guaranty Agreement as of December 17, 2018 (the "2018 Credit Agreement") with Bank of America, N.A. in its capacity as Administrative Agent, Swing Line Lender and L/C Issuer, and certain other lenders. The 2018 Credit Agreement amended and restated the Company's prior credit and guaranty agreement dated as of October 3, 2017 (the "2017 Credit Agreement"). The borrowings of the 2018 Amended Term Loan bear interest at an annual rate equal to the Eurocurrency Rate (i.e., the LIBOR rate) plus an Applicable Rate, which was equal to 1.375% as of March 28, 2020. The borrowings of the 2018 Amended Revolver bear interest at a rate equal to the LIBOR Daily Floating Rate plus an Applicable Rate equal to 1.375%.

Pursuant to ASC 470, Debt (ASC 470), the accounting related to entering into the 2018 Credit Agreement and using the proceeds to pay off the 2017 Credit Agreement was evaluated on a creditor-by-creditor basis to determine whether each transaction should be accounted for as a modification or extinguishment. Certain creditors under the 2017 Credit Agreement did not participate in this refinancing transaction and ceased being creditors of the Company. As a result, the Company recorded a debt extinguishment loss of $0.8 million in the first quarter of fiscal 2019. For the remainder of the creditors, this transaction was accounted for as a modification because on a creditor-by-creditor basis the present value of the cash flows between the two debt instruments before and after the transaction was less than 10%. Pursuant to ASC 470, subtopic 50-40, third-party costs of $0.8 million related to this transaction were recorded as interest expense and $1.9 million was recorded as a reduction to debt representing deferred issuance costs and debt discount for fees paid directly to the lenders.

In response to the current market uncertainties created by the COVID-19 pandemic, in March 2020, the Company borrowed $750 million under its revolver, which it intends to repay within one year, $250 million of which was used to pay off amounts outstanding under the asset securitization agreement, in order to have sufficient cash on hand. The Company has another $750 million available under its revolver as of March 28, 2020.

Interest expense, weighted average interest rate, and interest rate at the end of period under the Credit Agreements were as follows: 

 
Three Months Ended
 
Six Months Ended
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
Interest expense
$
13.0

 
$
16.8

 
$
26.6

 
$
35.5

Weighted average interest rate
2.75
%
 
3.86
%
 
2.93
%
 
3.84
%
Interest rate at end of period
2.33
%
 
3.87
%
 
2.33
%
 
3.87
%

The 2018 Credit Agreement contains two financial covenants; a total leverage ratio and an interest coverage ratio, both of which are measured as of the last day of each fiscal quarter. These terms, and calculations thereof, are defined in further detail in the 2018 Credit Agreement. As of March 28, 2020, the Company was in compliance with these covenants.

Senior Notes

On October 10, 2017, the Company completed a private placement of $350 million aggregate principal amount of its 4.375% Senior Notes due 2025 (the "2025 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2025 Senior Notes.

On January 19, 2018, the Company completed a private placement of $1.0 billion aggregate principal amount of senior notes, allocated between (i) an additional $600 million aggregate principal amounts of its 2025 Senior Notes pursuant to a supplement to the indenture governing the Company's existing 2025 Senior Notes at an offering price of 100% of the aggregate principal amount of the 2025 Senior Notes and (ii) $400 million aggregate principal amounts of its 4.625% Senior Notes due 2028 (the "2028 Senior Notes") at an offering price of 100% of the aggregate principal amount of the 2028 Senior Notes.

2025 Senior Notes

The total aggregate principal balance of 2025 Senior Notes is $950 million. The 2025 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on October 15, 2025.

2028 Senior Notes
    
The aggregate principal balance of the 2028 Senior Notes is $400 million. The 2028 Senior Notes are general senior unsecured obligations of the Company and are guaranteed on a senior unsecured basis by certain domestic subsidiaries and mature on February 1, 2028.
Interest expense for the 2028 Senior Notes and 2025 Senior Notes is as follows:
 
 
 
Three Months Ended
 
Six Months Ended
 
 
 
March 28, 2020
 
March 30, 2019
 
March 28, 2020
 
March 30, 2019
 
Interest Rate
 
Interest Expense
 
Interest Expense
 
Interest Expense
 
Interest Expense
2028 Senior Notes
4.625
%
 
$
4.8

 
$
4.8

 
$
9.6

 
$
9.6

2025 Senior Notes
4.375
%
 
10.9

 
10.9

 
21.8

 
21.8

Total
 
 
$
15.7

 
$
15.7

 
$
31.4

 
$
31.4


Accounts Receivable Securitization Program

On March 26, 2020, the Company paid-off the total amount outstanding of $250.0 million previously borrowed under the Accounts Receivable Securitization Program (the "Securitization Program"). As of March 28, 2020, the Company did not have any borrowings under this program. On April 13, 2020, the Company amended the Credit and Security agreement with the lenders, temporarily suspending the ability to borrow and the need to comply with covenants for up to a year.
XML 91 R11.htm IDEA: XBRL DOCUMENT v3.20.1
Leases (Notes)
6 Months Ended
Mar. 28, 2020
Leases [Abstract]  
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of March 28, 2020 was 2.59%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
March 28, 2020
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
82.6

$

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.1

$

Finance lease liabilities (current)
 
Finance lease obligations - short term
$

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
68.7

$

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$

$
18.4



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
Three Months Ended March 28, 2020
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
5.93

8.14

Weighted average discount rate
 
1.95
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended March 28, 2020
Six Months Ended March 28, 2020
Operating lease cost (a)
$
6.8

$
13.8

Finance lease cost - amortization of right-of-use assets
$

$
0.3

Finance lease cost - interest cost
$
0.3

$
0.5

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from finance leases
$
0.3

$
0.5

 
Operating cash flows from operating leases
$
5.7

$
11.7

 
Financing cash flows from finance leases
$
0.4

$
0.9

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.4

$
13.1

 
 
 
 
ROU assets arising from entering into new operating lease obligations
$
3.3

$
4.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for both the three and six months ended March 28, 2020.

In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of March 28, 2020 was 2.59%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
March 28, 2020
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
82.6

$

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.1

$

Finance lease liabilities (current)
 
Finance lease obligations - short term
$

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
68.7

$

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$

$
18.4



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
Three Months Ended March 28, 2020
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
5.93

8.14

Weighted average discount rate
 
1.95
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended March 28, 2020
Six Months Ended March 28, 2020
Operating lease cost (a)
$
6.8

$
13.8

Finance lease cost - amortization of right-of-use assets
$

$
0.3

Finance lease cost - interest cost
$
0.3

$
0.5

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from finance leases
$
0.3

$
0.5

 
Operating cash flows from operating leases
$
5.7

$
11.7

 
Financing cash flows from finance leases
$
0.4

$
0.9

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.4

$
13.1

 
 
 
 
ROU assets arising from entering into new operating lease obligations
$
3.3

$
4.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for both the three and six months ended March 28, 2020.

In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of March 28, 2020 was 2.59%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
March 28, 2020
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
82.6

$

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.1

$

Finance lease liabilities (current)
 
Finance lease obligations - short term
$

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
68.7

$

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$

$
18.4



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
Three Months Ended March 28, 2020
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
5.93

8.14

Weighted average discount rate
 
1.95
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended March 28, 2020
Six Months Ended March 28, 2020
Operating lease cost (a)
$
6.8

$
13.8

Finance lease cost - amortization of right-of-use assets
$

$
0.3

Finance lease cost - interest cost
$
0.3

$
0.5

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from finance leases
$
0.3

$
0.5

 
Operating cash flows from operating leases
$
5.7

$
11.7

 
Financing cash flows from finance leases
$
0.4

$
0.9

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.4

$
13.1

 
 
 
 
ROU assets arising from entering into new operating lease obligations
$
3.3

$
4.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for both the three and six months ended March 28, 2020.

In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.
Leases Leases
Lessee Activity - Leases where Hologic is the Lessee

The majority of the Company's facilities are occupied under operating lease arrangements with various expiration dates through 2035, some of which include options to extend the term of the lease, and some of which include options to terminate the lease within one year. The Company has operating leases for office space, land, warehouse and manufacturing space, vehicles and certain equipment. Leases with an initial term of 12 months or less are generally not recorded on the balance sheet and expense for these leases is recognized on a straight-line basis over the lease term. For leases executed in fiscal 2020 and later, the Company accounts for the lease components and the non-lease components as a single lease component. The Company's leases have remaining lease terms of one year to approximately 15 years, some of which may include options to extend the leases for up to 20 years and some include options to terminate early. These options have been included in the determination of the lease liability when it is reasonably certain that the option will be exercised. The Company does not have any leases that include residual value guarantees.

The Company determines whether an arrangement is or contains a lease based on the unique facts and circumstances present at the inception of an arrangement. The right-of-use assets and related liabilities for operating leases are included in other assets, accrued expenses, and other long-term liabilities in the consolidated balance sheet as of March 28, 2020. The Company's lease classified as a capital lease in fiscal 2019 is now classified as finance lease on the balance sheet as of March 28, 2020.
    
Right-of-use assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent the Company's obligation to make lease payments arising from the lease contract. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of fixed lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the estimated rate that would be incurred to borrow on a collateralized basis over a similar term at an amount equal to the lease payments in a similar economic environment. The weighted average discount rate utilized on the Company's operating and finance lease liabilities as of March 28, 2020 was 2.59%.

The following table presents supplemental balance sheet information related to the Company's operating and finance leases:
 
 
 
March 28, 2020
 
 
Balance Sheet Location
Operating Leases
Finance Lease
Assets
 
 
 
 
Lease right-of-use assets
 
Other assets
$
82.6

$

Liabilities
 
 
 
 
Operating lease liabilities (current)
 
Accrued expenses

$
22.1

$

Finance lease liabilities (current)
 
Finance lease obligations - short term
$

$
1.8

Operating lease liabilities (non-current)
 
Other long-term liabilities

$
68.7

$

Finance lease liabilities (non-current)
 
Finance lease obligations - long term

$

$
18.4



The finance lease was previously recorded as a capital lease in the consolidated balance at September 28, 2019, and the short-term and long-term liabilities were $1.8 million and $19.2 million, respectively.

The following table presents the weighted average remaining lease term and discount rate information related to the Company's operating and finance leases:

 
 
Three Months Ended March 28, 2020
 
 
Operating Leases
Finance Lease
Weighted average remaining lease term
 
5.93

8.14

Weighted average discount rate
 
1.95
%
5.1
%


The following table provides information related to the Company’s operating and finance leases:

 
 
Three Months Ended March 28, 2020
Six Months Ended March 28, 2020
Operating lease cost (a)
$
6.8

$
13.8

Finance lease cost - amortization of right-of-use assets
$

$
0.3

Finance lease cost - interest cost
$
0.3

$
0.5

Cash paid for amounts included in the measurement of lease liabilities:
 
 
 
Operating cash flows from finance leases
$
0.3

$
0.5

 
Operating cash flows from operating leases
$
5.7

$
11.7

 
Financing cash flows from finance leases
$
0.4

$
0.9

 
Total cash paid for amounts included in the measurement of lease liabilities
$
6.4

$
13.1

 
 
 
 
ROU assets arising from entering into new operating lease obligations
$
3.3

$
4.7

(a) Includes short-term lease expense and variable lease costs, which were immaterial in the three and six months ended March 28, 2020.
The following table presents the future minimum lease payments under non-cancellable operating lease liabilities and finance lease as of March 28, 2020:
Fiscal Year
 
Operating Leases
Finance Lease
2020 remaining
 
$
11.9

$
1.4

2021
 
22.5

2.9

2022
 
17.8

3.0

2023
 
11.4

3.0

2024
 
9.3

3.0

Thereafter
 
23.9

11.4

Total future minimum lease payments
 
96.8

24.7

Less: imputed interest
 
(6.0
)
(4.5
)
Present value of lease liabilities
 
$
90.8

$
20.2


Lessor Activity - Leases where Hologic is the Lessor

Certain assets, primarily diagnostics instruments, are leased to customers under contractual arrangements that typically include an operating or sales-type lease as well as performance obligations for reagents and other consumables. These contractual arrangements are subject to termination provisions which are evaluated in determining the lease term for lease accounting purposes. Sales-type leases are not significant. Contract terms vary by customer and may include options to terminate the contract or options to extend the contract. Where instruments are provided under operating lease arrangements, some portion or the entire lease revenue may be variable and subject to subsequent non-lease component (e.g., reagent) sales. The allocation of revenue between the lease and non-lease components is based on stand-alone selling prices. Lease revenue represented approximately 3% of the Company’s consolidated revenue for both the three and six months ended March 28, 2020.

In connection with the disposition of the Medical Aesthetics business, the Company entered into an agreement to sublease to Cynosure its U.S. headquarters and manufacturing location. As such, the Company derecognized $10.2 million for the right-of-use asset for the finance lease, included in property, plant and equipment, and recorded a lease receivable, which is $20.6 million as of March 28, 2020.
XML 92 R19.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation
6 Months Ended
Mar. 28, 2020
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
The following presents stock-based compensation expense in the Company’s Consolidated Statements of Operations:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Cost of revenues
$
1.7

 
$
2.0

 
$
3.8

 
$
4.0

Research and development
2.3

 
2.7

 
4.6

 
5.4

Selling and marketing
2.8

 
2.7

 
5.6

 
5.4

General and administrative
6.5

 
10.1

 
17.4

 
19.8

Restructuring
2.4

 

 
2.4

 

 
$
15.7

 
$
17.5

 
$
33.8

 
$
34.6


The Company granted options to purchase 0.9 million and 0.9 million shares of the Company's common stock during the six months ended March 28, 2020 and March 30, 2019, respectively, with weighted-average exercise prices of $45.82 and $41.25, respectively. There were 5.3 million options outstanding at March 28, 2020 with a weighted-average exercise price of $38.74.
The Company uses a binomial model to determine the fair value of its stock options. The weighted-average assumptions utilized to value these stock options are indicated in the following table:
 
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Risk-free interest rate
1.7
%
 
3.0
%
 
1.7
%
 
3.0
%
Expected volatility
33.6
%
 
34.3
%
 
33.6
%
 
34.3
%
Expected life (in years)
4.8

 
4.8

 
4.8

 
4.8

Dividend yield

 

 

 

Weighted average fair value of options granted
$
14.45

 
$
15.33

 
$
13.87

 
$
13.50


The Company granted 0.8 million and 0.9 million restricted stock units (RSUs) during the six months ended March 28, 2020 and March 30, 2019, respectively, with weighted-average grant date fair values of $45.76 and $41.11 per unit, respectively. In addition, the Company granted 0.1 million and 0.1 million performance stock units (PSUs) during the six months ended March 28, 2020 and March 30, 2019, respectively, to members of its senior management team, which have a weighted-average grant date fair value of $45.76 and $40.97 per unit, respectively. Each recipient of PSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years provided the Company’s defined Return on Invested Capital metrics are achieved. The Company also granted 0.1 million of PSUs based on a one-year free cash flow measure (FCF) to its senior management team, which had a grant date fair value of $45.76. Each recipient of FCF PSUs is eligible to receive between zero and 200% of the target number of shares of the Company's common stock at the end of the one-year measurement period, but the FCF PSUs vest at the end of the three year service period. The Company is recognizing compensation expense for PSUs and FCF PSUs ratably over the required service period based on its estimate of the number of shares that will vest. If there is a change in the estimate of the number of shares that are probable of vesting, the Company cumulatively adjusts compensation expense in the period that the change in estimate is made. The Company also granted 0.1 million and 0.1 million market-based awards (MSUs) to its senior management team during the six months ended March 28, 2020 and March 30, 2019, respectively. Each recipient of MSUs is eligible to receive between zero and 200% of the target number of shares of the Company’s common stock at the end of three years based upon achieving a certain total shareholder return relative to a defined peer group. The MSUs were valued at $43.90 and $55.13 per share using the Monte Carlo simulation model. The Company is recognizing compensation expense for the MSUs ratably over the service period. At March 28, 2020, there was 2.5 million in aggregate RSUs, PSUs, FCF PSUs and MSUs outstanding.
At March 28, 2020, there was $26.7 million and $70.6 million of unrecognized compensation expense related to stock options and stock units (comprised of RSUs, PSUs, FCF PSUs and MSUs), respectively, to be recognized over a weighted-average period of 2.6 and 2.0 years, respectively.
XML 93 R32.htm IDEA: XBRL DOCUMENT v3.20.1
Business Combinations (Tables)
6 Months Ended
Mar. 28, 2020
Faxitron  
Business Acquisition [Line Items]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The total purchase price was allocated to SSI's preliminary tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of November 21, 2019, as set forth below. The preliminary purchase price allocation is as follows:

Cash
$
2.6

Accounts receivable
7.1

Inventory
10.0

Property, plant and equipment
6.5

Other assets
4.4

Accounts payable and accrued expenses
(13.0
)
Deferred revenue
(1.8
)
Short and long-term debt
(8.8
)
Other liabilities
(3.8
)
Identifiable intangible assets:

       Developed technology
38.3

       Customer relationships
4.0

       Trade names
3.0

Deferred income taxes, net
(1.5
)
Goodwill
22.4

Purchase Price
$
69.4


Focal Therapeutics  
Business Acquisition [Line Items]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed
The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below:

Cash
$
2.2

Accounts receivable
2.0

Inventory
7.9

Other assets
0.5

Accounts payable and accrued expenses
(5.6
)
Long-term debt
(2.5
)
Identifiable intangible assets:
 
       Developed technology
83.1

       In-process research and development
11.4

       Trade names
2.7

Deferred income taxes, net
(12.7
)
Goodwill
31.1

Purchase Price
$
120.1


XML 94 R36.htm IDEA: XBRL DOCUMENT v3.20.1
Net Income (Loss) Per Share (Tables)
6 Months Ended
Mar. 28, 2020
Earnings Per Share [Abstract]  
Reconciliation of Basic and Diluted Share Amounts
A reconciliation of basic and diluted share amounts is as follows:
 
Three Months Ended
 
Six Months Ended
 
March 28,
2020
 
March 30,
2019
 
March 28,
2020
 
March 30,
2019
Basic weighted average common shares outstanding
263,238

 
269,235

 
265,566

 
269,913

Weighted average common stock equivalents from assumed exercise of stock options and issuance of stock units
1,268

 

 
1,548

 

Diluted weighted average common shares outstanding
264,506

 
269,235

 
267,114

 
269,913

Weighted-average anti-dilutive shares related to:
 
 
 
 
 
 
 
Outstanding stock options
1,677

 
4,031

 
1,483

 
4,578

Stock Units
10

 

 
6

 


XML 95 R5.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Current assets:    
Cash less assets held for sale $ 799.8 $ 601.8
Accounts receivable, less reserves of $16.0 and $17.8, respectively 597.2 648.7
Inventories 401.3 444.9
Prepaid Income Taxes-Current 62.6 34.9
Prepaid expenses and other current assets 75.7 62.8
Total current assets 1,936.6 1,793.1
Property, plant and equipment, net 445.3 470.9
Intangible assets, net 1,328.8 1,459.8
Goodwill 2,592.0 2,563.7
Other assets 519.1 154.6
Total assets 6,821.8 6,442.1
Current liabilities:    
Current portion of long-term debt 806.1 271.4
Accounts payable 134.4 186.5
Accrued expenses 366.0 430.9
Deferred revenue 172.6 179.5
Current portion of capital lease obligations 1.8 1.8
Total liabilities and stockholders’ equity 6,821.8 6,442.1
Total current liabilities 1,480.9 1,070.1
Long-term debt, net of current portion 2,749.3 2,783.6
Finance lease obligation - long term (capital lease obligation in 2019) 18.4 19.2
Deferred Income Tax Liabilities, Net 235.9 275.3
Deferred revenue 15.0 15.8
Other long-term liabilities 231.1 162.4
Stockholders’ equity:    
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued 0.0 0.0
Common stock, $0.01 par value – 750,000 shares authorized; 294,142 and 292,323 shares issued, respectively 2.9 2.9
Additional paid-in-capital 5,827.6 5,769.8
Accumulated deficit (2,206.0) (2,688.7)
Treasury stock, at cost – 35,941 and 24,638 shares, respectively (1,479.5) (926.0)
Accumulated other comprehensive loss (58.9) (42.3)
Total Hologic's stockholders’ equity 2,086.1 2,115.7
Stockholders' Equity Attributable to Noncontrolling Interest 5.1 0.0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $ 2,091.2 $ 2,115.7
XML 96 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.1 html 523 491 1 false 122 0 false 6 false false R1.htm 0001000 - Document - Cover Page Sheet http://www.hologic.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001000 - Statement - Consolidated Statements of Income Sheet http://www.hologic.com/role/ConsolidatedStatementsOfIncome Consolidated Statements of Income Statements 2 false false R3.htm 1002000 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 3 false false R4.htm 1002501 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical) Sheet http://www.hologic.com/role/ConsolidatedStatementsOfComprehensiveLossParenthetical Consolidated Statements of Comprehensive Loss (Parenthetical) Statements 4 false false R5.htm 1003000 - Statement - Consolidated Balance Sheets Sheet http://www.hologic.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 5 false false R6.htm 1003501 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.hologic.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 1004000 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.hologic.com/role/ConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity Statements 7 false false R8.htm 1005000 - Statement - Consolidated Statements of Cash Flows Sheet http://www.hologic.com/role/ConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 2101100 - Disclosure - Basis of Presentation Sheet http://www.hologic.com/role/BasisOfPresentation Basis of Presentation Notes 9 false false R10.htm 2102100 - Disclosure - Revenue Sheet http://www.hologic.com/role/Revenue Revenue Notes 10 false false R11.htm 2103100 - Disclosure - Leases (Notes) Notes http://www.hologic.com/role/LeasesNotes Leases (Notes) Notes 11 false false R12.htm 2104100 - Disclosure - Fair Value Measurements Sheet http://www.hologic.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2105100 - Disclosure - Business Combinations Sheet http://www.hologic.com/role/BusinessCombinations Business Combinations Notes 13 false false R14.htm 2107100 - Disclosure - Disposition Sheet http://www.hologic.com/role/Disposition Disposition Notes 14 false false R15.htm 2110100 - Disclosure - Borrowings and Credit Arrangements Sheet http://www.hologic.com/role/BorrowingsAndCreditArrangements Borrowings and Credit Arrangements Notes 15 false false R16.htm 2111100 - Disclosure - Derivatives Sheet http://www.hologic.com/role/Derivatives Derivatives Notes 16 false false R17.htm 2112100 - Disclosure - Commitments and Contingencies Sheet http://www.hologic.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 17 false false R18.htm 2113100 - Disclosure - Net Income (Loss) Per Share Sheet http://www.hologic.com/role/NetIncomeLossPerShare Net Income (Loss) Per Share Notes 18 false false R19.htm 2114100 - Disclosure - Stock-Based Compensation Sheet http://www.hologic.com/role/StockBasedCompensation Stock-Based Compensation Notes 19 false false R20.htm 2116100 - Disclosure - Other Balance Sheet Information Sheet http://www.hologic.com/role/OtherBalanceSheetInformation Other Balance Sheet Information Notes 20 false false R21.htm 2117100 - Disclosure - Business Segments and Geographic Information Sheet http://www.hologic.com/role/BusinessSegmentsAndGeographicInformation Business Segments and Geographic Information Notes 21 false false R22.htm 2118100 - Disclosure - Income Taxes Sheet http://www.hologic.com/role/IncomeTaxes Income Taxes Notes 22 false false R23.htm 2119100 - Disclosure - Intangible Assets and Goodwill Sheet http://www.hologic.com/role/IntangibleAssetsAndGoodwill Intangible Assets and Goodwill Notes 23 false false R24.htm 2120100 - Disclosure - Product Warranties Sheet http://www.hologic.com/role/ProductWarranties Product Warranties Notes 24 false false R25.htm 2121100 - Disclosure - Accumulated Other Comprehensive Loss Sheet http://www.hologic.com/role/AccumulatedOtherComprehensiveLoss Accumulated Other Comprehensive Loss Notes 25 false false R26.htm 2123100 - Disclosure - Share Repurchase Sheet http://www.hologic.com/role/ShareRepurchase Share Repurchase Notes 26 false false R27.htm 2124100 - Disclosure - New Accounting Pronouncements Sheet http://www.hologic.com/role/NewAccountingPronouncements New Accounting Pronouncements Notes 27 false false R28.htm 2224201 - Disclosure - New Accounting Pronouncements (Policies) Sheet http://www.hologic.com/role/NewAccountingPronouncementsPolicies New Accounting Pronouncements (Policies) Policies http://www.hologic.com/role/NewAccountingPronouncements 28 false false R29.htm 2302301 - Disclosure - Revenue (Tables) Sheet http://www.hologic.com/role/RevenueTables Revenue (Tables) Tables http://www.hologic.com/role/Revenue 29 false false R30.htm 2303301 - Disclosure - Leases (Tables) Sheet http://www.hologic.com/role/LeasesTables Leases (Tables) Tables http://www.hologic.com/role/LeasesNotes 30 false false R31.htm 2304301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.hologic.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.hologic.com/role/FairValueMeasurements 31 false false R32.htm 2305301 - Disclosure - Business Combinations (Tables) Sheet http://www.hologic.com/role/BusinessCombinationsTables Business Combinations (Tables) Tables http://www.hologic.com/role/BusinessCombinations 32 false false R33.htm 2307301 - Disclosure - Disposition Disposition (Tables) Sheet http://www.hologic.com/role/DispositionDispositionTables Disposition Disposition (Tables) Tables 33 false false R34.htm 2310301 - Disclosure - Borrowings and Credit Arrangements (Tables) Sheet http://www.hologic.com/role/BorrowingsAndCreditArrangementsTables Borrowings and Credit Arrangements (Tables) Tables http://www.hologic.com/role/BorrowingsAndCreditArrangements 34 false false R35.htm 2311301 - Disclosure - Derivatives (Tables) Sheet http://www.hologic.com/role/DerivativesTables Derivatives (Tables) Tables http://www.hologic.com/role/Derivatives 35 false false R36.htm 2313301 - Disclosure - Net Income (Loss) Per Share (Tables) Sheet http://www.hologic.com/role/NetIncomeLossPerShareTables Net Income (Loss) Per Share (Tables) Tables http://www.hologic.com/role/NetIncomeLossPerShare 36 false false R37.htm 2314301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.hologic.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.hologic.com/role/StockBasedCompensation 37 false false R38.htm 2316301 - Disclosure - Other Balance Sheet Information (Tables) Sheet http://www.hologic.com/role/OtherBalanceSheetInformationTables Other Balance Sheet Information (Tables) Tables http://www.hologic.com/role/OtherBalanceSheetInformation 38 false false R39.htm 2317301 - Disclosure - Business Segments and Geographic Information (Tables) Sheet http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationTables Business Segments and Geographic Information (Tables) Tables http://www.hologic.com/role/BusinessSegmentsAndGeographicInformation 39 false false R40.htm 2319301 - Disclosure - Intangible Assets and Goodwill (Tables) Sheet http://www.hologic.com/role/IntangibleAssetsAndGoodwillTables Intangible Assets and Goodwill (Tables) Tables http://www.hologic.com/role/IntangibleAssetsAndGoodwill 40 false false R41.htm 2320301 - Disclosure - Product Warranties (Tables) Sheet http://www.hologic.com/role/ProductWarrantiesTables Product Warranties (Tables) Tables http://www.hologic.com/role/ProductWarranties 41 false false R42.htm 2321301 - Disclosure - Accumulated Other Comprehensive Loss (Tables) Sheet http://www.hologic.com/role/AccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive Loss (Tables) Tables http://www.hologic.com/role/AccumulatedOtherComprehensiveLoss 42 false false R43.htm 2401401 - Disclosure - Basis of Presentation Details (Details) Sheet http://www.hologic.com/role/BasisOfPresentationDetailsDetails Basis of Presentation Details (Details) Details 43 false false R44.htm 2402402 - Disclosure - Revenue - Business Revenue (Details) Sheet http://www.hologic.com/role/RevenueBusinessRevenueDetails Revenue - Business Revenue (Details) Details 44 false false R45.htm 2402403 - Disclosure - Revenue - Geographical Revenue (Details) Sheet http://www.hologic.com/role/RevenueGeographicalRevenueDetails Revenue - Geographical Revenue (Details) Details 45 false false R46.htm 2402404 - Disclosure - Revenue - Revenue by Type (Details) Sheet http://www.hologic.com/role/RevenueRevenueByTypeDetails Revenue - Revenue by Type (Details) Details 46 false false R47.htm 2402405 - Disclosure - Revenue - Narrative (Details) Sheet http://www.hologic.com/role/RevenueNarrativeDetails Revenue - Narrative (Details) Details 47 false false R48.htm 2402406 - Disclosure - Revenue - Remaining Performance Obligation (Details) Sheet http://www.hologic.com/role/RevenueRemainingPerformanceObligationDetails Revenue - Remaining Performance Obligation (Details) Details 48 false false R49.htm 2403402 - Disclosure - Leases (Details) Sheet http://www.hologic.com/role/LeasesDetails Leases (Details) Details http://www.hologic.com/role/LeasesTables 49 false false R50.htm 2403403 - Disclosure - Leases - Supplemental Balance Sheet Information (Details) Sheet http://www.hologic.com/role/LeasesSupplementalBalanceSheetInformationDetails Leases - Supplemental Balance Sheet Information (Details) Details 50 false false R51.htm 2403404 - Disclosure - Leases - Additional Lease Information (Details) Sheet http://www.hologic.com/role/LeasesAdditionalLeaseInformationDetails Leases - Additional Lease Information (Details) Details 51 false false R52.htm 2403405 - Disclosure - Leases - Lease Liability Maturity Schedule (Details) Sheet http://www.hologic.com/role/LeasesLeaseLiabilityMaturityScheduleDetails Leases - Lease Liability Maturity Schedule (Details) Details 52 false false R53.htm 2404402 - Disclosure - Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) Sheet http://www.hologic.com/role/FairValueMeasurementsFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisDetail Fair Value Measurements - Fair Value Assets and Liabilities Measured on Recurring Basis (Detail) Details 53 false false R54.htm 2404403 - Disclosure - Fair Value Measurements - Additional Information (Detail) Sheet http://www.hologic.com/role/FairValueMeasurementsAdditionalInformationDetail Fair Value Measurements - Additional Information (Detail) Details 54 false false R55.htm 2405402 - Disclosure - Business Combination - Narrative (Details) Sheet http://www.hologic.com/role/BusinessCombinationNarrativeDetails Business Combination - Narrative (Details) Details 55 false false R56.htm 2405403 - Disclosure - Business Combination - Purchase Price Allocation (Details) Sheet http://www.hologic.com/role/BusinessCombinationPurchasePriceAllocationDetails Business Combination - Purchase Price Allocation (Details) Details 56 false false R57.htm 2405404 - Disclosure - Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details) Sheet http://www.hologic.com/role/BusinessCombinationsBusinessCombinationsPurchasePriceAllocationSupersonicDetails Business Combinations Business Combinations - Purchase Price Allocation, SuperSonic (Details) Details 57 false false R58.htm 2407402 - Disclosure - Disposition (Details) Sheet http://www.hologic.com/role/DispositionDetails Disposition (Details) Details http://www.hologic.com/role/DispositionDispositionTables 58 false false R59.htm 2407403 - Disclosure - Disposition - Schedule of Assets and Liabilities Held For Sale (Details) Sheet http://www.hologic.com/role/DispositionScheduleOfAssetsAndLiabilitiesHeldForSaleDetails Disposition - Schedule of Assets and Liabilities Held For Sale (Details) Details 59 false false R60.htm 2407404 - Disclosure - Disposition - Schedule of Disposition Related Income Statement Information (Details) Sheet http://www.hologic.com/role/DispositionScheduleOfDispositionRelatedIncomeStatementInformationDetails Disposition - Schedule of Disposition Related Income Statement Information (Details) Details 60 false false R61.htm 2410402 - Disclosure - Borrowings and Credit Arrangements - Company's Borrowings (Detail) Sheet http://www.hologic.com/role/BorrowingsAndCreditArrangementsCompanysBorrowingsDetail Borrowings and Credit Arrangements - Company's Borrowings (Detail) Details 61 false false R62.htm 2410403 - Disclosure - Borrowings and Credit Arrangements - Additional Information (Detail) Sheet http://www.hologic.com/role/BorrowingsAndCreditArrangementsAdditionalInformationDetail Borrowings and Credit Arrangements - Additional Information (Detail) Details 62 false false R63.htm 2410404 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) Sheet http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseCreditAgreementDetails Borrowings and Credit Arrangements - Interest Expense Credit Agreement (Details) Details 63 false false R64.htm 2410405 - Disclosure - Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) Notes http://www.hologic.com/role/BorrowingsAndCreditArrangementsInterestExpenseSeniorNotesDetails Borrowings and Credit Arrangements - Interest Expense Senior Notes (Details) Details 64 false false R65.htm 2411402 - Disclosure - Derivatives - Additional Information (Details) Sheet http://www.hologic.com/role/DerivativesAdditionalInformationDetails Derivatives - Additional Information (Details) Details 65 false false R66.htm 2411403 - Disclosure - Derivatives - Fair Value of Derivative Financial Instruments (Details) Sheet http://www.hologic.com/role/DerivativesFairValueOfDerivativeFinancialInstrumentsDetails Derivatives - Fair Value of Derivative Financial Instruments (Details) Details 66 false false R67.htm 2411404 - Disclosure - Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) Sheet http://www.hologic.com/role/DerivativesScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeDetails Derivatives - Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Details) Details 67 false false R68.htm 2411405 - Disclosure - Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) Sheet http://www.hologic.com/role/DerivativesGainLossOnFairValueHedgesRecognizedInEarningsDetails Derivatives - Gain (Loss) on Fair Value Hedges Recognized in Earnings (Details) Details 68 false false R69.htm 2412401 - Disclosure - Commitments and Contingencies (Detail) Sheet http://www.hologic.com/role/CommitmentsAndContingenciesDetail Commitments and Contingencies (Detail) Details http://www.hologic.com/role/CommitmentsAndContingencies 69 false false R70.htm 2413402 - Disclosure - Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) Sheet http://www.hologic.com/role/NetIncomeLossPerShareReconciliationOfBasicAndDilutedShareAmountsDetail Net Income (Loss) Per Share - Reconciliation of Basic and Diluted Share Amounts (Detail) Details http://www.hologic.com/role/NetIncomeLossPerShareTables 70 false false R71.htm 2414402 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) Sheet http://www.hologic.com/role/StockBasedCompensationStockBasedCompensationExpenseInConsolidatedStatementsOfOperationsDetail Stock-Based Compensation - Stock-Based Compensation Expense in Consolidated Statements of Operations (Detail) Details 71 false false R72.htm 2414403 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.hologic.com/role/StockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 72 false false R73.htm 2414404 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) Sheet http://www.hologic.com/role/StockBasedCompensationWeightedAverageAssumptionsUtilizedToValueStockOptionsDetail Stock-Based Compensation - Weighted-Average Assumptions Utilized to Value Stock Options (Detail) Details 73 false false R74.htm 2416402 - Disclosure - Other Balance Sheet Information - Inventories (Detail) Sheet http://www.hologic.com/role/OtherBalanceSheetInformationInventoriesDetail Other Balance Sheet Information - Inventories (Detail) Details 74 false false R75.htm 2416403 - Disclosure - Other Balance Sheet Information - Property, Plant and Equipment (Detail) Sheet http://www.hologic.com/role/OtherBalanceSheetInformationPropertyPlantAndEquipmentDetail Other Balance Sheet Information - Property, Plant and Equipment (Detail) Details 75 false false R76.htm 2417402 - Disclosure - Business Segments and Geographic Information - Additional Information (Detail) Sheet http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationAdditionalInformationDetail Business Segments and Geographic Information - Additional Information (Detail) Details 76 false false R77.htm 2417403 - Disclosure - Business Segments and Geographic Information - Segment Information (Detail) Sheet http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationSegmentInformationDetail Business Segments and Geographic Information - Segment Information (Detail) Details 77 false false R78.htm 2417404 - Disclosure - Business Segments and Geographic Information - Revenues by Geography (Detail) Sheet http://www.hologic.com/role/BusinessSegmentsAndGeographicInformationRevenuesByGeographyDetail Business Segments and Geographic Information - Revenues by Geography (Detail) Details 78 false false R79.htm 2418401 - Disclosure - Income Taxes (Details) Sheet http://www.hologic.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.hologic.com/role/IncomeTaxes 79 false false R80.htm 2419402 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) Sheet http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfIntangibleAssetsDetail Intangible Assets and Goodwill - Schedule of Intangible Assets (Detail) Details 80 false false R81.htm 2419403 - Disclosure - Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) Sheet http://www.hologic.com/role/IntangibleAssetsAndGoodwillScheduleOfEstimatedAmortizationExpenseDetail Intangible Assets and Goodwill - Schedule of Estimated Amortization Expense (Detail) Details 81 false false R82.htm 2419404 - Disclosure - Intangible Assets and Goodwill -Narrative (Details) Sheet http://www.hologic.com/role/IntangibleAssetsAndGoodwillNarrativeDetails Intangible Assets and Goodwill -Narrative (Details) Details 82 false false R83.htm 2420402 - Disclosure - Product Warranties - Product Warranty Activity (Detail) Sheet http://www.hologic.com/role/ProductWarrantiesProductWarrantyActivityDetail Product Warranties - Product Warranty Activity (Detail) Details 83 false false R84.htm 2421402 - Disclosure - Accumulated Other Comprehensive Income (Detail) Sheet http://www.hologic.com/role/AccumulatedOtherComprehensiveIncomeDetail Accumulated Other Comprehensive Income (Detail) Details http://www.hologic.com/role/AccumulatedOtherComprehensiveLossTables 84 false false R85.htm 2422402 - Disclosure - Restructuring (Details) Sheet http://www.hologic.com/role/RestructuringDetails Restructuring (Details) Details 85 false false R86.htm 2423401 - Disclosure - Share Repurchase Share repurchase (Details) Sheet http://www.hologic.com/role/ShareRepurchaseShareRepurchaseDetails Share Repurchase Share repurchase (Details) Details 86 false false R9999.htm Uncategorized Items - holxq2-2020.htm Sheet http://xbrl.sec.gov/role/uncategorizedFacts Uncategorized Items - holxq2-2020.htm Cover 87 false false All Reports Book All Reports holxq2-2020.htm holx-20200328.xsd holx-20200328_cal.xml holx-20200328_def.xml holx-20200328_lab.xml holx-20200328_pre.xml holxq2-2020ex311.htm holxq2-2020ex312.htm holxq2-2020ex321.htm holxq2-2020ex322.htm http://xbrl.sec.gov/country/2017-01-31 http://fasb.org/srt/2019-01-31 http://fasb.org/us-gaap/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true XML 97 R1.htm IDEA: XBRL DOCUMENT v3.20.1
Cover Page - shares
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 28, 2020
Apr. 23, 2020
Cover [Abstract]      
Title of 12(b) Security   Common Stock, $0.01 par value  
Document Transition Report   false  
Document Quarterly Report   true  
Entity Incorporation, State or Country Code   DE  
Entity Address, Postal Zip Code   01752  
Entity File Number   1-36214  
Document Type   10-Q  
Amendment Flag   false  
Document Period End Date   Mar. 28, 2020  
Document Fiscal Year Focus   2020  
Document Fiscal Period Focus   Q2  
Entity Registrant Name   HOLOGIC, INC  
Entity Central Index Key   0000859737  
Current Fiscal Year End Date   --09-28  
Entity Filer Category   Large Accelerated Filer  
Entity Emerging Growth Company   false  
Entity Small Business   false  
Entity Common Stock, Shares Outstanding     258,205,678
Entity Shell Company false    
Entity Current Reporting Status   Yes  
Entity Interactive Data Current   Yes  
City Area Code   (508)  
Local Phone Number   263-2900  
Entity Tax Identification Number   04-2902449  
Entity Address, Address Line One   250 Campus Drive,  
Entity Address, City or Town   Marlborough,  
Entity Address, State or Province   MA  
Trading Symbol   HOLX  
Security Exchange Name   NASDAQ  
XML 98 R27.htm IDEA: XBRL DOCUMENT v3.20.1
New Accounting Pronouncements
6 Months Ended
Mar. 28, 2020
Accounting Policies [Abstract]  
New Accounting Pronouncements New Accounting Pronouncements

See Note 1 for Recently Adopted Accounting Pronouncements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326) and subsequently a number of improvements. The guidance requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2016-13, as well as all codification improvements in ASU 2019-04, ASU 2019-10, ASU 2019-11 and ASU 2020-03, on its consolidated financial position and results of operations.
    
In November 2019, the FASB issued ASU No. 2019-08, Compensation - Stock Compensation (Topic 718) and Revenue from Contracts with Customers (Topic 606). The guidance identifies, evaluates, and improves areas of GAAP for which cost and complexity can be reduced while maintaining or improving the usefulness of the information provided. The amendments in that Update expanded the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. For entities that have adopted the amendments in Update 2018-07, the updated guidance is effective for annual periods beginning after December 15, 2019, and is applicable to the Company in fiscal 2021. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2019-08 on its consolidated financial position and results of operations.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying the Accounting for Income Taxes. The Board is issuing this Update as part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). For public business entities, the amendments in this Update are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. The Company is currently evaluating the impact of the adoption of ASU 2019-12 on its consolidated financial position and results of operations.

In January 2020, FASB issued ASU No. 2020-01, Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815). The Board is issuing this Update to clarify certain interactions between the guidance to account for certain equity securities under Topic 321, the guidance to account for
investments under the equity method of accounting in Topic 323, and the guidance in Topic 815. This update could change how an entity accounts for an equity security under the measurement alternative or a forward contract or purchased option to purchase securities that, upon settlement of the forward contract or exercise of the purchased option, would be accounted for under the equity method of accounting or the fair value option in accordance with Topic 825, Financial Instruments. For entities that have adopted the amendments in Update 2020-01, the updated guidance is effective for annual periods beginning after December 15, 2020, and is applicable to the Company in fiscal 2022. Early adoption is permitted. The Company is currently evaluating the impact of the adoption of ASU 2020-01 on its consolidated financial position and results of operations.
XML 99 R9.htm IDEA: XBRL DOCUMENT v3.20.1
Basis of Presentation
6 Months Ended
Mar. 28, 2020
Basis of Presentation [Abstract]  
Basis of Presentation Basis of Presentation
The consolidated financial statements of Hologic, Inc. (“Hologic” or the “Company”) presented herein have been prepared pursuant to the rules of the Securities and Exchange Commission (the “SEC”) for quarterly reports on Form 10-Q and do not include all of the information and disclosures required by U.S. generally accepted accounting principles (“GAAP”) for annual financial statements. These financial statements should be read in conjunction with the consolidated financial statements and related notes for the fiscal year ended September 28, 2019 included in the Company’s Form 10-K filed with the SEC on November 27, 2019. In the opinion of management, the financial statements and notes contain all adjustments (consisting of normal recurring accruals and all other necessary adjustments) considered necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented.
The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances have been eliminated in consolidation.
The preparation of financial statements in conformity with GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from management’s estimates if past experience or other assumptions do not turn out to be substantially accurate. Operating results for the three and six months ended March 28, 2020 are not necessarily indicative of the results to be expected for any other interim period or the entire fiscal year ending September 26, 2020.
COVID-19 Considerations
The pandemic caused by the spread of the novel strain of coronavirus disease 2019 ("COVID-19") has created significant volatility, uncertainty and economic disruption in the markets the Company sells its products into, primarily the U.S., Europe and Asia-Pacific. In the second quarter of fiscal 2020, the spread of COVID-19 has negatively impacted business activity globally. As healthcare systems respond to the increasing demands of managing COVID-19 and the resulting economic uncertainties, governments around the world have imposed measures designed to reduce the transmission of COVID-19, and individuals are responding to the fears of contracting COVID-19. In particular, elective procedures and exams are being delayed or cancelled, there has been a significant reduction in physician office visits, and hospitals are postponing or cancelling capital purchases as well as limiting or eliminating services. These responses have had, and the Company believes will continue to have, a negative impact on the Company's operating results and cash flows. While the effects of COVID-19 and the associated economic disruptions were felt primarily in the second half of March in many of the Company's end-markets and earlier in Asia, primarily China, the Company expects the effect on its financial results in the third fiscal quarter to be significant. While the Company believes the impact on its business will begin to lessen in the fourth quarter and continue to do so in subsequent periods the impacts on these periods could be significant.
The Company's belief is that COVID-19’s adverse impact on its operating results, cash flows and financial condition will be primarily driven by: the severity and duration of the COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. and international healthcare system, the U.S. economy and worldwide economy; and the timing, scope and effectiveness of U.S. and international governmental responses to the COVID-19 pandemic and associated economic disruptions.
In addition to adversely affecting demand for the Company's products, COVID-19 and associated economic disruptions could have an adverse impact on the Company's supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that it, other businesses and governments are taking. A reduction or interruption in any of the Company's manufacturing processes could have a material adverse effect on its business.
The Company expects that the uncertainty surrounding world financial markets and deteriorating worldwide macroeconomic conditions resulting from the pandemic have caused and may continue to cause the purchasers of medical equipment to decrease their medical equipment purchasing and procurement activities. Additionally, the pandemic has caused and may further cause constrictions in world credit markets that have and could cause its customers to experience increased difficulty in paying their existing obligations to the Company or in securing the financing necessary to purchase the Company's products. Economic uncertainty has and may continue to result in cost-conscious consumers focusing on acute care rather than wellness, which would also continue to adversely affect demand for the Company's products.
The terms of the Company's credit facilities require it to satisfy certain financial covenants. Should the Company's future business and operations be significantly impaired by the continuing COVID-19 pandemic and associated economic disruptions over an extended period of time or otherwise, the Company cannot assure that it will remain in compliance with its current financial covenants. In such event, the factors that adversely affect the Company's business may also similarly adversely affect the capital markets, and the Company cannot assure that it would be able to negotiate alternative covenants or alternative financing on favorable terms if at all. The Company's failure to comply with the covenants contained in its credit facilities, including financial covenants, could result in an event of default, which could materially and adversely affect its results of operations and financial condition.
As the Company assessed the potential longer term economic and capital market uncertainties resulting from the COVID-19 pandemic, at the end of March 2020 the Company suspended its accounts receivable securitization program and borrowed $750.0 million under its revolver. The Company used $250.0 million of these proceeds to pay off all amounts then owed under its accounts receivable securitization agreement, and retained the balance as cash reserve. As of March 28, 2020 the Company had another $750.0 million available under its revolver.
In response to the negative impact of COVID-19 on the Company's business, in April 2020 it initiated cost-cutting measures, which included not only reducing discretionary and variable spend, such as travel, marketing programs and the use of contractors, consultants and temporary help, but the Company also implemented employee furloughs, salary cuts primarily in the U.S., reduced hours and in certain instances employee terminations. Further, the Company has shut down certain manufacturing facilities temporarily and implemented reduced work-week schedules in response to lower near-term demand for many of its products. These actions, as they relate to the Company's manufacturing operations, are expected to reduce the efficiency of its manufacturing operations and could further adversely affect its results of operations. Future cost savings initiatives and other measures related to stopping the spread of COVID-19 could also adversely affect the Company's research and development activities, including its clinical trials.
The Company has also taken measures to ensure the safety of its employees and to comply with governmental orders. These measures could require that the Company's employees refrain from traveling to their normal workplace for extended periods of time, which in turn could result in a decrease in its commercial and marketing activities.
During the second quarter of fiscal 2020, the FDA granted Emergency Use Authorization (EUA) for the Company's Panther Fusion SARS-CoV-2 assay for testing for the COVID-19 virus. The Company is in the process of completing development of a second SARS-CoV-2 assay which will run on its more widely distributed Panther instrument. The Company has installed more than 1,800 Panther instruments, which are used by clinical laboratories around the world. Subject to obtaining the required authorizations, the Company expects to introduce the assay in May. However, the Company can give no assurance that this assay will be developed and authorized on a timely basis, if at all, or if introduced, will be commercially successful.
Recently Adopted Accounting Pronouncements
In February 2016, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842), referred to as ASC 842. The purpose of ASU 2016-02 is to increase the transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet, including those previously classified as operating leases under GAAP, and disclosing key information about leasing arrangements. ASC 842, as amended, is effective for public entities for annual periods beginning after December 15, 2018, including interim periods within those annual periods and was effective for the Company in fiscal 2020. The Company adopted the standard using the transition method provided by ASC Update No. 2018-11, Leases (Topic 842): Targeted Improvements. Under this method, the Company applied the new leasing rules on September 29, 2019, rather than at the earliest comparative period presented in the financial statements. Prior periods were presented in accordance with the existing lease guidance under ASC 840.
Upon transition, the Company applied the package of practical expedients permitted under ASC 842 transition guidance to its entire lease portfolio at September 29, 2019. As a result, the Company was not required to reassess (i) whether any expired or existing contracts are or contain leases, (ii) the classification of any expired or existing leases, and (iii) initial direct costs for any existing leases. Furthermore, as a lessee the Company elected to combine lease and non-lease components together for the majority of its leases. As a result, for these applicable classes of underlying assets, the Company accounted for each separate lease component and the non-lease components associated with that lease component as a single lease component.
Under ASC 842 as a lessor, in instances where the Company places instruments (or equipment) at customer sites as part of its reagent rental contracts, certain of the Company's reagent rental contracts could be classified as sales-type leases. Under sales-type leases, there is accelerated expense recognition for the cost of the placed equipment and potentially up-front revenue in the event there are fixed rental payments, a portion of which would be allocated to the equipment. The Company does not
expect to have a significant amount of sales-type leases. Under ASC 840, all instruments placed under the Company's reagent rental programs were classified as operating leases and instrument revenue and cost were recognized over the term of the contract.
Upon adoption of the new lease standard, the Company recognized operating lease right-of-use assets and finance lease right-of-use assets of $91.7 million and $10.2 million, respectively, and corresponding operating lease liabilities and finance lease liabilities of $96.6 million and $21.0 million, respectively. This includes recording the Company’s existing capital lease as a finance lease at transition. In addition, the Company derecognized $32.6 million of property, plant and equipment and $35.2 million of finance lease obligations recorded in accrued expenses and other long-term liabilities associated with two previously existing build-to-suit lease arrangements. Right-of-use assets and corresponding liabilities for these build-to-suit lease arrangements are included within the total amount recognized upon adoption of the new lease standard. The Company’s adoption of ASC 842 is more fully described in Note 3.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities. The guidance requires certain changes to the presentation of hedge accounting in the financial statements and also simplifies the application of hedge accounting and expands the strategies that qualify for hedge accounting. The Company adopted the standard in the first quarter of fiscal 2020. The adoption of ASU 2017-12 did not have a material effect on the Company's consolidated financial statements.
Subsequent Events Consideration
The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates or to identify matters that may require additional disclosure. Subsequent events have been evaluated as required. There were no material recognized or unrecognized subsequent events affecting the unaudited consolidated financial statements as of and for the three and six months ended March 28, 2020.
XML 100 R23.htm IDEA: XBRL DOCUMENT v3.20.1
Intangible Assets and Goodwill
6 Months Ended
Mar. 28, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible Assets and Goodwill Intangible Assets
Intangible assets consisted of the following:
 
Description
As of March 28, 2020
 
As of September 28, 2019
Gross
Carrying
Value
 
Accumulated
Amortization
 
Gross
Carrying
Value
 
Accumulated
Amortization
Acquired intangible assets:
 
 
 
 
 
 
 
Developed technology
$
3,925.6

 
$
2,779.6

 
$
3,927.7

 
$
2,654.8

Customer relationships
546.8

 
461.4

 
525.5

 
447.5

Trade names
244.0

 
176.1

 
245.4

 
171.1

Distribution agreement

 

 
2.5

 

Non-competition agreements
1.5

 
1.1

 
1.4

 
0.9

Business licenses
2.3

 
2.2

 
2.3

 
2.2

Total acquired intangible assets
$
4,720.2

 
$
3,420.4

 
$
4,704.8

 
$
3,276.5

 
 
 
 
 
 
 
 
Internal-use software
51.4

 
41.7

 
53.9

 
43.4

Capitalized software embedded in products
28.2

 
8.9

 
27.9

 
6.9

Total intangible assets
$
4,799.8


$
3,471.0


$
4,786.6


$
3,326.8


In the first quarter of fiscal 2020, the Company's Medical Aesthetics business met the criteria to be designated as assets held-for-sale. As a result, the Company recorded a $30.2 million charge to record the asset group at fair value less costs to sell. In addition, developed technology, customer lists, tradenames, and distribution agreement related to Medical Aesthetics of $24.1 million, $0.9 million, $2.0 million, and $1.2 million, respectively, were reclassified accordingly in the Company's Consolidated Balance Sheet to assets held-for-sale as of December 28, 2019 and subsequently disposed of in the second quarter of fiscal 2020.
In the second quarter of fiscal 2020, the Company reviewed its long-lived assets for indicators of impairment as a result of lowering its expectations for revenue and operating income in the short term from the impact of COVID-19 on its business as discussed in Note 1. The Company updated its long-term forecasts and performed an undiscounted cash flow analysis which indicated that the estimated future cash flows are sufficient to recover the carrying values of its asset groups. In addition, the Company had significant cushion from its most recent goodwill impairment test in each of its reporting units and believes, based on its procedures, current facts and expectations, that as of the date of this report it is it not more likely than not that the fair value of each of its reporting units is below their respective carrying values. Given the current uncertainty of the duration and scope of the COVID-19 pandemic, the related economic impact, and the potential longer term impact on the
Company's business, financial condition and results of operations, in the future the Company may be required to perform an interim impairment test, in addition to its annual test, and record an impairment charge.
Medical Aesthetics Impairment - Fiscal 2019

During the second quarter of fiscal 2019, in connection with commencing its company-wide annual budgeting and strategic planning process as well as evaluating the current operating performance of its Medical Aesthetics reporting unit (comprised solely of the Cynosure business), the Company reduced its short term and long term revenue and operating income forecasts. The updated forecast reflected reduced volume and market penetration projections primarily in the Body Contouring business due to increased competition in the non-invasive fat reduction category, and lower Women's Health product sales primarily from reduced sales volume of the MonaLisa Touch device, which the Company believed was primarily driven by the FDA's public letter in the fourth quarter of fiscal 2018 challenging various medical aesthetics companies marketing of devices for so called "vaginal rejuvenation" procedures relative to their FDA approvals. As a result of the revised forecasts in the second quarter of fiscal 2019, the Company determined indicators of impairment existed and performed an undiscounted cash flow analysis pursuant to ASC 360, Property, Plant, and Equipment - Overall, to determine if the cash flows expected to be generated by this asset group over the estimated remaining useful life of the primary assets were sufficient to recover the carrying value of the asset group, which was determined to be at the reporting unit level. Based on this analysis, which included evaluating various cash flow scenarios, the undiscounted cash flows were not sufficient to recover the carrying value of the asset group. As a result, the Company was required to perform Step 3 of the impairment test and determine the fair value of the asset group. To estimate the fair value, the Company utilized the income approach, which is based on a discounted cash flow (DCF) analysis and calculates the fair value by estimating the after-tax cash flows attributable to the asset group and then discounting the after-tax cash flows to present value using a risk-adjusted discount rate. Assumptions used in the DCF require significant judgment, including judgment about appropriate discount rates and terminal values, growth rates, and the amount and timing of expected future cash flows. The forecasted cash flows are based on the Company's most recent strategic plan and for periods beyond the strategic plan, the Company's estimates were based on assumed growth rates expected as of the measurement date. The Company believed its assumptions were consistent with the plans and estimates that a market participant would use to manage the business. The discount rate used is intended to reflect the risks inherent in future cash flow projections and was based on an estimate of the weighted average cost of capital (WACC) of market participants relative to the asset group. The Company used a discount rate of 11.0%. As a result of this analysis, the fair value of the Medical Aesthetics asset group was below its carrying value, and the Company recorded an impairment charge of $443.8 million during the second quarter of fiscal 2019. The impairment charge was allocated to the long-lived assets as follows: $373.3 million to developed technology, $14.4 million to customer relationships, $31.5 million to trade names, $17.8 million to distribution agreements and $6.8 million to equipment. The Company believed its assumptions used to determine the fair value of the asset group were reasonable. The Company completed the sale of the Medical Aesthetics business in the second quarter of fiscal 2020. Please refer to Note 6 for additional details.
The estimated remaining amortization expense of the Company's acquired intangible assets as of March 28, 2020 for each of the five succeeding fiscal years is as follows:
Remainder of Fiscal 2020
$
145.1

Fiscal 2021
$
269.1

Fiscal 2022
$
258.7

Fiscal 2023
$
161.2

Fiscal 2024
$
150.4


XML 101 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 102 R42.htm IDEA: XBRL DOCUMENT v3.20.1
Accumulated Other Comprehensive Loss (Tables)
6 Months Ended
Mar. 28, 2020
Accumulated Other Comprehensive Income [Abstract]  
Changes in Accumulated Other Comprehensive Income

The following tables summarize the changes in accumulated balances of other comprehensive loss for the periods presented:

 
Three Months Ended March 28, 2020
 
Six Months Ended March 28, 2020
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Hedged Interest Rate Swaps
 
Total
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Hedged Interest Rate Swaps
Total
Beginning Balance
$
(33.1
)
 
$
(1.7
)
 
$
(1.4
)
 
$
7.5

 
$
(28.7
)
 
$
(41.4
)
 
$
(1.7
)
 
$
(2.7
)
 
$
3.5

$
(42.3
)
Other comprehensive income (loss) before reclassifications
(5.4
)
 

 
(0.1
)
 
(25.1
)
 
(30.6
)
 
2.9

 

 
(0.1
)
 
(21.1
)
(18.3
)
Amounts reclassified to statement of income

 

 
0.4

 

 
0.4

 

 

 
1.7

 

1.7

Ending Balance
$
(38.5
)
 
$
(1.7
)
 
$
(1.1
)
 
$
(17.6
)
 
$
(58.9
)
 
$
(38.5
)
 
$
(1.7
)
 
$
(1.1
)
 
$
(17.6
)
$
(58.9
)

 
Three Months Ended March 30, 2019
 
Six Months Ended March 30, 2019
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
 
Foreign Currency Translation
 
Pension Plans
 
Hedged Interest Rate Caps
 
Total
Beginning Balance
$
(29.8
)
 
$
(1.1
)
 
$
(1.0
)
 
$
(31.9
)
 
$
(26.6
)
 
$
(1.1
)
 
$
2.2

 
$
(25.5
)
Other comprehensive income (loss) before reclassifications
2.4

 

 
(1.5
)
 
0.9

 
(0.8
)
 

 
(5.4
)
 
(6.2
)
Amounts reclassified to statement of income

 

 
0.5

 
0.5

 

 

 
1.2

 
1.2

Ending Balance
$
(27.4
)
 
$
(1.1
)
 
$
(2.0
)
 
$
(30.5
)
 
$
(27.4
)
 
$
(1.1
)
 
$
(2.0
)
 
$
(30.5
)



XML 103 R46.htm IDEA: XBRL DOCUMENT v3.20.1
Revenue - Revenue by Type (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Disaggregation of Revenue [Line Items]        
Revenues $ 756.1 $ 818.4 $ 1,606.6 $ 1,649.1
Capital equipment, components and software        
Disaggregation of Revenue [Line Items]        
Revenues 166.6 239.4 399.5 487.8
Consumables        
Disaggregation of Revenue [Line Items]        
Revenues 457.0 428.4 923.4 863.1
Service        
Disaggregation of Revenue [Line Items]        
Revenues 127.2 141.1 272.2 283.0
Other        
Disaggregation of Revenue [Line Items]        
Revenues $ 5.3 $ 9.5 $ 11.5 $ 15.2
XML 104 R65.htm IDEA: XBRL DOCUMENT v3.20.1
Derivatives - Additional Information (Details) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Mar. 28, 2020
Mar. 30, 2019
Sep. 28, 2019
Derivative [Line Items]          
Interest Rate Cap Agreements Aggregate Premium Payable $ 1.5   $ 0.0 $ 1.5 $ 3.7
Borrowed principal 1,000.0   1,000.0    
Loss reclassified from accumulated other comprehensive loss to the statement of income (0.4) $ (0.5) (1.7) $ (1.2)  
Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred     (1.1)    
Interest Rate Cash Flow Hedge Asset at Fair Value 0.0   0.0   $ 0.1
Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments (0.1)        
Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax 2.6 $ 1.1      
Notional Amount 51.0   51.0    
Interest Rate Swap          
Derivative [Line Items]          
Derivative notional amount $ 1,000.0   $ 1,000.0    
Variable interest rate 1.23%   1.23%    
Interest rate swap at fair value $ 22.9   $ 22.9    
Foreign Exchange Option          
Derivative [Line Items]          
Derivative notional amount $ 80.6   80.6    
Net unrealized loss     $ 1.1    
XML 105 R61.htm IDEA: XBRL DOCUMENT v3.20.1
Borrowings and Credit Arrangements - Company's Borrowings (Detail) - USD ($)
$ in Millions
Mar. 28, 2020
Sep. 28, 2019
Debt Instrument [Line Items]    
Current portion of long-term debt $ 806.1 $ 271.4
Total long-term debt obligations 2,749.3 2,783.6
Total debt obligations 3,555.4 3,055.0
Term Loan    
Debt Instrument [Line Items]    
Current portion of long-term debt 56.1 37.4
Long term debt obligations. excluding convertible notes 1,416.2 1,452.4
Revolver [Member]    
Debt Instrument [Line Items]    
Current portion of long-term debt 750.0 0.0
Securitization Program    
Debt Instrument [Line Items]    
Current portion of long-term debt 0.0 234.0
SSI [Member]    
Debt Instrument [Line Items]    
Long term debt obligations. excluding convertible notes 0.6 0.0
2025 Senior Notes    
Debt Instrument [Line Items]    
Long term debt obligations. excluding convertible notes 938.3 937.3
2028 Senior Notes    
Debt Instrument [Line Items]    
Long term debt obligations. excluding convertible notes $ 394.2 $ 393.9
XML 106 R69.htm IDEA: XBRL DOCUMENT v3.20.1
Commitments and Contingencies (Detail)
$ in Millions
6 Months Ended
Mar. 04, 2016
petition
Mar. 28, 2020
USD ($)
Jul. 27, 2018
USD ($)
Minerva      
Loss Contingencies [Line Items]      
Assessed damages     $ 4.8
Petitions filed | petition 2    
Cynosure      
Loss Contingencies [Line Items]      
Payment of settlement compensation   $ 8.5